



# PROGRAMME

**THE INTERNATIONAL  
LIVER CONGRESS™**

**APRIL 10 - 14, VIENNA, AUSTRIA**

**2019**

[WWW.ILC-CONGRESS.EU](http://WWW.ILC-CONGRESS.EU)

SEE YOU NEXT YEAR IN  
**LONDON - 15-19 APRIL 2020**

# Download the 2019 app

International Liver Congress™

## Full access to:

- + scientific programme
- + posters
- + abstracts
- + hall/exhibition area maps

## Plus...

- + see who's attending
- + search the full programme
- + save your favourite sessions
- + interact with speakers
- + create notes
- + and more...






Discover the full features  
[ilc-congress.eu/mobile-app](http://ilc-congress.eu/mobile-app)



# What's your COLOUR?

## Specialties

---



Follow the colour codes and pictogrammes throughout this book to find the sessions of interest to you

## Fields



Liver transplant and surgery



Public health



Basic and translational science



Imaging and interventional

# **LIVE** Streaming

Content at your fingertips.



- 24/7 access to key presentations
- Catch up on sessions you missed
- Watch in your home country
- Free of charge
- Available through the ILC website and ILC app

# THE INTERNATIONAL LIVER CONGRESS™

APRIL 10 - 14, VIENNA, AUSTRIA



[www.ilc-congress.eu](http://www.ilc-congress.eu)

## Organised by

**EASL – The Home of Hepatology**  
**European Association for the Study of the Liver**

Rue Daubin 7, 1203 Geneva, Switzerland  
ILC.information@easloffice.eu  
Tel: +41 (0)22 807 29 80  
[www.easl.eu](http://www.easl.eu)

## Registration agency

**Congrex Switzerland**  
**On behalf of The International Liver Congress™ 2019**

Peter Merian Strasse 80, 4002 Basel, Switzerland  
registration.ilc@congrex.com  
Tel: +41 (0)61 686 77 77

## Congress hotline

Monday 08 April:	08:00-18:00
Tuesday 09 April:	08:00-19:00
Wednesday 10 – Sunday 14 April:	during opening hours
Tel: +43 1 931 02 07 501	

## Housing agency

**b network**

Carrer Aragó 314 1º 1ª, 08009 Barcelona, Spain  
ilchotels@b-network.com  
Tel: + 34 (0)93 550 03 50

# Table of contents

<b>WELCOME MESSAGE</b>	<b>7</b>
Welcome message from the EASL Secretary General and Vice-Secretary	8
Welcome message from the Honorary President	10
<b>GENERAL CONGRESS INFORMATION</b>	<b>11</b>
Congress venue	12
General site plan & floor plans	13
Opening hours	19
Registration	22
Young Investigator bursaries	25
CME accreditation	25
<b>EASL</b>	<b>29</b>
EASL Governing Board	30
<b>AWARDS</b>	<b>33</b>
EASL award ceremonies and awardees	34
<b>SCIENTIFIC PROGRAMME OVERVIEW</b>	<b>39</b>
What's your colour?	40
Scientific highlights	42
Session format description	43
Abstract presentations	46
Daily Wednesday 10 April	50
Daily Thursday 11 April	52
Daily Friday 12 April	54
Daily Saturday 13 April	58
Daily Sunday 14 April	60

<b>SCIENTIFIC PROGRAMME</b>	<b>63</b>
Wednesday 10 April	63
Thursday 11 April	79
Friday 12 April	111
Saturday 13 April	141
Sunday 14 April	167
<b>LATE-BREAKER POSTERS</b>	<b>177</b>
<b>POSTERS</b>	<b>183</b>
Thursday 11 April	184
Friday 12 April	231
Saturday 13 April	285
<b>ACKNOWLEDGEMENTS</b>	<b>333</b>
Abstract reviewers	334
Sponsors	337
National associations' village	341
<b>INDUSTRY</b>	<b>343</b>
Industry programme overview	344
Satellite symposia programmes	346
Mini-workshops programmes	357
Exhibition	360
Exhibitors' list	362
Meeting rooms	364
Company profiles	365
Association profiles	386
Sponsors' adverts	392



Let's talk SCIENCE,  
but first, COFFEE

# SOCIAL MEDIA COFFEE LOUNGE

Like

Share



**EASLnews** ✓  
@EASLnews

Join the conversation and enjoy a free cup of coffee or a latte. Only at the EASL Community Hub for #ILC2019

2:11 PM 10 Apr 19

133 RETWEETS 1,170 LIKES



## WELCOME MESSAGES

# Welcome message from the EASL Secretary General and Vice-Secretary

Dear Colleagues,

Welcome to Vienna for The International Liver Congress™ 2019 (ILC 2019) – the 54<sup>th</sup> annual meeting of the European Association for the Study of the Liver (EASL).

We are delighted to invite you to join the international liver community at the Reed Messe congress centre in Vienna from 10 to 14 April 2019.

Hepatology is changing – major increases in the burden of metabolic liver disease and liver cancer worldwide, novel innovative treatments for rare liver diseases and hepatitis B emerging as a growing challenge. For hepatitis C attention is moving to case-finding and treatment of difficult to access cohorts. Recognising the multi-disciplinary nature of modern hepatology we are forming new alliances with diabetes, obesity and oncology associations to enhance educational programming and clinical care. Public health research is also booming and EASL is becoming ever more active in driving policy agendas.

ILC 2019 brings together clinicians, scientists and hepatologists from all around the world creating a unique opportunity to interact and discuss clinical innovation, scientific breakthroughs and research challenges and to network and develop future collaborations.

Some of the 2019 ILC highlights are:

- Over 1,500 original scientific projects presented – from almost 3,000 submitted abstracts
- Complete topic tracks within all major topics of hepatology tailored to your interest
- Enhanced interactivity throughout scientific and educational components, with further refinements to the “research think tanks” and “meet the experts” sessions
- The launching of the all new “hepatology arena” to maximise discussions on topical challenges
- Comprehensive public health track with involvement of all major stakeholders, including governmental agencies such as WHO and CDC
- Strong basic science representation, with a multi-day basic science course focusing on liver immunology and immunotherapy

- Clinical postgraduate education across a wide range of interactive formats, with this year postgraduate course focusing on end-stage liver disease
- State of the art lectures on “Shared mechanisms in cholestatic and fatty liver disease – implications for current and future treatment”, “How big data integration can provide new insight to liver biology and disease” and new this year – a translational state of the art lecture on “Cell therapy for advanced liver disease”
- Three full days of transplant and surgery programming, including a multidisciplinary postgraduate course
- Upgraded version of the “skills learning track”, with hands-on training opportunities for all
- Further developments of the “home of hepatology” concept with collaborative sessions with multiple societies
- For the first time, full online access to all sessions by free-of-charge webcasting
- Further development of the post-congress material, including PowerPoint slide-decks summarising the best original work from all topic tracks

Young Investigators, clinicians, basic scientists, nurses, researchers, industry partners, patients and policy advocates are all invited to attend. We look forward to seeing you for an exciting week of liver discoveries and exchange.

Looking forward to seeing you in Vienna.

Warmest regards,

**TOM  
HEMMING  
KARLSEN**



*EASL  
Secretary General*

A handwritten signature in blue ink, appearing to read 'Tom Hemming Karlsen', with a long horizontal line extending to the right.

**PHILIP N.  
NEWSOME**



*EASL  
Vice-Secretary*

A handwritten signature in blue ink, appearing to read 'Philip N. Newsome', with a long horizontal line extending to the right.

## Welcome message from the Honorary President

Dear Friends,

It's time. Time to prepare for our gathering. Time for our yearly fair. Time for business and entertainment. Time for showing off and taking back home. Time to confront old ideas and new facts. Time for sharing and mating paradigms; my emerging views and yours. Time for astonishments. Let's start moving. Here comes ILC, our annual EASL meeting.

It's the 2019 high. The crest of this year's mountain of team work. The high where we can all appreciate and celebrate our colleagues' achievements and consider new possibilities. The crest of the wave. The simple wave of liver science, which has come to break and deliver. As it has done every spring, for so many years.

Dear Friends, wherever you live. Come to Vienna. The city of Emperors, of so many wars and peace, past alliances and treaties, in the centre of our beloved old Europe. The heart of this continent in so many aspects. A place which knows how to show, how to merge and how to share.

DOMINIQUE-  
CHARLES  
VALLA

*Honorary President of The International  
Liver Congress™ 2019,  
Hôpital Beaujon, France*



## GENERAL CONGRESS INFORMATION

## Congress venue

### Reed Messe Wien Congress and Exhibition Center

Trabennstraße 7, Foyer D  
1020 Vienna  
Austria

#### Nearest tramway/metro stops: 'Krieau'

For your security in the congress venue, a full body and luggage check might be carried out upon your arrival in the entrance area (Foyer D). It is therefore recommended to arrive at least 30 minutes before your first session.

### Wi-Fi internet connection

**Network:** ILC2019

**Password:** No password necessary.

The Wi-Fi connection will be available throughout the congress centre.


**We ask that you please avoid downloading heavy files, movies or music during the congress as it will affect the connection speed for other attendees.**



#### Download The International Liver Congress™ 2019 app


The ILC2019 app provides full-access to the scientific programme, posters and abstracts, as well as floor plans of halls and the exhibition area.


# General site plan



General congress information

## Ground floor overview






**EXECUTIVE LOUNGE  
(1st Floor)**

**Faculty registration  
Speakers' ready room**

**Main entrance D**

**Registration area**



# Exhibition

For detailed meeting rooms floor plan see page 360.



LEGEND: MEETING ROOMS

# Poster area

General congress information

**POSTER  
POD  
1**

**LATE-BREAKERS**

- I-14
- I5-28
- 29-42

**POSTER  
POD  
2**


**MEETING  
POINT 4**   **MEETING  
POINT 3**   **MEETING  
POINT 2**   **MEETING  
POINT 1**

I-20	2I-40	4I-60	6I-80	8I-100	10I-120	12I-140	14I-160	16I-180	18I-200	20I-220
42I-440	40I-420	38I-400	36I-380	34I-360	32I-340	30I-320	28I-300	26I-280	24I-260	22I-240
44I-450	45I-460	46I-470	47I-480	48I-490	49I-500	50I-510				

**POSTER  
POD  
3**   **POSTER  
POD  
4**

General congress information

# 1st floor overview



## Opening hours

### Reed Messe Wien Congress and Exhibition Center

Opening: 30 minutes before the first session each day

Closing: 30 minutes after the last session each day

### Cloakroom (Hall D)

You will find the cloakroom by turning left towards Hall D from the registration area.

Wednesday 10 to Saturday 13 April 07:00-20:00

Sunday 14 April 07:00-14:00

## Foyer D

### Registration area

Membership fast-track, self-registration lanes, help desk, accommodation desk, congress material, congress app

Tuesday 09 April 16:00-19:00

Wednesday 10 to Saturday 13 April 07:00-19:00

Sunday 14 April 07:00-14:00

### Group badge pick-up

Monday 08 April 14:00-18:00

Tuesday 09 April 08:00-14:00

### Executive lounge, faculty registration & speakers' ready room (1<sup>st</sup> floor)

Located in the Panorama Lounge on the 1<sup>st</sup> floor of the registration area, the speakers' ready room will be available every day throughout the congress for invited speakers and oral presenters.

Tuesday 09 April 16:00-19:00

Wednesday 10 to Saturday 13 April 07:00-19:00

Sunday 14 April 07:00-14:00

On-site technicians will assist speakers during the above hours.

## Hall B

### EASL community hub

Share zone & networking lounge

Thursday 11 April 09:00-18:30

Friday 12 and Saturday 13 April 09:00-17:00

Network with ILC delegates and discover EASL activities (science, education, advocacy, social media coffee lounge, livestreaming)

### Poster area

Poster area and poster help desk.

Thursday 11 April 09:00\*-18:30

Friday 12 and Saturday 13 April 09:00\*-17:00

*\*Access will be granted 1 hour before public opening hours to poster presenters.*

Presenter poster collection\*\*

Thursday 11 April 18:30-19:00

Friday 12 and Saturday 13 April 16:00-17:00

*\*\*Should you wish to recover your poster, you can do so on your presentation day. All unremoved posters will be dismantled and destroyed by on-site staff after 19:00 on Thursday 11 April and after 17:00 on Friday 12 and Saturday 13 April.*

### Patient lounge

Thursday 11 April 09:00-18:30

Friday 12 and Saturday 13 April 09:00-17:00

A patient lounge will be available everyday throughout the congress for delegates looking for a private space or needing to rest.

### Skills Learning Centre (SLC)

Practical activities (hands-on sessions):

Wednesday 10 April: 18:00-19:30

Thursday 11 April: 07:30-08:30 and 18:30-20:00

Friday 12 April: 18:30-20:00

## Exhibition

Thursday 11 April:	09:00-18:30
Friday 12 and Saturday 13 April	09:00-17:00

Exhibitors and poster presenters have a special access as of 08:00.

Please refer to the list of exhibitors on page 358 for further info.

## Meeting rooms B1 to B10

Wednesday 10 to Saturday 13 April	07:00-19:00
Sunday 14 April	07:00-14:00

## Exhibition & meeting rooms service centre (located outside of Hall B)

Monday 08 and Tuesday 09 April	08:00-20:00*
Wednesday 10 April	07:00-19:00*
Thursday 11 to Saturday 13 April	07:00-19:00
Sunday 14 April	07:00-14:00*

*\*Only for exhibitors and authorised delegates*

## Complimentary catering

Lunch and coffee are not included in the registration fee, however EASL provides a certain amount of complimentary catering on a first come first served basis during the breaks.

A small number of catering outlets are available on-site where delegates can purchase food and beverages.

## Catering outlets

### Flash Café (Hall D)

Wednesday 10 April to Sunday 14 April	07:00-18:00
---------------------------------------	-------------

### Café Modern Times (Near Hall B)

Wednesday 10 April to Saturday 13 April	09:00-17:00
Sunday 14 April	07:30-18:00

### Espresso Mobil

Wednesday 10 April to Saturday 13 April	08:00-17:00
---	-------------

## Hall C

### Press office

Wednesday 10 to Saturday 13 April	07:00-19:00
Sunday 14 April	07:00-12:00

### Meeting rooms (ground and 1<sup>st</sup> floor)

Wednesday 10 to Saturday 13 April	07:00-19:00
Sunday 14 April	07:00-14:00

Ground floor meeting rooms: B 1-10 (in hall B), Stolz 3-4, Media lounge A-B, Büro congress

1<sup>st</sup> floor meeting rooms: Atrium 1-3, Piazza, Schubert 1-6, Business suites 1-4, Offices 1-2, Galerie 1-20, Lounge 1-4

## Registration

On-site registration, congress material pick-up, and badge collection will be available at the registration area in Foyer D. For opening hours, please refer to page 19.

### Badges

All delegates and exhibitors must wear their ILC badge at all times to access the congress venue. Delegates not wearing an ILC badge will not be granted access past the registration area.

All congress attendees will be provided with one of the following badge types. Coloured ribbons can be collected from the EASL booth in the mall.

## Badge categories



### Participants

Participants are admitted into the lecture halls and other scheduled activities, as well as the catering areas.



### Exhibitors

Exhibitors are admitted into the exhibition area as well as the catering areas but have no access to the lecture halls. They can also attend the industry satellite symposia of their respective company.



### Nurses & AHP forum

Nurses and Allied Health Professionals are granted access only Friday 12 April 2019. They are admitted into the lecture halls and other scheduled activities, as well as the catering areas.



### Media

The media badge gives access to the congress sessions and media areas. You will be asked to provide proof to show that you are the person indicated on the badge, so please ensure that you have your ID card or passport with you at all times.

## Lost badges

If a badge is lost or forgotten, an administrative fee of EUR 30.00 (incl. 10% VAT) will be charged to reprint the badge after identity verification (passport, driving license or other recognised identification document).

If both badges are brought back at the registration desk, the administrative fee will be refunded.

## Coloured ribbons

The coloured ribbons attached to the congress badges indicate the following:



**EASL member**

---



**Emeritus EASL member**

---



**New EASL member**

---



**Faculty**

---



**Young Investigator**

---



**EASL Secretary General, EASL Vice-Secretary,  
ILC Honorary President**

---



**EASL Governing Board and EASL staff**

## Young Investigator bursaries

**Bursary payments will be made by bank transfer after the congress, however only to those whose presence was verified on-site.**

To verify physical presence on-site, poster presenters need to check-in before noon on the day of their presentation, at the poster help desk in Hall B next to the poster area.

Kindly note that a passport, driving license or other official identification proof will be requested to verify your identity.

Those eligible to claim a bursary will be notified approximately 14 days after the congress.

## CME accreditation

An application has been made to the EACCME® for CME accreditation of this event.

Go to **[www.ilc-congress.eu/accreditation](http://www.ilc-congress.eu/accreditation)** for the latest update.



## Attendance and CME certificate

### Important note:

The CME evaluation form will only be available as of Monday 15 April. A link directing to the CME evaluation form will be sent by e-mail after the congress. Upon completion of the CME evaluation form, you will be able to download your CME certificate in electronic version on your ILC registration portal.

Please use your congress registration credentials (e-mail and password) to login.

**No printed certificate of attendance will be available on-site.**

## Mobile phones



Mobile phones must be switched to silent mode during all sessions.

**Contribute to the Twitter discussion online using #ILC2019** 

## Images and recordings

As a registered attendee of The International Liver Congress™ 2019 you grant permission for EASL to use your likeness in a photograph or video in any and all of its publications and presentations, including website entries, without payment or any other consideration. You authorise EASL to edit, alter, copy, exhibit, publish or distribute the photograph or video for purposes of publicising EASL's programmes or for any other lawful purpose. You waive the right to inspect or approve the finished product, including written or electronic copy, wherein your likeness appears. You also agree that these materials will become the property of EASL.

Please note that only accredited media can record in the congress premises.

This is an abstract of the Conditions of Use you accepted when registering for the EASL ILC 2019 congress. The full Conditions of Use and Privacy Policy are available on [m-anage.com](http://m-anage.com). Login with your ILC credentials.



## Smoking policy



Smoking is prohibited at all times in all congress centre areas.  
Your compliance is appreciated.

# Upcoming meetings

September 2019

26-28  
**Sep**  
2019

## NAFLD Summit 2019

**EASL meetings**  
Sevilla, Spain

SPONSORSHIP  
OPPORTUNITIES

October 2019

## EASL - AASLD ALD Endpoints

**EASL meetings**  
USA

05-06  
**Oct**  
2019

December 2019

05-07  
**Dec**  
2019

## EASL-AASLD Masterclass

**EASL Courses, Schools & Masterclasses**  
Amsterdam, Netherlands

January 2020

## Viral Hepatitis

**EASL meetings**  
Athens, Greece

23-25  
**Jan**  
2020

February 2020

**Feb**  
2020

## Liver Cancer Summit 2020

**EASL meetings**  
Prague, Czech Republic

SPONSORSHIP  
OPPORTUNITIES

**EASL**

## EASL Governing Board

EASL

### Secretary General



**Prof. Tom Hemming  
Karlsen**  
*Oslo, Norway*

### Vice-Secretary



**Prof. Philip N. Newsome**  
*Birmingham, United Kingdom*

### Treasurer



**Prof. Mauro Bernardi**  
*Bologna, Italy*

## Scientific committee members



**Prof. Annalisa Berzigotti**  
*Bern, Switzerland*



**Prof. Markus Cornberg**  
*Hannover, Germany*



**Prof. Marco Marziani**  
*Ancona, Italy*



**Prof. Pierre-Emmanuel Rautou**  
*Paris, France*



**Prof. Maria Reig**  
*Barcelona, Spain*

## Educational councillors



**Prof. Ulrich Beuers**  
*Amsterdam, Netherlands*



**Prof. Massimo Pinzani**  
*London, United Kingdom*

EASL

## EU policy councillor



**Prof. Helena Cortez-Pinto**  
*Lisbon, Portugal*

## ILC 2019 Honorary President



**Prof. Dominique-Charles Valla**  
*Clichy, France*

# 2-day postgraduate course

on end stage liver disease

Wednesday 10, 11:30-17:30  
Thursday 11, 08:30-12:00



Download  
the app



Share your opinion



Take part in our  
interactive  
session



## AWARDS

## EASL award ceremonies

EASL

### Friday 12 April

Main plenary, 08:30-10:30

#### Award ceremony I

EASL recognition awards

### Saturday 13 April

Main plenary, 10:00-12:00

#### Award ceremony II

EASL registry grants  
 EASL Post-graduate fellowship Sheila Sherlock  
 EASL PhD studentship Juan Rodes  
 EASL Daniel Alagille Award  
 Best basic and best clinical oral abstract awards  
 Best poster presentation awards  
 EASL Young Investigator Awards  
 PSC Partners' Award

## EASL recognition awards 2019

EASL introduced the recognition award to acknowledge the men and women who are writing the history of EASL. The awards are our way of saying 'Thank You' to the scientists in the liver research field who dedicate their lives and careers to hepatology by providing major scientific contributions.

EASL's annual award recognises the outstanding contribution of an individual to liver disease care and research in Europe. The following awards will be presented during the award ceremony I, Friday 12 April in the main plenary:



**Flair José Carrilho**  
*São Paulo, Brasil*



**Deidre Kelly**  
*Birmingham, United Kingdom*



**Vincenzo Mazzaferro**  
*Milano, Italy*

## EASL Post-graduate fellowship Sheila Sherlock



**Ingrid Wei Zhang**  
*Germany*

Acute-on-chronic liver failure:  
Evaluation of the role of mitochondria  
in disease etiology and experimental  
treatment of mitochondrial dysfunction



**Gloria Álvarez-Sola**  
*Spain*

Function of sulfatides in the bile duct,  
and biomarker potential of sulfatides and  
5-cyprinolsulfate in PSC.

EASL

## EASL PhD Studentship Juan Rodés



**Sonia Emilia Selicean**  
*Romania*

Inhibition of the stiffness-derived  
molecular axis to improve liver cirrhosis  
and portal hypertension



**Teresa Brevini**  
*Italy*

Generation of human-sized  
bio-engineered bile ducts using  
primary cholangiocyte organoids and  
biological scaffolds

## EASL Daniel Alagille Award

EASL



**André A. Santos**

*Portugal*

Targeting miR-21 in PSC-IBD patients

## EASL Young Investigator Award

The EASL YI Award is a yearly award specifically dedicated to young fellows. Every year, the EASL Governing Board and YI Task Force select two YI Awardees based on their international liver research achievements to-date.



**Martin Guilliams**

*Belgium*



**Virginia Hernandez-Gea**

*Spain*

## EASL 2019 mentorship programme

EASL

### MENTEES



**Andrés Conthe**  
*Spain*

Gregorio Marañón Hospital



**Coskun Ozer Demirtas**  
*Turkey*

Ege University,  
School of Medicine

### MENTORS



**Maurizia Rossana Brunetto**  
*Italy*

Adjunct Professor of Internal Medicine at the University Pisa and Director of the Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital



**Thomas Berg**  
*Germany*

Head of the Section of Hepatology at the University Hospital in Leipzig

**NEW**

# Hepatology **Arena**

## **4 sessions**

- + Pros and cons
- + Solve the case
- + Critical reflection on a landmark paper
- + Grand rounds

**Including an EASL Symposium:**

Transplant oncology from 2019 to 2025


**Get into the action!**

# SCIENTIFIC PROGRAMME OVERVIEW

## What's your colour?

Scientific content is presented in a way that enables you to make informed choices on sessions of interest. The programme indicates specialties, fields and session types.

### Specialties



## Fields



Scientific programme overview

## Additional icons of interest



## Scientific highlights

### Brand new this year

Scientific  
programme  
overview

#### Livestream

ILC2019 goes live! Get the latest advances in hepatology and liver research! Over 100, free of access, scientific sessions available on the ILC mobile app and congress website for you to watch live.



#### Solve the case

##### Saturday 13 & Sunday 14 April

##### See page 58 for daily programme

Discussion based session where two challenging cases are presented. Based on three questions related to the case, the chairs will lead the discussion between the presenters and the audience. This session will take place in the new Hepatology arena.

#### Pros and cons

Key issues will be discussed in a debate format with experts from both sides. This session will take place in the new Hepatology arena.

#### Skills Learning Centre (SLC) / skills in hepatology

Hands-on practical activities every day **Wednesday to Friday in the Skills Learning Centre (SLC) in Hall B**. Delegates will meet in small groups to look, learn, ask questions, and test material used for procedures under the tutelage of experts in the field. This activity is presented in a relaxed and friendly atmosphere during which delegates can talk with experts and ask an array of questions related to the practice of interventions in patients with liver disease.

Skills in hepatology sessions are aimed at increasing the awareness of diagnostic and therapeutic techniques and offer delegates the possibility of examining their knowledge and skills.

## Session format description

### Basic science seminar

**Wednesday 10 April, 11:30-17:30**

**Thursday 11 April, 08:30-12:00**

The basic science seminar aims to foster interaction with the audience and is organised like a workshop, with no classical lectures. The purpose of this seminar is to attract more people from the basic science field and to discuss specific topics where invited speakers have the opportunity not only to present their success stories, but also failures, generating a lively and informative discussion.

A second objective is to showcase Young Investigator presentations selected by the invited speaker (typically one of their fellows).

The usual format is as follows:

- 10-minute presentation by a Senior Speaker (lecture format)
- 10-minute presentation by a Young Investigator (abstract format)
- 10-minute discussion

This year's basic science seminar is on **Liver immunology and immunotherapy**.

### Basic science highlights

**Friday 12 April, 11:30-12:30**

This session runs in parallel to the Grand Rounds and offers a basic science alternative where speakers present selected publications on a current research topic. This year's basic science seminar is on **Single cell sequencing approaches in experimental hepatology**.

### Breakfast morning rounds

**Friday 12 & Sunday 14 April, 07:30-08:20**

Come and enjoy a coffee during the breakfast morning rounds. With four breakfast morning rounds per day in plenary halls, you will have no problem finding a case of interest to you.

KOLs will attend with junior peers to present a case and to replicate activities that take place at hospital rounds. A panel of 3 to 4 experts is invited to interact and provide an external view to each case which will undoubtedly animate the discussions.

No pre-registration is required. Free sessions open to all.

## Critical reflection on landmark papers 2018

**Friday 12 April, 16:00-18:00**

A chair will select four recent publications on hot topics and invite the authors to present and discuss with the audience. A specialist from the field will be invited to discuss and debate the paper with the author.

## Fellowships and registry grants

**Thursday 11 April, 12:00-13:30**

EASL Fellowship awardees and Registry Grant recipients are invited to present their research and findings made possible thanks to the funding provided by EASL.

## Grand rounds

**Friday 12 April, 11:30-12:30**

Senior members of major European institutions will present an interesting or challenging case together with a junior member of his/her team. Each case presented will represent a challenge of broad interest to the audience and aims to nurture discussions. A co-chair from another institution will be present with the intention of animating the debate. The objective is to foster interaction with a broad audience of clinicians through lively discussion and live polling of the audience around interesting clinical cases.

## Meet the experts

**Thursday 11 to Sunday 14 April**

An ideal opportunity to meet with some of the biggest names in hepatology in a face-to-face interactive setting. Invited experts will provide answers to challenging questions in 36 separate informal workshops covering all major hepatology topics.

### **Gain time with a fast-track ticket!**

If you didn't book a fast-track ticket during your online registration, you can get one on-site at the registration desk located in Foyer D (limited number of tickets). Please note that your fast-track ticket won't be accepted after the session has started.

Didn't manage to get a fast track ticket before the session? You still have the chance to get in on a first come first serve basis up to five minutes after the beginning of the session.

## Nurses and Allied Health Professionals forum

**Friday 12 April, 10:00-11:30 & 13:30-15:00**


The lectures will address the specific needs of this target group.

Come and meet the EASL Nurses and Allied Health Professionals Task Force at the end of the session!

## Postgraduate course

**Wednesday 10 April, 11:30-17:30**

**Thursday 11 April, 08:30-12:00**



The postgraduate course highlights many clinical practice dilemmas and engages the audience with world-renowned experts on how to make the best management decisions to help patients with liver disease.

A printed course syllabus will be distributed at the entrance of the main plenary hall and made available in PDF format on the congress website.

The postgraduate course is divided into five sessions. During each session, a case is presented. Live voting will be available, and the audience will be able to reply to questions from chairs through the ILC 2019 mobile app.

This year's postgraduate course will discuss **end stage liver disease** and specialists will provide their input on the presented cases.

## Research think tanks

**Wednesday 10 April, 08:00-11:00**

Stimulate your brain at one of the EASL research think tanks through collaborative participation with invited groups. EASL will facilitate discussions between topically related organisations and/or consortia enabling highly interactive sessions focusing on emerging or developing research trends. Wednesday morning workshops will be divided into two sessions; a first session of 90 minutes with 3-4 speakers/experts followed by a coffee break then a 60-minute interactive panel discussion.

No registration required, just drop by!

## State-of-the-art lectures

**Thursday 11 April, 12:00-12:30**

**Friday 12 April, 10:30-11:00**

**Saturday 13 April, 12:00-12:30**

There are three 30-minute lectures (one clinical and one basic) running without sessions in parallel. Come and see the new translational state-of-the-art lecture on **cell therapy for advanced liver disease**, Thursday at the end of the postgraduate course.

## Symposia

**Friday 12 and Saturday 13 April, 14:00-15:30**

**Sunday 14 April, 10:30-11:30**

Symposia belonging to the educational sessions of the congress programme will provide the audience with a comprehensive, updated, and balanced summary of the diagnostic, prognostic, and therapeutic procedures related to the relevant topics.

## Abstract presentations

### Oral presentations

#### General/parallel and late-breaker sessions

Presentations based on selected abstracts.

### Poster presentations

EASL offers abstract presentations in both paper poster and electronic (ePoster) formats.

#### Poster reception

Meet poster presenters around drinks and food in the poster area (Hall B – exhibition area) on Thursday 11 April from 17:30-18:30.

## Paper posters

EASL will present the latest scientific data in the field on boards in Hall B, from Thursday 11 to Saturday 13 April, between 09:00-17:00.

There will be over 1,500 posters on display over three days. Visit the poster area to see the new data!

**Late-breaker abstracts** An entire row of poster boards will be dedicated to late-breaker abstracts. These will be on display from Thursday 11 to Saturday 13 April and will not change.

View page 20 for poster area opening hours.

## Poster tours



During lunch and coffee breaks, Key Opinion Leader (KOL) guides will tour the poster area (Hall B) with a group of 30 delegates to showcase 3-4 **selected** paper posters and discuss them with the respective presenters.

Different tours will be scheduled, allowing 2-3 tours per break. Find out more about the tour topics, tour guides and **selected** posters in the poster tour schedule below.

To join a tour, come to the meeting point corresponding to the tour in front of the poster help desk (Hall B) at the beginning of the break.

## Poster tour schedule

Thursday 11 April	Friday 12 April	Saturday 13 April
10:00-10:30	11:00-11:30	–
12:30-13:00	12:30-13:00	13:00-14:00
15:30-16:00	15:30-16:00	15:30-16:00

## ePosters

All electronic posters (ePosters) are available **throughout the congress** from Wednesday to Sunday, on multiple dedicated plasma screens and simultaneously on the ILC 2019 mobile app and the ePoster platform.

### Oral ePoster sessions



Selected posters will be presented in the four pods in the paper poster area in Hall B on **Thursday, Friday and Saturday** followed by questions from the audience. Oral ePoster sessions last from 30 minutes to one hour each and are provided in a very informal set-up allowing you to come and go as you please.

There will be several oral ePoster sessions to attend on three consecutive days during coffee and lunch breaks. See schedule below:

### Schedule

Thursday 11 April	Friday 12 April	Saturday 13 April
10:00-10:30	11:00-11:30	–
12:00-13:00	12:30-13:30	13:00-14:00
15:30-16:00	15:30-16:00	15:30-16:00



**The overarching aim of LITMUS is to develop, robustly validate and advance towards regulatory qualification biomarkers that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage.**

Discover more on [litmus-project.eu](http://litmus-project.eu)



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777377. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. IMI.

## Daily programme at a glance

Scientific  
programme  
overview

08:00-08:30	<b>RESEARCH THINK TANK</b> ■ <b>Lehar 3</b> Factors aggravating portal hypertension
08:30-09:00	■ <b>Lehar 1</b> EASL Regenerative Hepatology ■ <b>Strauss 3</b> Autoimmune and cholestatic liver diseases
09:00-09:30	■ <b>Strauss 1-2</b> Chronic liver failure ■ <b>Hall C1</b> Liver tumours
09:30-10:00	■ <b>Main Plenary</b> NAFLD ■ <b>Lehar 4</b> Alcoholic liver disease
10:00-10:30	■ <b>Hall C3</b> Viral Hepatitis: vaccines and prison ■ <b>Hall C2</b> Hepatitis B cure
10:30-11:00	■ <b>Lehar 2</b> Addressing drug user health to achieve HCV elimination
11:00-11:30	
11:30-12:00	
12:00-12:30	<b>POSTGRADUATE COURSE</b> ■ <b>Main Plenary</b> End stage liver disease
12:30-13:00	Diagnosis of cirrhosis and portal hypertension: non-invasive or invasive tests?
13:00-13:30	
13:30-14:00	Lunch 
14:00-14:30	<b>POSTGRADUATE COURSE</b> ■ <b>Main Plenary</b> End stage liver disease
14:30-15:00	Bleeding and thrombosis
15:00-15:30	
15:30-16:00	Coffee break 
16:00-16:30	<b>POSTGRADUATE COURSE</b> ■ <b>Main Plenary</b> End stage liver disease
16:30-17:00	Cirrhosis and comorbidities
17:00-17:30	
17:30-18:00	
18:00-18:30	
18:30-19:00	<b>INDUSTRY SYMPOSIA</b>
19:00-19:30	

# Wednesday 10 April 2019

 Scientific  
programme  
overview

<b>SKILLS IN HEPATOLOGY</b> <b>■ Hepatology Arena</b> Liver tumour board	08:00-08:30
	08:30-09:00
	09:00-09:30
Coffee break 	09:30-10:00
<b>SKILLS IN HEPATOLOGY</b> <b>■ Hepatology Arena</b> Vascular liver disease board	10:00-10:30
	10:30-11:00
<b>BASIC SCIENCE SEMINAR</b> <b>■ Hall C3</b> Liver immunology and immunotherapy Liver immunology	11:00-11:30
	11:30-12:00
	12:00-12:30
	12:30-13:00
Lunch 	13:00-13:30
	13:30-14:00
<b>BASIC SCIENCE SEMINAR</b> <b>■ Hall C3</b> Liver immunology and immunotherapy From discovery to therapy	14:00-14:30
	14:30-15:00
	15:00-15:30
Coffee break 	15:30-16:00
<b>BASIC SCIENCE SEMINAR</b> <b>■ Hall C3</b> Liver immunology and immunotherapy Liver inflammation and immune-oncology	16:00-16:30
	16:30-17:00
	17:00-17:30
<b>SKILLS LEARNING CENTRE</b> <b>■ SLC 1</b> US simulators Vascular liver disease and focal liver lesion	17:30-18:00
	18:00-18:30
	18:30-19:00
	19:00-19:30

## Daily programme at a glance

Scientific  
programme  
overview

07:30-08:00			
08:00-08:30			
08:30-09:00	<b>POSTGRADUATE COURSE</b> ■ <b>Main Plenary</b> End stage liver disease Managing bacterial infections and impaired renal function	<b>BASIC SCIENCE SEMINAR</b> ■ <b>Hall C3</b> Liver immunology and immunotherapy Exploiting adaptive and innate immune mechanisms	<b>EIFL SYMPOSIUM</b> ■ <b>Lehar 4</b> Liver Disease in Africa
09:00-09:30			
09:30-10:00			
10:00-10:30	Coffee break 		
10:30-11:00	<b>POSTGRADUATE COURSE</b> ■ <b>Main Plenary</b> End stage liver disease HE and ACLF in end-stage liver disease	<b>BASIC SCIENCE SEMINAR</b> ■ <b>Hall C3</b> Liver immunology and immunotherapy Disease applications: Viral hepatitis and cancer, cholestasis and fatty liver disease	
11:00-11:30			
11:30-12:00			
12:00-12:30	<b>TRANSLATIONAL STATE OF THE ART LECTURE</b> ■ <b>Main Plenary</b> Cell therapy in advanced liver disease	■ <b>Hall C1</b> EASL Public Health Session: Influencing food and alcohol policy to reduce liver disease ■ <b>Hall C2</b> Data management in registries ■ <b>Lehar 2</b> EASL Fellowship presentations ■ <b>Lehar 3</b> Gender related topics in Hepatology	
12:30-13:00	Lunch 	<b>EASL-ESCMID SYMPOSIUM</b>	
13:00-13:30		■ <b>Strauss 3</b> New diagnostic markers in viral hepatitis <b>EASL-CDC SYMPOSIUM</b> ■ <b>Lehar 4</b> Best Practices in HCV Elimination <b>PROS &amp; CONS SESSION</b> ■ <b>Hepatology Arena</b> NASH does not alter a patient's natural history – only fibrosis does	
13:30-14:00			
14:00-14:30	■ <b>Main Plenary</b>		
14:30-15:00	<b>GENERAL SESSION I AND OPENING CEREMONY</b>		
15:00-15:30			
15:30-16:00	<b>ORAL ePOSTER</b> ■ ■ ■		
16:00-16:30	<b>PARALLEL SESSIONS</b>		
16:30-17:00	■ <b>Lehar 1</b> Liver disease immunology ■ <b>Lehar 2</b> Mechanism of regeneration response to injury ■ <b>Hall C2</b> Autoimmune and cholestasis I		
17:00-17:30	■ <b>Hall C3</b> Portal Hypertension – Refining risk stratification and therapy ■ <b>Lehar 3</b> Liver tumours – Experimental		
17:30-18:00	■ <b>Hall C1</b> NAFLD Pathophysiology – Target identification ■ <b>Strauss 1-2</b> NAFLD – Clinical burden natural history ■ <b>Main Plenary</b> Hepatitis B/D/E – Clinical aspects		
18:00-18:30			
18:30-19:00			
19:00-19:15	<b>INDUSTRY SYMPOSIA</b>		
19:15-19:30			
19:30-20:00			
19:30-20:00			

## Thursday 11 April 2019

Scientific  
programme  
overview

<b>SKILLS LEARNING CENTRE</b> ■ <b>SLC 1</b> US simulators: Vascular liver disease and focal liver lesion		07:30-08:00 08:00-08:30
<b>MEET THE EXPERTS</b> ■ <b>Stolz 2</b> Wilson's disease ■ <b>Stolz 1</b> Is screening for HCC recurrence cost-effective after liver transplantation. Do we need to perform HCC screening after liver transplantation?		08:30-09:00 09:00-09:30 09:30-10:00
<b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Exercise or diet – which is best for NAFLD ■ <b>Stolz 2</b> Hepatitis C: What are the remaining difficult to treat patients and how to manage them?		<b>ORAL ePOSTER</b> ■ ■ ■ <b>POSTER TOUR</b> ■ ■ ■
<b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Preventing long-term complications in OLT ■ <b>Stolz 2</b> JHEP reports – Meet the new editorial team		10:30-11:00 11:00-11:30
<b>MEET THE EXPERTS</b> ■ <b>Stolz 2</b> Animal models of liver disease ■ <b>Stolz 1</b> How to decide for resection versus other therapies in HCC?		<b>ORAL ePOSTER</b> ■ ■ ■ <b>POSTER TOUR</b> ■ ■ ■
		<b>ELPA SYMPOSIUM 2019 NAFLD AND NASH FROM PATIENT PERSPECTIVE</b> ■ <b>Strauss 1-2</b> What are the patient problems?
		11:30-12:00 12:00-12:30 12:30-13:00
		13:00-13:30
		13:30-14:00 14:00-14:30 14:30-15:00 15:00-15:30
<b>POSTER TOUR</b> ■ ■ ■		15:30-16:00
<b>MEET THE EXPERTS</b> ■ <b>Stolz 2</b> Artificial intelligence in hepatology – where are the applications? ■ <b>Stolz 1</b> Local therapies in HCC		<b>SYMPOSIUM</b> ■ <b>Hepatology Arena</b> Transplant oncology from 2019 to 2025 ■ <b>Strauss 3</b> Cascade of care towards elimination of VH ■ <b>Lehar 4</b> Launch of EILF centre of excellence in VH elimination in Georgia
<b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Renal dysfunction in the cirrhotic patient ■ <b>Stolz 2</b> How to manage the chronic hepatitis Delta?		16:00-16:30 16:30-17:00 17:00-17:30 17:30-18:00
<b>SKILLS LEARNING CENTRE</b> ■ <b>SLC 1</b> Diagnostic ultrasound and elastography in hepatology		18:00-18:30 18:30-19:00 19:00-19:15
<b>SKILLS LEARNING CENTRE</b> ■ <b>SLC 1</b> Diagnostic ultrasound and elastography in hepatology		19:15-19:30 19:30-20:00
■ <b>SLC 2</b> Invasive diagnostics methods		
■ <b>SLC 2</b> Invasive diagnostics methods		

## Daily programme at a glance

Scientific  
programme  
overview

07:30-08:00	<b>BREAKFAST MORNING ROUNDS</b>	
08:00-08:30	<ul style="list-style-type: none"> <li>■ <b>Lehar 3</b> Differential diagnosis of hyperferritinemia in patients with liver disease</li> <li>■ <b>Lehar 2</b> HCC therapy: When to use locoregional or systemic therapy and when to switch?</li> </ul>	
08:30-09:00	<ul style="list-style-type: none"> <li>■ <b>Main Plenary</b> <b>GENERAL SESSION II AND AWARD CEREMONY I</b></li> </ul>	
09:00-09:30		
09:30-10:00		
10:00-10:30		
10:30-11:00	<b>CLINICAL STATE-OF-THE-ART</b> <ul style="list-style-type: none"> <li>■ <b>Main Plenary</b> Jean-Pierre Benhamou clinical state-of-the-art: Shared mechanisms in cholestatic and fatty liver disease – implications for current and future treatment</li> </ul>	
11:00-11:30		
11:30-12:00	<b>GRAND ROUNDS</b> <ul style="list-style-type: none"> <li>■ <b>Strauss 1-2</b> Management of puritus</li> <li>■ <b>Hall C3</b> Managing alcohol addiction and alcohol-related complications in patients with cirrhosis</li> <li>■ <b>Hepatology Arena</b> Diagnostic tools for hepatocolangiocarcinoma: How do we manage these patients?</li> <li>■ <b>Main Plenary</b> When to evaluate patients with NASH for HCC</li> <li>■ <b>Hall C2</b> Expect the unexpected: HBV reactivation</li> </ul>	<b>OCCUPATIONAL MEDICINE AND HEPATOLOGY</b> <ul style="list-style-type: none"> <li>■ <b>Lehar 1</b> <b>YOUNG INVESTIGATORS SEMINAR</b></li> <li>■ <b>Lehar 2</b> Critical thinking in science</li> <li>■ <b>BASIC SCIENCE HIGHLIGHTS</b></li> <li>■ <b>Lehar 3</b> Single cell sequencing approaches in experimental hepatology</li> </ul>
12:00-12:30		
12:30-13:00		
13:00-13:30	 <b>EASL GENERAL ASSEMBLY</b> <b>Members only – Strauss 3</b>	Lunch 
13:30-14:00		

# Friday 12 April 2019

Scientific programme overview

<p>■ <b>Lehar 4</b> Immune mediated hepatitis related to the new oncological therapies</p> <p>■ <b>Strauss 3</b> Hepatitis Delta: how to manage? Are new therapies on the horizon?</p>	07:30-08:00
	08:00-08:30
	08:30-09:00
	09:00-09:30
	09:30-10:00
	10:00-10:30
	10:30-11:00
<p><b>NURSES AND ALLIED HEALTH PROFESSIONALS FORUM</b></p>	
<p>■ <b>Lehar 2</b> Case study session: Acute alcoholic hepatitis</p>	
<p><b>EASL-WHO SYMPOSIUM</b></p>	<p><b>ORAL ePOSTER POSTER TOUR</b></p>
<p>■ <b>Lehar 4</b> Promoting access to DAAs for children and adolescents and experience of use in pregnant women</p>	11:00-11:30
<p>■ <b>Hall C1 HOT TOPICS IN LIVER TRANSPLANTATION</b> Part I Preparing for the drastic changes in transplant medicine: Donor and recipient aging and co-morbidities</p>	<p><b>MEET THE EXPERTS</b></p> <p>■ <b>Stolz 2</b> Management of coagulation changes in patients with liver disease undergoing an invasive procedure</p> <p>■ <b>Stolz 1</b> Multidisciplinary approach for management of alcohol related liver disease</p>
	11:30-12:00
	12:00-12:30
<p><b>ORAL ePOSTER</b></p>	<p><b>POSTER TOUR</b></p>
	12:30-13:00
	13:00-13:30
	13:30-14:00

Continued on the next page >>>

## Daily programme at a glance (*cont.*)

Scientific  
programme  
overview

14:00-14:30	<b>SYMPOSIA</b> <b>Lehar 3</b> Liver disease in pregnancy <b>Main Plenary</b> Albumin therapy in advanced liver disease – From plasma expander to pleiotropic agent	<b>PROS &amp; CONS SESSION</b> <b>Hepatology Arena</b> Issues in the radiological evaluation of advanced hepatocellular carcinoma
14:30-15:00	<b>EASL-APASL SYMPOSIUM</b> <b>Hall C3</b> Recognising and managing the lean NAFLD patient <b>EASL-ECDC SYMPOSIUM</b> <b>Lehar 4</b> Using real world data to inform Hepatitis B and C elimination strategies	
15:00-15:30	<b>FUSION HEPATOLOGY AROUND THE WORLD</b> <b>Strauss 1-2</b> HCC – Special consideration in HBV infection <b>EASL-ESMO SYMPOSIUM</b> <b>Lehar 1</b> Multidisciplinary approach of Cholangiocarcinoma. From Diagnosis to treatment according to patient profile	<b>PROS &amp; CONS SESSION</b> <b>Hepatology Arena</b> Patients with immunotolerant HBeAg positive infection should/should not be treated
15:30-16:00	Coffee break 	
16:00-16:30	<b>PARALLEL SESSIONS</b> <b>Strauss 3</b> Autoimmune and cholestasis II <b>Hall C3</b> Cirrhosis - Clinical aspects <b>Lehar 3</b> Liver fibrosis	
16:30-17:00	<b>Lehar 4</b> Acute and acute-on-chronic liver failure – Translational aspects <b>Strauss 1-2</b> Liver cancer – From Prognosis to locoregional treatments	
17:00-17:30	<b>Main Plenary</b> NAFLD – Clinical Therapy <b>Hall C2</b> Hepatitis B – Drug development	
17:30-18:00		
18:00-18:30		
18:30-19:00		
19:00-19:15	<b>INDUSTRY SYMPOSIA</b>	
19:15-19:30		
19:30-20:00		

## Friday 12 April 2019

Scientific  
programme  
overview

<b>NURSES AND ALLIED HEALTH PROFESSIONALS FORUM</b> <b>Lehar 2</b> Adding value – the role of specialist liver nurses and Allied Health Professionals	<b>Hall C1 HOT TOPICS IN LIVER TRANSPLANTATION</b> Part II Innovative strategies to increase the donor pool: Living donor liver transplant, split liver transplant, DCD	<b>MEET THE EXPERTS</b> <b>Stolz 1</b> Hepatic encephalopathy <b>Stolz 2</b> Management of immunosuppression in AIH	14:00-14:30
			14:30-15:00
			15:00-15:30
	<b>ORAL ePOSTER</b> 	<b>POSTER TOUR</b> 	15:30-16:00
<b>Hepatology arena</b> Critical reflection on landmark papers 2018 <b>Lehar 1</b> Complementarity of academia and industry in viral hepatitis elimination strategies	<b>Hall C1 HOT TOPICS IN LIVER TRANSPLANTATION</b> Part III Multidisciplinary peri-transplant management of advanced liver diseases: Critical care in transplantation	<b>MEET THE EXPERTS</b> <b>Stolz 1</b> Cell therapy for liver disease <b>Stolz 2</b> Endoscopic versus surgical bariatric approaches as interventions for NAFLD	16:00-16:30
			16:30-17:00
		<b>MEET THE EXPERTS</b> <b>Stolz 1</b> Targeted therapies in genetic errors of metabolism <b>Stolz 2</b> Management of symptoms of PBC	17:00-17:30
			17:30-18:00
			18:00-18:30
<b>SKILLS LEARNING CENTRE</b> <b>SLC 1</b> Diagnostic ultrasound and elastography in hepatology <b>SLC 2</b> Invasive diagnostics methods			18:30-19:00
			19:00-19:15
<b>SKILLS LEARNING CENTRE</b> <b>SLC 1</b> Diagnostic ultrasound and elastography in hepatology <b>SLC 2</b> Invasive diagnostics methods			19:15-19:30
			19:30-20:00

## Daily programme at a glance

08:00-08:30	<b>PARALLEL SESSIONS</b>	
	■ <b>Strauss 1-2</b> Non-invasive assessment of liver disease	
08:30-09:00	■ <b>Strauss 3</b> Clinical developments in rare liver disease	
	■ <b>Lehar 3</b> Liver transplantation I	
09:00-09:30	■ <b>Hall C3</b> Cirrhosis – Experimental aspects	
	■ <b>Hall C2</b> Liver cancer – Systemic treatment and immunotherapy	
	■ <b>Hall C1</b> NAFLD – Preclinical pipeline	
09:30-09:45	■ <b>Lehar 2</b> Gut-Liver Axis	
	■ <b>Lehar 4</b> Alcohol related liver disease	
	■ <b>Main Plenary</b> Hepatitis C – Treatment and resistance	
	■ <b>Lehar 1</b> Translational virology	
09:45-10:00		
10:00-10:30		
10:30-11:00		
11:00-11:15	■ <b>Main Plenary</b>	
11:15-11:30	<b>GENERAL SESSION III AND AWARD CEREMONY II</b>	
11:30-12:00		
	<b>BASIC STATE-OF-THE-ART</b>	
12:00-12:30	■ <b>Main Plenary</b> Karl Wilhelm von Kupffer basic state-of-the-art: The power of ONE: Immunology in the age of single cell genomics	
12:30-13:00		
13:00-13:30	<b>INDUSTRY SYMPOSIA</b>	
13:30-14:00		
	<b>SYMPOSIUM</b>	<b>PROS &amp; CONS SESSION</b>
14:00-14:30	■ <b>Lehar 3</b> Bioartificial livers, cell therapies and tissue engineering – The future of regenerative hepatology?	■ <b>Hepatology Arena</b>
	■ <b>Main Plenary</b> Patient prioritization for HCC treatment	Prolonged antibiotic prophylaxis in patients with cirrhosis is harmful?
14:30-15:00	■ <b>Hall C3</b> Multidisciplinary approaches to the management of NAFLD	
	<b>EASL-ALEH SYMPOSIUM</b>	
	■ <b>Hall C2</b> DILI	
	<b>EASL-WHO SYMPOSIUM</b>	
15:00-15:30	■ <b>Strauss 1-2</b> Best practices and lessons learned from global viral hepatitis scale-up	
15:30-16:00		
16:00-16:30	<b>SOLVE THE CASE</b>	
16:30-17:00	■ <b>Hepatology Arena</b> Cholestasis and Autoimmune	
17:00-17:30	<b>SOLVE THE CASE</b>	
17:30-18:00	■ <b>Hepatology Arena</b> Advanced liver disease	

## Saturday 13 April 2019

Scientific  
programme  
overview

<b>SOLVE THE CASE</b> ■ <b>Hepatology Arena</b> NASH		<b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Kidney failure after liver transplantation ■ <b>Stolz 2</b> When to use TIPS in cirrhosis		08:00-08:30
				08:30-09:00
				09:00-09:30
<b>MEET THE EXPERTS</b> ■ <b>Stolz 2</b> New MRI contrast agents in the diagnosis and staging of liver tumours ■ <b>Stolz 1</b> Hepatitis B: When to stop NA therapy?				09:30-09:45
				09:45-10:00
				10:00-10:30
				10:30-11:00
				11:00-11:15
				11:15-11:30
				11:30-12:00
				12:00-12:30
		<b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Assessing patients with NASH for transplantation ■ <b>Stolz 2</b> Hepatitis B: Which new drugs are in development and how do they work?		12:30-13:00
<b>ORAL ePOSTER</b> ■ ■ ■ ■ ■	<b>POSTER TOUR</b> ■ ■ ■ ■ ■			13:00-13:30
		<b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Bile duct strictures in PSC: observation or intervention? ■ <b>Stolz 2</b> Gut microbiota and liver disease – where are the therapeutic opportunities?		13:30-14:00
<b>YI FUSION</b> ■ <b>Strauss 3</b> Research opportunities for young investigators in biliary diseases		<b>THE BEST OF JHep</b> ■ <b>Lehar 2</b> 2015-2019 <b>YOUNG INVESTIGATORS SEMINAR</b> ■ <b>Lehar 4</b> Hepatology in 2030 <b>FLASH ABSTRACT</b> ■ <b>Pod 1</b> HBV and Pregnancy		14:00-14:30
		<b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Clinical management of polycystic liver disease ■ <b>Stolz 2</b> Weaning of immunosuppression after liver transplantation		14:30-15:00
				15:00-15:30
		<b>ORAL ePOSTER</b> ■ ■ ■	<b>POSTER TOUR</b> ■ ■ ■	15:30-16:00
				16:00-16:30
				16:30-17:00
				17:00-17:30
				17:30-18:00

## Daily programme at a glance

07:30-08:00	<b>BREAKFAST MORNING ROUNDS</b>	
08:00-08:30	<ul style="list-style-type: none"> <li>■ <b>Lehar 4</b> PSC: How is the surveillance? When do we need interventions (ERC), when and how to use UDC? When to consider liver transplantation?</li> <li>■ <b>Lehar 3</b> Cirrhosis and Portal hypertension: When TIPS, when and how Betablocker (propranolol or carvedilol?) and how to monitor?</li> </ul>	
08:30-09:00	<b>PARALLEL SESSIONS</b> <ul style="list-style-type: none"> <li>■ <b>Strauss 3</b> Liver transplantation II</li> <li>■ <b>Strauss 1-2</b> NAFLD – Staging and prognosis</li> </ul>	<b>LIVER DISEASE AND THE COMMUNITY</b> <ul style="list-style-type: none"> <li>■ <b>Lehar 4</b> Part 1: EASL Policy Statements – Alcohol and food</li> </ul>
09:00-09:30		
09:30-10:00		
10:00-10:30	Coffee break 	
10:30-11:00	<b>SYMPOSIA</b> <ul style="list-style-type: none"> <li>■ <b>Lehar 2</b> Preclinical models of NASH: in vitro, in vivo</li> <li>■ <b>Strauss 3</b> Therapy of hepatitis C after DAA failure</li> <li>■ <b>Lehar 3</b> What do you need to know about Hepatitis E</li> </ul>	<b>LIVER DISEASE AND THE COMMUNITY</b> <ul style="list-style-type: none"> <li>■ <b>Lehar 4</b> Part 2: Hepatitis elimination</li> </ul>
11:00-11:30		
11:30-12:00	<ul style="list-style-type: none"> <li>■ <b>Strauss 1-2</b></li> </ul>	
12:00-12:30	<b>ILC 2019 WRAP UP SESSION</b>	
12:30-13:00		

# Sunday 14 April 2019

Scientific  
programme  
overview

<p>■ <b>Lehar 1</b> Extrahepatic manifestation of HCV: Response to DAA and when to use immunosuppression?</p>	07:30-08:00	
<p>■ <b>Lehar 2</b> Hepatitis B: When to start and when to stop Nuc therapy in HBeAg negative patients?</p>	08:00-08:30	
<p><b>SOLVE THE CASE</b> ■ <b>Hepatology Arena</b> Hepatological challenges</p>	<p><b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Portosinusoidal vascular disease: What is there behind this new name? ■ <b>Stolz 2</b> Haemochromatosis</p>	<p>08:30-09:00 09:00-09:30</p>
<p><b>MEET THE EXPERTS</b> ■ <b>Stolz 2</b> Management of gastric varices ■ <b>Stolz 1</b> Management of non response to therapy in PBC patients</p>	<p>09:30-10:00 10:00-10:30</p>	
<p><b>PROS &amp; CONS SESSION</b> ■ <b>Hepatology Arena</b> PBC patients with inadequate response to UDCA: obeticholic acid or bezafibrate?</p>	<p><b>MEET THE EXPERTS</b> ■ <b>Stolz 1</b> Acute liver failure ■ <b>Stolz 2</b> Pharmacotherapy in NAFLD – which endpoints to use in everyday practice?</p>	<p>10:30-11:00 11:00-11:30</p>
<p>11:30-12:00 12:00-12:30 12:30-13:00</p>		



 **EASL**<sup>™</sup>  
The Home of Hepatology

Live Tweeting

Follow @EASLedu  
@EASLnews and  
#LC2019



@EASLnews

**SCIENTIFIC PROGRAMME**  
WEDNESDAY 10 APRIL 2019

## Wednesday 10 April 2019

### Research Think Tank – NAFLD

### Main Plenary

#### Chairs:

Quentin ANSTEE, *United Kingdom*

Laurent CASTERA, *France*

Philip NEWSOME, *United Kingdom*

08:00-08:05

#### Concept and session and unmet needs in NAFLD

Philip NEWSOME, *United Kingdom*

### EU NAFLD consortia-an update

08:05-08:15

#### LITMUS

Quentin ANSTEE, *United Kingdom*

08:15-08:25

#### LiverScreen

Laurent CASTERA, *France*

08:25-08:35

#### Discussion

08:35-08:55

#### Natural history of NAFLD-why the variation?

Mary RINELLA, *United States*

08:55-09:15

#### Non-invasive biomarkers in NAFLD

Quentin ANSTEE, *United Kingdom*

09:15-09:30

#### Discussion

09:30-10:00

#### Coffee break

### This house believes in screening for NAFLD

10:00-10:10

#### Introduction and voting from the audience

10:10-10:20

#### The opening case FOR?

Isabel GRAUPERA, *Spain*

10:20-10:30

#### The opening case AGAINST?

Naveed SATTAR, *United Kingdom*

10:30-10:40

#### Audience questions

10:40-10:45

#### Riposte

Isabel GRAUPERA, *Spain*

10:45-10:50

#### Riposte

Naveed SATTAR, *United Kingdom*

10:50-11:00

#### Audience questions and final vote

## Research Think Tank – Viral Hepatitis – Prevention: Vaccine and prisons

Hall C3



### Chairs:

Francesco NEGRO, *Switzerland*

Alex THOMPSON, *Australia*

Scientific  
programme

### Treatment as prevention: the case for upscaling treatment for hepatitis C in prisons

08:00-08:20 **Modelling the benefit of prison treatment programs for HCV-can we achieve elimination?**

Peter VICKERMAN, *United Kingdom*

08:20-08:40 **Barriers to elimination of hepatitis C in prisons**

Jeffrey LAZARUS, *Spain*

08:40-09:00 **Treatment of hepatitis C in prisons-the view from the Inside**

Alex THOMPSON, *Australia*

09:00-09:30 **Coffee break**

### Perspectives for a vaccine to eliminate hepatitis C

09:30-10:00 **Introduction: the molecular and immunological hurdles**

Ralf BARTENSCHLAGER, *Germany*

10:00-10:30 **What is the most effective approach to a HCV vaccine**

Eleanor BARNES, *United Kingdom*

10:30-11:00 **Panel discussion: shall we test/foresee the use of a vaccine in prisons?**

## Research Think Tank – Liver tumours

Hall C1

### Chairs:

Maria REIG, *Spain*

Augusto VILLANUEVA, *United States*

08:00-08:05 **Welcome and introduction**

### Liver cancer and NAFLD: Is it time to change paradigms?

08:05-08:20 **What is the molecular link between liver cancer and NAFLD?**

Jens MARQUARDT, *Germany*

08:20-08:35 **Does the cancer risk justify surveillance?**

Amit SINGAL, *United States*

08:35-09:00 **Round Table: HCC screening in the NAFLD epidemic**

09:00-09:30 **Coffee break**

### Liver cancer microenvironment: How to leverage immune-cancer interactions

09:30-09:50 **Immune-based therapies beyond advanced HCC**

Bruno SANGRO, *Spain*

09:50-10:10 **Assessment of tumour response under Immune-based therapies**

Jordi RIMOLA, *Spain*

10:10-10:55 **Round Table: Clinical utility of immune-based therapies**

10:55-11:00 **Closing remarks and farewell**

Maria REIG, *Spain*

Augusto VILLANUEVA, *United States*

### Research Think Tank – Hepatitis B cure

Hall C2

#### Chairs:

Markus CORNBERG, *Germany*

Peter REVILL, *Australia*

Fabien ZOULIM, *France*

### HBV cure: the main gaps to overcome

08:00-08:30 **Linking clinical endpoint of cure to novel biomarkers**

Anna LOK, *United States*

08:30-08:45 **Current approaches to accelerate cure? What did we learn from recent studies?**

Thomas BERG, *Germany*

08:45-09:00 **Effect of HBV on infected hepatocytes: how does it impact cure? Is cure possible?**

Jane MCKEATING, *United Kingdom*

09:00-09:30 **Discussion: Is HBV cure possible and how is it defined? Where are the obstacles?**

Thomas BERG, *Germany*

Markus CORNBERG, *Germany*

Anna LOK, *United States*

Mala MAINI, *United Kingdom*

Jane MCKEATING, *United Kingdom*

Peter REVILL, *Australia*

Barbara TESTONI, *France*

Fabien ZOULIM, *France*

09:30-10:00 **Coffee break**

**Discussion-hot topics on HBV cure**

- 10:00-10:15 **How to impact cccDNA kinetics by new treatments ? Do we need cccDNA quantification or epigenetic studies?**  
Barbara TESTONI, *France*
- 10:15-10:30 **How to overcome the defects in innate and adaptive immunity to cure HBV infection ? What are the technical requirements?**  
Mala MAINI, *United Kingdom*
- 10:30-11:00 **Discussion: What are the best concepts to cure HBV? What are the technical requirements? How should we do the studies?**  
Fabien ZOULIM, *France*  
Thomas BERG, *Germany*  
Anna LOK, *United States*  
Mala MAINI, *United Kingdom*  
Jane MCKEATING, *United Kingdom*  
Barbara TESTONI, *France*

Scientific  
programme

**Research Think Tank – Chronic liver failure:  
Newer concepts in the management of patients with  
decompensated cirrhosis**

**Strauss 1-2**

**Chairs:**

Jasmohan S BAJAJ, *United States*  
Paolo CARACENI, *Italy*  
Adrian GADANO, *Argentina*  
Pierre-Emmanuel RAUTOU, *France*

- 08:00-08:05 **Introduction**
- 08:05-08:25 **Finessing the updated natural history of decompensated cirrhosis: clinical stages, acute decompensation and acute-on-chronic liver failure**  
Pere GINÈS, *Spain*
- 08:25-08:50 **New avenues for prevention and treatment of ACLF and mortality**  
Salvatore PIANO, *Italy*
- 08:50-09:10 **Prevention of hepatic encephalopathy: a world of opportunities beyond the usual drugs**  
Debbie SHAWCROSS, *United Kingdom*
- 09:10-09:30 **Discussion**

09:30-10:00 **Coffee break**

10:00-10:20 **Prevention of hospitalizations and early re-admissions in decompensated cirrhosis**  
Elliot TAPPER, *United States*

10:20-11:00 **Discussion**

### Research Think Tank – Autoimmune and cholestatic liver diseases

Strauss 3

**Chairs:**

Emma ANDERSSON, *Sweden*  
Chantal HOUSSET, *France*

#### Part 1: Actual pathophysiological concepts in 15 min

08:00-08:20 **Autoimmune hepatitis**  
Rodrigo LIBERAL, *United Kingdom*

08:20-08:40 **Primary biliary cholangitis**  
Jesus M. BANALES, *Spain*

08:40-09:00 **Primary sclerosing cholangitis**  
Verena KEITEL, *Germany*

09:00-09:20 **IgG4-associated cholangitis**  
Ulrich BEUERS, *Netherlands*

09:20-09:30 **Wrap up**

09:30-10:00 **Coffee break**

**Chairs:**

Verena KEITEL, *Germany*  
Michael TRAUNER, *Austria*

10:00-11:00 **Part 2: Novel therapeutic concepts: Panel discussion**  
Christophe CORPECHOT, *France*  
Christoph SCHRAMM, *Germany*  
Ulrich BEUERS, *Netherlands*

## Research Think Tank – Addressing drug user health to achieve HCV elimination

Lehar 2



### Chairs:

Jason GREBELY, *Australia*  
 Matthew HICKMAN, *United Kingdom*  
 Marco MARZIONI, *Italy*

Scientific  
 programme

- 08:00-08:15 **Enhancing access to health care for people who use drugs**  
 Martin KÅBERG, *Sweden*
- 08:15-08:30 **Why is it critical to integrate care for drug user health and hepatitis C prevention, testing, and treatment?**  
 Matthew HICKMAN, *United Kingdom*
- 08:30-08:45 **How can we address barriers towards the engagement of drug and alcohol practitioners in hepatitis C testing, linkage to care and treatment?**  
 Stacey TROOSKIN, *United States*
- 08:45-09:30 **Panel discussion: Challenges and opportunities for better integration of HCV care within care for substance use**  
 Ricardo BAPTISTA LEITE, *Portugal*  
 Matthew HICKMAN, *United Kingdom*  
 Judy CHANG, *United Kingdom*  
 Martin KÅBERG, *Sweden*  
 Marco MARZIONI, *Italy*  
 Stacey TROOSKIN, *United States*
- 09:30-10:00 **Coffee break**
- 10:00-10:15 **Addressing harm reduction, drug user health and drug policies as key components to enhance hepatitis C prevention and care for people who use drugs**  
 Judy CHANG, *United Kingdom*
- 10:15-10:30 **How can we better engage policy makers to enhance efforts to improve drug user health and hepatitis C prevention and treatment?**  
 Ricardo BAPTISTA LEITE, *Portugal*

- 10:30-11:00 **Panel discussion: How can stakeholders better work together to collectively improve hepatitis C care and drug user health for people who inject drugs?**  
 Ricardo BAPTISTA LEITE, *Portugal*  
 Matthew HICKMAN, *United Kingdom*  
 Judy CHANG, *United Kingdom*  
 Martin KÅBERG, *Sweden*  
 Marco MARZIONI, *Italy*  
 Stacey TROOSKIN, *United States*

## Research Think Tank – Factors aggravating portal hypertension

Lehar 3

### Chairs:

Annalisa BERZIGOTTI, *Switzerland*  
 Sarwa Darwish MURAD, *Netherlands*  
 Emmanuel TSOCHATZIS, *United Kingdom*

- 08:00-08:20 **Non-genetic cofactors and the multiple etiologies impacting on portal hypertension**  
 Guadalupe GARCIA-TSAO, *United States*
- 08:20-08:40 **Genetic factors aggravating progression of liver disease**  
 Mattias MANDORFER, *Austria*
- 08:40-09:00 **Obesity and portal vein thrombosis**  
 Christophe BUREAU, *France*
- 09:00-09:20 **Inflammation and thrombosis**  
 Yacine BOULAFALI, *France*

### 09:30-10:00 Coffee break

- 10:00-11:00 **Discussion: What is the best way to manage co-factors in portal hypertension?**  
 Salvador AUGUSTIN, *Spain*  
 Annalisa BERZIGOTTI, *Switzerland*  
 Yacine BOULAFALI, *France*  
 Christophe BUREAU, *France*  
 Mattias MANDORFER, *Austria*  
 Sarwa Darwish MURAD, *Netherlands*  
 Guadalupe GARCIA-TSAO, *United States*  
 Virginia HERNANDEZ-GEA, *Spain*  
 Emmanuel TSOCHATZIS, *United Kingdom*

## Research Think Tank – Alcoholic liver disease: Screening for early ALD. Advantages and methods

Lehar 4



### Chairs:

Helena CORTEZ-PINTO, *Portugal*  
Sebastian MUELLER, *Germany*

08:00-08:20

### Advantages of screening for ALD: Why and who should we screen?

Maja THIELE, *Denmark*

08:20-08:40

### SALVE histopathology group: a histological scoring and staging of ALD -SALVE score

Carolin LACKNER, *Austria*

08:40-09:00

### Non invasive vs invasive assessment in alcoholic liver disease

Sebastian MUELLER, *Germany*

09:00-09:30

### Discussion

09:30-10:00

### Coffee break

10:00-10:15

### What can we learn about the Natural History of ALD from Registries

Christophe MORENO, *Belgium*

10:15-10:30

### SALVE-Presentation of the registry platform

Philippe MATHURIN, *France*

10:30-11:00

### Discussion

## Skills in hepatology

## Hepatology Arena

08:00-09:30

### Liver tumour board



#### Chair: Fabio PISCAGLIA, *Italy*

Hepatologists: Fabio PISCAGLIA, *Italy* and Maria VARELA, *Spain*

Radiologist: Max SEIDENSTICKER, *Germany*

Surgeon: Pietro MAJNO, *Switzerland*

Pathologist: Luigi TERRACIANO, *Switzerland*

09:30-10:00

### Coffee break

Scientific  
programme

10:00-11:00

**Vascular liver disease board****Chair:** Juan-Carlos GARCIA-PAGAN, *Spain*Hepatologists: Juan-Carlos GARCIA-PAGAN, *Spain* and  
Robert DE KNEGT, *Netherlands*Radiologist: Max SEIDENSTICKER, *Germany*Surgeon: Pietro MAJNO, *Switzerland*Pathologist: Luigi TERRACIANO, *Switzerland*Angiologist: Walter AGENO, *Italy***Research think tank – EASL Regenerative Hepatology:  
Take-off event****Lehar 1****Chairs:**Pedro BAPTISTA, *Spain*Massimo PINZANI, *United Kingdom*

08:30-08:40

**Welcome and introduction of the newly formed EASL Consortium  
for Regenerative Hepatology (in short EASL Regenerative  
Hepatology)**Massimo PINZANI, *United Kingdom*

08:40-09:00

**Development and use of iPSc organoids in liver regenerative  
medicine and disease modelling**Romina FIOROTTO, *United States*

09:00-09:20

**Hepatoblast organoids and hiPSCs derived hepatocytes**Ludovic VALLIER, *United Kingdom*

09:20-09:30

**General Discussion**

09:30-10:00

**Coffee break**

10:00-10:20

**Strategies for Large-scale expansion of adult stem cells for liver  
bio-engineering**Bart SPEE, *Netherlands*

10:20-10:40

**The DELiver project: Runding Regenerative Hepatology with the  
H2020 Program**Pedro BAPTISTA, *Spain*

10:40-10:50

**Regenerative Hepatology: One of the pillars of the EASL  
International Liver Foundation**Massimo COLOMBO, *Italy*

10:50-11:00

**General discussion and conclusions**

## PGC – End stage liver disease

## Main Plenary

**Organisers:**Annalisa BERZIGOTTI, *Switzerland*François DURAND, *France*Pere GINÈS, *Spain***Diagnosis of cirrhosis and portal hypertension: non-invasive or invasive tests?****Chairs:**Tilman SAUERBRUCH, *Germany*Annalisa BERZIGOTTI, *Switzerland*François DURAND, *France*Pere GINÈS, *Spain*Scientific  
programme

11:30-11:35

**Opening and presentation of the PGC**Annalisa BERZIGOTTI, *Switzerland*François DURAND, *France*Pere GINÈS, *Spain*

11:35-11:45

**Presentation of the clinical case and key questions regarding the challenge**Isabel GRAUPERA, *Spain*

11:45-12:05

**Are serum markers and liver stiffness tests sufficient to diagnose cirrhosis?**Laurent CASTERA, *France*

12:05-12:25

**Imaging diagnosis of cirrhosis**Valérie VILGRAIN, *France*

12:25-12:45

**Information provided by liver biopsy in the diagnosis of cirrhosis**Ian WANLESS, *Canada*

12:45-13:05

**Hepatic venous pressure measurement and splanchnic hemodynamics**Virginia HERNANDEZ-GEA, *Spain*

13:05-13:30

**Panel discussion**

13:30-14:00

**Lunch****Bleeding and thrombosis****Chairs:**Jaime BOSCH, *Spain*Annalisa BERZIGOTTI, *Switzerland*

14:00-14:05

**Presentation of the clinical case and key questions regarding the challenge**Mattias MANDORFER, *Austria*

- 14:05-14:20      **Prevention of variceal bleeding and medical management of acute variceal bleeding**  
Juan-Carlos GARCIA-PAGAN, *Spain*
- 14:20-14:35      **When to use TIPS in gastrointestinal bleeding?**  
Karel CACA, *Germany*
- 14:35-14:50      **Coagulation changes in cirrhosis: from bleeding to prothrombotic state**  
Marco SENZOLO, *Italy*
- 14:50-15:05      **Portal vein thrombosis in cirrhosis: who should be treated and how?**  
Erica VILLA, *Italy*
- 15:05-15:30      **Panel discussion**
- 15:30-16:00      **Coffee break**

### Cirrhosis and Comorbidities

#### Chairs:

Frank LAMMERT, *Germany*

François DURAND, *France*

- 16:00-16:05      **Presentation of the clinical case and key questions regarding the challenge**  
Matthew ARMSTRONG, *United Kingdom*
- 16:05-16:20      **Assessment and relevance of sarcopenia and frailty**  
Shira ZELBER-SAGI, *Israel*
- 16:20-16:35      **Cardiovascular comorbidities in cirrhosis: the emerging burden of NASH**  
Josh LEVITSKY, *United States*
- 16:35-16:50      **Management of diabetes in patients with cirrhosis: which treatments, which targets?**  
Chris BYRNE, *United Kingdom*
- 16:50-17:05      **Indications for and access to transplantation in patients with comorbidities**  
Julie HEIMBACH, *United States*
- 17:05-17:30      **Panel discussion**

## Basic Science Seminar – Liver immunology and immunotherapy

Hall C3



### Liver immunology

#### Chairs:

David ADAMS, *United Kingdom*

Andrea SCHIETINGER, *United States*

Robert THIMME, *Germany*

Scientific  
programme

11:30-12:00

### Cellular and molecular basis of immunometabolism

Federica MARELLI-BERG, *United Kingdom*

12:00-12:30

### Intravital microscopy analysis of hepatic T cell dynamics

Matteo IANNAcone, *Italy*

### Intravital microscopy analysis of hepatic T cell dynamics: Fellow presentation

Valeria FUMAGALLI, *Italy*

#### Discussion

12:30-13:00

### A human liver-cell atlas

Dominic GRUEN, *Germany*

### Revealing adult human liver progenitors by single-cell RNA-sequencing

Nadim AIZARANI, *Germany*

#### Discussion

13:00-13:30

### Unconventional liver-resident lymphocytes

Paul KLENERMAN, *United Kingdom*

### Fine needle aspiration of the liver as a method of obtaining cells for immune analysis

Kate LYNCH, *United Kingdom*

#### Discussion

13:30-14:00

### Lunch

**From discovery to therapy****Chairs:**David ADAMS, *United Kingdom*Andrea SCHIETINGER, *United States*Robert THIMME, *Germany*

14:00-14:30

**Microbiome, metabolites and immunity**Christoph THAISS, *United States***Microbiome control of metabolic homeostasis**Lenka DOHNALOVA, *United States***Discussion**

14:30-15:00

**Molecular programs of T cell self-tolerance in the liver**Andrea SCHIETINGER, *United States***Chromatin states defining tumor-specific T cell differentiation and therapeutic reprogrammability**Mary PHILIP, *United States***Discussion**

15:00-15:30

**Epigenetic landscape of T cell exhaustion: lessons for immunotherapy**Georg LAUER, *United States***The impact of antigen removal on the epigenetic landscape of exhausted T cells**Debattama SEN, *United States***Discussion**

15:30-16:00

**Coffee break****Liver inflammation and immune-oncology****Chairs:**David ADAMS, *United Kingdom*Andrea SCHIETINGER, *United States*Robert THIMME, *Germany*

16:00-16:30

**Systemic immunity in cirrhosis**Zeinab ABDULLAH, *Germany***Shut down of T-cell responses during liver fibrosis**Helena HORVATIC, *Germany***Discussion**

16:30-17:00

**Immunotherapy for HCC: principle and perspectives**Pablo SAROBE, *Spain***Combination therapies to overcome resistance to checkpoint inhibitors**Diana LLOPIZ, *Spain***Discussion**

17:00-17:30

**Scavenger receptors as novel targets for HCC immunotherapy**Shishir SHETTY, *United Kingdom***Liver Endothelial Scavenger receptors regulate the immune microenvironment**Daniel PATTEN, *United Kingdom***Discussion**Scientific  
programme**Skills learning centre: US simulators: Vascular liver disease and focal liver lesions****SLC 1****Chairs:**Robert DE KNEGT, *Netherlands*Michael GEBEL, *Germany***Tutors:**Sandra COENEN, *Netherlands*Sarwa Darwish MURAD, *Netherlands*Andrej POTTHOFF, *Germany*Christoph TERKAMP, *Germany*

18:00-19:30

**Industry Symposium**

18:00-19:30

**Please refer to the industry section for more details**

# EASL POSTGRADUATE COURSE END STAGE LIVER DISEASE



Available for download at  
[www.easl.eu](http://www.easl.eu)

**SCIENTIFIC PROGRAMME**  
THURSDAY 11 APRIL 2019

# Thursday 11 April 2019

## Industry Symposium

07:30-08:30

**Please refer to the industry section for more details**Scientific  
programme

## Skills learning centre: US simulators: Vascular liver disease and focal liver lesions

SLC 1



### Chairs:

Robert DE KNEGT, *Netherlands*Michael GEBEL, *Germany*

### Tutors:

Sandra COENEN, *Netherlands*Sarwa Darwish MURAD, *Netherlands*Andrej POTTHOFF, *Germany*Christoph TERKAMP, *Germany*

07:30-08:30

## PGC-End stage liver disease

Main Plenary

### Managing bacterial infections and impaired renal function

#### Chairs:

Manuela MERLI, *Italy*Pere GINÉS, *Spain*

08:30-08:40

#### **Presentation of the clinical case and key questions regarding the challenge**

Elisa POSE, *Spain*

08:40-08:55

#### **Epidemiology of bacterial infections in cirrhosis and resistance to antibiotics worldwide**

Salvatore PIANO, *Italy*

08:55-09:10

#### **Optimal use of antibiotics in patients with cirrhosis: which type of infection, which antibiotic(s), which dose?**

Guadalupe GARCIA-TSAO, *United States*

09:10-09:25

#### **Acute kidney injury in cirrhosis: redefining the syndromes**

Claire FRANCOZ, *France*

Thursday 11 April 2019

09:25-09:40 **Management of hepato-renal syndrome**  
Elsa SOLÀ, *Spain*

09:40-10:00 **Panel discussion**

10:00-10:30 **Coffee break**

Scientific  
programme

### Hepatic encephalopathy and ACLF in end-stage liver disease

#### Chairs:

Paolo ANGELI, *Italy*

Annalisa BERZIGOTTI, *Switzerland*

François DURAND, *France*

Pere GINÈS, *Spain*

10:30-10:40 **Presentation of the clinical case and key questions regarding the challenge**

Sarah RAEVENS, *Belgium*

10:40-10:55 **New options in the treatment of hepatic encephalopathy: from lactulose to non-absorbable antibiotics**

Sara MONTAGNESE, *Italy*

10:55-11:10 **ACLF: From pathogenesis to prognosis**

Rafael BAÑARES, *Spain*

11:10-11:25 **Management of ACLF in the ICU and the role of liver support systems**

Constantine KARVELLAS, *Canada*

11:25-11:40 **Rescue liver transplantation in patients with ACLF: where are the limits?**

Patrick S. KAMATH, *United States*

11:40-12:00 **Panel discussion**

Thursday 11 April 2019

## Basic Science Seminar-Liver immunology and immunotherapy:

Hall C3



### Exploiting adaptive and innate immune mechanisms

#### Chairs:

David ADAMS, *United Kingdom*

Andrea SCHIETINGER, *United States*

Robert THIMME, *Germany*

08:30-09:00 **Intrahepatic NK cells**  
Mala MAINI, *United Kingdom*

**NK cell regulation of antiviral responses to HBV therapeutic vaccination**Mariana DINIZ, *United Kingdom***Discussion**

09:00-09:30

**Mechanisms of T cell failure in viral hepatitis**Christoph NEUMANN-HAEFELIN, *Germany***Mechanisms of T cell failure in viral hepatitis: Fellow presentation**Janine KEMMING, *Germany***Discussion**

09:30-10:00

**Liver immunology in HCC**Mathias HEIKENWÄLDER, *Germany***Deciphering TCR signaling in metabolic activated T-cells in NASH and liver cancer development**Dominik PFISTER, *Germany***Discussion**

10:00-10:30

**Coffee break****Viral hepatitis and cancer, cholestasis and fatty liver disease****Chairs:**David ADAMS, *United Kingdom*Andrea SCHIETINGER, *United States*Robert THIMME, *Germany*

10:30-11:00

**T cell therapy for chronic hepatitis B and hepatocellular carcinoma**Ulrike PROTZER, *Germany***Novel TCRs and CARs to redirect T cells against HBV**Karin WISSKIRCHEN, *Germany***Discussion**

11:00-11:30

**Cholestatic liver disease**Tom Hemming KARLSEN, *Norway***Comprehensive mapping of the human biliary tree immunological landscape in health and inflammation**Christine ZIMMER, *Sweden***Discussion**

11:30-12:00

**MAIT cells in chronic liver diseases**Sophie LOTERSZTAJN, *France***MAIT cells as a profibrogenic immune cell population**Manon ALLAIRE, *France***Discussion**Scientific  
programme**Translational state of the art lecture: Cell therapy  
in advanced liver disease****Main Plenary****12:00-12:30****Stuart FORBES, *United Kingdom*****Biography**

Stuart Forbes is Professor of Transplantation and Regenerative Medicine and Director of The MRC Centre for Regenerative Medicine, University of Edinburgh (<http://www.crm.ed.ac.uk/>) and a Hepatologist at the Scottish Liver Transplant Unit.

**Lecture summary**

Cell Therapy is developing as a clinical possibility for several forms of liver disease. This lecture will attempt to give an overview of where the field is currently. Past and present clinical studies will be discussed. It will also contain information on research and the basic mechanisms that will inform future clinical studies.

**EASL International Liver Foundation (EILF)  
Symposium: Liver Disease in Africa****Lehar 4****Viral Hepatitis****Chair:**Geoffrey DUSHEIKO, *United Kingdom*

08:30-08:45

**Simplification of patient assessment**Maud LEMOINE, *United Kingdom*

08:45-09:00

**New diagnostics for HBV & HCV**Stéphane CHEVALIEZ, *France*

09:00-09:15

**Making antiviral drugs available**Charles GORE, *Switzerland*

09:15-09:30

**Surveillance and treatment of early HCC**Massimo COLOMBO, *Italy*

Thursday 11 April 2019

**Public Health****Chair:**Maud LEMOINE, *United Kingdom*

09:30-09:45

**Epidemiological models to guide targets**Shevanthi NAYAGAM, *United Kingdom*

09:45-10:00

**Making the economic case: cost and reward of treatment scale up**Robert HECHT, *United States*

10:00-10:15

**Case finding strategies: cost effective approaches**Manal Hamdy EL-SAYED, *Egypt*

10:15-10:30

**Integrating hepatitis services within broader health systems**Neil GUPTA, *United States*Fredrick KATEERA, *Rwanda***Agencies and strategic support****Chair:**Mark THURSZ, *United Kingdom*

10:30-10:45

**WHO strategy in Africa**Olufunmilayo LESI, *Nigeria*

10:45-11:00

**CDC in Africa**Francisco AVERHOFF, *United States*

11:00-11:15

**A role for faith-based organisations**Robert J. VITILLO, *Vatican*

11:15-11:30

**Panel Discussion –Addressing the challenges to meet WHO Targets**Jeffrey LAZARUS, *Spain*

**Meet the Experts: Is screening for HCC recurrence cost-effective after liver transplantation. Do we need to perform HCC screening after liver transplantation?**

**Stolz 1****Chairs:**Christophe DUVOUX, *France*Christian TOSO, *Switzerland*

08:30-09:20

**Meet the Experts: Wilson's disease**

**Stolz 2**

**Chairs:**

Peter FERENCI, *Austria*  
Peter OTT, *Denmark*

08:30-09:20

Scientific  
programme

**Meet the Experts: Exercise or diet – which is best for NAFLD**

**Stolz 1**

**Chairs:**

Mike TRENELL, *United Kingdom*  
Shira ZELBER-SAGI, *Israel*

09:30-10:20

**Meet the Experts: Hepatitis C: What are the remaining  
difficult to treat patients and how to manage them?**

**Stolz 2**

**Chairs:**

Alessandra MANGIA, *Italy*  
Stefan ZEUZEM, *Germany*

09:30-10:20

Thursday 11 April 2019



## Oral ePoster

10:00-10:30



### Complication of cirrhosis-Experimental and pathophysiology

#### Chair:

Philipp SCHWABL, *Austria*

#### Poster pod 1



### Imaging and drug targeting

#### Chair:

Twan LAMMERS, *Germany*

#### Poster pod 2

### DILI

#### Chair:

Maria Isabel LUCENA, *Spain*

#### Poster pod 3

### Rare liver diseases-including pediatric and genetic

#### Chair:

Emmanuel GONZALES, *France*

#### Poster pod 4



## Poster tour

## Meeting point 1

10:00-10:30

### Viral hepatitis C: Therapy and resistance

#### Chair:

Tarik ASSELAH, *France*

#### Meeting point 1

### Fibrosis

#### Chair:

Fiona OAKLEY, *United Kingdom*

#### Meeting point 2



### Liver tumours: Experimental and pathophysiology

#### Chair:

Augusto VILLANUEVA, *United States*

#### Meeting point 4

## ELPA Symposium 2019 NAFLD and NASH from patient perspective: What are the patient problems?

Strauss 1-2

### Chairs:

Teresa CASANOVAS, *Spain*Helena CORTEZ-PINTO, *Portugal*

10:30-10:40

### Welcome and introduction

Marko KORENJAK, *Belgium*

10:40-10:55

### Diagnosis of NAFLD/NASH

Emmanuel TSOCHATZIS, *United Kingdom*

10:55-11:10

### NAFLD/NASH and importance of right nutrition

Shira ZELBER-SAGI, *Israel*

11:10-11:25

### Clear information is the key for patients

Antonio J. AMOR, *Spain*

11:25-11:40

### Role of Transient Elastography (Fibroscan)

Laurent CASTERA, *France*

11:40-11:55

### How to find the patients—research project LiverScreen

Núria FABRELLAS, *Spain*

11:55-12:10

### NAFLD/NASH Policy Review from patient perspective

Jeffrey LAZARUS, *Spain*

12:10-12:25

### Patients views and problems in NAFLD/NASH

Julio BURMAN, *Belgium*Reham ELSAYED, *Egypt*Marko KORENJAK, *Belgium*

12:25-12:50

### Group discussion closing remarks

Tatjana REIC, *Belgium*Scientific  
programme

Thursday 11 April 2019

## Meet the Experts: Preventing long-term complications in OLT Stolz 1



### Chairs:

Marina BERENQUER HAYM, *Spain*Puneeta TANDON, *Canada*

10:30-11:20

## Meet the Experts: JHEP reports – Meet the new editorial team Stolz 2

### Chairs:

Jessica ZUCMAN-ROSSI, *France*

Sven FRANQUE, *Belgium*

Morris SHERMAN, *Canada*

10:30-11:20

Scientific  
programme

## EASL Public Health Session: Influencing food and alcohol policy to reduce liver disease

Hall C1



### Chairs:

Philip NEWSOME, *United Kingdom*

Shira ZELBER-SAGI, *Israel*

12:00-12:20

### Lessons from the UK Lancet Commission

Roger WILLIAMS, *United Kingdom*

12:20-12:40

### Epidemiology of alcohol-related diseases-The limitations of meta-analyses etc. Perspectives from WHO

Jürgen REHM, *Canada*

12:40-13:00

### Alcohol control: are NGO's being able to influence EU policies?

Peter RICE, *United Kingdom*

13:00-13:20

### Control of obesity: how effective are policies of food and physical activity?

Johanna RALSTON, *Switzerland*

13:20-13:30

### Discussion and wrap up

## Data management in registries

Hall C2

### Chairs:

Annika M BERGQUIST, *Sweden*

Christian TRAUTWEIN, *Germany*

12:00-12:20

### How to achieve the compliance with the GDPR

Martine PLOEM, *Netherlands*

12:20-12:40

### Differences in data management between a clinical trial and a registry

Ioana RIAÑO, *Spain*

Thursday 11 April 2019

- 12:40-13:00 **How to ensure the quality of data in a registry for infrequent diseases**  
Christoph SCHRAMM, *Germany*
- 13:00-13:20 **How to ensure the quality of data in a registry for frequent diseases**  
Quentin ANSTEE, *United Kingdom*
- 13:20-13:30 **Discussion and wrap up**

Scientific  
programme

### EASL-ESCMID symposium: New diagnostic markers in viral hepatitis

Strauss 3



#### Chairs:

Markus CORNBERG, *Germany*  
Mario Umberto MONDELLI, *Italy*

- 12:00-12:20 **New markers for paving the way to cure HBV infection**  
Maurizia BRUNETTO, *Italy*
- 12:30-12:50 **New Hepatitis C tests for improving linkage to care and elimination of HCV**  
Stéphane CHEVALIEZ, *France*
- 13:00-13:20 **What is the standard for the diagnosis/monitoring of Hepatitis E?**  
Sandra CIESEK, *Germany*

### EASL Fellowship presentations

Lehar 2

#### Chairs:

Massimo PINZANI, *United Kingdom*  
Jessica ZUCMAN-ROSSI, *France*

- 12:00-12:10 **EASL support to excellent young investigators: Presentation of the awardee of 2018 and update on EASL fellowship programs**  
Massimo PINZANI, *United Kingdom*
- 12:10-12:20 **Free fatty acids and their metabolites lead to dysfunctional intrahepatic regulatory T cells which promotes ongoing non-alcoholic steato-hepatitis (NASH)**  
Muhammad ATIF, *France*

Thursday 11 April 2019

- 12:20-12:30 **The fibrogenic and contractile phenotype of human hepatic stellate cells cultured in 3D extracellular matrix scaffolds derived from normal and cirrhotic human liver**  
Elisabetta CAON, *United Kingdom*
- 12:30-12:40 **Prevalence of Non-Alcoholic Fatty Liver Disease in patients with Type 2 Diabetes Mellitus. Screening policy, economic implications and cost analysis**  
Roberta FORLANO, *United Kingdom*
- 12:40-12:50 **Toll-like receptor 4: a novel target for the treatment of hyperammonemia and hepatic encephalopathy**  
Annarein KERBERT, *United Kingdom*
- 12:50-13:00 **Cracking the Notch code: single-cell receptor-ligand interactions and outcomes in vivo**  
Jan MAŠEK, *Sweden*
- 13:00-13:10 **Targeting the microRNA miR-873-5p in paediatric and adult genetic cholestatic diseases**  
Teresa CARDOSO DELGADO, *Spain*
- 13:10-13:30 **Concluding remarks**  
Jessica ZUCMAN-ROSSI, *France*

## Gender related topics in Hepatology

Lehar 3

### Chairs:

Marina BERENQUER HAYM, *Spain*

John IREDALE, *United Kingdom*

- 12:00-12:20 **Improving science/research outcomes at an institutional level: role of Associations, Institutions and Social Networks**  
Didier SAMUEL, *France*
- 12:20-12:40 **Equally interchangeable?-How sex and gender affect liver transplantation**  
Marina BERENQUER HAYM, *Spain*
- 12:40-13:00 **Understanding the challenges that women face in research**  
Emma ANDERSSON, *Sweden*
- 13:00-13:30 **Discussion**

## EASL-CDC symposium: Best Practices in HCV Elimination

Lehar 4

**Chairs:**

Muazzam NASRULLAH, *United States*  
 Markus PECK-RADOSAVLJEVIC, *Austria*

12:00-12:05

**Opening remarks**

Muazzam NASRULLAH, *United States*

12:05-12:15

**The critical role of partnerships in HCV elimination, Georgia**

David SERGEENKO, *Georgia*

12:15-12:25

**Reaching the hardest-to-reach populations with HCV infection, Egypt**

Wahed DOSS, *Egypt*

12:25-12:35

**HCV elimination in Pakistan: Opportunities and challenges**

Huma QURESHI, *Pakistan*

12:35-12:45

**Successful treatment of HCV infection through task shifting to non-specialist providers in Rwanda**

Sabin NSANZIMANA, *Rwanda*

12:45-12:55

**A novel approach to funding HCV and HBV treatment for all, Uzbekistan pilot project**

Homie RAZAVI, *United States*

12:55-13:05

**Increasing access to HCV diagnostics through simplification, integration, and decentralization**

Sonjelle SHILTON, *Switzerland*

13:05-13:15

**HCV elimination: Benefits beyond treatment**

Francisco AVERHOFF, *United States*

13:15-13:25

**Q & A / Discussion**

13:25-13:30

**Closing remarks**

Markus PECK-RADOSAVLJEVIC, *Austria*

Scientific  
programme

Thursday 11 April 2019

## Pros & Cons Session: NASH does not alter a patient's natural history – only fibrosis does

Hepatology Arena

### Chairs:

William ALAZAWI, *United Kingdom*

Arun SANYAL, *United States*

12:00-12:10

### Overview

Michael RODEN, *Germany*

12:10-12:20

### Pros

Mattias EKSTEDT, *Sweden*

12:20-12:30

### Cons

Quentin ANSTEE, *United Kingdom*

12:30-13:00

### Discussion

## Meet the Experts: How to decide for resection versus other therapies in HCC?

Stolz 1



### Chairs:

Alejandro FORNER, *Spain*

Vincenzo MAZZAFERRO, *Italy*

12:00-12:50

## Meet the Experts: Animal models of liver disease

Stolz 2



### Chairs:

Jordi GRACIA-SANCHO, *Spain*

Chantal HOUSSET, *France*

12:00-12:50


Oral ePoster

12:00-13:00

**HBV/HDV Clinical-Therapy, new compounds, resistance**  
**Chair:**  
 Katja DETERDING, *Germany*  
**Poster pod 1**

**HCV-Clinical-Except therapy**  
**Chair:**  
 Sabela LENS, *Spain*  
**Poster pod 2**



**Non-invasive assessment of liver disease**  
**Chair:**  
 Javier AMPUERO, *Spain*  
**Poster pod 3**



**Fatty liver disease-Clinical**  
**Chair:**  
 Münevver DEMIR, *Germany*  
**Poster pod 4**

Scientific  
programme

Thursday 11 April 2019


Poster tour

12:30-13:00

**Cirrhosis: ACLF and critical illness**  
**Chair:**  
 Elsa SOLÀ, *Spain*  
**Meeting point 2**

**Alcoholic liver disease**  
**Chair:**  
 Philippe MATHURIN, *France*  
**Meeting point 3**



**Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology**  
**Chair:**  
 Jesus M. BANALES, *Spain*  
**Meeting point 4**

## General session I and opening ceremony

## Main Plenary

**Chairs:**Tom Hemming KARLSEN, *Norway*Dominique VALLA, *France*Scientific  
programme

13:30-14:00

**Opening Ceremony**

14:00-14:15

GS-01

**Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, double-blind, randomized, placebo-controlled, phase II study**Takaomi KESSOKU, *Japan*

14:15-14:30

GS-02

**Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial**Pietro INVERNIZZI, *Italy*

14:30-14:45

GS-03

**Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts**Alessandra MANGIA, *Italy*

14:45-15:00

GS-04

**Addition of stent placement to angioplasty for Budd-Chiari syndrome improves recanalization patency and reduces symptom recurrence with adequate safety: A randomised controlled trial**Guohong HAN, *China*

15:00-15:15

GS-05

**MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans**Ilaria ESPOSITO, *United Kingdom*

15:15-15:30

GS-06

**Positive results from REGENERATE: A Phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH**Zobair YOUNOSSI, *United States*

Thursday 11 April 2019



## Oral ePoster

15:30-16:00



**Public health**  
**Chair:**  
 Jason GREBELY, *Australia*  
**Poster pod 1**



**Autoimmune and cholestatic liver disease – Experimental and pathophysiology**  
**Chair:**  
 Espen MELUM, *Norway*  
**Poster pod 2**

**HCV – Post SVR and long term follow up**  
**Chair:**  
 Michelle CHEUNG, *United Kingdom*  
**Poster pod 3**

Scientific programme

Thursday 11 April 2019



## Poster tour

15:30-16:00

**Viral hepatitis B/D: Clinical aspects except therapy**  
**Chair:**  
 Teresa POLLICINO, *Italy*  
**Meeting point 1**



**Public Health**  
**Chair:**  
 Patrizia BURRA, *Italy*  
**Meeting point 2**

**NAFLD: Clinical aspects except therapy**  
**Chair:**  
 Luca MIELE, *Italy*  
**Meeting point 3**

## Parallel session: Hepatitis B/D/E – Clinical aspects

## Main Plenary

**Chairs:**Barbara COCO, *Italy*Heiner WEDEMEYER, *Germany*Scientific  
programme16:00-16:15  
PS-049**Tenofovir alafenamide for hepatitis B virus prophylaxis post-liver transplantation is associated with improved renal function: An interim analysis of a multicenter real-world experience**Ryan PERUMPAIL, *United States*16:15-16:30  
PS-050**Integrated analyses of both human and HBV genome to predict HCC development**Masaya SUGIYAMA, *Japan*16:30-16:45  
PS-051**Mortality and morbidity of hepatitis E in Scotland: A multicentre study**Sebastian WALLACE, *United Kingdom*16:45-17:00  
PS-052**End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection**Ohad ETZION, *Israel*17:00-17:15  
PS-053**A rapid point-of-care device for the diagnosis of hepatitis delta virus infection**Volkan SAKIN, *Germany*17:15-17:30  
PS-054**Quantitative antibodies against hepatitis B core antigen differ in NUC suppressed caucasian HbeAG-negative patients compared to patients who achieved either “NUC induced” or “spontaneous” functional cure of HBV**Alessandro LOGLIO, *Italy*17:30-17:45  
PS-055**The markers of HBV transcriptional activity-HBcrAg and pre-genomic HBV DNA during antiviral therapy with nucleos(t)ide analogue help to predict optimal timing of therapy withdrawal**Ivana CAREY, *United Kingdom*17:45-18:00  
PS-056**Higher relapse and retreatment rates in patients who started as HBeAg positive than negative after stopping long-term nucleos(t)ide analogue therapy: Results from the randomized controlled STOP study**Seng LIEM, *Canada*

Thursday 11 April 2019

**Parallel session: Portal Hypertension – Refining risk stratification and therapy**
**Hall C3**
**Chairs:**

 Juan-Carlos GARCIA-PAGAN, *Spain*

 Dominique THABUT, *France*

- 16:00-16:15  
PS-017      **Long-term impact of sustained virological response on systemic and pulmonary hemodynamics in HCV-cirrhotic patients with portal hypertension**  
Sabela LENS, *Spain*
- 16:15-16:30  
PS-018      **Paroxysmal nocturnal hemoglobinuria and Budd Chiari syndrome: Impact of Eculizumab therapy on survival and liver outcome in 54 patients: A multicentric valdig study**  
Aurélie PLESSIER, *France*
- 16:30-16:45  
PS-019      **Response of liver and spleen stiffness to portal pressure lowering drugs in a rat model of cirrhosis**  
Omar ELSHAARAWY, *Germany*
- 16:45-17:00  
PS-020      **Spleen T1 and spleen diameter criteria can identify and exclude oesophageal varices accurately**  
Christina LEVICK, *United Kingdom*
- 17:00-17:15  
PS-021      **The development of portosystemic shunts depends on liver dysfunction rather than on PIGF-driven neoangiogenesis**  
Katharina LAMPICHLER, *Austria*
- 17:15-17:30  
PS-022      **Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding**  
Aleksander KRAG, *Denmark*
- 17:30-17:45  
PS-023      **Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS**  
Juan-Carlos GARCIA-PAGAN, *Spain*
- 17:45-18:00  
PS-024      **Early TIPS with covered stent versus standard treatment for acute variceal bleeding among patients with advanced cirrhosis: A randomised controlled trial**  
Guohong HAN, *China*

 Scientific  
programme

Thursday 11 April 2019

## Parallel session: NAFLD Pathophysiology – Target identification

Hall C1

### Chairs:

Isabelle LECLERQ, *Belgium*

Chris WESTON, *United Kingdom*

Scientific  
programme

16:00-16:15

PS-001

### **Roles of CC chemokine receptor 9 in the progression and carcinogenesis of murine non-alcoholic steatohepatitis**

Rei MORIKAWA, *Japan*

16:15-16:30

PS-002

### **Persistence of hepatic and adipose tissue alterations in T helper 17 cells, CD8+ cytotoxic T cells and regulatory T cells despite metabolic and histological improvement upon diet reversal in a high-fat high-fructose mouse model of NAFLD**

Mikhail VAN HERCK, *Belgium*

16:30-16:45

PS-003

### **Activation of the miR-34a/SIRT1:AMPK axis contributes for insulin resistance and mitochondrial dysfunction in the NAFLD muscle**

André L. SIMÃO, *Portugal*

16:45-17:00

PS-004

### **Western diet triggers a unique inflammatory phenotype of myeloid leukocytes in bone marrow and liver**

Jana HUNDERTMARK, *Germany*

17:00-17:15

PS-005

### **Evaluation of neuromedin-B receptor variants effect on iron metabolism and liver disease**

Raffaella RAMETTA, *Italy*

17:15-17:30

PS-006

### **MBOAT7 downregulation induces hepatic lipid accumulation**

Marica MERONI, *Italy*

17:30-17:45

PS-007

### **Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis**

Sander LEFERE, *Belgium*

17:45-18:00

PS-008

### **E2F2 mediated repression of fatty acid B-oxidation is mitigated through CREB1 in progressive non-alcoholic fatty liver disease**

Francisco GONZALEZ-ROMERO, *Spain*

Thursday 11 April 2019

## Parallel session: Autoimmune and cholestasis I

Hall C2

**Chairs:**Annika M BERGQUIST, *Sweden*Michael TRAUNER, *Austria*

16:00-16:15

PS-009

**Proteome of primary biliary cholangitis in naïve and UDCA treatment patients**Ben MILLAR, *United Kingdom*

16:15-16:30

PS-010

**24-nor-ursodeoxycholic acid ameliorates inflammation by reshaping mTOR proteome and immunometabolism sensing programs in CD8 T-cells**Ci ZHU, *Austria*

16:30-16:45

PS-011

**New synthetic conjugates of ursodeoxycholic acid inhibit hepatorenal cystogenesis in experimental models of polycystic liver disease**Francisco Javier CABALLERO, *Spain*

16:45-17:00

PS-012

**Validation of histologic and noninvasive measures of fibrosis as surrogate endpoints of disease progression in patients with primary sclerosing cholangitis**Christopher BOWLUS, *United States*

17:00-17:15

PS-013

**Evaluation of serological markers of extracellular matrix remodeling in primary sclerosing cholangitis**Christian RUPP, *Germany*

17:15-17:30

PS-014

**Disease clustering in autoimmune liver diseases points towards environmental factors being important in their aetiology**Jessica DYSON, *United Kingdom*

17:30-17:45

PS-015

**Role of methylation-controlled J-protein, endogenous repressor of the mitochondrial respiratory chain, in cholestatic liver disease**Paula IRUZUBIETA, *Spain*

17:45-18:00

PS-016

**Prospective evaluation of serum alkaline phosphatase variability and prognostic utility in primary sclerosing cholangitis using controlled clinical trial data**Palak TRIVEDI, *United Kingdom*Scientific  
programme

Thursday 11 April 2019

**Parallel session: NAFLD – Clinical burden natural history Strauss 1-2**
**Chairs:**

 Helena CORTEZ-PINTO, *Portugal*

 Jean-François DUFOUR, *Switzerland*

 Scientific  
programme

 16:00-16:15  
PS-057

**Redefining risk of liver disease in the general population: Analysis of the health survey for England 2016**

 Kate GLYN-OWEN, *United Kingdom*

 16:15-16:30  
PS-058

**The socio-economic burden of NASH in Europe and the United States: The gain study**

 Leonardo RUIZ, *United Kingdom*

 16:30-16:45  
PS-059

**Increased healthcare resource utilization and costs in non-alcoholic fatty liver disease/nonalcoholic steatohepatitis patients with liver disease progression: A multivariate analysis of French national hospital care**

 Jerome BOURSIER, *France*

 16:45-17:00  
PS-060

**Increasing risk of disease progression and mortality in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients with advanced liver disease: A German real-world analysis**

 Ali CANBAY, *Germany*

 17:00-17:15  
PS-061

**Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization and costs: Results from Italian administrative databases**

 Salvatore PETTA, *Italy*

 17:15-17:30  
PS-062

**The increasing importance of non-alcoholic fatty liver disease in human deficiency virus (HIV) positive patients**

 Zobair YOUNOSSI, *United States*

 17:30-17:45  
PS-063

**Screening diabetic patients for non-alcoholic fatty liver disease: Is it cost-effective**

 Yaakov MAOR, *Israel*

 17:45-18:00  
PS-064

**NAFLD simulator: An interactive open-access tool for long-term risks of NAFLD and NASH**

 Jagpreet CHHATWAL, *United States*

Thursday 11 April 2019

**Parallel session: Cascade of care towards elimination of viral hepatitis**

**Strauss 3**

**Chairs:**

Mojca MATICIC, *Slovenia*  
 Francesco NEGRO, *Switzerland*

- 16:00-16:15  
 PS-065 **The global investment case for hepatitis C elimination**  
 Margaret HELLARD, *Australia*
- 16:15-16:30  
 PS-066 **Patient flow across physician specialties over the course of the hepatitis C care cascade: A real-world analysis from the United States**  
 Nancy S REAU, *United States*
- 16:30-16:45  
 PS-067 **Increasing incidence of HCV-GT2 as well as reinfections within the ongoing epidemic of acute HCV infections among MSM in Central Europe**  
 David CHROMY, *Austria*
- 16:45-17:00  
 PS-068 **The hepatitis C cascade of care and treatment outcomes among people who inject drugs in a Norwegian low-threshold setting: A real life experience**  
 Håvard MIDGARD, *Norway*
- 17:00-17:15  
 PS-069 **Towards HCV elimination: Feasibility of complete linkage to care by testing and treatment on the same day of screening: A pilot study**  
 Gamal SHIHA, *Egypt*
- 17:15-17:30  
 PS-070 **Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study**  
 Heather VALERIO, *Australia*
- 17:30-17:45  
 PS-071 **Piloting of integrated HCV, TB and HIV screening model at primary care level in Georgia**  
 Irma KHONELIDZE, *Georgia*
- 17:45-18:00  
 PS-072 **Is homelessness the biggest hurdle to treatment success in the management of HCV in the era of direct acting antivirals? Results from the TraP HepC nationwide treatment initiative in Iceland**  
 Magnús GOTTFREDSSON, *Iceland*

Scientific  
 programme

Thursday 11 April 2019

## Parallel session: Liver disease immunology

Lehar 1

**Chairs:**Carlo FERRARI, *Italy*Robert THIMME, *Germany*Scientific  
programme16:00-16:15  
PS-025**Elevated tissue homing of monocytes and increased cytotoxic activity of CD8+ T-cells in immune checkpoint inhibitor-induced hepatitis**Cathrin L.C. GUDD, *United Kingdom*16:15-16:30  
PS-026**FOXO1-activity controls effector function of CXCR6+CD8+ T-cells and prevents liver immune pathology during viral hepatitis and non-alcoholic steatohepatitis**Michael DUDEK, *Germany*16:30-16:45  
PS-027**The LLT1-CD161 interaction : An important inhibitory interaction for NK cells in cirrhosis**Naveenta KUMAR, *United Kingdom*16:45-17:00  
PS-028**Viral escape contributes to the failure of hepatitis D virus-specific CD8+ T-cells and drives evolution of HDV**Valerie OBERHARDT, *Germany*17:00-17:15  
PS-029**Eradication of HCV by DAAs provides patients with immunological benefits by the restoration of antigen-presenting dendritic cells**Sachio YOSHIO, *Japan*17:15-17:30  
PS-030**Cure of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T-cell responses**Amare AREGAY, *Germany*17:30-17:45  
PS-031**RNAseq of liver biopsies following DAA-based therapy reveals a greater enrichment in immune, interferon, cytokine and cell cycle pathways compared to IFN-based therapy: Implications for DAA-related sequelae**Jacinta HOLMES, *Australia*17:45-18:00  
PS-032**Impact of antigen recognition on memory-like HCV-specific CD8+ T-cells**Nina HENSEL, *Germany*

Thursday 11 April 2019

**Parallel session: Mechanism of regeneration response to injury**
**Lehar 2**
**Chairs:**

 Maurizio PAROLA, *Italy*

 Cecilia M. P RODRIGUES, *Portugal*

 16:00-16:15  
PS-033

**Hepatocyte-specific deletion of ERK5 modulates liver regeneration in mice**

 Giovanni DI MAIRA, *Italy*

 16:15-16:30  
PS-034

**MCJ: A therapeutic target in hepatic ischemia and reperfusion injury**

 Naroa GOIKOETXEA, *Spain*

 16:30-16:45  
PS-035

**The role of pericentral hepatocytes in homeostatic liver regeneration: Caveats to lineage tracing from Axin2**

 Callum LIVINGSTONE, *United Kingdom*

 16:45-17:00  
PS-036

**Optimization and validation of a novel three-dimensional co-culture system in decellularized human liver scaffold for the study of liver fibrosis and cancer**

 Kessarín THANAPIROM, *United Kingdom*

 17:00-17:15  
PS-037

**SMURF1 aggravates liver steatosis by stabilizing SREBP-1C in an E3 catalytic activity independent manner**

 Ping XIE, *China*

 17:15-17:30  
PS-038

**A humanized bile acid pool induced by somatic CRISPR/Cas9-mediated deletion of Cyp2c70 modulates effects of pharmacological FXR activation in mice**

 Jan Freark DE BOER, *Netherlands*

 17:30-17:45  
PS-039

**Role of ductular reaction on the hepatic microenvironment in chronic liver disease**

 Silvia ARIÑO MONS, *Spain*

 17:45-18:00  
PS-040

**Bacterial infection upregulates TGR5 expression in a Krüppel-like-factor 5-dependent manner**

 Maria REICH, *Germany*

 Scientific  
programme

Thursday 11 April 2019

## Parallel session: Liver tumours – Experimental

Lehar 3

**Chairs:**Valérie PARADIS, *France*Augusto VILLANUEVA, *United States*Scientific  
programme16:00-16:15  
PS-041**Intense angiocrine crosstalk between liver endothelial cell subtypes leads to liver capillarization and recruitment of myeloid progenitors**Stefan THOMANN, *Germany*16:15-16:30  
PS-042**Interventional targeting of cyclin E1 during hepatocarcinogenesis limits stem cell traits and hepatic myeloid cell homing and attenuates cancer progression**Roland SONNTAG, *Germany*16:30-16:45  
PS-043**Dual targeting of G9a and DNMT-methyltransferase-1 for the treatment of experimental cholangiocarcinoma**Leticia COLYN, *Spain*16:45-17:00  
PS-044**Identification of a pan-gamma-secretase inhibitor response signature for notch-driven cholangiocarcinoma**Colm O ROURKE, *Denmark*17:00-17:15  
PS-045**HCC promotes autophagy in hepatic stellate cells, leading to HCC progression via IL-6/STAT3 signaling**Yuta MYOJIN, *Japan*17:15-17:30  
PS-046**Suppression of complex protumorigenic phenotypes in chronic injury-associated hepatocarcinogenesis is dependent on IL-6/STAT3 signaling**Eithan GALUN, *Israel*17:30-17:45  
PS-047**HSD17B13 loss of function variant protects from hepatocellular carcinoma developed on alcohol related liver disease**Jie YANG, *France*17:45-18:00  
PS-048**Definition of aneuploidy profiles and their impact on tumour progression and immune features in hepatocellular carcinoma**Roger ESTEBAN-FABRÓ, *Spain*

Thursday 11 April 2019



## Launch of EASL International Liver Foundation (EILF) centre of excellence in viral hepatitis elimination in Georgia

Lehar 4



### Chairs:

Francisco AVERHOFF, *United States*  
Antons MOZALEVSKIS, *Denmark*

Scientific  
programme

### Session 1: Setting the Stage

- 16:00-16:10 **Introducing the 1<sup>st</sup> EILF Centre of Excellence in Viral Hepatitis**  
Jeffrey LAZARUS, *Spain*
- 16:10-16:20 **The road to elimination in Georgia**  
David SERGEENKO, *Georgia*
- 16:20-16:30 **Q&A**

### Session 2: HCV Elimination in Georgia: The Highlights

- 16:30-16:45 **The HCV care cascade and treatment outcomes**  
Tengiz TSERTSVADZE, *Georgia*
- 16:45-16:55 **HCV micro-elimination among people who inject drugs in pursuit of national elimination**  
Maia BUTSASHVILI, *Georgia*
- 16:55-17:05 **Beyond treatment: HCV elimination provides collateral benefits to the health system**  
Francisco AVERHOFF, *United States*
- 17:05-17:15 **Q&A**

### Session 3: HCV Elimination in Georgia: Next Steps

- 17:15-17:25 **Key role of partnerships in global HCV elimination**  
Muazzam NASRULLAH, *United States*
- 17:25-17:35 **Key challenges and strategies to reach HCV elimination**  
Amiran GAMKRELIDZE, *Georgia*
- 17:35-17:45 **Q&A**
- 17:45-18:00 **Closing remarks**  
David SERGEENKO, *Georgia*  
Massimo COLOMBO, *Italy*

Thursday 11 April 2019

## Symposium: Transplant oncology from 2019 to 2025

Hepatology Arena

### Chairs:

Joana FERRER, *Spain*

Didier SAMUEL, *France*

16:00-16:20

### What have we learnt from the HCC metroticket system relevant to other cancers?

Vincenzo MAZZAFERRO, *Italy*

16:20-16:40

### Liver transplantation for colorectal and neuroendocrine tumor metastasis -how to select the right patients?

Pål Dag LINE, *Norway*

16:40-17:00

### Current consensus on liver transplantation for cholangiocarcinoma and biliary dysplasia

Gonzalo SAPISOCHIN, *Canada*

17:00-17:20

### Management of post-transplant cancer recurrence

Julie HEIMBACH, *United States*

17:20-18:00

### Discussion

## Meet the Experts: Local therapies in HCC

Stolz 1

### Chairs:

Peter GALLE, *Germany*

Roman KLOCKNER, *Germany*

16:00-16:50

## Meet the Experts: Artificial intelligence in hepatology – where are the applications?

Stolz 2

### Chairs:

Andre ESTEVA, *United States*

Frank TACKE, *Germany*

16:00-16:50

## Meet the Experts: Renal dysfunction in the cirrhotic patient **Stolz 1**

### Chairs:

Claire FRANCOZ, *France*  
Salvatore PIANO, *Italy*

17:00-17:50

Scientific  
programme

## Meet the Experts: How to manage the chronic hepatitis Delta? **Stolz 2**

### Chairs:

Maria BUTI, *Spain*  
Mario RIZZETTO, *Italy*

17:00-17:50

## Skills learning centre: Diagnostic ultrasound and elastography in hepatology **SLC 1**

### Chairs:

Robert DE KNEGT, *Netherlands*  
Fabio PISCAGLIA, *Italy*

### Tutors:

Sandra COENEN, *Netherlands*  
Thomas KARLAS, *Germany*  
Andrej POTTHOFF, *Germany*  
Davide ROCCARINA, *United Kingdom*  
Horia STEFANESCU, *Romania*  
Francesco TOVOLI, *Italy*  
Mette VESTERHUS, *Norway*



18:30-19:15

Thursday 11 April 2019

## Skills learning centre: Diagnostic ultrasound and elastography in hepatology

SLC 1



### Chairs:

Robert DE KNEGT, *Netherlands*

Fabio PISCAGLIA, *Italy*

### Tutors:

Sandra COENEN, *Netherlands*

Thomas KARLAS, *Germany*

Andrej POTTHOFF, *Germany*

Davide ROCCARINA, *United Kingdom*

Horia STEFANESCU, *Romania*

Francesco TOVOLI, *Italy*

Mette VESTERHUS, *Norway*

19:15-20:00

## Skills learning centre: Invasive diagnosis and therapy

SLC 2

18:30-19:15



### Hepatic hemodynamics

Pierre-Emmanuel RAUTOU, *France*

Mattias MANDORFER, *Austria*

Thomas REIBERGER, *Germany*

### TIPS

Virginia HERNANDEZ-GEA, *Spain*

Roberto MIRAGLIA, *Italy*

### Thermal ablation

Christiane KUHL, *Germany*

Peter ISFORT, *Germany*

Markus ZIMMERMANN, *Germany*

### Endoscopy

Andres CARDENAS, *Spain*

Arnulf FERLITSCH, *Austria*

### SX-ELLA Danis Stent

Enric REVERTER, *Spain*

**Skills learning centre: Invasive diagnostics methods****SLC 2**

19:15-20:00

**Hepatic hemodynamics**

Pierre-Emmanuel RAUTOU, *France*  
 Mattias MANDORFER, *Austria*  
 Thomas REIBERGER, *Germany*

**TIPS**

Virginia HERNANDEZ-GEA, *Spain*  
 Roberto MIRAGLIA, *Italy*

**Thermal ablation**

Christiane KUHL, *Germany*  
 Peter ISFORT, *Germany*  
 Markus ZIMMERMANN, *Germany*

**Endoscopy**

Andres CARDENAS, *Spain*  
 Arnulf FERLITSCH, *Austria*

**SX-ELLA Danis Stent**

Enric REVERTER, *Spain*

Scientific  
programme

Thursday 11 April 2019

**Industry Symposium**

18:30-20:00

**Please refer to the industry section for more details**

# **LIVE** Streaming

Content at your fingertips.



- 24/7 access to key presentations
- Catch up on sessions you missed
- Watch in your home country
- Free of charge
- Available through the ILC website and ILC app

**SCIENTIFIC PROGRAMME**  
FRIDAY 12 APRIL 2019

## Friday 12 April 2019

### Breakfast morning rounds: Hepatitis Delta: how to manage? Are new therapies on the horizon?

Strauss 3

07:30-08:20

**Chair:**Cihan YURDAYDIN, *Turkey***Case presentation**Onur KESKIN, *Turkey***Expert**Katja DETERDING, *Germany*Grazia NIRO, *Italy*Vicente SORIANO, *Spain*

### Breakfast morning rounds: HCC therapy: When to use locoregional or systemic therapy and when to switch?

Lehar 2

07:30-08:20

**Chair:**Arndt VOGEL, *Germany***Case presentation**Martha KIRSTEIN, *Germany***Expert**Irene BARGELLINI, *Italy*Lorenza RIMASSA, *Italy*Marcus-Alexander WORNIS, *Germany*

### Breakfast morning rounds: Differential diagnosis of hyperferritinemia in patients with liver disease

Lehar 3

07:30-08:20

**Chair:**Heinz ZOLLER, *Austria***Case presentation**André VIVEIROS, *Austria***Expert**Edouard BARDOU-JACQUET, *France*Uta MERLE, *Germany*John RYAN, *United Kingdom*Scientific  
programme

Friday 12 April 2019

## Breakfast morning rounds: Immune mediated hepatitis related to the new oncological therapies

Lehar 4

07:30-08:20

**Chair:**Didier SAMUEL, *France***Case presentation**Eleonora DE MARTIN, *France***Expert**Raul J. ANDRADE, *Spain*Maria-Carlota LONDOÑO, *Spain*Heiner WEDEMEYER, *Germany*Scientific  
programme

## General session II and award ceremony I

Main Plenary

**Chairs:**Michael FRIED, *United States*Philip NEWSOME, *United Kingdom*08:30-08:45  
GS-07

### **Real-world safety, effectiveness, and patient-reported outcomes in patients with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: Data from the German Hepatitis C-Registry**

Markus CORNBERG, *Germany*08:45-09:00  
GS-08

### **The prevalence of non-alcoholic fatty liver disease in young adults: An impending public health crisis?**

Kushala ABEYSEKERA, *United Kingdom*09:00-09:15  
GS-09

### **Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)**

Peter GALLE, *Germany*

09:15-09:45

**Recognition Award Presentations**09:45-10:00  
GS-10

### **A germline mutation in SEMA4D leads to a familial syndrome of sclerosing cholangitis**

Xiaojun JIANG, *Norway*10:00-10:15  
GS-11

### **Baseline neutrophil-to-lymphocyte ratio indicates both prevalent and incident infection and acute kidney injury, and is related to corticosteroid Lille response in alcoholic hepatitis**

Ewan FORREST, *United Kingdom*10:15-10:30  
GS-12

### **Ascending dose cohort study of inarigivir – A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial**

Man-Fung YUEN, *Hong Kong*

Friday 12 April 2019

## Nurses and Allied Health Professionals Forum

Lehar 2

## Case study session: Acute alcoholic hepatitis

**Chairs:**Marjan BIJMOLLEN, *Netherlands*Kirstine LETH HJORT, *Denmark*

10:00-10:05

**Introduction of the case**Paul RICHARDSON, *United Kingdom*

10:05-10:20

**Care considerations**Ramona BÖTTCHER, *Germany*

10:20-10:35

**Role of addiction specialist nurse**Liz SHEPHERD, *United Kingdom*

10:35-10:50

**Role of nutrition**Mette BORRE, *Denmark*

10:50-11:05

**Should this individual be transplanted?-Advantages**Didier SAMUEL, *France*

11:05-11:15

**Should this individual be transplanted?-Drawbacks**Steven MASSON, *United Kingdom*

11:15-11:20

**Summary of case**Paul RICHARDSON, *United Kingdom*

11:20-11:30

**Questions, results of live voting and close**

11:30-13:30

**Lunch break**

## Adding value – the role of specialist liver nurses and Allied Health professionals

**Chairs:**Neus LLARCH, *Spain*Denise SCHÄFER, *Austria*

13:30-13:50

**Abstract presentation: Measuring the impact of a new liver specialist nursing service on patient care**Dianne BACKHOUSE, *United Kingdom*

13:50-14:10

**NAFLD: what is the role of the physiotherapist?**Kate HALLSWORTH, *United Kingdom*

14:10-14:30

**Effects on health-related quality of life: role of nurse led clinic**Maria HJORTH, *Sweden*

14:30-14:50

**Epidemiology of HCC: impacting factors**Nathalie GOUTTE, *France*

14:50-15:00 **Questions and Close****Meet the Nurses and AHPs Task Force**

15:00-15:30

**Jean-Pierre Benhamou clinical state-of-the-art:  
Shared mechanisms in cholestatic and fatty liver  
disease – implications for current and future treatment** **Main Plenary**

Scientific  
programme**10:30-11:00** **Michael TRAUNER, Austria****Biography**

**Michael Trauner, MD**, received his medical education at the Karl-Franzens-University in Graz, Austria, where he started his residency and fellowship in internal medicine in 1991. From 1994 to 1997 he was trained as an Erwin Schrödinger postdoctoral research fellow of the Austrian Science Foundation at Yale University's Department of Internal Medicine and Liver Center in New Haven, USA, where he worked on the molecular alterations of hepatobiliary transport systems in cholestasis. After returning to Graz, he completed his training in internal medicine and a fellowship in gastroenterology and hepatology. He then established an internationally recognized research group in cholestatic and fatty liver diseases, and founded the Liver Center at the Medical University of Graz, serving as professor of experimental and clinical hepatology. Since 2010 he has been professor of gastroenterology and hepatology and chair of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, where he is also division head of one of the largest clinical gastroenterology, endoscopy, and liver services in Europe.

Dr. Trauner's main research interests are the molecular mechanisms of bile acid transport and signaling in cholestatic and fatty liver diseases, the mechanisms of cell injury in cholestatic and fatty liver disease, and the development of novel pharmacologic treatments for cholestatic and fatty liver diseases. He has published more than 460 peer-reviewed scientific papers listed in Pubmed (H-index 69), 45 book chapters and has edited 3 books. He has delivered more than 250 invited lectures at international scientific meetings, mainly on molecular and clinical aspects of cholestatic and metabolic liver diseases, and holds three patents on the treatment of cholestatic and metabolic liver diseases.

Dr. Trauner is past president of the Austrian Society of Gastroenterology and Hepatology, a corresponding member of the Austrian Academy of Sciences, member of the Academia Europaea, a fellow of the American Gastroenterological Association (AGAF) and American Association for the Study of Liver Diseases (FAASLD), as well as a member of several other national and international professional and scientific societies. He has served on editorial boards and scientific committees, such as the European Association for the Study of the Liver (EASL) Governing Board and the United European Gastroenterology Council. He has also served as associate editor of *Journal of Hepatology* (2000 – 2009) and *Hepatology* (since 2009).

Friday 12 April 2019

**Talk Summary**

Cholestatic and fatty liver disease share several key mechanisms of metabolic cell stress/injury (e.g. ER stress, apoptotic pathways) in hepatocytes and cholangiocytes, ultimately resulting in inflammation with activation of pro-fibrogenic and carcinogenic pathways. Changes of the gut-liver axis and gut microbiota play an important role in both disease entities. Despite different prevalences, both entities are important and rising indications for liver transplantation, reflecting our limitations in effectively preventing and treating these disorders with our currently available pharmacological options. I will discuss the role of nuclear receptors (FXR, PPARs, THR) regulating both metabolism and inflammation, alterations in bile acid/fatty acid metabolism and signaling, gut-liver hormonal axis (FGF-19, GLP-1), as well as microbiota, inflammation/immunity and fibrosis as common therapeutic targets for novel immunometabolic approaches shared by both disease entities. Several of these new therapeutic approaches are currently developed and tested in the treatment of both cholestatic and fatty liver disease and have shown already first promising clinical results. The mutual stimulation and crossfertilization of research in both areas can be expected to further advance our treatment options for cholestatic and fatty liver disease in the near future.

## EASL-WHO symposium: Promoting access to DAAs for children and adolescents and experience of use in pregnant women Lehar 4

**Chairs:**

Marc BULTERYS, *Switzerland*  
 Philippa EASTERBROOK, *Switzerland*  
 Manal Hamdy EL-SAYED, *Egypt*

11:00-11:20 **Where are we now? Overview and HCV paediatric drug optimisation initiative**  
 Philippa EASTERBROOK, *Switzerland*  
 Giuseppe INDOLFI, *Italy*

### Country perspectives on HCV response and challenges in adolescents and children

11:20-11:30 **China**  
 Lai WEI, *China*

11:30-11:40 **Egypt**  
 Manal Hamdy EL-SAYED, *Egypt*

11:40-11:50 **Russia**  
 Anna TURKOVA, *Russian Federation*

11:50-12:10 **Discussion: What do we need to do to advance access to care and treatment for children and adolescents?**

12:10-12:30 **Hepatitis C: Screening and DAA treatment during pregnancy**  
 Ali JUDD, *United Kingdom*



## Oral ePoster

11:00-11:30

**HAV, HBV, HDV clinical (except therapy)**  
**Chair:**  
 Christoph HOENER ZU SIEDERDISSEN, *Germany*  
**Poster pod 1**



**Liver transplantation and hepatobiliary surgery-Clinical aspects**  
**Chair:**  
 Pål Dag LINE, *Norway*  
**Poster pod 2**

**Gut microbiota and liver disease**  
**Chair:**  
 Gianluca SVEGLIATI-BARONI, *Italy*  
**Poster pod 3**

**Viral Hepatitis A, B, C, D, E: Immunology**  
**Chair:**  
 Christoph NEUMANN-HAEFELIN, *Germany*  
**Poster pod 4**

Scientific  
programme

Friday 12 April 2019



## Poster tour

11:00-11:30

**Viral hepatitis B/D: Therapy**  
**Chair:**  
 Fabien ZOULIM, *France*  
**Meeting point 1**



**Cirrhosis and its complications: Experimental and pathophysiology**  
**Chair:**  
 Jordi GRACIA-SANCHO, *Spain*  
**Meeting point 2**

**Liver tumours: Therapy**  
**Chair:**  
 Lorenza RIMASSA, *Italy*  
**Meeting point 3**

**Rare liver diseases (including paediatric and genetic)**  
**Chair:**  
 Pavel STRNAD, *Germany*  
**Meeting point 4**

**Grand rounds: When to evaluate patients with NASH for HCC****Main Plenary****Chairs:**Jörn M. SCHATTENBERG, *Germany*Elisabetta BUGIANESI, *Italy*

11:30-12:30

**Case Presenter**Eva KALLIGA, *Germany***Grand rounds: Managing alcohol addiction and alcohol-related complications in patients with cirrhosis****Hall C3****Chairs:**Sebastian MUELLER, *Germany*Dominique THABUT, *France*

11:30-12:30

**Case Presenter**Omar ELSHAARAWY, *Germany***Grand rounds: Expect the unexpected: HBV reactivation****Hall C2****Chairs:**Maria BUTI, *Spain*Kosh AGARWAL, *United Kingdom*

11:30-12:30

**Case Presentation 1**Cristina MARCOS FOSCH, *Spain***Grand rounds: Management of puritus****Strauss 1-2****Chairs:**Pietro INVERNIZZI, *Italy*Albert PARES, *Spain*

11:30-12:30

**Case Presenter**Laura Patricia LLOVET, *Spain*

## Grand rounds: Diagnostic tools for hepatocarcinoma. How do we manage these patients?

Hepatology Arena

### Chairs:

Tom LÜDDE, *Germany*  
Jean-François DUFOUR, *Switzerland*

11:30-12:30

### Case Presenter

Sven LOOSEN, *Germany*

Scientific  
programme

## Hot topics in liver transplantation

Hall C1



### Part I: Preparing for the drastic changes in transplant medicine: donor and recipient aging and co-morbidities

#### Chairs:

Patrizia BURRA, *Italy*  
Darius F. MIRZA, *United Kingdom*

11:00-11:20

### Aging liver in the setting of liver transplantation: pathophysiology

Stuart FORBES, *United Kingdom*

11:20-11:40

### Impact of aging/marginal livers on transplant outcomes

Wojciech POLAK, *Netherlands*

11:40-12:00

### Impact of obesity and metabolic syndrome on waiting list mortality and post-transplant outcomes

Henrik PETROWSKY, *Switzerland*

12:00-12:20

### Impact of pre transplant frailty and/or sarcopaenia on outcomes

Jeroen VAN VUGT, *Netherlands*

12:20-12:30

### Discussion

12:30-14:00

### Lunch break

### Part II: Innovative strategies to increase the donor pool: living donor liver transplant (LDLT), split liver transplant, DCD

#### Chairs:

Christophe DUVOUX, *France*  
Kwan MAN, *Hong Kong*

14:00-14:15

### Why are LDLT rates lower in the USA and Europe vs Asia?

Yaman TOKAT, *Turkey*

14:15-14:30

### How to increase LDLT rates?

Gregory MCKENNA, *United States*

Friday 12 April 2019

14:30-14:45 **Split liver transplant-what are the limits?**  
Roberto Ivan TROISI, *Saudi Arabia*

14:45-15:00 **Extended criteria graft & DCD liver transplant**  
Costantino FONDEVILA, *Spain*

15:00-15:30 **Panel Discussion**

15:30-16:00 **Coffee break**

**Part III: Multidisciplinary peri-transplant management of advanced liver diseases: critical care in transplantation**

**Chairs:**

Fuat SANER, *Germany*

Eli ZUCKERMAN, *Israel*

16:00-16:20 **Setting quality standards in liver ITU-where do we stand?**  
Catherine PAUGAM-BURTZ, *France*

16:20-16:40 **Early recovery after Liver transplantation-revisited in 2019?**  
Gianni BIANCOFIORE, *Italy*

16:40-17:00 **Machine perfusion in liver transplantation-the status quo**  
Paolo MUIESAN, *United Kingdom*

**Should machine perfusion be adopted into routine clinical practice for high-risk organs?**

17:00-17:10 **Yes**  
Ina JOCHMANS, *Belgium*

17:10-17:20 **No**  
Chris WATSON, *United Kingdom*

17:20-17:30 **Discussion**

**Occupational medicine and hepatology**

**Lehar 1**

**Chairs:**

Massimo COLOMBO, *Italy*

Maria REIG, *Spain*

11:30-11:45 **Occupational and environmental exposures in liver disease**  
Marcello LOTTI, *Italy*

11:45-12:10 **EASL / EILF CPG in occupational medicine in hepatology**  
Maria Isabel LUCENA, *Spain*

12:10-12:25 **Occupational medicine and liver disease case finding- Opportunities for NAFLD and alcohol**  
Nick SHERON, *United Kingdom*

**Young investigators seminar: Critical thinking in science****Lehar 2****Chairs:**

Rajiv JALAN, *United Kingdom*  
 Jean-Charles NAULT, *France*

11:30-11:45

**Why are study results not reproducible?**

Jessica ZUCMAN-ROSSI, *France*

11:45-12:00

**Misconduct in science: why and how to avoid?**

Mario Umberto MONDELLI, *Italy*

12:00-12:15

**How to improve quality of science: the editor's point of view**

Rajiv JALAN, *United Kingdom*

12:15-12:30

**Q&A and conclusions**Scientific  
programme**Basic science highlights: Single cell sequencing approaches  
in experimental hepatology****Lehar 3****Chairs:**

Kerstin MEYER, *United Kingdom*  
 Frank TACKE, *Germany*

11:30-11:50

**Immune cells**

Martin GUILLIAMS, *Belgium*

11:50-12:10

**Mesenchymal cells**

Neil HENDERSON, *United Kingdom*

12:10-12:30

**The Human Cell Atlas**

Kerstin MEYER, *United Kingdom*

**Meet the Experts: Multidisciplinary approach for  
management of alcohol related liver disease****Stolz 1****Chairs:**

Giovanni ADDOLORATO, *Italy*  
 Aleksander KRAG, *Denmark*

11:30-12:20

Friday 12 April 2019

## Meet the Experts: Management of coagulation changes in patients with liver disease undergoing an invasive procedure Stolz 2



### Chairs:

Ton LISMAN, *Netherlands*

Erica VILLA, *Italy*

11:30-12:20

## EASL General Assembly Strauss 3

12:30-14:00



### EASL Members' General Assembly

IMPORTANT: Access restricted to active EASL members



## Oral ePoster

12:30-13:30

### HCV – Clinical – Therapy I

#### Chair:

Soo ALEMAN, *Sweden*

#### Poster pod 1

### Complication of cirrhosis – Clinical

#### Chair:

Laure ELKRIEF, *Switzerland*

#### Poster pod 2

### NAFLD – Therapy

#### Chair:

Matthew ARMSTRONG, *United Kingdom*

#### Poster pod 3

### Liver Tumours -Clinical

#### Chair:

Maria VARELA, *Spain*

#### Poster pod 4

 <b>Poster tour</b>	
12:30-13:30	<p><b>Viral Hepatitis A, B, C, D, E – Immunology</b>  <b>Chair:</b>            Antonio BERTOLETTI, <i>Singapore</i>  <b>Meeting point 1</b></p>
	<p><b>Autoimmune and chronic cholestatic liver disease: Clinical aspects</b>  <b>Chair:</b>            Olivier CHAZOUILLÈRES, <i>France</i>  <b>Meeting point 2</b></p>
	<p><b>Gut microbiota and liver disease</b>  <b>Chair:</b>            Reiner WIEST, <i>Switzerland</i>  <b>Meeting point 3</b></p>
	<p><b>Nurses and AHPs' research in hepatology</b>  <b>Chair:</b>            Michelle CLAYTON, <i>United Kingdom</i>  <b>Meeting point 4</b></p>

Scientific programme

Friday 12 April 2019

## Symposium: Albumin therapy in advanced liver disease – From plasma expander to pleiotropic agent

Main Plenary

**Chairs:**

Paolo CARACENI, *Italy*  
 Elsa SOLÀ, *Spain*

- 14:00-14:20 **Human albumin-a pleiotropic molecule**  
 Alessandra DI MASI, *Italy*
- 14:20-14:40 **Albumin use in Hepatology-a changing paradigm**  
 Shiv Kumar SARIN, *India*
- 14:40-15:00 **Long-term albumin administration in decompensated cirrhosis-critical appraisal of the recent clinical trials**  
 Rafael BAÑARES, *Spain*
- 15:00-15:30 **Panel discussion on recently acquired and future perspectives**

## EASL-APASL Symposium: Recognising and managing the lean NAFLD patient

Hall C3

### Chairs:

Diana PAYAWAL, *Philippines*  
Frank TACKE, *Germany*

14:00-14:20

### Clinical presentation of the lean NAFLD patient: The Asian perspective

Lai WEI, *China*

14:20-14:40

### Which secondary causes of steatosis do you need to look for in a lean NAFLD patient?

Verena KEITEL, *Germany*

14:40-15:00

### What is Lean NASH in Asia-does it exist and should I manage it differently?

Jacob GEORGE, *Australia*

15:00-15:20

### Lean NASH in Europe-how should I manage these patients?

Vlad RATZIU, *France*

15:20-15:30

### Wrap-up and discussion

## Fusion hepatology around the world: HCC – Special consideration in HBV infection

Strauss 1-2

### Chairs:

Markus CORNBERG, *Germany*  
Zhongping DUAN, *China*  
Tetsuo TAKEHARA, *Japan*

14:00-14:20

### The road to HCC in HBV

Jessica ZUCMAN-ROSSI, *France*

14:20-14:40

### HCC risk and HBV in patients with metabolic comorbidity

Zobair YOUNOSSI, *United States*

14:40-15:00

### Risk factors for HCC in HBV patients-Implications for therapy

Jinlin HOU, *China*

15:00-15:20

### Clinical impact of HBV reactivation during anti-HCC therapy with TACE or immune checkpoint inhibitors

Yasuhito TANAKA, *Japan*

15:20-15:30

### Panel discussion

## EASL-ESMO Symposium: Multidisciplinary approach of Cholangiocarcinoma. From Diagnosis to treatment according to patient profile

Lehar 1

### Chairs:

Jordi BRUIX, *Spain*

Juan VALLE, *United Kingdom*

14:00-14:10

### Current pathology criteria for ICC diagnosis

Valérie PARADIS, *France*

14:10-14:20

### Imaging techniques for staging and response evaluation

Jens RICKE, *Germany*

14:20-14:30

### Molecular profiling and link to treatment

John BRIDGEWATER, *United Kingdom*

14:30-14:40

### Global treatment approach

Lorenza RIMASSA, *Italy*

14:40-15:00

### Panel discussion

Scientific  
programme

Friday 12 April 2019

## Symposium: Liver disease in pregnancy

Lehar 3

### Chairs:

Catherine WILLIAMSON, *United Kingdom*

Michael A HENEGHAN, *United Kingdom*

14:00-14:20

### Management of pregnancy in women with chronic liver disease

Rachel WESTBROOK, *United Kingdom*

14:20-14:40

### Management of women with acute fatty liver of pregnancy and severe gestational hypertension

Michael A HENEGHAN, *United Kingdom*

14:40-15:00

### Implications of intrahepatic cholestasis of pregnancy for maternal and fetal health

Hanns-Ulrich MARSCHALL, *Sweden*

15:00-15:20

### Viral hepatitis in pregnancy

Rakesh AGGARWAL, *India*

15:20-15:30

### Panel discussion: Current algorithms for managing liver disease in pregnancy

## EASL-ECDC Symposium: Using real world data to inform Hepatitis B and C elimination strategies

Lehar 4



Scientific programme

Friday 12 April 2019

**Chairs:**Erika DUFFELL, *Sweden*Francesco NEGRO, *Switzerland*

14:00-14:20

**Data for action: Using information from different sources relating the epidemics of hepatitis B and C in EU/EEA countries to inform response**

Lina NERLANDER, *Sweden*

14:20-14:40

**The attributable fraction of deaths due to hepatitis: results from a sentinel surveillance pilot and lessons learnt for future clinical-public health partnerships**

Erika DUFFELL, *Sweden*

14:40-15:00

**The short and long term impact of scaling up treatment for hepatitis B and C on disease burden**

Homie RAZAVI, *United States*

15:00-15:30

**The effective use of data to inform testing and treatment scale up: Lessons from Scotland**

Sharon HUTCHINSON, *United Kingdom*

## Pros & Cons Session: Issues in the radiological evaluation of advanced hepatocellular carcinoma Hepatology Arena

**Chairs:**Fabio PISCAGLIA, *Italy*Valérie VILGRAIN, *France*

14:00-14:10

**We need to use CEUS –US**Maria Assunta ZOCCO, *Italy*

14:10-14:20

**Pros speaker: The current criteria are useful**Riccardo LENCIONI, *Italy*

14:20-14:30

**Cons speaker: I'm afraid not**Jordi RIMOLA, *Spain*

14:30-15:00

**Discussion**

**Meet the Experts: Hepatic encephalopathy****Stolz 1****Chairs:**

Jasmohan S BAJAJ, *United States*  
Sara MONTAGNESE, *Italy*

14:00-14:50

Scientific  
programme**Meet the Experts: Management of immunosuppression in AIH** **Stolz 2****Chairs:**

Ansgar LOHSE, *Germany*  
Giorgina MIELI-VERGANI, *United Kingdom*

14:00-14:50

**Pros & Cons Session: Patients with immuntolerant  
HBeAg positive infection should/should not  
be treated****Hepatology Arena****Chairs:**

Patrick KENNEDY, *United Kingdom*  
Seng Gee LIM, *Singapore*

15:00-15:10

**Overview**

Anna LOK, *United States*

15:10-15:20

**Pros**

Maria BUTI, *Spain*

15:20-15:30

**Cons**

George PAPTAEODORIDIS, *Greece*

15:30-16:00

**Discussion**

Friday 12 April 2019



## Oral ePoster

15:30-16:00

### HEV

#### Chair:

Thomas VANWOLLEGHEM, *Netherlands*

#### Poster pod 1

### Alcoholic liver disease

#### Chair:

Sebastian MUELLER, *Germany*

#### Poster pod 2



### Liver development, physiology and regeneration

#### Chair:

Tobias CANTZ, *Germany*

#### Poster pod 3

### Fibrosis

#### Chair:

Neil HENDERSON, *United Kingdom*

#### Poster pod 4



## Poster tour

15:30-16:00

### Viral hepatitis C: Clinical aspects except therapy

#### Chair:

Ola WEILAND, *Sweden*

#### Meeting point 1

### Acute liver failure and drug induced liver injury

#### Chair:

Dominique LARREY, *France*

#### Meeting point 2



### NAFLD: Experimental and pathophysiology

#### Chair:

William ALAZAWI, *United Kingdom*

#### Meeting point 3



### Liver transplantation and hepatobiliary surgery: Clinical aspects

#### Chair:

François DURAND, *France*

#### Meeting point 4

## Parallel session: NAFLD – Clinical Therapy

## Main Plenary

**Chairs:**Elisabetta BUGIANESI, *Italy*Naga CHALASANI, *United States*16:00-16:15  
PS-105**Significant regression in fibrosis in paired liver biopsies following a 12-week aerobic exercise intervention in individuals with non-alcoholic fatty liver disease**Philip O'GORMAN, *Ireland*16:15-16:30  
PS-106**An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients**Rohit LOOMBA, *United States*16:30-16:45  
PS-107**SGLT2 inhibition does not reduce hepatic steatosis in overweight, insulin resistant patients without type 2 diabetes**Thomas MARJOT, *United Kingdom*16:45-17:00  
PS-108**NGM313, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects**Alex DEPAOLI, *United States*17:00-17:15  
PS-109**Partial inhibition of de novo lipogenesis with the acetyl-CoA carboxylase inhibitor PF-05221304 does not increase circulating triglycerides in humans and is sufficient to lower steatosis in rats**William ESLER, *United States*17:15-17:30  
PS-110**Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with nonalcoholic fatty liver disease**Roberto CALLE, *United States*17:30-17:45  
PS-111**Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444)**Stephen HARRISON, *United States*17:45-18:00  
PS-112**Endoscopic duodenal mucosal resurfacing improves hepatic fat fraction, glycemic and lipid profiles in type 2 diabetes**Guruprasad AITHAL, *United Kingdom*Scientific  
programme

Friday 12 April 2019

## Parallel session: Cirrhosis – Clinical aspects

Hall C3

**Chairs:**Annalisa BERZIGOTTI, *Switzerland*Dhiraj TRIPATHI, *United Kingdom*Scientific  
programme

16:00-16:15

PS-081

**Systemic arterial blood pressure determines the therapeutic window of non selective betablockers in patients with decompensated liver cirrhosis**Tammo Lambert TERGAST, *Germany*

16:15-16:30

PS-082

**Plasma metabolomic changes modulate the impact of Middle Eastern versus Western Diet in an international cirrhosis cohort**Jasmohan S BAJAJ, *United States*

16:30-16:45

PS-083

**Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study**Paolo CARACENI, *Italy*

16:45-17:00

PS-084

**Pregabalin for muscle cramps in patients with liver cirrhosis: A randomized, double-blind, placebo-controlled trial**Won KIM, *Korea, Rep. of South*

17:00-17:15

PS-085

**The impact of ABO blood group on von Willebrand factor levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease**Bernhard SCHEINER, *Austria*

17:15-17:30

PS-086

**Sustained virologic response in patients with cirrhosis from chronic hepatitis C leads to sustained and long-term improvement of health-related quality of life, fatigue, and work productivity**Zobair YOUNOSSI, *United States*

17:30-17:45

PS-087

**Fecal microbiota capsules are safe and effective in patients with recurrent hepatic encephalopathy: A randomized, blinded, placebo-controlled trial**Jasmohan S BAJAJ, *United States*

17:45-18:00

PS-088

**Impaired cardiac contractile reserve on dobutamine stress echocardiography predicts development of hepatorenal syndrome**Anoop KOSHY, *Australia*

Friday 12 April 2019

## Parallel session: Hepatitis B – drug development

Hall C2

**Chairs:**Eleanor BARNES, *United Kingdom*Massimo LEVRERO, *France*

- 16:00-16:15  
PS-073 **Preclinical profile of HBV core protein inhibitor, ABI-H3733, a potent inhibitor of cccDNA generation in HBV infected cells**  
Richard COLONNO, *United States*
- 16:15-16:30  
PS-074 **A first-in-class orally available HBV cccDNA destabilizer ccc\_R08 achieved sustainable HBsAg and HBV DNA suppression in the HBV circle mouse model through elimination of cccDNA-like molecules in the mouse liver**  
Lu GAO, *China*
- 16:30-16:45  
PS-075 **AAV-delivered IL-21 activates CD8+ T-cells to clear HBV replicon plasmid and cccDNA in mice**  
zhongliang SHEN, *China*
- 16:45-17:00  
PS-076 **Antiviral activity of JNJ-4964 (AL-034/TQ-A3334), a selective toll-like receptor 7 agonist, in AAV/HBV mice after oral administration for 12 weeks**  
An DE CREUS, *Belgium*
- 17:00-17:15  
PS-077 **Lenvetermab, a monoclonal antibody against HBsAg, can induce sustained HBsAg loss in a chronic hepatitis B mouse model**  
Jung-Hwan KIM, *Korea, Rep. of South*
- 17:15-17:30  
PS-078 **A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection**  
Mark THURSZ, *United Kingdom*
- 17:30-17:45  
PS-079 **HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy**  
Christine, Y.L. THAM, *Singapore*
- 17:45-18:00  
PS-080 **Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/mL threshold**  
Man-Fung YUEN, *Hong Kong*

Scientific  
programme

Friday 12 April 2019

## Parallel session: Liver cancer – From Prognosis to locoregional treatments

Strauss 1-2

### Chairs:

Pierre NAHON, *France*

Maria REIG, *Spain*

Scientific  
programme

Friday 12 April 2019

- 16:00-16:15  
PS-113 **Analysis of the HSD17B13: TA allelic variant as a putative protective factor towards hepatocellular carcinoma in patients with and without chronic hepatitis C**  
Carla DE BENEDITTIS, *Italy*
- 16:15-16:30  
PS-114 **Stabilization of UBQLN1 by circRNA\_104797 mediates acquired sorafenib resistance in hepatocellular carcinoma**  
Lin Ji, *China*
- 16:30-16:45  
PS-115 **Evaluation of LI-RADS v2018 by magnetic resonance in US-detected nodules <2 cm in cirrhotics**  
Alejandro FORNER, *Spain*
- 16:45-17:00  
PS-116 **Use of cyclooxygenase inhibitor and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nested case-control study using a nationwide population-based data**  
Sohn WON, *Korea, Rep. of South*
- 17:00-17:15  
PS-117 **Multiplatform analysis of HCC tumors uncovered molecularly distinct subtypes**  
Ju-Seog LEE, *United States*
- 17:15-17:30  
PS-118 **HCV eradication before or following curative management of HCC in patients with cirrhosis allows optimal tumour management and improves survival: The French multicentre prospective ANRS C012 CirVir cohort experience**  
Pierre NAHON, *France*
- 17:30-17:45  
PS-119 **Time-varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization**  
Claudia CAMPANI, *Italy*
- 17:45-18:00  
PS-120 **Post progression survival in patients with intermediate-stage hepatocellular carcinoma after receiving transarterial chemoembolization**  
Yukiko SHIMA, *Japan*

## Parallel session: Autoimmune and cholestasis II

Strauss 3

**Chairs:**Domenico ALVARO, *Italy*Jessica DYSON, *United Kingdom*

16:00-16:15

PS-121

**Obeticholic acid limits cholestasis induced cognitive decline by maintaining blood-brain barrier integrity and preserving neuronal health**Lucy GEE, *United Kingdom*

16:15-16:30

PS-122

**Seladelpar for the treatment of primary biliary cholangitis: Experience with 26 cirrhotic patients**Marlyn J. MAYO, *United States*

16:30-16:45

PS-123

**Biliary tree stem/progenitor cells mediate the regeneration in biliary lining after injury**Lorenzo NEVI, *Italy*

16:45-17:00

PS-124

**Cholestasis-induced kidney injury is ameliorated in Nlrp3 deficient mice**Mick FRISSEN, *Netherlands*

17:00-17:15

PS-125

**Gut pathobionts underlie intestinal barrier dysfunction and liver Th17 immune response in primary sclerosing cholangitis**Nobuhiro NAKAMOTO, *Japan*

17:15-17:30

PS-126

**Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis**Sara LEMOINNE, *France*

17:30-17:45

PS-127

**Analysis of liver infiltrating lymphocytes in primary sclerosing cholangitis by surface antigen and single cell RNAseq**Kate LYNCH, *United Kingdom*

17:45-18:00

PS-128

**Risk of gall bladder cancer in patients with primary sclerosing cholangitis and gall bladder polyps: An opportunity to revisit the guidelines**Liselot VAN ERP, *Canada*Scientific  
programme

Friday 12 April 2019



## EASL-EILF seminar: Complementarity of academia and industry in viral hepatitis elimination strategies

Lehar 1

Scientific  
programme

Friday 12 April 2019

- Chairs:**  
 Maria BUTI, *Spain*  
 Massimo COLOMBO, *Italy*
- 16:00-16:15 **The viral hepatitis elimination strategy of the EILF**  
 Jeffrey LAZARUS, *Spain*
- 16:15-16:30 **Perspectives on viral hepatitis elimination**  
 Gregg ALTON, *United States*
- 16:30-16:45 **Perspectives on viral hepatitis elimination**  
 Fernando TATSCH, *United States*
- 16:45-17:00 **Perspectives on viral hepatitis elimination**  
 Boris AZAIS, *France*
- 17:00-17:15 **Role of public-private partnerships (PPP) in viral hepatitis elimination**  
 Stefan WIKTOR, *United States*
- 17:15-17:30 **Summary of a global commission on viral hepatitis elimination**  
 Graham COOKE, *United Kingdom*
- 17:30-18:00 **Panel discussion: What are the crucial components of an effective strategy?**  
 Gregg ALTON, *United States*  
 Boris AZAIS, *France*  
 Maria BUTI, *Spain*  
 Massimo COLOMBO, *Italy*  
 Graham COOKE, *United Kingdom*  
 Philippa EASTERBROOK, *Switzerland*  
 Jeffrey LAZARUS, *Spain*  
 Jean-Michel PAWLITSKY, *France*  
 Fernando TATSCH, *United States*  
 Norah TERRAULT, *United States*  
 Stefan WIKTOR, *United States*

## Parallel session: Liver fibrosis

## Lehar 3

**Chairs:**Sophie LOTERSZTAJN, *France*Krista ROMBOOTS, *United Kingdom*16:00-16:15  
PS-089**Development of advanced alcoholic liver fibrosis involves intensive remodelling of a wide range of extracellular matrix proteins and is characterised by imbalance between collagen formation and -degradation and dysfunctional wound-healing**Stine JOHANSEN, *Denmark*16:15-16:30  
PS-090**SOX9 regulates extracellular matrix proteins in liver fibrosis that correlate with severity of fibrosis**Varinder ATHWAL, *United Kingdom*16:30-16:45  
PS-091**Targeted disruption of TGF-B activation by an AVB1 integrin inhibitor significantly reduces liver fibrosis in CCl4 mice and Human NASH liver slices**Scott TURNER, *United States*16:45-17:00  
PS-092**Lack of monoacylglycerol lipase protects from MCD-induced hepatic inflammation and fibrosis**Francesca BRUSCHI, *Austria*17:00-17:15  
PS-093**The dynamics of elastin in collagen-based liver fibrosis: Accumulates late during progression and degrades slowly in regression**Wei CHEN, *China*17:15-17:30  
PS-094**Selective activation of JAK-STAT1-mediated apoptosis in hepatic stellate cells as a new therapeutic option for liver fibrosis: Role of rilpivirine**Ana BLAS-GARCÍA, *Spain*17:30-17:45  
PS-095**MerTK-mediated cytokine secretion mediates a cross-talk between M2c macrophages and hepatic stellate cells to induce fibrosis**Mirella PASTORE, *Italy*17:45-18:00  
PS-096**Validation study of the impact of hepatic iron concentration on the development of advanced hepatic fibrosis in HFE hemochromatosis**Justin CHIN, *Australia*Scientific  
programme

Friday 12 April 2019

## Parallel session: Acute and acute-on-chronic liver failure – Translational aspects

Lehar 4

Scientific  
programme

Friday 12 April 2019

### Chairs:

François DURAND, *France*Claire FRANCOZ, *France*16:00-16:15  
PS-097

### The association between liver type fatty acid binding protein serum levels and clinical outcomes in patients with non-acetaminophen acute liver failure: A cohort study

Constantine KARVELLAS, *Canada*16:15-16:30  
PS-098

### Prevalence and risk factors of first line anti-tuberculosis drug induced liver injury: Large cohort study involving 4652 patients

Yan HUADONG, *China*16:30-16:45  
PS-099

### PP100-01 (calmangafodipir) for overdose of paracetamol (The POP trial): Principal results

James DEAR, *United Kingdom*16:45-17:00  
PS-100

### Bench-to-clinical development of plasminogen as a novel prognostic biomarker for patients with hepatitis B virus related acute-on-chronic liver failure

Daxian WU, *China*17:00-17:15  
PS-101

### Inhibition of toll-like receptor 4 using TAK-242 is a novel therapy for prevention and treatment of acute-on-chronic liver failure

Mohammed SHEIKH, *United Kingdom*17:15-17:30  
PS-102

### Circulating native albumin in patients with cirrhosis admitted to hospital for acute decompensation and acute-on-chronic liver failure: Relation to serum albumin levels, albumin function, and patient outcomes

Maurizio BALDASSARRE, *Italy*17:30-17:45  
PS-103

### BTLA expression contributes to HBV-related acute-on-chronic liver failure morbidity and mortality by inducing CD4+ T-cell exhaustion

Xueping YU, *China*17:45-18:00  
PS-104

### Prognosis assessment of acute-on-chronic liver failure in patients with hepatitis B virus-related cirrhosis requires specific criteria

Hai LI, *China*

## Critical reflection on landmark papers 2018

## Hepatology Arena

- Chair:**  
Fabio PISCAGLIA, *Italy*
- 16:00-16:30 **A placebo-controlled trial of bezafibrate in primary biliary cholangitis**  
Lead author: Christophe CORPECHOT, *France*  
Challenger: Pietro INVERNIZZI, *Italy*  
Discussion
- 16:30-17:00 **(TBD)**  
Lead author  
Challenger  
Discussion
- 17:00-17:30 **Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide**  
Lead author: Salvatore PIANO, *Italy*  
Challenger: Rajiv JALAN, *United Kingdom*  
Discussion
- 17:30-18:00 **Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer**  
Lead author: Matam VIJAY-KUMAR, *United States*  
Challenger: Mathias HEIKENWALDER, *Germany*  
Discussion

Scientific  
programme

Friday 12 April 2019

## Meet the Experts: Cell therapy for liver disease

## Stolz 1

- Chairs:**  
Stuart FORBES, *United Kingdom*  
Michael OTT, *Germany*

16:00-16:50

## Meet the Experts: Endoscopic versus surgical bariatric approaches as interventions for NAFLD

## Stolz 2



16:00-16:50

- Chairs:**  
Lars AABAKKEN, *Norway*  
Jude A. OBEN, *United Kingdom*

## Meet the Experts: Targeted therapies in genetic errors of metabolism

Stolz 1

### Chairs:

Elmar AIGNER, *Austria*Paul GISSEN, *United Kingdom*

17:00-17:50

## Meet the Experts: Management of symptoms of PBC

Stolz 2

### Chairs:

Annarosa FLOREANI, *Italy*Albert PARES, *Spain*

17:00-17:50

## Skills learning centre: Diagnostic ultrasound and elastography in hepatology

SLC 1

### Chairs:

Robert DE KNEGT, *Netherlands*Fabio PISCAGLIA, *Italy*

### Tutors:

Sandra COENEN, *Netherlands*Thomas KARLAS, *Germany*Sarwa Darwish MURAD, *Netherlands*Davide ROCCARINA, *United Kingdom*Horia STEFANESCU, *Romania*Christoph TERKAMP, *Germany*Francesco TOVOLI, *Italy*Mette VESTERHUS, *Norway*

18:30-19:15

## Skills learning centre: Diagnostic ultrasound and elastography in hepatology

SLC 1



### Chairs:

Robert DE KNEGT, *Netherlands*

Fabio PISCAGLIA, *Italy*

### Tutors:

Sandra COENEN, *Netherlands*

Thomas KARLAS, *Germany*

Sarwa Darwish MURAD, *Netherlands*

Davide ROCCARINA, *United Kingdom*

Horia STEFANESCU, *Romania*

Christoph TERKAMP, *Germany*

Francesco TOVOLI, *Italy*

Mette VESTERHUS, *Norway*

19:15-20:00

Scientific  
programme

Friday 12 April 2019

## Skills learning centre: Invasive diagnostics methods

SLC 2

18:30-19:15



### Hepatic hemodynamics

Pierre-Emmanuel RAUTOU, *France*

Mattias MANDORFER, *Austria*

Thomas REIBERGER, *Germany*

### TIPS

Virginia HERNANDEZ-GEA, *Spain*

Roberto MIRAGLIA, *Italy*

### Thermal ablation

Christiane KUHL, *Germany*

Peter ISFORT, *Germany*

Markus ZIMMERMANN, *Germany*

### Endoscopy

Andres CARDENAS, *Spain*

Arnulf FERLITSCH, *Austria*

### SX-ELLA Danis Stent

Enric REVERTER, *Spain*

**Skills learning centre: Invasive diagnostics methods****SLC 2**

19:15-20:00

**Hepatic hemodynamics**Pierre-Emmanuel RAUTOU, *France*Mattias MANDORFER, *Austria*Thomas REIBERGER, *Germany***TIPS**Virginia HERNANDEZ-GEA, *Spain*Roberto MIRAGLIA, *Italy***Thermal ablation**Christiane KUHL, *Germany*Peter ISFORT, *Germany*Markus ZIMMERMANN, *Germany***Endoscopy**Andres CARDENAS, *Spain*Arnulf FERLITSCH, *Austria***SX-ELLA Danis Stent**Enric REVERTER, *Spain*Scientific  
programme

Friday 12 April 2019

**Industry Symposium**

18:30-20:00

**Please refer to the industry section for more details**

**SCIENTIFIC PROGRAMME**  
SATURDAY 13 APRIL 2019

## Saturday 13 April 2019

### Parallel session: Hepatitis C – Treatment and resistance Main Plenary

#### Chairs:

Jean-Michel PAWLITSKY, *France*

Tania WELZEL, *Germany*

08:00-08:15  
PS-178

**Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study**

Gregory DORE, *Australia*

08:15-08:30  
PS-179

**Analysis of long-term persistence of HCV resistance-associated substitutions within NS3, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure**

Julia DIETZ, *Germany*

08:30-08:45  
PS-180

**ns5a resistance profile of genotype 1b virological failures that impacts outcome of re-treatment by glecaprevir/pibrentasvir: Nation-wide real world study**

Masayuki KUROSAKI, *Japan*

08:45-09:00  
PS-181

**Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes : Implications for global elimination**

Kate CHILDS, *United Kingdom*

09:00-09:15  
PS-182

**Effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 infection who receive opioid agonist therapy: Treatment utilization and the impact of concomitant psychiatric medications**

Amy PUENPATOM, *United States*

09:15-09:30  
PS-183

**Association of patient-reported outcomes with cerebral metabolism in patients with chronic hepatitis C at baseline and post sustained virologic response**

Zobair YOUNOSSI, *United States*

09:30-09:45  
PS-184

**Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis**

Marcello PERSICO, *Italy*

Scientific  
programme

Saturday 13 April 2019

## Parallel session: Cirrhosis – Experimental aspects

Hall C3

**Chairs:**Isabelle COLLE, *Belgium*Pierre-Emmanuel RAUTOU, *France*08:00-08:15  
PS-143**High-dimensional profiling of immune response in cirrhosis: Key role for activated CD8+ T-cells and relationship with prognosis**Elsa SOLÀ, *Spain*08:15-08:30  
PS-144**Autotaxin mediates lipid dysregulation in acute-on-chronic liver failure, promoting persistence of systemic inflammation via lysophosphatidic acid-mediated monocyte activation**Mark J W MCPHAIL, *United Kingdom*08:30-08:45  
PS-145**Albumin protects the liver from tumour necrosis factor alpha-induced cell death**Marta DURAN-GÜELL, *Spain*08:45-09:00  
PS-146**Intestinal mucus and vascular barrier: FxR-modulated entry sites for pathological bacterial translocation in liver cirrhosis independent from portal hypertension and lymphatic route**Marcel SORRIBAS, *Switzerland*09:00-09:15  
PS-147**Simvastatin-loaded nanoparticles are more effective and less toxic than conventional statins in a pre-clinical model of advanced chronic liver disease**Diana HIDE, *Spain*09:15-09:30  
PS-148**Liver sinusoidal endothelial cells significantly cooperate in the phagocytic immune activities and activation of the adaptive T cell response in a model of experimental cirrhosis by CCl4**Esther CAPARRÓS, *Spain*09:30-09:45  
PS-149**Recombinant glutamine synthetase: A novel strategy for the treatment of hyperammonemia and consequent hepatic encephalopathy in rodent model of cirrhosis and urea cycle enzyme deficiency**Guangjun SONG, *China*Scientific  
programme

Saturday 13 April 2019

## Parallel session: NAFLD – Preclinical pipeline

Hall C1

**Chairs:**Luca VALENTI, *Italy*Arun SANYAL, *United States*Scientific  
programme08:00-08:15  
PS-130**Preclinical pharmacology of CJ-14199, a new and potent ileum bile acid transporter inhibitor for non-alcoholic steatohepatitis**Dong-Kyu KIM, *Korea, Rep. of South*08:15-08:30  
PS-131**Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model**Robert WALCZAK, *France*08:30-08:45  
PS-132**The acetyl-CoA carboxylase inhibitor PF-05221304 exerts direct effects on hepatic inflammation and fibrosis independent of benefits on steatosis**Trenton ROSS, *United States*08:45-09:00  
PS-133**LXR inverse agonists reduce steatosis and fibrosis in the STAM mouse model but also improve insulin sensitivity in a high fat diet mouse clamp study**Eva HAMBRUCH, *Germany*09:00-09:15  
PS-134**Oral treatment with PBI-4547 promotes beta-oxidation and energy expenditure, and reverses liver damage and white adipose tissue fibrosis in high-fat diet and ob/ob mouse models of NAFLD.**Brigitte GROUX, *Canada*09:15-09:30  
PS-135**MSDC-0602K, a PPAR-gamma sparing modulator of the mitochondrial pyruvate carrier, improves NASH outcome in a diet-induced animal model of non-alcoholic steatohepatitis**Jerry COLCA, *United States*09:30-09:45  
PS-129**The glucocorticoid antagonist ST001 prevents development of NASH and improves aspects of the metabolic syndrome in the DIAMOND™ mouse model**Manohar KATAKAM, *United States*

Saturday 13 April 2019

**Parallel session: Liver cancer – Systemic treatment and immunotherapy**
**Hall C2**
**Chairs:**

 Lorenza RIMASSA, *Italy*

 Bruno SANGRO, *Spain*

 08:00-08:15  
PS-136

**Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis**

 Atsushi HIRAOKA, *Japan*

 08:15-08:30  
PS-137

**A multicentric study on real-life impact of nivolumab in patients with hepatocellular carcinoma**

 Leonardo GOMES DA FONSECA, *Spain*

 08:30-08:45  
PS-138

**PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort**

 Matthias PINTER, *Austria*

 08:45-09:00  
PS-139

**Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy**

 Morven CUNNINGHAM, *Canada*

 09:00-09:15  
PS-140

**Association of gut microbiome with clinical response to nivolumab in advanced hepatocellular carcinoma: A pilot study**

 Pei-Chang LEE, *Taiwan*

 09:15-09:30  
PS-141

**CyTOF-based immune monitoring of HBV-HCC patients receiving autologous anti-tumour T-cell therapy**

 Antonio BERTOLETTI, *Singapore*

 09:30-09:45  
PS-142

**Analysis of sorafenib-regorafenib sequential therapy in patients with advanced hepatocellular carcinoma using baseline date of sorafenib**

 Sae YUMITA, *Japan*

 Scientific  
programme

Saturday 13 April 2019

## Parallel session: Non-invasive assessment of liver disease

Strauss 1-2



### Chairs:

Laurent CASTERA, *France*

Mette VESTERHUS, *Norway*

Scientific  
programme

Saturday 13 April 2019

08:00-08:15  
PS-185

**Magnetic resonance risk score and liver stiffness by transient elastography have complementary prognostic values in patients with primary sclerosing cholangitis**

Nora CAZZAGON, *Italy*

08:15-08:30  
PS-186

**Functional liver imaging score derived from gadoxetic acid-enhanced MRI predicts outcomes in patients with advanced chronic liver disease**

Mattias MANDORFER, *Austria*

08:30-08:45  
PS-187

**Transient elastography is the most reliable non-invasive predictor of advanced liver fibrosis in fontan-associated liver disease: The VALDIG FONLIVER study**

Luis TÉLLEZ, *Spain*

08:45-09:00  
PS-188

**A novel non-invasive technology for liver fibrosis detection**

Hao CHEN, *United States*

09:00-09:15  
PS-189

**Toronto HCC risk index and albumin predict low risk of hepatocellular carcinoma after sustained virological response in hepatitis C infection**

Jason LAU, *Canada*

09:15-09:30  
PS-190

**Cirrhotic cardiomyopathy evaluated by myocardial deformation imaging and new diastolic dysfunction criteria: Prevalence and relationship with circulatory dysfunction**

Francisco CUEVA RECALDE, *Spain*

09:30-09:45  
PS-191

**External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) for identifying subjects at risk of hepatocellular carcinoma among patients with chronic liver disease**

Valentina PETA, *France*

**Parallel session: Clinical developments in rare liver disease Strauss 3**
**Chairs:**

 Emma ANDERSSON, *Sweden*

 Ansgar LOHSE, *Germany*

- 08:00-08:15  
PS-192 **Janreotide reduces liver growth in autosomal dominant polycystic kidney disease: Data from a 120-week randomized clinical trial**  
René VAN AERTS, *Netherlands*
- 08:15-08:30  
PS-193 **Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis**  
Emmanuel GONZALES, *France*
- 08:30-08:45  
PS-194 **Effects of the ileal bile acid transport inhibitor A4250 on serum bile acids, pruritus and sleep in patients with Alagille syndrome: Phase 2 study results**  
Ulrich BAUMANN, *Germany*
- 08:45-09:00  
PS-195 **Predicting long-term outcome after surgical biliary diversion in Bsep-deficiency patients: Results from the NAPPED consortium**  
Daan VAN WESSEL, *Netherlands*
- 09:00-09:15  
PS-196 **Efficacy and safety of sebelipase alfa over 144 weeks in a diverse population of children and adults with lysosomal acid lipase deficiency**  
Florian ABEL, *Switzerland*
- 09:15-09:30  
PS-197 **Heterozygous alpha1-antitrypsin deficiency (Pi\*MZ) is associated with increased liver stiffness and elevated liver enzymes in a multi-center European cohort**  
Carolin Victoria HEIMES, *Germany*
- 09:30-09:45  
PS-198 **Fibroscan improves diagnosis of cystic fibrosis related liver disease**  
Jennifer SCOTT, *United Kingdom*

 Scientific  
programme

Saturday 13 April 2019

## Parallel session: Translational virology

Lehar 1

**Chairs:**Maura DANDRI, *Germany*Darius MORADPOUR, *Switzerland*Scientific  
programme08:00-08:15  
PS-150**Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos(t)ide therapy with detectable but not quantifiable HBV DNA**Dara BURDETTE, *United States*08:15-08:30  
PS-151**Hepatitis E virus infection induces mitochondrial fusion to facilitate viral replication through induction of autophagy**Yijin WANG, *China*08:30-08:45  
PS-152**Formation of semi-enveloped particles as a unique feature of a HBV deletion mutant**Eberhard HILDT, *Germany*08:45-09:00  
PS-153**The pre-s2 deletion HBV mutants are responsible for the intracellular accumulation of the HBS protein, ER stress and mitochondria dysfunction**Jenny Yuh-Jin LIANG, *Taiwan*09:00-09:15  
PS-154**Dissecting the different roles of ORF3 in HEV spread and fecal shedding in a humanized mouse model**Gulce SARI, *Netherlands*09:15-09:30  
PS-155**HBV entry inhibition after interferon alpha treatment hinders HBV rebound in hepatocytes that became negative for all HBV markers during interferon treatment**Lena ALLWEISS, *Germany*09:30-09:45  
PS-156**Antigen suppression effect of the core protein allosteric modulator R07049389 in AAV-HBV mice is accompanied by transient upregulation of immune-cell gene signatures in the liver**Lu GAO, *China*

Saturday 13 April 2019

## Parallel session: Gut-Liver Axis

## Lehar 2

**Chairs:**Patricia LALOR, *United Kingdom*Christian TRAUTWEIN, *Germany*

- 08:00-08:15  
PS-157 **Gut microbiome signature for cirrhosis due to non-alcoholic fatty liver disease: A prospective twin and family study**  
Cyrielle CAUSSY, *United States*
- 08:15-08:30  
PS-158 **Paneth cells drive microbial induced signals to promote angiogenesis and regulate portal hypertension**  
Mohsin HASSAN, *Switzerland*
- 08:30-08:45  
PS-159 **Intestinal dysbiosis fuels liver disease progression via NLRP3 in the Mdr2-/- mouse model of primary sclerosing cholangitis**  
Kai Markus SCHNEIDER, *Germany*
- 08:45-09:00  
PS-160 **miRNA-21 signals through a gut-liver axis to regulate experimental cholestasis**  
André A. SANTOS, *Portugal*
- 09:00-09:15  
PS-161 **Lactobacillus rhamnosus GG culture supernatant improves energy expenditure and glucose tolerance in high-fat-high-fructose fed mice exposed to chronic intermittent hypoxia through regulation of intestinal microbiota and bile acid homeostasis**  
Qi LIU, *China*
- 09:15-09:30  
PS-162 **Gut microbiota is closely involved in the prognosis of HBV-related acute-on-chronic liver failure**  
KE WANG, *China*
- 09:30-09:45  
PS-163 **Faecal microbiota transplantation with tenofovir is superior to tenofovir alone in improving clinical outcomes in acute-on-chronic liver failure due to hepatitis B: An open label randomized controlled trial (NCT02689245)**  
Juned AHMAD, *India*

Scientific  
programme

Saturday 13 April 2019

## Parallel session: Liver transplantation I

Lehar 3

**Chairs:**

Marina BERENQUER HAYM, *Spain*  
Christian TOSO, *Switzerland*

Scientific  
programme

08:00-08:15  
PS-164

**Patients with non-alcoholic steatohepatitis have inferior liver transplant outcomes**

Dilip MOONKA, *United States*

08:15-08:30  
PS-165

**Handgrip strength adds more prognostic value to the MELD score than imaging-based measures of muscle mass in men awaiting liver transplantation**

Marie SINCLAIR, *Australia*

08:30-08:45  
PS-166

**Repopulation of decellularized porcine bile ducts with human cholangiocyte organoids for the generation of human-sized bioengineered biliary tissue**

Fotios SAMPAZIOTIS, *United Kingdom*

08:45-09:00  
PS-167

**Bile as a non-invasive source of cholangiocyte organoids for developing patient-specific disease modelling and personalized regenerative medicine**

Floris ROOS, *Netherlands*

09:00-09:15  
PS-168

**Novel real time prediction of liver graft function during hypothermic oxygenated machine perfusion prior to liver transplantation**

Philipp DUTKOWSKI, *Switzerland*

09:15-09:30  
PS-169

**Umbilical cords-derived mesenchymal stem cells ameliorated hepatocellular apoptosis mediated by PINK1-dependent mitophagy in liver ischemia/reperfusion injury dependent on AMPK $\alpha$  activation**

Jun ZHENG, *China*

09:30-09:45  
PS-170

**A trend towards a lower patient survival is observed when either NAT+ve or NAT-ve donors with positive HCV Ab are transplanted into HCV negative recipients**

Paul J. THULUVATH, *United States*

Saturday 13 April 2019

## Parallel session: Alcohol related liver disease

Lehar 4

**Chairs:**Maja THIELE, *Denmark*Mark THURSZ, *United Kingdom*08:00-08:15  
PS-171**Survival in a 10 year prospective cohort of heavy drinkers: Liver stiffness is the best long-term prognostic parameter**Johannes MUELLER, *Germany*08:15-08:30  
PS-172**Acute adipocyte death preferentially induces liver injury and inflammation via the activation of CCR2+ macrophages and lipolysis**Bin GAO, *United States*08:30-08:45  
PS-173**Differential contribution of RIP3-mediated cell death in alcohol and non-alcohol related liver disease**Laura NAGY, *United States*08:45-09:00  
PS-174**Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis**Luke D. TYSON, *United Kingdom*09:00-09:15  
PS-175**The burden of alcoholic cirrhosis is critically increasing in Canada: A population-based study**Hassan AZHARI, *Canada*09:15-09:30  
PS-176**Hyperoxidized albumin promotes platelet dysregulation to induce systemic inflammation in severe alcoholic hepatitis**Adil BHAT, *India*09:30-09:45  
PS-177**HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis**Felix STICKEL, *Switzerland*Scientific  
programme

Saturday 13 April 2019

**Solve the Case: NASH****Hepatology Arena****Chairs:**

Elisabetta BUGIANESI, *Italy*  
 Frank TACKE, *Germany*

08:00-09:00

Scientific  
programme**Meet the Experts: Kidney failure after liver transplantation****Stolz 1****Chairs:**

Patrizia BURRA, *Italy*  
 Didier SAMUEL, *France*

08:00-08:50

Saturday 13 April 2019

**Meet the Experts: When to use TIPS in cirrhosis****Stolz 2****Chairs:**

Christophe BUREAU, *France*  
 Guadalupe GARCIA-TSAO, *United States*

08:00-08:50

**Meet the Experts: Hepatitis B: When to stop NA therapy?****Stolz 1****Chairs:**

Maurizia BRUNETTO, *Italy*  
 George PAPTAEODORIDIS, *Greece*

09:00-09:50

**Meet the Experts: New MRI contrast agents in the diagnosis and staging of liver tumours****Stolz 2****Chairs:**

Carmen AYUSO, *Spain*  
 Fabio PISCAGLIA, *Italy*

09:00-09:50

## General session III and award ceremony II

## Main Plenary

**Chairs:**Mauro BERNARDI, *Italy*Maria BUTI, *Spain*

10:00-10:15

GS-13

**Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in with PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection**

Heiner WEDEMEYER, *Germany*

10:15-10:30

GS-14

**ENVISION, a phase 3 study to evaluate efficacy and safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients**

Manisha BALWANI, *United States*

10:30-10:45

GS-15

**Deficiency of the ABC transporter ABCC12/MRP9 is associated with chronic cholestasis syndromes and causes bile duct paucity in zebrafish and mouse model organisms**

Lingfen XU, *United States*

10:45-11:15

**Award ceremony II**

11:15-11:30

GS-16

**Safety and tolerability of liver-derived stem cells (HepaStem) infused in patients with acute-on-chronic liver failure or acute decompensation: A European phase I/IIa open-labelled study**

Etienne SOKAL, *Belgium*

11:30-11:45

GS-17

**The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative disease: Implications for the treatment and management of CHB**

Romina SALPINI, *Italy*

11:45-12:00

GS-18

**Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival**

Christophe CORPECHOT, *France*Scientific  
programme

Saturday 13 April 2019

## Karl Wilhelm von Kupffer basic state-of-the-art: The power of ONE: Immunology in the age of single cell genomics

Main Plenary

12:00-12:30

Ido AMIT, *Israel*

### Biography

Born on Kibbutz Hatzor, Prof. Ido Amit earned his PhD in biological regulation at the Weizmann Institute of Science in 2007. For four years, he was a postdoctoral fellow at the Broad Institute of Harvard University and the Massachusetts Institute of Technology, before joining the Weizmann Institute in 2011.

Ido Amit is a Professor at the Immunology Department at the Weizmann Institute of Science. His lab pioneered single cell genomic technologies and their application to characterize the immune system. Amit's research answers some of the most fundamental questions in immunology which are being translated into innovative new targets for immunotherapy in autoimmune diseases, neurodegeneration and cancer. Prof. Amit is also known in the science community as a leader in the field of immunogenomics, aimed at detecting and engineering genome sequences that are essential for the function of the immune system in physiology and disease. Among others, Prof. Amit is a recipient of the EMBO Gold Medal award and an HHMI International Research Scholar for his work to reveal the function of the immune system.

### Lecture Summary

The immune system is a complex, dynamic and plastic network composed of various interacting cell types that are constantly sensing and responding to environmental cues. From very early on, the immunology field has invested great efforts and ingenuity to characterize the various immune cell types and elucidate their functions. However, accumulating evidence indicates that current technologies and classification schemes are limited in their ability to account for the functional heterogeneity of immune processes. Single cell genomics hold the potential to revolutionize the way we characterize complex immune cell assemblies and study their spatial organization, dynamics, clonal distribution, pathways, and crosstalk. This emerging field can greatly affect basic and translational research of the immune system. I will discuss how recent single cell genomic studies are changing our perspective of various immune related pathologies from cancer to neurodegeneration. Finally, I will consider recent and forthcoming technological and analytical advances in single cell genomics and their potential impact on the future of immunology research and immunotherapy.

## Industry Symposium

12:30-14:00

**Please refer to the industry section for more details**

## Meet the Experts: Assessing patients with NASH for transplantation

Stolz 1



### Chairs:

Michael CHARLTON, *United States*  
Frank TACKE, *Germany*

12:30-13:20

## Meet the Experts: Hepatitis B: Which new drugs are in development and how do they work?

Stolz 2

### Chairs:

Ulrike PROTZER, *Germany*  
Fabien ZOULIM, *France*

12:30-13:20



## Oral ePoster

13:00-14:00

### HCV – Clinical – Therapy II

#### Chair:

Johannes VERMEHREN, *Germany*

#### Poster pod 1

### Autoimmune and Cholestatic liver disease – Clinical

#### Chair:

Douglas THORBURN, *United Kingdom*

#### Poster pod 2

Scientific programme

Saturday 13 April 2019



### Liver transplantation and hepatobiliary surgery – Experimental

#### Chair:

Renato ROMAGNOLI, *Italy*

**Poster pod 3**



### Fatty liver disease – Experimental

#### Chair:

Rui CASTRO, *Portugal*

**Poster pod 4**



## Poster tour

13:00-13:30

### Viral Hepatitis A, B, C, D, E: Virology

#### Chair:

Philip MEULEMAN, *Belgium*

**Meeting point 1**

13:00-14:00

### Cirrhosis and its complications: Clinical

#### Chair:

Sara MONTAGNESE, *Italy*

**Meeting point 2**

13:00-13:30

### NAFLD: Therapy

#### Chair:

Sven FRANcqUE, *Belgium*

**Meeting point 3**

13:00-13:30

### Liver tumours: Clinical aspects except therapy

#### Chair:

Pierre NAHON, *France*

**Meeting point 4**

13:30-14:00

### Viral hepatitis A/E: Clinical aspect

#### Chair:

Heiner WEDEMEYER, *Germany*

**Meeting point 1**

13:30-14:00

### Molecular and cellular biology

#### Chair:

Krista ROMBOUITS, *United Kingdom*

**Meeting point 4**



## Meet the Experts: Bile duct strictures in PSC: observation or intervention?

Stolz 1

### Chairs:

Annika M BERGQUIST, *Sweden*  
Stephen PEREIRA, *United Kingdom*

13:30-14:20

Scientific  
programme

## Meet the Experts: Gut microbiota and liver disease – where are the therapeutic opportunities?

Stolz 2

### Chairs:

David ADAMS, *United Kingdom*  
Raffaella GADALETA, *Italy*

13:30-14:20

Saturday 13 April 2019

## Symposium: Patient prioritization for HCC treatment

Main Plenary

### Chair:

Peter GALLE, *Germany*

14:00-14:30

### Who is the optimal candidate for surgical therapy and who is not?

Vincenzo MAZZAFERRO, *Italy*

14:30-15:00

### Who is the optimal candidate for locoregional intervention and who is not?

Riccardo LENCIONI, *Italy*

15:00-15:30

### Who is the optimal candidate for systemic therapy and who is not?

Maria REIG, *Spain*

## Symposium: Multidisciplinary approaches to the management of NAFLD

Hall C3

### Chairs:

Laurent CASTERA, *France*  
Rachel PRYKE, *United Kingdom*  
Shira ZELBER-SAGI, *Israel*

14:00-14:25

### Role and perspective of primary care in the management of NASH

Christos LIONIS, *Greece*

14:25-14:50

### Optimal management of diabetes in the setting of NASH

Norbert STEFAN, *Germany*

14:50-15:15 **Optimal management of obesity in the setting of NASH**  
Roberto VETTOR, *Italy*

15:15-15:30 **Panel discussion**

Scientific  
programme

## EASL-ALEH Symposium: DILI

Hall C2

### Chairs:

Raul J. ANDRADE, *Spain*

Mario PESSOA, *Brazil*

14:00-14:20 **Liver injury related to herbal and dietary supplements:  
A global perspective**  
Fernando BESSONE, *Argentina*

14:20-14:40 **Assessment of patients with DILI suspicion in 2019**  
Raul J. ANDRADE, *Spain*

14:40-15:00 **Mechanism and management of DILI induced by biologics and  
immunotherapeutic agents**  
Nêlia HERNANDEZ, *Uruguay*

15:00-15:20 **DILI and HIV: Still a problem?**  
Mark SONDERUP, *South Africa*

15:20-15:30 **Conclusions**

Saturday 13 April 2019

## EASL-WHO symposium: Best practices and lessons learned from global viral hepatitis scale-up

Strauss 1-2



### Chairs:

Massimo COLOMBO, *Italy*

Gottfried HIRNSCHALL, *Switzerland*

14:00-14:10 **Global progress towards hepatitis elimination-an update**  
Marc BULTERYS, *Switzerland*

14:10-14:20 **The price tag-what is it going to cost?**  
Mehlika TOY, *United States*

14:20-14:30 **Q&A**

14:30-14:40 **What are the good practices and lessons learned from country  
response?-A global project**  
Philippa EASTERBROOK, *Switzerland*

- 14:40-15:00 **Good Practices 1: Access to drugs and diagnostics**  
Sean REGAN, *United States*
- 15:00-15:10 **Good Practices 2: Training the workforce**  
Ena ORU, *Switzerland*
- 15:10-15:20 **Good Practices 3: Prevention and Harm reduction-Ukraine, Vietnam and Kenya**  
Ernst WISSE, *France*
- 15:20-15:30 **Good Practices 4: Community leadership and engagement-Video Columbia, Indonesia, India**  
Maria DONATELLI KLINGER, *France*
- 15:30-16:00 **Q&A and Panel discussion**

Scientific  
programme

### YI Fusion: Research opportunities for young investigators in biliary diseases

Strauss 3

#### Chairs:

Ulrich BEUERS, *Netherlands*Julie HEIMBACH, *United States*

- 14:00-14:20 **Biliary organoids as tools for studying cholangiocyte biology: Cookbook for the inexperienced**  
Fotis SAMPAZIOTIS, *United Kingdom*
- 14:20-14:40 **Pathogenesis of cholangiocarcinoma in infectious and inflammatory bile duct diseases**  
Feng REN, *China*
- 14:40-15:00 **Distinct autoantibodies of IgG4-related sclerosing cholangitis (IgG4-SC) and primary sclerosing cholangitis (PSC)**  
Masahiro SHIOKAWA, *Japan*
- 15:00-15:20 **Biomarkers for biliary inflammation and neoplasia**  
María Jesús PERUGORRIA, *Spain*
- 15:20-15:40 **Perspectivating remarks: Are bile duct diseases important?**  
Ulrich BEUERS, *Netherlands*

Saturday 13 April 2019

**The best of JHEP: 2015-2019****Lehar 2****Chair:**Rajiv JALAN, *United Kingdom*

14:00-14:10

**How JHEP reached an IF of 15**Rajiv JALAN, *United Kingdom***The best papers in JHEP: An editors' view**

14:10-14:18

**Cancer**Jessica ZUCMAN-ROSSI, *France*

14:18-14:26

**Basic Science**Sophie LOTERSZTAJN, *France*

14:26-14:34

**Cirrhosis/Liver Failure**Rajiv JALAN, *United Kingdom*

14:34-14:42

**Viral Hepatitis**Thomas BERG, *Germany*

14:42-14:50

**ALD/NAFLD**Ramon BATALLER, *United States*

14:50-15:00

**The best reviews in JHEP**Richard MOREAU, *France*

15:00-15:08

**Extending JHEP excellence into JHEP Reports**Jessica ZUCMAN-ROSSI, *France*

15:08-15:16

**Growing the JHEP tradition: Introducing the new JHEP team**Paolo ANGELI, *Italy*

15:16-15:30

**Conclusions and Questions****Symposium: Bioartificial livers, cell therapies and tissue engineering – The future of regenerative hepatology?****Lehar 3****Chairs:**Pedro BAPTISTA, *Spain*Etienne SOKAL, *Belgium*

14:00-14:30

**Bioartificial livers: Past, ELAD and futur**Jan STANGE, *Germany*

14:30-15:00 **Liver cell therapies: hepatocytes and beyond**  
Stephen STROM, *Sweden*

15:00-15:30 **Human liver bioengineering**  
Giuseppe MAZZA, *United Kingdom*

### Young investigators seminar: Hepatology in 2030

Lehar 4

**Chairs:**

Andre ESTEVA, *United States*  
Sabela LENS, *Spain*

14:00-14:20 **Unmet needs in viral hepatitis in 2030: Will there be any?**  
Darius MORADPOUR, *Switzerland*

14:20-14:40 **Changing landscape in liver transplantation: New technologies**  
Peter FRIEND, *United Kingdom*

14:40-15:00 **Artificial intelligence (AI) in medicine**  
Andre ESTEVA, *United States*

15:00-15:20 **Liquid biopsy: How will it be used in daily practice?**  
Helen Louise REEVES, *United Kingdom*

15:20-15:30 **Q&A and conclusions**

### Pros & Cons Session: Prolonged antibiotic prophylaxis in patients with cirrhosis is harmful? Hepatology Arena

**Chairs:**

Vicente ARROYO, *Spain*  
Salvatore PIANO, *Italy*

14:00-14:10 **Overview**  
Dhiraj TRIPATHI, *United Kingdom*

14:10-14:20 **Pros**  
Javier FERNÁNDEZ, *Spain*

14:20-14:30 **Cons**  
Guadalupe GARCIA-TSAO, *United States*

14:30-15:00 **Discussion**

Scientific  
programme

Saturday 13 April 2019

## Meet the Experts: Clinical management of polycystic liver disease

Stolz 1

### Chairs:

Joost DRENTH, *Netherlands*Mario STRAZZABOSCO, *United States*

14:30-15:20

## Meet the Experts: Weaning of immunosuppression after liver transplantation

Stolz 2



### Chairs:

Giuseppe TISONE, *Italy*Alberto SANCHEZ-FUEYO, *United Kingdom*

14:30-15:20

## Flash Abstract Session: HBV and Pregnancy

Poster pod 1

### Chair:

Pietro LAMPERTICO, *Italy*

14:00-14:10

FA-01

### Prevalence of mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis

Naijuan YAO, *China*

14:10-14:20

FA-02

### The efficacy of two different dosages hepatitis B immunoglobulin in interrupting mother-to-infant transmission of hepatitis B virus: A systematic review and meta-analysis

Shan FU, *China*

14:20-14:30

FA-03

### Caesarean section versus vaginal delivery to prevent mother-to-child transmission of hepatitis B virus: A meta-analysis

Juan LI, *China*

14:30-14:40

FA-04

### Tenofovir disoproxil fumarate use during pregnancy and maternal bone health: The tenofovir in pregnancy (TiP) pilot study

Athena KOURTIS, *United States*

14:40-14:50

FA-05

### Tenofovir disoproxil fumarate treatment is safe and efficacy for chronic hepatitis B mothers from early pregnancy

Yali FENG, *China*

- 14:50-15:00  
FA-06 **Maternal nucleoside analogues treatment and infant immunoprophylaxis to prevent chronic hepatitis B in children: A prospective eight-year real-world study**  
Yang LI, *China*
- 15:00-15:10  
FA-07 **A Bayesian network analysis of the efficacy and safety of antiviral therapy for chronic hepatitis B infection during different trimesters of pregnancy**  
Yuchao WU, *China*
- 15:10-15:20  
FA-08 **Hepatic flare after antiviral treatment withdraw in post-partum for pregnancy of chronic hepatitis B viral infection: A pairwise and Bayesian network meta-analysis**  
Yali FENG, *China*

Scientific  
programme

Saturday 13 April 2019


Oral ePoster

15:30-16:00



**Liver tumours – Experimental and pathophysiology**  
**Chair:**  
Jean-Charles NAULT, *France*  
**Poster pod 2**



**Viral Hepatitis A, B, C, D, E: Virology**  
**Chair:**  
Sofia PEREZ-DEL-PULGAR, *Spain*  
**Poster pod 3**

**Cirrhosis – ACLF and Critical illness**  
**Chair:**  
Thierry GUSTOT, *Belgium*  
**Poster pod 4**



## Poster tour

15:30-16:00

### **Viral Hepatitis C: Post SVR and long term follow up**

**Chair:**

Ulrich SPENGLER, *Germany*

**Meeting point 1**

### **Immunology except viral hepatitis**

**Chair:**

Mala MAINI, *United Kingdom*

**Meeting point 2**



### **NAFLD: Diagnostics and non-invasive assessment**

**Chair:**

Jerome BOURSIER, *France*

**Meeting point 3**



### **Non-invasive assessment of liver disease except NAFLD**

**Chair:**

Emmanuel TSOCHATZIS, *United Kingdom*

**Meeting point 4**

Saturday 13 April 2019

Scientific  
programme

## Late Breaker

## Main Plenary

**Chairs:**

Thomas BERG, *Germany*

Maria REIG, *Spain*

16:00-16:15  
LBO-01

### **Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension**

Guadalupe GARCIA-TSAO, *United States*

16:15-16:30  
LBO-02

### **Elafibranor, a peroxisome proliferator-activated receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment**

Velimir LUKETIC, *United States*

16:30-16:45  
LBO-03

### **Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B**

Terry CF YIP, *Hong Kong*

- 16:45-17:00  
LBO-04 **Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E – The HepNet SofE pilot study**  
Markus CORNBERG, *Germany*
- 17:00-17:15  
LBO-05 **Bezafibrate improves the effect of obeticholic acid on cholestasis in patients with primary biliary cholangitis**  
Lena SMETS, *Belgium*
- 17:15-17:30  
LBO-06 **Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naïve and treatment-suppressed chronic hepatitis B patients**  
Jacob LALEZARI, *United States*
- 17:30-17:45  
LBO-07 **Effectiveness of therapy in 16,567 directly-acting antiviral treated people in England: High response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis**  
Kate DRYSDALE, *United Kingdom*
- 17:45-18:00  
LBO-08 **Growth analysis in children with progressive familial intrahepatic cholestasis treated with the apical sodium-dependent bile acid transporter inhibitor maralixibat**  
Richard THOMPSON, *United Kingdom*

Scientific  
programme

Saturday 13 April 2019

**Solve the Case: Cholestasis and Autoimmune****Hepatology Arena****Chair:**Annarosa FLOREANI, *Italy*Frank LAMMERT, *Germany*

16:00-17:00

**Solve the Case: Advanced liver disease****Hepatology Arena****Chair:**Rajiv JALAN, *United Kingdom*Dominique VALLA, *France*

17:00-18:00



# ALIVER

The ALIVER Consortium has developed and optimized a novel 'liver dialysis device' – DIALIVE



## Overview of ALIVER:

- + Consortium comprised of experts in liver failure, hospitals, SMEs, not-for-profit organisations
- + Funded from EU Horizon 2020 research and innovation programme
- + Benefits from 25 years of experimental research and data collection on extracorporeal perfusion as a therapy option in liver failure

For more info, visit [www.aliver.info](http://www.aliver.info)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733057.



**SCIENTIFIC PROGRAMME**  
SUNDAY 14 APRIL 2019

## Sunday 14 April 2019

### Breakfast morning rounds: Extrahepatic manifestation of HCV: Response to DAA and when to use immunosuppression? Lehar 1

07:30-08:20

**Chair:**Patrice CACOUB, *France***Case presentation**Alexandre LE JONCOUR, *France***Expert**Benjamin MAASOUMY, *Germany*Michael MAKARA, *Hungary*Anna Linda ZIGNEGO, *Italy*

### Breakfast morning rounds: Hepatitis B: When to start and when to stop Nuc therapy in HBeAg negative patients? Lehar 2

07:30-08:20

**Chair:**Maurizia BRUNETTO, *Italy***Case presentation**Gabriele RICCO, *Italy***Expert**Sabela LENS, *Spain*Spilios MANOLAKOPOULOS, *Greece*Florian VAN BÖMMEL, *Germany*

### Breakfast morning rounds: Cirrhosis and Portal hypertension: When TIPS, when and how Betablocker (propranolol or carvedilol?) and how to monitor? Lehar 3

07:30-08:20

**Chair:**Dhiraj TRIPATHI, *United Kingdom***Case presentation**Faisal KHAN, *United Kingdom***Expert**Virginia HERNANDEZ-GEA, *Spain*Peter JEPSEN, *Denmark*Mattias MANDORFER, *Austria*Scientific  
programme

Sunday 14 April 2019

**Breakfast morning rounds: PSC: How is the surveillance?  
When do we need interventions (ERC), when and how to  
use UDC? When to consider liver transplantation?**

**Lehar 4**

07:30-08:20



**Chair:**

Annika M BERGQUIST, *Sweden*

**Case presentation**

Erik VON SETH, *Sweden*

**Expert**

Helena ISONIEMI, *Finland*

Cyriel PONSIOEN, *Netherlands*

Christoph SCHRAMM, *Germany*

Scientific  
programme

**Parallel session: NAFLD – Staging and prognosis**

**Strauss 1-2**

**Chairs:**

Dina TINIAKOS, *United Kingdom*

Emmanuel TSOCHATZIS, *United Kingdom*

08:30-08:45  
PS-199

**sqFibrosis: A robust liver fibrosis scoring system for artificial intelligence telepathology**

Sakkarin CHIRAPONGSATHORN, *Thailand*

08:45-09:00  
PS-200

**The combination of HEPamet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD**

Javier AMPUERO, *Spain*

09:00-09:15  
PS-201

**External validation in NAFLD cohorts of the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST to identify patients with active NASH (NAS $\geq$ 4) and significant fibrosis (F $\geq$ 2)**

Jerome BOURSIER, *France*

09:15-09:30  
PS-202

**Genome-wide association studies of abdominal MRI scans identifies loci associated with liver fat and liver iron in the UK Biobank**

Henry WILMAN, *United Kingdom*

09:30-09:45  
PS-203

**Dietary risk factors for non-alcoholic fatty liver disease by cirrhosis status: The US multiethnic cohort**

Mazen NOUREDDIN, *United States*

Sunday 14 April 2019

09:45-10:00  
PS-204

**The relationship between FIB-4 progression and liver outcome among patients with type 2 diabetes mellitus: A population based hospital study**

Lucia PARLATI, *France*

10:00-10:15  
PS-205

**Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease: An international study in non-cirrhotic, biopsy-proven patients**

Ramy YOUNES, *Italy*

**Parallel session: Liver transplantation II**

**Strauss 3**



**Chairs:**

Giacomo GERMANI, *Italy*

Helena ISONIEMI, *Finland*

08:30-08:45  
PS-206

**Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis**

Brian LEE, *United States*

08:45-09:00  
PS-207

**Molecular classifier for T-cell-mediated and antibody-mediated rejection after liver transplantation**

Richard TAUBERT, *Germany*

09:00-09:15  
PS-208

**Impact of successful DAA therapy at 3 years of follow-up in liver transplant recipients with hepatitis C recurrence and moderate/severe fibrosis**

Marco SACCO, *Italy*

09:15-09:30  
PS-209

**Whole Human liver decellularisation-recellularisation for future liver transplantation and extracorporeal device application**

Walid AL-AKKAD, *United Kingdom*

09:30-09:45  
PS-210

**Repeated hepatic regeneration stimuli promoted biliary decompression via formation of extrahepatic biliary collaterals**

Beate RICHTER, *Germany*

09:45-10:00  
PS-211

**Liver transplantation for HCC: Applicability and performance of the AFP score in real life. The French organization for organ sharing (ABM) experience**

Christophe DUVOUX, *France*

10:00-10:15  
PS-212

**Liver transplantation in patients with grade 3 acute-on-chronic liver failure: Pre-transplant risk factors of post-transplant mortality**

Thierry ARTZNER, *France*

## Liver disease and the community: Part 1: EASL Policy Statements – Alcohol and food

Lehar 4



### Chairs:

Antonio CRAXI, *Italy*  
Shira ZELBER-SAGI, *Israel*

08:30-08:35

### Introductory remarks

Helena CORTEZ-PINTO, *Portugal*

08:35-08:50

### Alcohol and alcoholic liver disease

Helena CORTEZ-PINTO, *Portugal*

08:50-09:05

### Food and obesity

Shira ZELBER-SAGI, *Israel*

09:05-09:20

### Dealing with Nanny State arguments

Charles GORE, *Switzerland*

09:20-10:00

### Q&A

Scientific  
programme

Sunday 14 April 2019

## Liver disease and the community: Part 2: Hepatitis elimination

Lehar 4



### Chairs:

Maria BUTI, *Spain*  
Antonio CRAXI, *Italy*

10:30-10:45

### Presentation of the Policy Statements on Hepatitis C elimination and Migrant Health

Francesco NEGRO, *Switzerland*

10:45-11:30

### Panel Discussion:

- 1) How to deal with migrant health
- 2) PWID as a target for elimination – an opportunity for integrated care
- 3) Generics for DAA's: In which countries, and what are the barriers?

Antonio CRAXI, *Italy*  
Charles GORE, *Switzerland*  
Dagmar HEDRICH, *Portugal*  
Mojca MATIČIČ, *Slovenia*  
Francesco NEGRO, *Switzerland*

**Solve the Case: Hepatological challenges****Hepatology Arena**

08:30-09:30

**Chairs:**Alejandro FORNER, *Spain*  
Peter GALLE, *Germany***Meet the Experts: Portosinusoidal vascular disease:  
What is there behind this new name?****Stolz 1****Chairs:**Laure ELKRIEF, *Switzerland*  
Juan-Carlos GARCIA-PAGAN, *Spain*

08:30-09:20

**Meet the Experts: Haemochromatosis****Stolz 2****Chairs:**Frank LAMMERT, *Germany*  
Heinz ZOLLER, *Austria*

08:30-09:20

**Meet the Experts: Management of non response  
to therapy in PBC patients****Stolz 1****Chairs:**Olivier CHAZOUILLÈRES, *France*  
Michael TRAUNER, *Austria*

09:30-10:20

**Meet the Experts: Management of gastric varices****Stolz 2****Chairs:**Arnulf FERLITSCH, *Austria*  
Virginia HERNANDEZ-GEA, *Spain*

09:30-10:20

## Symposium: Therapy of hepatitis C after DAA failure

Strauss 3

**Chair:**Stefan ZEUZEM, *Germany*

10:30-10:50

**PRO testing for HCV resistance-associated variants (RAVs) in patients after DAA failure and impact on subsequent drug selection**Ira JACOBSON, *United States*

10:50-11:10

**CONTRA testing for HCV resistance-associated substitutions (RASs) in patients after DAA failure and choices of re-treatment**Jean-Michel PAWLOTSKY, *France*

11:10-11:30

**Management and treatment options in patients who fail second line DAA therapy**Christoph SARRAZIN, *Germany*Scientific  
programme

## Symposium: Preclinical models of NASH: in vitro, in vivo

Lehar 2

**Chair:**Patricia LALOR, *United Kingdom*

10:30-10:50

**What is the best mouse model to recreate physiology and pathology of human NAFLD?**Ina BERGHEIM, *Austria*

10:50-11:10

**Which is the best in vitro model for preclinical assessment of novel NAFLD drugs?**Banu COLE, *United States*

11:10-11:30

**Can we use rodent models to understand the pathogenesis of NASH to HCC transition?**Mathias HEIKENWÄLDER, *Germany*

Sunday 14 April 2019

**Symposium: What do you need to know about Hepatitis E****Lehar 3****Chair:**Nassim KAMAR, *France*

10:30-10:50

**When and how to screen for HEV infection?**Jacques IZOPET, *France*

10:50-11:10

**HEV beyond the liver?**Annemiek VAN DER EIJK, *Netherlands*

11:10-11:30

**How to manage HEV infection?**Sven PISCHKE, *Germany***Pros & Cons Session: PBC patients with inadequate response to UDCA: obeticholic acid or bezafibrate?****Hepatology Arena****Chairs:**Michael MANNES, *Germany*Michael TRAUNER, *Austria*

10:30-11:30

**Overview**Ulrich BEUERS, *Netherlands*

10:40-10:50

**Pros**Gideon HIRSCHFIELD, *United Kingdom*

10:50-11:00

**Cons**Christophe CORPECHOT, *France*

11:00-11:30

**Discussion****Meet the Experts: Acute liver failure****Stolz 1****Chairs:**Fin STOLTZE LARSEN, *Denmark*Julia WENDON, *United Kingdom*

10:30-11:20

**Meet the Experts: Pharmacotherapy in NAFLD –  
which endpoints to use in everyday practice?****Stolz 2****Chairs:**Sven FRANcqUE, *Belgium*Vlad RATZIU, *France*

10:30-11:20

Scientific  
programme**ILC 2019 wrap up session****Strauss 1-2****Chairs:**Ulrich BEUERS, *Netherlands*Massimo PINZANI, *United Kingdom*

11:30-11:48

**Metabolic and alcohol related liver disease**Fabio MARRA, *Italy*

11:48-12:06

**Autoimmune and rare liver disease**Ansgar LOHSE, *Germany*

12:06-12:24

**Cirrhosis and complications**Marina BERENQUER HAYM, *Spain*

12:24-12:42

**Liver tumours**Jordi BRUIX, *Spain*

12:42-13:00

**Viral hepatitis**Xavier FORNS, *Spain*

Sunday 14 April 2019



# Comparison of efficacy between sorafenib monotherapy and transarterial chemoembolization (TACE)-sorafenib sequential therapy in patients with extrahepatic metastasis: An interim analysis of randomized controlled trial

Hyoung Seon Yoo<sup>1</sup>, Sang Hui Park<sup>2</sup>, Young Eun Kim<sup>3</sup>, Sang Beom Cho<sup>4</sup>, Woo Ae Chung<sup>5</sup>, Young Seok Kim<sup>6</sup>, Gyeom Park<sup>7</sup>, Jun Young Park<sup>8</sup>

<sup>1</sup> Department of Internal Medicine, Seoul National University College of Medicine, Seoul, <sup>2</sup> Department of Internal Medicine, Chonnam National University Medical School, Gwangju, <sup>3</sup> Department of Internal Medicine, Seoul National University College of Medicine, Seoul, <sup>4</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju, <sup>5</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju, <sup>6</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju, <sup>7</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju, <sup>8</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju

## RESULTS

### Baseline Characteristics

Characteristic	Intention-to-treat (n=100)	ITT (n=100)	ITT (n=100)
Age, mean (SD)	62.8 (10.5)	62.8 (10.5)	62.8 (10.5)
Male, n (%)	78 (78)	78 (78)	78 (78)
ECOG performance grade, n (%)			
0	10 (10)	10 (10)	10 (10)
1	90 (90)	90 (90)	90 (90)
ECOG performance grade ≥ 2, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 3, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 4, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 5, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 6, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 7, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 8, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 9, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 10, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 11, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 12, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 13, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 14, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 15, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 16, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 17, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 18, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 19, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 20, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 21, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 22, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 23, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 24, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 25, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 26, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 27, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 28, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 29, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 30, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 31, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 32, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 33, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 34, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 35, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 36, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 37, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 38, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 39, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 40, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 41, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 42, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 43, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 44, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 45, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 46, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 47, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 48, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 49, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 50, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 51, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 52, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 53, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 54, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 55, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 56, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 57, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 58, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 59, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 60, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 61, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 62, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 63, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 64, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 65, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 66, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 67, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 68, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 69, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 70, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 71, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 72, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 73, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 74, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 75, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 76, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 77, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 78, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 79, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 80, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 81, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 82, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 83, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 84, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 85, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 86, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 87, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 88, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 89, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 90, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 91, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 92, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 93, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 94, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 95, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 96, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 97, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 98, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 99, n (%)	0 (0)	0 (0)	0 (0)
ECOG performance grade ≥ 100, n (%)	0 (0)	0 (0)	0 (0)



### Overall Control Rate

Time point (months)	ITT (n=100)	ITT (n=100)
0	100 (100%)	100 (100%)
1	95 (95%)	95 (95%)
2	85 (85%)	85 (85%)
3	75 (75%)	75 (75%)
4	65 (65%)	65 (65%)
5	55 (55%)	55 (55%)
6	45 (45%)	45 (45%)
7	35 (35%)	35 (35%)
8	25 (25%)	25 (25%)
9	15 (15%)	15 (15%)
10	5 (5%)	5 (5%)
11	0 (0%)	0 (0%)
12	0 (0%)	0 (0%)
13	0 (0%)	0 (0%)
14	0 (0%)	0 (0%)
15	0 (0%)	0 (0%)
16	0 (0%)	0 (0%)
17	0 (0%)	0 (0%)
18	0 (0%)	0 (0%)
19	0 (0%)	0 (0%)
20	0 (0%)	0 (0%)
21	0 (0%)	0 (0%)
22	0 (0%)	0 (0%)
23	0 (0%)	0 (0%)
24	0 (0%)	0 (0%)
25	0 (0%)	0 (0%)
26	0 (0%)	0 (0%)
27	0 (0%)	0 (0%)
28	0 (0%)	0 (0%)
29	0 (0%)	0 (0%)
30	0 (0%)	0 (0%)
31	0 (0%)	0 (0%)
32	0 (0%)	0 (0%)
33	0 (0%)	0 (0%)
34	0 (0%)	0 (0%)
35	0 (0%)	0 (0%)
36	0 (0%)	0 (0%)
37	0 (0%)	0 (0%)
38	0 (0%)	0 (0%)
39	0 (0%)	0 (0%)
40	0 (0%)	0 (0%)
41	0 (0%)	0 (0%)
42	0 (0%)	0 (0%)
43	0 (0%)	0 (0%)
44	0 (0%)	0 (0%)
45	0 (0%)	0 (0%)
46	0 (0%)	0 (0%)
47	0 (0%)	0 (0%)
48	0 (0%)	0 (0%)
49	0 (0%)	0 (0%)
50	0 (0%)	0 (0%)
51	0 (0%)	0 (0%)
52	0 (0%)	0 (0%)
53	0 (0%)	0 (0%)
54	0 (0%)	0 (0%)
55	0 (0%)	0 (0%)
56	0 (0%)	0 (0%)
57	0 (0%)	0 (0%)
58	0 (0%)	0 (0%)
59	0 (0%)	0 (0%)
60	0 (0%)	0 (0%)
61	0 (0%)	0 (0%)
62	0 (0%)	0 (0%)
63	0 (0%)	0 (0%)
64	0 (0%)	0 (0%)
65	0 (0%)	0 (0%)
66	0 (0%)	0 (0%)
67	0 (0%)	0 (0%)
68	0 (0%)	0 (0%)
69	0 (0%)	0 (0%)
70	0 (0%)	0 (0%)
71	0 (0%)	0 (0%)
72	0 (0%)	0 (0%)
73	0 (0%)	0 (0%)
74	0 (0%)	0 (0%)
75	0 (0%)	0 (0%)
76	0 (0%)	0 (0%)
77	0 (0%)	0 (0%)
78	0 (0%)	0 (0%)
79	0 (0%)	0 (0%)
80	0 (0%)	0 (0%)
81	0 (0%)	0 (0%)
82	0 (0%)	0 (0%)
83	0 (0%)	0 (0%)
84	0 (0%)	0 (0%)
85	0 (0%)	0 (0%)
86	0 (0%)	0 (0%)
87	0 (0%)	0 (0%)
88	0 (0%)	0 (0%)
89	0 (0%)	0 (0%)
90	0 (0%)	0 (0%)
91	0 (0%)	0 (0%)
92	0 (0%)	0 (0%)
93	0 (0%)	0 (0%)
94	0 (0%)	0 (0%)
95	0 (0%)	0 (0%)
96	0 (0%)	0 (0%)
97	0 (0%)	0 (0%)
98	0 (0%)	0 (0%)
99	0 (0%)	0 (0%)
100	0 (0%)	0 (0%)

### CONCLUSIONS

- TACE-sorafenib sequence showed better overall survival, time to progression, and progression-free survival compared with sorafenib monotherapy.
- TACE-sorafenib sequence showed better overall control rate compared with sorafenib monotherapy.
- Use patients expect better survival, TTP, PFS, and OS after 1st line TACE.

### CONTACT

Dr. Hyoung Seon Yoo  
Seoul National University College of Medicine  
Department of Internal Medicine  
501-747, Yongsan-gu, Seoul 151-747, Korea  
E-mail: hsyoo@plaza.snu.ac.kr

Survival and Progression in all patients  
• Median OS: 4.3 (95% CI: 3.4-5.2) months  
• Median TTP: 2.4 (95% CI: 1.8-3.0) months  
• Median PFS: 2.6 (95% CI: 2.0-3.2) months



Paper posters change **every day.**

## LATE-BREAKER POSTERS

## Late-breaker posters

Late-breaker  
posters

- LBP-01** **In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: Follow-up of population surveys**  
Fredrik ÅBERG, *Sweden*
- LBP-02** **Association between HBsAg loss and long-term clinical outcome in chronic hepatitis B: a systematic review and meta-analysis analysis**  
Ryan ANDERSON, *United States*
- LBP-03** **LPCN 1144, an androgen receptor agonist targeted for NASH, reduces liver fat and key serum biomarkers**  
Jonathan BAKER, *United States*
- LBP-04** **Investigation of synbiotic treatment in non-alcoholic fatty liver disease (NAFLD): Results of the INSYTE study**  
Chris BYRNE, *United Kingdom*
- LBP-05** **Classification and mutation prediction based on liver cancer histopathological images using deep learning**  
Mingyu CHEN, *China*
- LBP-06** **High seroprotection rates achieved with two doses of Sci-B-Vac, a third generation hepatitis B containing PreS1, PreS2 and S antigens**  
Francisco DIAZ-MITOMA, *Canada*
- LBP-07** **Association of pharmacogenomics and pharmacokinetics with antiviral activity of Pradefovir for treatment of chronic hepatitis B infection**  
Yanhua DING, *China*
- LBP-08** **The world's largest hepatitis C screening program in Egypt**  
Magdi EL-SERAFY, *Egypt*
- LBP-09** **Liver humanization of Fah *-/-* /Rag2 *-/-* /Il2rg *-/-* NOD mice with human hepatocytes homozygous for M148I PNPLA3 allows the assessment of specific genotype contribution to NASH development in vivo**  
Lander FOQUET, *United States*
- LBP-10** **A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALT and gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH**  
David A. FRASER, *Netherlands*
- LBP-11** **Is it possible to successfully link migrants from low-income countries to HBV, HCV, and HIV services upon arrival in the European Union?**  
Jeffrey LAZARUS, *Spain*

- LBP-12** **Phase 1a study of the safety, tolerability and pharmacokinetics of ABI-H2158, a novel second-generation HBV core inhibitor, in healthy volunteers**  
Edward GANE, *New Zealand*
- LBP-13** **Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort**  
Stuart C GORDON, *United States*
- LBP-14** **Magnetic resonance biomarkers for early phase steatohepatitis clinical trials: Short term evaluation in adolescents, transitoriness or stability in steatosis (STEATOSIS)**  
Nidhi GOYAL, *United States*
- LBP-15** **Urinary Liver Fatty-Acid-Binding Protein (uL-FABP) improves accuracy of MELD score to predict short-term mortality in patients with decompensated cirrhosis**  
Adria JUANOLA, *Spain*
- LBP-16** **Phase II trial to evaluate immunogenicity and safety of a new adjuvanted HBAl20 Hepatitis B vaccine in non-responders: BE RESPONDER**  
Özgür KOC, *Belgium*
- LBP-17** **Robust Mucosal-associated invariant T (MAIT) cell activation in response to interactions with primary human liver cell subsets**  
Martin LETT, *Switzerland*
- LBP-18** **Effect of obeticholic acid on liver function in patients with fibrosis due to NASH**  
Naim ALKHOURI, *United States*
- LBP-19** **NGM282 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis in mice**  
Lei LING, *United States*
- LBP-20** **VK2809, a novel liver-directed thyroid receptor beta agonist, significantly reduces liver fat with both low and high doses in patients with non-alcoholic fatty liver disease: A phase 2 randomized, placebo-controlled trial**  
Rohit LOOMBA, *United States*
- LBP-21** **Effect of NGM282, an FGF19 analogue, on pruritus in patients with primary sclerosing cholangitis: Analysis of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial**  
Marlyn J. MAYO, *United States*

Late-breaker  
posters

- LBP-22** **Outcome of 119 cirrhotic patients with splanchnic thrombosis: A single center real-life experience**  
Giorgia MICUCCI, *Italy*
- LBP-23** **Prognostic impact of peritumoral neutrophil infiltration on hepatocellular carcinoma recurrence following liver transplantation**  
Marc NAJJAR, *United States*
- Late-breaker posters
- LBP-24** **Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with non-alcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study**  
Philip NEWSOME, *United Kingdom*
- LBP-25** **A phase 1 clinical trial of therapeutic vaccine t101 in chronic hepatitis B(CHB) patients: a randomized, double-blind, placebo-controlled, single and multiple injections, dose escalation study**  
Junqi NIU, *China*
- LBP-26** **Magnetically controlled capsule endoscopy as a noninvasive tool for risk stratification of gastroesophageal varices in compensated cirrhosis (CHESS1801): A prospective multicenter study**  
Xiaolong QI, *China*
- LBP-27** **Preliminary analysis of SuperDOT-C: A cluster randomised controlled trial of pharmacy-led versus conventional treatment for HCV positive patients receiving daily opioid substitution therapy - The Tayside sites**  
Andrew RADLEY, *United Kingdom*
- LBP-29** **BI089-100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys**  
Moti ROSENSTOCK, *Israel*
- LBP-30** **Changes in serum bile acids correlate with 7alpha-hydroxy-4-cholesten-1-one and fibrogenesis biomarker pro-C3 with NGM282 therapy in patients with non-alcoholic steatohepatitis**  
Arun SANYAL, *United States*
- LBP-31** **AXA1665, a novel composition of amino acids restores the dysregulated amino acid profile, lowers ammonia, and improves body composition and function in Child-Pugh class A and B subjects**  
Manu CHAKRAVARTHY, *United States*
- LBP-32** **The natural history of ferroportin disease – first results of the international, multicenter EASL non-HFE registry**  
Benedikt SCHAEFER, *Austria*

- LBP-33** **Gelesis superabsorbent hydrogel prevents hepatic steatosis in a high fat diet-induced NAFLD pre-clinical model**  
Elaine CHIQUETTE, *United States*
- LBP-34** **Effect of resistance associated substitutions on retreatment of HCV infected patients with prior failure to direct acting antiviral therapy**  
David SMITH, *United Kingdom*
- LBP-35** **Kupffer cell development: A link between Notch signaling and LXR $\alpha$**   
Wouter T'JONCK, *Belgium*
- LBP-36** **Inhibition of glutamine synthetase in monocytes from patients with Acute-on-Chronic Liver Failure resuscitates their antibacterial and inflammatory capacity**  
Schalk VAN DER MERWE, *Belgium*
- LBP-37** **Evaluation of hepatitis C virus rapid diagnostic test in HCV mono- and HCV/HIV co-infected patients from low and middle income countries**  
Beatrice VETTER, *Switzerland*
- LBP-38** **Increasing number of metabolic co-morbidities are associated with higher risk of advanced fibrosis in patients with non-alcoholic steatohepatitis**  
Robert WONG, *United States*
- LBP-40** **Development of oligonucleotide-based miR-132 antagonists for the treatment of NASH**  
Shoutian ZHU, *United States*

Late-breaker  
posters



# Comparison of efficacy between sorafenib monotherapy and transarterial chemoembolization (TACE)-sorafenib sequential therapy in patients with extrahepatic metastasis: An interim analysis of randomized controlled trial

Hyoung Seon Yoo<sup>1</sup>, Sang Hui Park<sup>2</sup>, Young Kwi Hong<sup>3</sup>, Sang Beom Cho<sup>4</sup>, Woo Ae Chung<sup>5</sup>, Young Seok Kim<sup>6</sup>, Gyeom Park<sup>7</sup>, Jun Young Park<sup>8</sup>

<sup>1</sup> Department of Internal Medicine, Seoul National University College of Medicine, Seoul, <sup>2</sup> Department of Internal Medicine, Chonnam National University Medical School, Gwangju, <sup>3</sup> Department of Internal Medicine, Seoul National University College of Medicine, Seoul, <sup>4</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju, <sup>5</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju, <sup>6</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju, <sup>7</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju, <sup>8</sup> Department of Internal Medicine, Jeonju National University College of Medicine, Jeonju

## RESULTS

### Baseline Characteristics

Characteristic	Intentional (n=100)	Control (n=100)
Age, mean (SD)	62.5 (10.5)	62.5 (10.5)
Male, n (%)	85 (85)	85 (85)
ECOG performance grade, n (%)		
0	10 (10)	10 (10)
1	90 (90)	90 (90)
ECOG performance grade, n (%)		
0	10 (10)	10 (10)
1	90 (90)	90 (90)
ECOG performance grade, n (%)		
0	10 (10)	10 (10)
1	90 (90)	90 (90)
ECOG performance grade, n (%)		
0	10 (10)	10 (10)
1	90 (90)	90 (90)

### Overall Survival



### Time to Progression



### Progression-Free Survival



### Overall Control Rate

Characteristic	Intentional (n=100)	Control (n=100)
Overall control rate, n (%)	10 (10%)	10 (10%)
ECOG performance grade, n (%)		
0	10 (10%)	10 (10%)
1	90 (90%)	90 (90%)
ECOG performance grade, n (%)		
0	10 (10%)	10 (10%)
1	90 (90%)	90 (90%)

### CONCLUSIONS

- 1. TACE followed by sorafenib significantly improved overall survival compared with sorafenib alone.
- 2. TACE followed by sorafenib significantly improved time to progression compared with sorafenib alone.
- 3. TACE followed by sorafenib significantly improved progression-free survival compared with sorafenib alone.

### CONTACT

Dr. Hyoung Seon Yoo, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. Email: hsyoo@plaza.snu.ac.kr



Paper posters change **every day.**

**POSTERS**

THURSDAY 11 APRIL 2019

## Thursday 11 April 2019

### Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology



- THU-001** **Identifying intrahepatic lymphocyte permutations in active untreated, resistant and treated autoimmune hepatitis**  
YI  
Gautham APPANNA, *United Kingdom*
- THU-002** **Macrophage activation marker neopterin predicts liver transplantation-free survival in primary sclerosing cholangitis**  
YI  
Amandeep K DHILLON, *Norway*
- THU-003** **European multicenter validation of autoantibodies against huntingtin-interacting protein 1-related protein for the diagnosis of autoimmune hepatitis in adults**  
YI  
Bastian ENGEL, *Germany*
- THU-004** **Lactobacillus rhamnosus GG prevents liver fibrosis through intestinal FXR/FGF15-mediated inhibition of bile acid synthesis and the increase of bile acid excretion in mice**  
Wenke FENG, *United States*
- THU-005** **Activation regulators of peripheral blood and intrahepatic T effector cells in autoimmune hepatitis**  
YI  
Pamela FILPE, *Germany*
- THU-006** **Aberrant DNA methylation in bile accurately detects cholangiocarcinoma in patients with primary sclerosing cholangitis**  
Trine FOLSERAAS, *Norway*
- THU-007** **Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through anti-inflammatory bile acid composition and signaling**  
Claudia FUCHS, *Austria*
- THU-008** **Circulating fibroblast growth factor 21 regulates bile acids homeostasis in cholestatic patients**  
Chiara GABBI, *Italy*
- THU-009** **High throughput RNA sequencing unravels pathways associated with cognitive deficit in primary biliary cholangitis**  
YI  
Lucy GEE, *United Kingdom*

Posters

Thursday 11 April 2019

- THU-010** **Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis**  
YI  
Alessio GERUSSI, *Italy*
- THU-011** **Cholecystectomy causes worsening of primary sclerosing cholangitis features in Abcb4 knockout mice**  
YI  
Ester GONZALEZ-SANCHEZ, *France*
- THU-012** **Prevalence of autoimmune liver disease related autoantibodies in various non autoimmune liver diseases**  
Rakesh Kumar JAGDISH, *India*
- THU-013** **Investigating the potential immunomodulatory role of mesenchymal stromal cells in primary sclerosing cholangitis**  
YI  
Ashnila JANMOHAMED, *United Kingdom*
- THU-014** **Primary sclerosing cholangitis-associated biliary neoplasia demonstrates a high inter- and intratumour heterogeneity**  
YI  
Eline KAMP, *Netherlands*
- THU-015** **Mutational signatures during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis**  
YI  
Eline KAMP, *Netherlands*
- THU-016** **Loss of signaling through the G-protein coupled bile acid receptor Tgr5 confers protection from fibrosis in the progressive cholangiopathy of Mdr2-/- mice**  
YI  
Nelson MATUSCHEK, *United States*
- THU-017** **Glucagon like peptide-2 treatment improves liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis**  
YI  
Moritz MENZ, *Austria*
- THU-018** **c-Jun N-terminal kinases act synergistically in hepatocytes to protect mice from cholestatic liver injury**  
YI  
Mohamed Ramadan MOHAMED, *Germany*
- THU-019** **Impact of metabolic stress on the pathogenesis of autoimmune liver disease in subjects bearing missense variant of negative immune regulator Lnk/Sh2b3**  
YI  
Taizo MORI, *Japan*
- THU-020** **Postprandial changes in the hepatic bile acid transport in healthy human subjects measured by 11C-CSar PET/CT**  
YI  
Nikolaj Worm ORNTOFT, *Denmark*

**Autoimmune and chronic cholestatic liver disease:  
Experimental and pathophysiology (Cont.)**

- THU-021** **Loss of bile salt export pump (Bsep/Abcb11) aggravates lipopolysaccharide induced hepatic inflammation in mice**  
YI  
Jelena REMETIC, *Austria*
- THU-022** **CM-101- a Novel anti CCL24 monoclonal antibody reduces cholangiocytes proliferation in experimental cholestasis models**  
Neta BARASHI, *Israel*
- THU-023** **Monoacylglycerol lipase inhibition protects from hepatic inflammation and fibrosis in mouse models of sclerosing cholangitis**  
YI  
Matteo TARDELLI, *Austria*
- THU-024** **Methylation signatures in blood show accelerated epigenetic aging in patients with primary sclerosing cholangitis compared to healthy controls**  
Michael TRAUNER, *Austria*
- THU-025** **Pathway-analysis using datasets of GWAS and microarray identified IFNG as the most significant upstream-regulator in primary biliary cholangitis**  
Kazuko Ueno UENO, *Japan*
- THU-026** **Natural killer T cells promote cholestatic liver disease in bile duct ligated mice**  
YI  
Laura VALESTRAND, *Norway*
- THU-027** **The human apical sodium dependent bile salt transporter (ASBT) activates a bile salt-induced defense in human cholangiocytes**  
YI  
Jorrit VAN NIEKERK, *Netherlands*
- THU-028** **Gut derived bacteria, presented by liver dendritic cells can activate liver MAIT cells in primary sclerosing cholangitis**  
Suzan WARNER, *United Kingdom*
- THU-029** **Interleukin 23 produced by hepatic monocyte-derived macrophages is essential for the development of primary biliary cholangitis**  
Ehud ZIGMOND, *Israel*

**Cirrhosis: ACLF and Critical illness**

- THU-031 Hemorrhagic and thrombotic complications in critically patients with cirrhosis**  
William BERNAL, *United Kingdom*
- THU-032 Peritoneal CD206 links macrophage heterogeneity in decompensated cirrhosis with outcome of spontaneous bacterial peritonitis**  
Tony BRUNS, *Germany*
- THU-033 Impact of early Hemodynamic correction of AKI in acute on chronic liver failure patients with large ascites**  
YI  
Shreya BUTALA, *India*
- THU-034 Serum metabolite profiling predicts survival in patients with hepatitis B virus related acute-on-chronic liver failure**  
Ermei CHEN, *China*
- THU-035 A shorter period of a subsequent episode of acute decompensation of cirrhosis predicts worse outcome: A single center experience**  
Po-Sung CHU, *Japan*
- THU-036 First description of the immune checkpoint receptor landscape in decompensated cirrhosis and ACLF**  
YI  
Douglas CORRIGALL, *United Kingdom*
- THU-037 Soluble MAdCAM-1 as a novel marker of hepatic endothelial dysfunction in acutely decompensated cirrhosis**  
YI  
Jonathon GRAHAM, *United Kingdom*
- THU-038 Fungal pneumonia in critically ill cirrhotics: Spectrum and outcomes**  
YI  
Pratibha Ramchandra KALE, *India*
- THU-039 LPS-induced upregulation of RANTES in a new mouse model of bacterial infection related acute-on-chronic liver injury**  
Ersin KARATAYLI, *Germany*
- THU-040 AARC score: A dynamic model to predict outcome in acute on chronic liver failure patients**  
Karan KUMAR, *India*
- THU-041 Immune-metabolism disorder in progression of hepatitis B virus-related acute-on-chronic liver failure characterized by transcriptomics**  
Jun LI, *China*

Posters

Thursday 11 April 2019

**Cirrhosis: ACLF and Critical illness (Cont.)**

- THU-042** **Hypoxia aggravates acute on chronic hepatitis through MIR-210 mediated macrophage autophagy impairment**  
Feifei LIU, *China*
- THU-043** **Declining mortality of cirrhotic patients requiring admission to intensive care units for serious infections: A bi-national cohort study**  
Ammar MAJEED, *Australia*
- THU-044** **Cystatin C as a predictive biomarker of ACLF development and mortality on the liver transplant waiting list**  
YI  
Ezequiel MAURO, *Argentina*
- THU-045** **Natural history of sepsis, organ failure and organ dysfunction in critically ill patients with acute on chronic liver failure**  
Manjul MISHRA, *India*
- THU-046** **Implementation of acute kidney injury criteria to patients with acute-on-chronic liver failure: Characteristics of effect on outcomes**  
Laura NAPOLEONE, *Spain*
- THU-047** **Recalbration of the CLIF-C ACLF score after weighting by organ and by the presence of TIPS in patients with acute-on-chronic liver failure**  
Enric REVERTER, *Spain*
- THU-048** **Intermittent high-flux albumin dialysis with continuous venovenous hemodialysis for acute-on-chronic liver failure and acute kidney injury**  
Jacek ROZGA, *Poland*
- THU-049** **Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure**  
YI  
Sabrina RUESCHENBAUM, *Germany*
- THU-050** **Genetic variants of innate immunity receptors are associated with mortality but not with bacterial infections in liver cirrhosis**  
YI  
Jelte SCHAAAPMAN, *Netherlands*
- THU-051** **Establishment of a new animal model for the acute-on-chronic liver failure**  
YI  
Katharina SCHWARZKOPF, *Germany*
- THU-052** **Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK+ immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure**  
YI  
Arjuna SINGANAYAGAM, *United Kingdom*

- THU-053** **Usefulness of lactate-free Asian Pacific Association for The Study of Liver acute-on-chronic liver failure research consortium ACLF score for predicting short-term mortality in patient with alcoholic liver disease**  
Do Seon SONG, *Rep. of South Korea*
- THU-054** **Acute variceal bleed leads to acute on chronic liver failure like syndrome in a small proportion of cirrhotic patients:an analysis of 3845 patients from AARC data base**  
Harsh Vardhan TEVETHIA, *India*
- THU-055** **Improved stratification of liver failure syndromes using broad-panel bile acid LCMS phenotyping demonstrates novel pathways of dysregulation in tertiary bile acids in acute-on-chronic liver failure**  
Kate WOLFER, *United Kingdom*
- THU-056** **Artificial liver support system improves short-term survival of patients with hepatitis B virus-related acute-on-chronic liver failure: A propensity-score matched analysis**  
Lingling YANG, *China*
- THU-057** **The homeostasis imbalance of autophagy in acute-on-chronic liver failure patients caused by acute exacerbation of chronic hepatitis B**  
Xiangying ZHANG, *China*
- THU-058** **Gene profiling of toll-like receptor signaling pathways in patients with acute-on-chronic liver failure**  
Ruihong ZHAO, *China*

Posters

Thursday 11 April 2019

**Fibrosis**

- THU-061** **Statins reduces liver fibrosis progression and promotes fibrosis regression in mice**  
YI  
Rola AL- SAYEGH, *Lebanon*
- THU-062** **Exploring the immune environment in chronic hepatitis C associated fibrosis by examining the portal vein**  
YI  
Rabab Oun Ali Anwar ALI, *United States*
- THU-063** **Synergistic antifibrotic effect of rapamycin and zoledronic acid in advanced murine biliary fibrosis**  
YI  
Misbah ASLAM, *Germany*
- THU-064** **Identification of new epigenetic targets in hepatic fibrosis**  
YI  
Marina BÀRCENA-VARELA, *Spain*
- THU-065** **Metformin reverses liver fibrosis via AMPK/PGC-1 $\alpha$  mediated mitochondrial metabolic switch**  
Jianye CAI, *China*
- THU-066** **Association of apri index and elastography by shear wave elastography**  
Eira CERDA REYES, *Mexico*
- THU-067** **Selective targeting of GLI1 suppresses the differentiation of hepatic progenitor cell towards fibrogenic cholangiocyte and fibrosis progression**  
YI  
Jiamei CHEN, *China*
- THU-068** **Alcoholic and nonalcoholic fatty liver disease and liver-related mortality: A cohort study**  
Yong Kyun CHO, *Rep. of South Korea*
- THU-069** **Human adipose derived stem cells exhibit enhanced liver regeneration in liver fibrosis model by controlled releasing hepatocyte growth factor**  
Ja Sung CHOI, *Rep. of South Korea*
- THU-070** **The nuclear factor TCF20 regulates the severity of liver fibrosis in mice**  
Bernat CORDOBA-JOVER, *Spain*
- THU-071** **Matrix modulation in chronic liver injury and resolution**  
Marika CRESCENZI, *Italy*
- THU-072** **N-ras protects against experimental liver fibrosis by maintaining hepatocyte homeostasis**  
Francisco Javier CUBERO, *Spain*

- THU-073** **The use of APRI and FIB-4 scores versus transient elastography for the assessment of liver fibrosis stage in patients with chronic hepatitis C: Is it possible to reduce the need for elastography?**  
Melanie DEUTSCH, *Greece*
- THU-074** **Anti-fibrotic effect of dimethyl fumarate on rat liver fibrosis induced by thioacetamide: Role of NF-kappa B, NLRP3, Nrf2 and autophagy**  
YI  
Durgesh DWIVEDI, *India*
- THU-075** **2d- shear wave elastography for the spleen stiffness evaluation: A noninvasive marker for predicting high risk varices in patients with compensated liver cirrhosis**  
Renata FOFIU, *Romania*
- THU-076** **SPP1 gene knockout in human hepatic stellate cells decreased profibrogenic cytokines and collagen gene expression**  
Joseph GEORGE, *Japan*
- THU-077** **Fibro-protective molecular and cellular mechanisms emerge during resolution from thioacetamide-induced fibrosis**  
YI  
Francis GRATTE, *Australia*
- THU-078** **PBI-4050 inhibits hepatic stellate cell activation, restores autophagy, and reduces CCl4-induced liver fibrosis**  
Brigitte GROUX, *Canada*
- THU-079** **Study of anti-fibrotic activity of human umbilical-cord tissue-derived mesenchymal stromal cells during fibrogenesis or resolution in murine models of liver fibrosis**  
YI  
Debashis HALDAR, *United Kingdom*
- THU-080** **Survivin aggravates fibrogenicity of hepatic stellate cells via mediating TGF-beta/PI3K/Akt pathway**  
YI  
Arun Kumar JAJORIYA, *India*
- THU-081** **Saracatinib, a Src family kinase inhibitor, decreases liver fibrosis**  
Byoung Kuk JANG, *Rep. of South Korea*
- THU-082** **Thymosin beta 4 is a potential regulator of radiation-induced liver fibrosis**  
YI  
Jieun KIM, *Rep. of South Korea*
- THU-083** **Predicting advanced liver fibrosis using deep learning based biopsy image analysis**  
Sergey KLIMOV, *United States*

Posters

Thursday 11 April 2019

**Fibrosis (Cont.)**

- THU-084** **A comparative study of anti-Fibrotic therapeutics using aptamer-based quantitative proteomics in a rat model of nonalcoholic steatohepatitis cirrhosis**  
Smitha KRISHNAN, *United States*
- THU-085** **Efficacy of enhanced liver fibrosis score and transient elastography for assessment of severity of fibrosis in chronic hepatitis C**  
YI  
Manish KUMAR, *India*
- THU-086** **Clinical study on plasma golgi protein 73 and the progression of viral hepatitis C-induced hepatic fibrosis**  
YI  
Liu LINGDI, *China*
- THU-087** **A 3-dimensional dynamic model to explore the immunomodulatory properties of the extracellular matrix and their implications in liver fibrosis**  
YI  
Claire MCQUITTY, *United Kingdom*
- THU-088** **Serum markers of interstitial matrix formation (PRO-C3) and basement membrane remodeling (PRO-C4 and C4M) predict recurrence of fibrosis and survival in post-liver transplanted patients**  
YI  
Mette Juul NIELSEN, *Denmark*
- THU-089** **Characterization of CDAA mouse model for non-alcoholic steatohepatitis at various time-points**  
Larissa PFISTERER, *Germany*
- THU-090** **Non-invasive fibrosis scores (APRI, FIB4 index, BARD): Useful tools for evaluating fatty liver disease**  
Alina POPESCU, *Romania*
- THU-091** **Alcalcemic vitamin D analogues show antifibrotic effects in vitro while paricalcitol prevents progression of established fibrosis in the CCI4 mouse-model**  
Florian Paul REITER, *Germany*
- THU-092** **Role of endothelial mitophagy during endothelial dysfunction and liver fibrosis**  
Maria RUART, *Spain*
- THU-093** **The calpain inhibitor, BLD-2660, has robust anti-fibrotic activity in a rat model of nonalcoholic steatohepatitis**  
YI  
Mozhdeh SOJODI, *United States*

- THU-094** **Simple prediction score to predict fibrosis in type 2 diabetes mellitus patients**  
Ioan SPOREA, *Romania*
- THU-095** **Short and long-term evaluation of liver fibrosis and outcomes in patients with chronic hepatitis C after INF-free antiviral treatment**  
Cristina STASI, *Italy*
- THU-096** **Development and validation of true serum biomarkers of liver fibrogenesis and fibrolysis**  
Rambabu SURABATTULA, *Germany*
- THU-097** **Serum infrared spectral profile is predictive of the degree of hepatic fibrosis in chronic hepatitis C patients**  
Gérard THIÉFIN, *France*
- THU-098** **Changes in liver stiffness measurements following DAA treatment among HIV/HCV-coinfected individuals: Does HIV contribute to liver disease after HCV cure?**  
Daniela VAN SANTEN, *Australia*
- THU-099** **Collagen is not just collagen: Differential matrix expression induced by TgF-beta and PDGFs**  
Ida VILLESEN, *Denmark*
- THU-100** **FGL2 regulates liverfibrosis progression and reversal by promoting profibrotic infiltrating macrophages maintenance**  
Xiaoyang WAN, *China*
- THU-101** **Artery density in human liver: A valuable measure for staging of chronic liver disease**  
Ian WANLESS, *Canada*
- THU-103** **HBEAG negative CHB patients is associated with more severe liver fibrosis than hbeag positive CHB patients: A propensity score matching analysis**  
Chao WU, *China*
- THU-104** **New fibroblast activation protein inhibitor, CPD60, attenuates fibrosis and chronic liver disease progression in CCL4 induced liver fibrosis, but not in MDR2-/- mice**  
Ai Ting YANG, *China*
- THU-105** **Modulation of G protein alpha inhibiting activity polypeptide 2 in hepatocytes regulate liver fibrosis**  
Qinggong YUAN, *Germany*

**Viral hepatitis C: Therapy and resistance**

- THU-111** **High efficacy and safety of the combination HCV regimen elbasvir and grazoprevir for 8 weeks in treatment-naïve non-severe fibrosis HCVGT1b-infected patients: Final results of the STREAGER study**  
Armand ABERGEL, *France*
- THU-112** **Real-world health care resource utilization and quality of life with G/P treatment: A pooled analysis from post-marketing observational studies**  
Alessio AGHEMO, *Italy*
- THU-113** **Comparison between safety and efficacy of two treatment regimens for pediatric patients with chronic hepatitis C virus: Sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimen**  
Mohamed AHMED, *Egypt*
- THU-114** **A comparison of currently available direct acting antiviral HCV therapy in Canada: On the path to elimination**  
Arshia ALIMOHAMMADI, *Canada*
- THU-115** **Effects of health-related quality of life of interferon-free antiviral therapy for chronic hepatitis C infection – Results from the GermanHepatitis C-Registry (DHC-R)**  
Schäfer ARNE, *Germany*
- THU-116** **Effectiveness of the salvage therapy sofosbuvir-velpatasvir-voxilaprevir (SOF-VEL-VOX) in chronic hepatitis C: Clinical practice experience from the TRIO Network**  
Bruce BACON, *United States*
- THU-117** **Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naïve to direct acting antivirals: Particular focus on natural resistance**  
Silvia BARBALISIA, *Italy*
- THU-118** **Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study**  
Sofia BARTLETT, *Canada*
- THU-119** **Direct-acting antiviral regimens without protease inhibitors may help maintain a healthy lipid profile after hepatitis C eradication**  
Javier FUENTES, *Spain*
- THU-120** **Hepatitis C In children: Clinical profile and outcomes In the era of directly-acting antivirals in a tertiary centre in North India**  
Vybhav GUMMADI, *India*

- THU-121** **Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/glecaprevir/pibrentasvir**  
Alison BOYLE, *United Kingdom*
- THU-122** **Sofosbuvir/velpatasvir +/- ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen**  
Giuseppina BRANCACCIO, *Italy*
- THU-123** **No effect of alcohol consumption or dependence on treatment outcome in chronic hepatitis C patients treated with Elbasvir/Grazoprevir in a real-world setting**  
Jean-Pierre BRONOWICKI, *France*
- THU-124** **Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C)**  
Jose A. CARRIÓN, *Spain*
- THU-125** **High real-world effectiveness of elbasvir/grazoprevir in PWID on opioid substitution therapy with HCV genotype 1 infection: Results from the German hepatitis C registry (DHC-R)**  
Stefan CHRISTENSEN, *Germany*
- THU-126** **HCV treatment outcomes among current and remote injection drug users: Real- life data**  
Brian CONWAY, *Canada*
- THU-127** **Clinical Practice experience with pan genotypic therapies glecaprevir-pibrentasvir and sofosbuvir-velpatasvir in the TRIO Network**  
Michael CURRY, *United States*
- THU-128** **Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study**  
Roberta D'AMBROSIO, *Italy*
- THU-129** **New antiviral therapy and the quality of life in patients with HCV infection**  
**YI** Claudia Monica DANILESCU, *Romania*
- THU-130** **Management strategies for drug drug interactions between direct oral anticoagulants and hepatitis C directly acting agents: A multi-centre review**  
Katherine DAVIDSON, *United Kingdom*

Posters

Thursday 11 April 2019

**Viral hepatitis C: Therapy and resistance (Cont.)**

- THU-131** **Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks**  
Elisabetta DEGASPERI, *Italy*
- THU-132** **Decentralised care with generic direct antivirals is effective in the management of patients with hepatitis C in a public health care setting: The Punjab model**  
Radha Krishan DHIMAN, *India*
- THU-133** **Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience**  
Velia Chiara DI MAIO, *Italy*
- THU-134** **Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment**  
Julia DIETZ, *Germany*
- THU-135** **Real-world HCV treatment in HCV-HIV coinfecting population: Data from the TRIO network**  
Rick ELION, *United States*
- THU-136** **Ledipasvir/sofosbuvir for 8 weeks cures genotype 4 chronic hepatitis C in non-cirrhotic children and adolescents**  
Manal Hamdy EL-SAYED, *Egypt*
- THU-137** **DAA therapy in women of child bearing age: Accidental conception during therapy and pregnancy outcome**  
Manal Hamdy EL-SAYED, *Egypt*
- THU-138** **High efficacy and improvement in CPT class with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis**  
Steven FLAMM, *United States*
- THU-139** **Real world experience of chronic hepatitis C retreatment with genotype specific regimens in non-responders to previous interferon-free therapy**  
Robert FLISIAK, *Poland*
- THU-140** **Characteristics of patients and effectiveness of chronic hepatitis C treatment during the initial 4 years of access to interferon-free therapy**  
Robert FLISIAK, *Poland*

- THU-141 Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients**  
Martina GAMBATO, *Italy*
- THU-142 Sofosbuvir + velpatasvir + voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program**  
Christophe HEZODE, *France*
- THU-143 High effectiveness of elbasvir/grazoprevir treatment in patients with HCV genotype 1a infection in German real-world: Results from the German hepatitis C registry (DHC-R)**  
Holger HINRICHTSEN, *Germany*
- THU-144 Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis**  
Tsung-Hui HU, *Taiwan*
- THU-145 High real-world effectiveness of elbasvir/grazoprevir in a HCV genotype 1 population with a migration background and predominant subtype 1b infection: Results from the German hepatitis C registry (DHC-R)**  
Dietrich HÜPPE, *Germany*
- THU-146 LDV/SOF/RBV is an effective first-line DAA regimen as well as re-treatment option for RF1\_2k/1b patients within Georgian national hepatitis C elimination program**  
Marika KARCHAVA, *Georgia*
- THU-147 Improvement of neutrophil function in hepatitis C patients under direct acting anti-viral treatment is associated with hemolysis parameters**  
YI Irina KOMAROVA, *Austria*
- THU-148 Variability of selected extracellular matrix proteins concentrations in HCV infected patients treated with sofosbuvir and ledipasvir**  
YI Krzysztof TOMASIEWICZ, *Poland*
- THU-149 Efficiency and safety of direct acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey**  
Behice KURTARAN, *Turkey*
- THU-150 Factors associated with treatment failure with SOF+RBV in patients with genotype 2 chronic hepatitis C and consideration of retreatment with GLE+PIB in patients not responding to SOF+RBV**  
Atsunori KUSAKABE, *Japan*

Posters

Thursday 11 April 2019

**Viral hepatitis C: Therapy and resistance (Cont.)**

- THU-151** **Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies**  
Pietro LAMPERTICO, *Italy*
- THU-152** **New in France: Universal access for HCV-treatment as demonstrated by a nationwide real-world cohort**  
Dominique LARREY, *France*
- THU-153** **Is sofosbuvir-based regimen safe and effective in hepatitis C virus-infected patients with stage 4-5 chronic kidney disease? A systematic review and meta-analysis**  
Mingshu LI, *China*
- THU-154** **Low rate of hepatitis B reactivation among patients with chronic hepatitis C during direct acting antiviral therapy**  
Seng LIEM, *Canada*
- THU-155** **Polymeric, metallic nanoparticles, and curcumin as inhibitors of hepatitis C virus genotype 4a replication in vitro**  
Samah LOUTFY, *Egypt*
- THU-156** **Real world outcomes for Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an unselected cohort**  
Fiona MARRA, *United Kingdom*
- THU-157** **Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection**  
Marianne MARTINELLO, *Australia*
- THU-158** **High efficacy of sofosbuvir and velpatasvir regardless of patients' clinical characteristics**  
Vitor Hugo MARTINS, *Italy*
- THU-159** **Real-world efficacy of elvasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group**  
Toshie MASHIBA, *Japan*
- THU-160** **Outcomes of the national strategy on hepatitis C treatment with direct acting antivirals in a real-life setting: Results from a national survey in Slovenia**  
Mojca MATIČIČ, *Slovenia*

- THU-161** **Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs: Results from the German hepatitis C registry (DHC-R)**  
Stefan MAUSS, *Germany*
- THU-162** **The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patients**  
Shahin MERAT, *Iran*
- THU-163** **Efficacy and safety of direct-acting antivirals for hepatitis C in elderly patients: a systematic review and meta-analysis**  
YI  
Marcus MÜCKE, *Germany*
- THU-164** **High cure rates of hepatitis C in a genotype 3 predominant Pakistani community using generic direct acting antivirals**  
YI  
Ammara NAVEED, *Pakistan*
- THU-165** **The risk of HBV reactivation among HBV/HCV co-infected patients treated with direct-acting antiviral agents: A single center experience**  
YI  
Young Joo PARK, *Rep. of South Korea*
- THU-166** **Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy**  
Luisa PASULO, *Italy*
- THU-167** **Prevalence, linkage to care and treatment of hepatitis C virus in person who inject drugs under opioid substitution therapy in a Spanish area**  
YI  
Ylenia PÉREZ CASTAÑO, *Spain*
- THU-168** **Real-life effectiveness and safety of glecaprevir/pibrentasvir in HCV infected patients with chronic kidney disease**  
Marcello PERSICO, *Italy*
- THU-169** **Genotype 4 RAS patterns in a European hepatitis C cohort**  
YI  
Stephanie POPPING, *Netherlands*
- THU-170** **Real-world effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 4 infection: Results from a Veterans Affairs population**  
Amy PUENPATOM, *United States*
- THU-171** **Effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 infection receiving dialysis**  
Amy PUENPATOM, *United States*

**Viral hepatitis C: Therapy and resistance (Cont.)**

- THU-172** **It's the ribavirin, stupid: an analysis of >10,000 hepatitis C treatment monitoring encounters and the factors associated with side-effects and non-adherence**  
Adelaide RANDAZZO, *United Kingdom*
- THU-173** **Sofosbuvir based anti-HCV therapy: Safe in hemodialysis**  
Adnan SALIM, *Pakistan*
- THU-174** **Efficacy of L-Carnitine on the ribavirin induced hemolytic anemia for patients with HCV infection**  
Shinya SATO, *Japan*
- THU-175** **Eligibility and feasibility of hepatitis C treatment in the era of direct-acting antiviral agents: Our experience in real-world practice**  
Monica SCHIAVINI, *Italy*
- THU-176** **Weight gain after interferon-free clearance of chronic hepatitis C: Results from the German hepatitis C registry (DHC-R)**  
Bernhard SCHLEVOGT, *Germany*
- THU-177** **Interim results of an ongoing project to eliminate chronic hepatitis C in people who inject drugs with ongoing intravenous drug use and a high risk of non-adherence to direct-acting antivirals in Vienna**  
Caroline SCHMIDBAUER, *Austria*
- THU-178** **Drug-drug interactions in HCV therapy: Still relevant for clinical practice?**  
**YI**  
Benjamin SCHULTE, *Germany*
- THU-179** **Never too old to be direct acting antiviral treated for hepatitis C virus**  
Stephen SHAFRAN, *Canada*
- THU-180** **Treatment of genotype 3 HCV infection in the large real-life „Navigatore Lombardia“ multicentre cohort: Results from three different regimens**  
Alessandro SORIA, *Italy*
- THU-181** **Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study**  
Richard STERLING, *United States*
- THU-182** **The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C- transforming decision-making for patients, providers, and stakeholders**  
Mark SULKOWSKI, *United States*

- THU-183** **Prospective multicenter study of glecaprevir plus pibrentasvir combination therapy for patients with chronic hepatitis C**  
Akihiro TAMORI, *Japan*
- THU-184** **Correlates of unsuccessful hepatitis C virus therapy and recurrent viremia among active drug users: A mixed methods analysis**  
Astou THIAM, *Canada*
- THU-185** **Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases – EpiTer-2 database analysis**  
Krzysztof TOMASIEWICZ, *Poland*
- THU-186** **Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-August 2018**  
Tengiz TSERTSVADZE, *Georgia*
- THU-187** **Objective evidence of neurocognitive impairment associated with hepatitis C virus infection and of its regression after viral clearance with direct antivirals**  
Gloria VAGHI, *Italy*
- THU-188** **Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure: An analysis from the German hepatitis C registry (DHC-R)**  
Johannes VERMEHREN, *Germany*
- THU-189** **Role of comorbidites in sofosbuvir-based treatment response: Clinical experience from an Italian real life cohort**  
Giulia VERZON, *Italy*
- THU-190** **Characteristics associated with sustained virologic response in chronic hepatitis C patients who received an abbreviated course of direct-acting antiviral therapy**  
Kirsten VEST, *United States*
- THU-191** **The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK**  
Zoe WARD, *United Kingdom*
- THU-192** **All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china**  
Lai WEI, *China*
- THU-193** **4 week treatment for hepatitis C: A randomized controlled trial (4RIBC)**  
Lone WULFF MADSEN, *Denmark*

**Viral hepatitis C: Therapy and resistance (Cont.)****THU-194 Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies**

Betty YAO, *United States*

**THU-195 An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution**

Ming-Lung YU, *Taiwan*

**THU-196 Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting**

Dorota ZARĘBSKA-MICHALUK, *Poland*

**THU-197 Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis**

Dorota ZARĘBSKA-MICHALUK, *Poland*

**THU-198 Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies**

Eli ZUCKERMAN, *Israel*

**THU-199 Awake the dormants: Barriers to access to care and cure in patients with chronic HCV infection**

Eli ZUCKERMAN, *Israel*

**THU-200 The Real-World Israeli experience of treating mild and severe chronic hepatitis C patients with elbasvir/grazoprevir: A large multi-center cohort study**

Eli ZUCKERMAN, *Israel*

## Viral hepatitis B/D: Clinical aspects except therapy

- THU-203** **Hepatitis D infection and risk of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies**  
Dulce ALFAIATE, *Switzerland*
- THU-204** **Analysis of interleukin 28B rs12979860 polymorphism relationship with spontaneous clearance of hepatitis D virus infection in Mongolian population**  
ZI  
Zaya BATSUURI, *Mongolia*
- THU-205** **Evaluation of HBV outcomes after treatment discontinuation from 4 phase 3 studies**  
Maria BUTI, *Spain*
- THU-206** **HBV DNA relapse after stopping nucleoside analogue therapy in patients with HBsAg loss: Detectable pre-genomic HBV RNA is a better predictor of relapse than ultra-sensitive HBsAg – ,implications for HBV cure'**  
Ivana CAREY, *United Kingdom*
- THU-207** **A retrospective review of the incidence of hepatocellular carcinoma in patients with chronic hepatitis B attending the regional hepatitis clinic in Northern Ireland**  
Geraldine CARROLL, *United Kingdom*
- THU-208** **Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA**  
Gian Paolo CAVIGLIA, *Italy*
- THU-209** **Dynamics of a transient elastography-based risk prediction model for hepatocellular carcinoma treated with antiviral therapy in chronic hepatitis B: A multi-center retrospective cohort study from the Korean Transient Elastography Study Group**  
YI  
Hye Yeon CHON, *Rep. of South Korea*
- THU-210** **HBcrAg levels at baseline are not predictive for HBsAg and HBeAg loss in patients treated with adefovir and PEG-interferon**  
YI  
Robin ERKEN, *Netherlands*
- THU-211** **Evaluation of point shearwave elastography using acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in HBeAg-negative chronic HBV infection: A prospective longitudinal study**  
YI  
Christiana GRAF, *Germany*

Posters

Thursday 11 April 2019

**Viral hepatitis B/D: Clinical aspects except therapy (Cont.)**

- THU-212** **Reactivation of occult HBV infection in HIV treated for HCV: A retrospective study**  
YI  
Bianca GRANOZZI, *Italy*
- THU-213** **Distinct features of hepatitis delta in a Mediterranean setting**  
Helena HERNÁNDEZ-ÉVOLE, *Spain*
- THU-214** **Annual average of integral FIB-4 index and HBV core-related antigen as an appropriate indicators for starting nucleoside analogues at an optimum timing**  
Itaru OZEKI, *Japan*
- THU-215** **Association between core mutations and annual decline rate of HBVDNA and HBsAg in chronic hepatitis B patients treated with nucleoside analogue**  
Takashi HONDA, *Japan*
- THU-216** **Rapid turnover of HBV cccDNA in nucleoside-treated chronic hepatitis B patients during drug resistance emergence and breakthrough**  
Qi HUANG, *United States*
- THU-217** **Low risk of HBV reactivation in a large European cohort of HBV/HCV coinfecting patients treated with DAA**  
Jerzy JAROSZEWICZ, *Poland*
- THU-218** **Immune reconstitution inflammatory syndrome and CD4 lymphocyte count as predictive factors for HBsAg seroclearance in HBV/HIV patients treated with antiretroviral therapy**  
Yasuharu KAWAMOTO, *Japan*
- THU-219** **Long-term outcome in Caucasian patients with hepatitis B e antigen-negative chronic infection: An observational cohort study**  
YI  
Özgür KOC, *Belgium*
- THU-220** **Early steep decline of liver stiffness predicts histological reverse of fibrosis in chronic hepatitis B patients treated with entecavir**  
Yuanyuan KONG, *China*
- THU-221** **Xpert HBV VL, simplifying HBV viral load testing and disease management**  
Pietro LAMPERTICO, *Italy*
- THU-222** **The application of novel HBV pgRNA assay to predict HBeAg clearance on long-term nucleos(t)ide analogues**  
Daryl LAU, *United States*

- THU-223** **Development of an optimized risk prediction model for hepatocellular carcinoma in chronic hepatitis B patients with well-controlled viremia by antivirals**  
Hye Won LEE, *Rep. of South Korea*
- THU-224** **Validation of modified PAGE B in patients with chronic hepatitis B undergoing antiviral treatment**  
Hye Won LEE, *Rep. of South Korea*
- THU-225** **Risk prediction model for hepatocellular carcinoma after hepatitis b e antigen seroclearance in patients treated with entecavir or tenofovir**  
Tae Seop LIM, *Rep. of South Korea*
- THU-226** **Concomitant diabetes mellitus increases risk of liver fibrosis in treatment-naïve chronic hepatitis B with low viral loads: Results from a matched case-control study**  
Hei Chun Justin MA, *Hong Kong*
- THU-227** **NTCP S267F variant associates with decreased susceptibility to HBV infection and decelerated progression of related liver diseases**  
Thanh Binh MAI, *Germany*
- THU-228** **HBV RNA can influence HBV viral load results depending on the test used**  
Ed G. MARINS, *United States*
- THU-229** **Increased gaps in hepatitis B pregnancy care identified among „low-risk“ populations**  
YI  
Rena MEI, *United States*
- THU-230** **HBV and HDV confection trends in HIV+ patients in Vienna**  
Caroline SCHMIDBAUER, *Austria*
- THU-231** **Risk of hepatocellular carcinoma in patients with immune-tolerant chronic hepatitis B**  
Gyeol SEONG, *Rep. of South Korea*
- THU-232** **Hepatitis B vaccination is effective among HIV-infected adults in Uganda**  
Emmanuel SEREMBA, *Uganda*
- THU-233** **Whole exome sequencing analysis of the role of rare human variation in chronic hepatitis B infection**  
Patrick R. SHEA, *United States*

Posters

Thursday 11 April 2019

**Viral hepatitis B/D: Clinical aspects except therapy (Cont.)**

**THU-234 High body-mass index is associated with increased risk of alanine aminotransferase elevation and hepatocellular carcinoma in chronic hepatitis B patients with sustained viral control**

Jian SUN, *China*

**THU-235 Hepatitis B virus testing and cascade of care in a tertiary referral centre, Maastricht The Netherlands**

Eva VAN OORSCHOT, *Netherlands*

**THU-236 Integration of HBV DNA near cancer-related genes in HBsAg-negative hepatocellular carcinoma patients**

Danny WONG, *Hong Kong*

**THU-237 Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017**

Grace Lai-Hung WONG, *Hong Kong*

**THU-238 Low rates of antiviral therapy among treatment-eligible adults with chronic hepatitis B virus infection**

Robert WONG, *United States*

**THU-239 Improving patient knowledge about hepatitis B virus leads to improvements in HBV disease monitoring**

Robert WONG, *United States*

**THU-240 Glial cell line-derived neurotrophic factor is associated with fibrosis in patients with chronic viral hepatitis B**

Liu WU, *China*

**THU-241 Influence of HBV genotype on the risk of hepatocellular carcinoma: mediating roles of different phase of viral infection and epigenetic modifications**

Wan-Jung WU, *Taiwan*

**THU-242 Clinical non-invasive markers for hepatic inflammation and fibrosis assessment in chronic hepatitis B with normal alanine aminotransferase**

Zhao WU, *China*

**THU-243 Occult hepatitis B virus infection after haploidentical haematopoietic stem cell transplantation patients: incidence and characterization of HBV pres/s gene mutations**

Haiying ZHANG, *China*

**THU-244 Virological and clinical characteristics of chronic hepatitis delta patients of Mongolia**

Delgersaikhan ZULKHUU, *Mongolia*

**Alcoholic liver disease**

- THU-251** **Metabolic risk factors for advanced liver disease among alcohol risk users in the general population**  
Fredrik ÅBERG, *Sweden*
- THU-252** **Nursing staff volume is the most significant predictor of improved in-hospital mortality among alcoholic hepatitis patients admitted with ascites or hepatic encephalopathy: US nationwide population-based study**  
YI  
Hassan AZHARI, *Canada*
- THU-253** **Equal efficacy of gastric and jejunal tube feeding in liver cirrhosis and/or alcoholic hepatitis: A randomised controlled trial**  
Palle BAGER, *Denmark*
- THU-254** **Cumulative effects of WESTERN DIET and ALCOHOL abuse: A novel MODEL of ASH/NASH-derived liver injury**  
YI  
Raquel BENEDE, *Spain*
- THU-255** **Long term outcomes of alcoholic patients without clinical evidence of liver disease: A 15 years follow-up study**  
YI  
Sonia BERNARDO, *Portugal*
- THU-256** **Alpha-1 antitrypsin ameliorates experimental alcoholic liver disease and predicts patient outcome**  
Grander CHRISTOPH, *Austria*
- THU-257** **Fungal dysbiosis in alcoholic patients is associated with the severity of the liver injury**  
YI  
Dragos CIOCAN, *France*
- THU-258** **Comparison of a fast corticosteroid tapering with the standard corticosteroid schedule in severe alcoholic hepatitis**  
YI  
Berta CUYAS, *Spain*
- THU-259** **The gene signature-MELD score and alcohol consumption determine long-term prognosis of patients with severe alcoholic hepatitis**  
Pierre DELTENRE, *Belgium*
- THU-260** **Alcoholic cirrhosis is associated with higher in-patient mortality compared to non-alcoholic cirrhosis**  
YI  
Xiaowen FAN, *United States*
- THU-261** **Validation of the pre-treatment neutrophil-to-lymphocyte ratio to predict response to corticosteroids in severe alcoholic hepatitis**  
Ewan FORREST, *United Kingdom*

Posters

Thursday 11 April 2019

**Alcoholic liver disease (Cont.)**

- THU-262** **A modified Glasgow alcoholic hepatitis score incorporating the neutrophil-to-lymphocyte ratio is superior to other baseline scores of prognosis in alcoholic hepatitis**  
Ewan FORREST, *United Kingdom*
- THU-263** **The demonstration of antibodies to histone 2B of the IgA-type helps to differentiate between alcoholic liver disease and non-alcoholic fatty liver disorder**  
Amelie FRANK, *Germany*
- THU-264** **Transmission electron microscopy reveals dramatic hepatic zonal changes upon chronic alcohol feeding**  
Raquel FUCHO, *Spain*
- THU-265** **In severe alcoholic hepatitis, serum transferrin indicates impaired HNF4a signaling and predicts mortality independently of disease severity**  
Karim HAMESCH, *Germany*
- THU-266** **Comparison of clinical features and prognosis in different types of severe alcoholic hepatitis: Is it time to classify?**  
Tao HAN, *China*
- THU-267** **the increasing burden of alcohol related liver disease: A single tertiary centre experience**  
Arif HUSENBUX, *United Kingdom*
- THU-268** **Human microfibrillar-associated protein 4 expressed in the liver and serum in alcoholic liver disease predicts liver fibrosis severity with accuracy similar to transient elastography and enhanced liver fibrosis test**  
Bjørn MADSEN, *Denmark*
- THU-269** **Abnormal lipoproteins in alcoholic hepatitis cause hepatocellular injury via inflammasome activation**  
Maria PEREZ-MATOS, *United States*
- THU-270** **Severe alcoholic hepatitis has no influence on prognosis of variceal bleeding in patients with alcoholic cirrhosis**  
Fischer PETRA, *Romania*
- THU-271** **Metabolic syndrome increases the risk of hepatic fibrosis in subjects with increased alcohol consumption: Results from a population-based cohort**  
Elisa POSE, *Spain*

- THU-272** **A study investigating the effect of extracorporeal cellular therapy with C3A cells on the survival of alcoholic hepatitis designed along the guidelines of the NIAAA**  
Nikolaos T. PYRSOPOULOS, *United States*
- THU-273** **Role of PNPLA3 rs738409 and MBOAT7 rs626283 during alcohol detoxification: Indication of different mechanisms for fibrosis development**  
Vanessa RAUSCH, *Germany*
- THU-274** **Utility of quantitative CD64 expression on neutrophils in differentiating between bacterial infection and inflammation in severe alcoholic hepatitis**  
Gaurav PANDE, *India*
- THU-275** **Blood transcript modules differentiate steroid responders from non-responders at baseline in severe alcoholic hepatitis**  
Shvetank SHARMA, *India*
- THU-276** **Women, Native Americans, and Asians experience the greatest increase in alcoholic hepatitis hospitalizations: An analysis of the 2008-2014 U.S. nationwide inpatient sample**  
Farah SHIRAZI, *United States*
- THU-277** **Significant differences in alcoholic hepatitis related mortality in the United States by sex, race/ethnicity, and insurance: An analysis of the 2008-2014 nationwide inpatient sample**  
Farah SHIRAZI, *United States*
- THU-278** **Increasing hospitalizations and resource utilization for alcohol associated liver disease and acute on chronic liver failure in young american adults**  
Ashwani SINGAL, *United States*
- THU-279** **The prognostic stratification using acute-on-chronic liver failure scoring systems for predicting short-term mortality in patients with alcoholic hepatitis**  
Do Seon SONG, *Rep. of South Korea*
- THU-280** **Quantitative fibrosis assessment independently predicts outcome in alcoholic liver disease**  
Rudolf E. STAUBER, *Austria*
- THU-281** **Single nucleotide polymorphisms associated with no interferon lambda 4 production are associated with reduced mortality in alcoholic hepatitis**  
Sidsel STØY, *Denmark*

Posters

Thursday 11 April 2019

**Alcoholic liver disease (Cont.)****THU-282 Augment of liver regeneration protects against ethanol-induced acute liver injury by promoting autophagy**Ping XIE, *China***THU-283 FGF15 deficiency aggregates experimental alcoholic steatohepatitis in mice: A critical role for lipocalin 2 signaling**Min YOU, *United States***THU-284 Hepatocyte-specific deletion of splicing factor SRSF3 exacerbates experimental alcoholic steatohepatitis in mice**Min YOU, *United States***THU-285 Loss of X-Box Protein-1 in intestinal epithelial cells promotes the development of alcoholic liver disease in the liver****YI**Kang ZHENG, *Spain***THU-286 Activation of the NLRP3 inflammasome correlates with the severity of alcoholic liver disease**Zhengsheng ZOU, *China*

Posters

Thursday 11 April 2019

**NAFLD: Clinical aspects except therapy**

- THU-291** **Is non-alcoholic fatty liver disease a risk factor for chronic kidney disease?**  
Takemi AKAHANE, *Japan*
- THU-292** **The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes**  
Naim ALKHOURI, *United States*
- THU-293** **Increased risk of advanced liver disease independently of classic metabolic risk factors or drug induced hepatotoxicity in patients with psoriasis**  
María Teresa ARIAS LOSTE, *Spain*
- THU-294** **Non-invasive measures of liver fibrosis in NAFLD is associated with cardiovascular risk**  
Sebastian BACHMAYER, *Austria*
- THU-295** **Nonalcoholic fatty liver disease is associated with QTc lengthening in the general population**  
YI  
Bubu BANINI, *United States*
- THU-296** **Hepatic and visceral adipose tissue expression of vitamin D receptor and vitamin D hydroxylases in relation to non-alcoholic fatty liver disease and adipose tissue inflammation**  
YI  
Ilaria BARCHETTA, *Italy*
- THU-297** **Prediction of NAFLD progression according to duration of exposure to obesity and diabetes: New approach to adapt therapeutic and research strategies**  
YI  
Pierre BAUVIN, *France*
- THU-298** **Clinical characteristics of NAFLD/NASH patients from gastroenterology and endocrinology clinics**  
YI  
Rachel BOTCHLETT, *United States*
- THU-299** **Increased risk of mortality with liver disease progression in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients: An analysis of French national hospital care**  
Jerome BOURSIER, *France*
- THU-300** **Prevalence of NAFLD in patients with a first episode of stroke and impact on the mortality and severity at 3 months**  
Teresa BROQUETAS, *Spain*
- THU-301** **Weight loss significantly reduces the risk of chronic kidney disease development in patients with non-alcoholic fatty liver disease**  
Young Eun CHON, *Rep. of South Korea*

Posters

Thursday 11 April 2019

**NAFLD: Clinical aspects except therapy (Cont.)**

- THU-302 Association between advanced fibrosis in fatty liver disease and overall mortality in terms of body size and body fat distribution**  
Goh Eun CHUNG, *Rep. of South Korea*
- THU-303 Report from the trenches: Real-life challenges to recruitment and enrollment in NAFLD clinical trials**  
Amreen DINANI, *United States*
- THU-304 Modeling NAFLD-related disease progression among the PITER SVR12 cohort**  
Chris ESTES, *United States*
- THU-305 Comparing perceptions of illness among patients with chronic liver disease**  
Jordan FELD, *Canada*
- THU-306 Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?**  
YI  
Roberta FORLANO, *United Kingdom*
- THU-307 Whipple procedure increases the risk for non-alcoholic fatty liver disease**  
YI  
Jordan GOLDSTEIN, *United States*
- THU-308 More than 4 times higher healthcare costs for end-stage liver disease patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis**  
Stuart C GORDON, *United States*
- THU-309 Cardiovascular risk assessment and management improves outcomes in a specialist multidisciplinary non-alcoholic fatty liver disease clinic**  
Atul GOYALE, *United Kingdom*
- THU-310 Non-alcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm**  
Jimin HAN, *Rep. of South Korea*
- THU-311 Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study**  
YI  
Ma Ai Thanda HAN, *United States*
- THU-312 Physician-recommended lifestyle interventions and associated effects among non-alcoholic steatohepatitis patients with and without cardiovascular-metabolic related comorbidities: A European real-world study**  
Victoria HIGGINS, *United Kingdom*

- THU-313** **Differences between non-alcoholic steatohepatitis patient characterisation and management approaches: A multinational real-world study**  
Victoria HIGGINS, *United Kingdom*
- THU-314** **Serum Zinc levels as a prognostic factor for extra-hepatic carcinogenesis in Japanese patients with non-alcoholic liver disease**  
Takanori ITO, *Japan*
- THU-315** **Non-cirrhotic patients with non-alcoholic fatty liver disease have impaired quality of life: Independently predicted by body mass index, diabetes and liver stiffness**  
Benjamin KADLER, *United Kingdom*
- THU-316** **Cognitive impairment or hepatic encephalopathy? A prospective cross-sectional study in patients with non-alcoholic fatty liver disease**  
Helena KATCHMAN, *Israel*
- THU-317** **The prescribing patterns and use of statins in patients with non-alcoholic fatty liver disease**  
Vandana KHUNGAR, *United States*
- THU-318** **Elevated urinary bisphenol A levels are associated with nonalcoholic fatty liver disease among adults in the United States**  
Donghee KIM, *United States*
- THU-319** **Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis**  
Saekyung JOO, *Rep. of South Korea*
- THU-320** **Evaluation of atherosclerosis and coronary artery stenosis of non-alcoholic fatty liver disease**  
Yoshihito KUBOTSU, *Japan*
- THU-321** **Fluorodeoxyglucose perfusion and uptake in abdominal organs is associated with hepatic disease state in patients with non-alcoholic fatty liver disease**  
Alexander KUO, *United States*
- THU-322** **Statin use on development and progression of nonalcoholic fatty liver disease: A nationwide cohort study**  
Jung Il LEE, *Rep. of South Korea*
- THU-323** **Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes**  
Rosa LOMBARDI, *Italy*

**NAFLD: Clinical aspects except therapy (Cont.)**

- THU-324** **Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions**  
YI  
Peter LYKKE ERIKSEN, *Denmark*
- THU-325** **Regional liver function investigated by galactose positron emission tomography is reduced in patients with non-alcoholic steatohepatitis**  
YI  
Peter LYKKE ERIKSEN, *Denmark*
- THU-326** **Relative fat mass: A new definition of obesity and NAFLD**  
Mariana MACHADO, *Portugal*
- THU-327** **Lifestyle modification leads to a significant decline in aminotransferase activity even without weight reduction in children with non-alcoholic fatty liver disease**  
Anna MANIA, *Poland*
- THU-328** **The prevalence of NAFLD in morbidly obese subjects revisited**  
YI  
Abraham MEIJNIKMAN, *Netherlands*
- THU-329** **Opioid use is common in patients with non-alcoholic fatty liver disease and associated with severity of liver disease, hepatic encephalopathy and psychiatric comorbidities**  
Andrew MOON, *United States*
- THU-330** **Biochemical liver tests reflect the genetic risk for fatty liver disease with increasing body weight but not with alcohol consumption**  
YI  
Elena MUELLER, *Austria*
- THU-331** **Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume**  
YI  
Benjamin H. MULLISH, *United Kingdom*
- THU-332** **Healthcare resource utilisation, demographics, and comorbidities by diagnosis codes and histological stage in non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis in a large integrated healthcare delivery system in the U.S**  
Lisa NYBERG, *United States*
- THU-333** **The HSD17B13:TA (rs72613567) splice variant protects against severity of non-alcoholic fatty liver disease but not fibrosis**  
YI  
Rafael PATERNOSTRO, *Austria*

- THU-334** **PNPLA3 rs738409 C>G variant predicts liver-related events and death in non-alcoholic fatty liver**  
Salvatore PETTA, *Italy*
- THU-335** **FXR rs35724 C>G variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver**  
Salvatore PETTA, *Italy*
- THU-336** **Possible ways of concomitant hypothyroidism effect on the course of nonalcoholic fatty liver disease**  
**YI**  
VasyI PRYSYAZHNYUK, *Ukraine*
- THU-337** **Cardiovascular risk factors and fibrosis severity in NAFLD: is there a link?**  
Davide ROCCARINA, *United Kingdom*
- THU-338** **Prevalence and dynamics of NAFLD-associated fibrosis among HIV+ from first presentation to last follow-up**  
Caroline SCHMIDBAUER, *Austria*
- THU-339** **The relationship between the PNPLA3, TLL1 polymorphism combination and advanced fibrosis in Japanese patients with non-alcoholic fatty liver disease**  
Yuya SEKO, *Japan*
- THU-340** **Epidemiology of NAFLD and advanced fibrosis in the French general population: A population-based cohort study in 118,664 subjects (NASH-CO study)**  
Lawrence SERFATY, *France*
- THU-341** **Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load**  
Amir SHLOMAI, *Israel*
- THU-342** **Development of a model to predict survival in recipients of liver transplant for non-alcoholic steatohepatitis**  
**YI**  
RavikIran SINDHUVALADA KARNAM, *Canada*
- THU-343** **Systematic review: Patient reported quality of life outcomes in non-alcoholic fatty liver disease: Effect of disease severity and duration**  
**YI**  
Humaira UD-DIN, *United Kingdom*
- THU-344** **The influence of non-alcoholic fatty liver disease on a two year prognosis of the patients with stable coronary heart disease depending on SYNTAX score II**  
Nataliya VIRSTYUK, *Ukraine*

**NAFLD: Clinical aspects except therapy (Cont.)**

- THU-345** **Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD**  
Anna LOK, *United States*
- THU-346** **Plasma ApoE levels are associated with non-alcoholic fatty liver disease: the PREVENT cohort study**  
YI  
Elaine H. WOUTERS-VAN DEN BERG, *Netherlands*
- THU-347** **Economic and clinical burden of non-alcoholic steatohepatitis in patients with type II diabetes in the United States**  
Zobair YOUNOSSI, *United States*
- THU-348** **Patients with non-alcoholic steatohepatitis experience severe impairment of health related quality of life**  
Zobair YOUNOSSI, *United States*

Posters

Thursday 11 April 2019

## Imaging and drug targeting



- THU-363** **Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression**  
Valerie FERREIRA, *Netherlands*
- THU-364** **Liver cT1 predicts clinical outcomes in patients with chronic liver disease**  
Arjun JAYASWAL, *United Kingdom*
- THU-365** **Adeno-associated virus-serotype-specific transduction patterns in mice and non-human primates liver tissue: Implications for therapeutic efficacy**  
Anna MAJOWICZ, *Netherlands*
- THU-367** **Linking diabetic cardiovascular disease with non-alcoholic fatty liver disease through L-carnitine: A hyperpolarized MRS study**  
Dragana SAVIC, *United Kingdom*
- THU-368** **Multimodal pre-clinical imaging of liver inflammation and fibrosis**  
Anja SCHMIDT-CHRISTENSEN, *Sweden*
- THU-369** **Efficacy and safety of endoscopic ultrasound-guided liver biopsies in parenchymal liver diseases: A systematic review and meta-analysis**  
Anup SHAH, *United States*
- THU-370** **Quantification of hepatic metal overload by laser ablation inductively coupled plasma mass spectrometry imaging (LA-ICP-MSI)**  
Ralf WEISKIRCHEN, *Germany*

Posters

Thursday 11 April 2019

**Liver development, physiology and regeneration**

- THU-371** **Modulation of H3K27 methylation by EZH2 and UTX/JMJD3 small molecules inhibitors impacts on proliferation and differentiation of hepatic progenitor cells and differentiated hepatocytes plasticity**  
Laura BELLONI, *Italy*
- THU-372** **Exosomes from human umbilical cord mesenchymal stem cells promote liver regeneration in aged mice after major hepatectomy via activating sirtuin1 pathway**  
Liang CHEN, *China*
- THU-373** **IL-6 trans-sginaling controls liver regeneration after partial hepatectomy**  
YI  
Nastaran FAZEL MODARES, *Germany*
- THU-374** **The lncRNA H19-derived MIR-675 promotes liver necroptosis by targeting fadd**  
Eithan GALUN, *Israel*
- THU-375** **Transcription factor TRIM33 controls liver progenitor cell towards hepatocyte differentiation through synergizing with SMAD2/3 following massive parenchymal loss**  
YI  
Tao LIN, *Germany*
- THU-376** **A viral mediated liver repopulation assay without the use of transgenic animals**  
YI  
Wei-Yu LU, *United Kingdom*
- THU-377** **Systemic blood pressure is not associated with hepatic perfusion and metabolic activity by 18F-FDG PET in patients with NAFLD**  
Souvik SARKAR, *United States*
- THU-378** **Messenger RNA transcriptome profiling reveals a distinct phenotype of human bone marrow mesenchymal stem cell-derived hepatocytes**  
YI  
Dongyan SHI, *China*
- THU-379** **Deficiency of apoptosis-stimulating protein two of p53 promotes liver regeneration in mice by activating mammalian target of rapamycin**  
Hongbo SHI, *China*
- THU-380** **DLL4 restores damaged liver by protecting hepatocytes and enhancing cholangiocyte differentiation**  
YI  
Suwan SUN, *China*
- THU-381** **Characterization of regeneration in chronic hepatitis B before and after entecavir treatment in 20 patients**  
Ian WANLESS, *Canada*

## Public Health



- THU-382** **Use of facility-based provider initiated testing and counselling approach to ascertain viral hepatitis C status in high burden populations in Nigeria**  
Chukwuemeka AGWUOCHA, Nigeria
- THU-383** **Dried blood spots: A useful tool for virologically characterising the hepatitis C virus epidemic**  
YI  
Adrian ANTUORI TORRES, *Spain*
- THU-384** **Clinical Performance of determine TM HBsAg 2 rapid test for hepatitis B detection**  
Ana AVELLON CALVO, *Spain*
- THU-385** **Targeted screening for hepatitis C and predictors of advanced liver disease in the birth cohort in a tertiary primary care clinic**  
Aqel BASHAR, *United States*
- THU-386** **Interim results of hepatitis prevention, control and elimination program in Ulaanbaatar, Mongolia**  
YI  
Purevjargal BAT-ULZII, *Mongolia*
- THU-387** **Eliminating viral hepatitis C in Belgium: A mathematical model of the micro-elimination approach**  
Dana BUSSCHOTS, *Belgium*
- THU-388** **Annual healthcare costs double for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients who progress to advanced liver disease: A multivariable analysis of German real-world data**  
Ali CANBAY, *Germany*
- THU-389** **Assessment of hepatitis C screening strategies in different community settings in a Canadian metropolitan area**  
Camelia CAPRARU, *Canada*
- THU-390** **Results of a birth cohort hepatitis C screening program in an academic emergency department in Canada**  
Camelia CAPRARU, *Canada*
- THU-391** **Impact of early screening and treatment of hepatitis C virus and improvements in risk reduction on HCV transmission among HIV-infected men who have sex with men in France: A modeling approach**  
YI  
Mathieu CASTRY, *France*

Posters

Thursday 11 April 2019

Public Health (*Cont.*)

- THU-392** **Building capacity within a hepatitis C treatment model. the validation process for a hepatitis C pre-treatment pharmacist assessment complex intervention toolkit**  
 YI  
 Miriam COGHLAN, *Ireland*
- THU-393** **HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort**  
 Curtis COOPER, *Canada*
- THU-394** **Cancer risk among people with HIV, HBV, and/or HCV infections**  
 YI  
 Maryam DARVISHIAN, *Canada*
- THU-395** **Hepatitis C elimination by enhancing care and treatment among HIV co-infected individuals (the co-EC study): Real world evidence of decreasing HCV incidence and prevalence**  
 Joseph DOYLE, *Australia*
- THU-396** **Hepatitis C screening among the population of Georgia within the national elimination program**  
 YI  
 AmIran GAMKRELIDZE, *Georgia*
- THU-397** **Screening strategies for hepatitis C virus elimination in Italy**  
 YI  
 Ivane GAMKRELIDZE, *United States*
- THU-398** **Circulating HCV resistant strains may result in long-term challenges to HCV elimination: A modeling study**  
 YI  
 Ilias GOUNTAS, *Greece*
- THU-399** **First Belgian hepatitis E seroprevalence study shows low stable birth-cohort specific seroprevalence until 2014, with recent 2016-2018 increase in single centre estimates**  
 YI  
 Erwin HO, *Belgium*
- THU-400** **Alanine-aminotransferase and 20-year risk of liver disease, cancer, ischemic heart disease, and diabetes in a Danish general population sample aged 30-49 years**  
 YI  
 Morten Daniel JENSEN, *Denmark*
- THU-401** **Changes in mortality due to chronic liver diseases in Spain during the period 2002-2016**  
 Mathew KEYS, *Spain*

- THU-402 Tailored message interventions using social marketing approach versus traditional message for increasing participation in viral hepatitis screening for Japanese workers**  
Masaaki KORENAGA, *Japan*
- THU-403 The consensus hepatitis C cascade of care: Methodology and initial findings from three countries**  
Jeffrey LAZARUS, *Spain*
- THU-405 Complications of chronic hepatitis B: Prevalence and disparities in a US health system cohort 2006-2016**  
Stuart C GORDON, *United States*
- THU-406 Cost-effectiveness analysis of „treat all“ guidelines for chronic hepatitis C in Brazil**  
YI  
Everton MACÊDO SILVA\*, *Brazil*
- THU-407 Implementation of a hepatitis C testing and linkage to care program in the Philadelphia jail system**  
Lora MAGALDI, *United States*
- THU-408 Screening for viral immunity prior to immunosuppressive or biologic therapy**  
YI  
Richard MANFREDDY, *United States*
- THU-409 Progress on scaling up testing and treatment for hepatitis C elimination in Punjab, Pakistan: Hepatitis prevention and treatment program**  
YI  
Ammara NAVEED, *Pakistan*
- THU-410 Hepatitis B prevention of mother to child transmission integrated into antenatal care services in Mozambique**  
YI  
Aude NGUYEN, *Switzerland*
- THU-411 Effectiveness of direct-acting antivirals for the treatment of viral hepatitis C in Rwanda**  
YI  
Alida NGWIJE, *Rwanda*
- THU-412 Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: Results from the treatment as prevention for hepatitis C (Trap HepC) program**  
Sigurdur OLAFFSSON, *Iceland*
- THU-413 Service delivery for hepatitis C care: A systematic review and meta-analysis**  
Ena ORU, *Switzerland*

Posters

Thursday 11 April 2019

Public Health (*Cont.*)

- THU-414** **Low rate of treatment uptake amongst recently released prisoners with active HCV infection**  
Tim PAPALUCA, *Australia*
- THU-415** **Changing patterns of liver disease in Wales: First results from the Wales liver disease registry**  
Andrew YEOMAN, *United Kingdom*
- THU-416** **Use of telemedicine as a cost-effective program to achieve microelimination of hepatitis C virus infection among patients in a public health care system in a low-income country**  
Jose Luis PEREZ HERNANDEZ, *Mexico*
- THU-417** **CURE-IT Program – Introducing equity, removing barriers and treating patients hepatitis C close to home: The Queensland experience**  
Tony M RAHMAN, *Australia*
- THU-418** **Community-based screening for significant liver fibrosis among apparently asymptomatic adults in Delhi**  
YI  
Archana RAMALINGAM, *India*
- THU-419** **Prevalence of hepatitis B and C virus infections in Mongolian children and adolescents**  
Khishigtogtokh SEREENENDORJ, *Mongolia*
- THU-420** **Examination of patient and provider perceptions of hepatitis C care in Rwanda**  
YI  
Janvier SERUMONDO, *Rwanda*
- THU-421** **Lower alcohol taxes are associated with increased liver transplant listing**  
YI  
Nicole SHEN, *United States*
- THU-422** **Referral, treatment uptake and self-reported barriers in drug users diagnosed with active hepatitis C attending a low-threshold methadone program in Lisbon**  
Mario Jorge SILVA, *Portugal*
- THU-423** **Patient group monitoring of implementation of WHO viral hepatitis C recommendations: Identifying the gaps between policy and practice in Europe**  
YI  
Adam PALAYEW, *Canada*
- THU-424** **HCV care cascade of PWIDs reached within the Global Fund needle and syringe program in Georgia**  
Ketevan STVILIA, *Georgia*

- THU-425** **Questioning the concept of cure: The morbidity and mortality of a homeless population following HCV treatment**  
Julian SUREY, *United Kingdom*
- THU-426** **Further validation of a liver 'traffic light' test as a prediction model for survival and development of serious liver-related events**  
YI  
Rochelle SYLVESTER, *United Kingdom*
- THU-427** **A community-based fast-track seek-test-treat program to enhance diagnosis and linkage to care for hepatitis C infection among people who inject drugs in Athens, Greece (ARISTOTLE HCV-HIV program)**  
Vana SYPSA, *Greece*
- THU-428** **Routine point of care antenatal screening of hepatitis B virus in windhoek, Namibia: Feasibility of implementation**  
YI  
Cynthia TAMANDJOU, *South Africa*
- THU-429** **Serial testing with the enhanced liver fibrosis test and liver stiffness is cost-effective for detection of advanced alcoholic liver disease in primary care**  
Maja THIELE, *Denmark*
- THU-430** **Changing prevalence of aetiological factors among Australians hospitalized for cirrhosis**  
Patricia VALERY, *Australia*
- THU-431** **The burgeoning growth in cirrhosis-related hospitalization in Australia, 2008-2016**  
Patricia VALERY, *Australia*
- THU-432** **Viral sustained response in chronic hepatitis C did not reduce short term health expenditure**  
Mercedes VERGARA GÓMEZ, *Spain*
- THU-433** **Availability of information in drug labels for appropriate prescribing in patients with hepatic impairment**  
Rianne A. WEERSINK, *Netherlands*
- THU-434** **Poorly chosen upper limits of normal for alanine aminotransferase may burden the patient and health system unnecessarily**  
Johannes WIEGAND, *Germany*
- THU-435** **A threshold analysis for the cost-effectiveness of hepatitis B and hepatitis C testing in emergency departments in the UK**  
YI  
Jack WILLIAMS, *United Kingdom*

Posters

Thursday 11 April 2019

**Public Health (Cont.)**

**THU-436** **The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the National Health Service health check programme for 40 to 74 year olds in England**  
**YI**

Jack WILLIAMS, *United Kingdom*

**THU-437** **The Global Epidemiology on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis**

Zobair YOUNOSSI, *United States*

**THU-438** **The presence of type 2 diabetes is independently associated with impairment of patient-reported outcomes in patients with non-alcoholic steatohepatitis**

Zobair YOUNOSSI, *United States*

**THU-439** **Variability in liver function test results and the risk of heart disease and mortality: A nationwide population-based study**

Su Jong YU, *Rep. of South Korea*

**THU-440** **Changing incidence of reported hepatitis B and its different trends amongst age groups in china from 2004-2016**  
**YI**

Mingyuan ZHANG, *China*

## Liver tumours: Experimental and pathophysiology



- THU-441** **Site-specific structural N-glycan alterations limit CD73 nucleotidase activity in human hepatocellular carcinoma**  
 YI  
 Karel ALCEDO, *United States*
- THU-442** **Role of drug transporters in the chemoresistance of hepatoblastoma**  
 YI  
 Maitane ASENSIO, *Spain*
- THU-443** **Unexpected pro-tumorigenic effect of the chemokine Cxcl10 by modulation of tumor stroma in a murine model of HCC**  
 YI  
 Elisa Fabiana BRANDT, *Germany*
- THU-444** **Alteration of miRNAs expression in patients with HCV-related cirrhosis who developed HCC after therapy with DAAs**  
 YI  
 Alessandra BROCCA, *Italy*
- THU-445** **Beta-catenin signaling controls NKG2D ligands expression in liver tumorigenesis**  
 YI  
 Mathilde CADOUX, *France*
- THU-446** **AMPK/PGC-1 $\alpha$ -mediated metabolic reprogramming of hepatic stellate cells promote stemness of hepatocellular carcinoma via metabolite lactate shuttle**  
 Jianye CAI, *China*
- THU-447** **DNA damage response CHK2 activates senescence cellular program and supports oxidative metabolism to drive hepatocellular carcinoma development**  
 Vinicio CARLONI, *Italy*
- THU-448** **Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study**  
 YI  
 Andrea CASADEI GARDINI, *Italy*
- THU-449** **Nuclear orphan receptor COUP-TF2 increases the resistance to anoikis and induces amoeboid movement and metastatic potential in hepatocellular carcinoma**  
 Elisabetta CENI, *Italy*
- THU-450** **RFX5 promotes hepatocellular carcinoma progression via transcriptional activation of YWHAQ**  
 YI  
 Dongbo CHEN, *China*

Posters

Thursday 11 April 2019

**Liver tumours: Experimental and pathophysiology (Cont.)**

- THU-451** **Characterization of cholangiocarcinoma primary, circulating and metastatic stem-like cells**  
YI  
Margherita CORRENTI, *Italy*
- THU-452** **TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma**  
Cedric COULOUARN, *France*
- THU-453** **Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer**  
YI  
Carolin CZAUDERNA, *Germany*
- THU-454** **Dual CCR2/CCR5 antagonism as macrophage targeted therapy in experimental hepatocellular carcinoma**  
YI  
Helena DEGROOTE, *Belgium*
- THU-455** **Metabolomic analysis by 1H-nuclear magnetic resonance spectroscopy suggest that there are 2 phenotypes of human hepatocellular carcinoma developed in non-alcoholic fatty liver disease according to fibrosis level (F0F1 vs F3F4)**  
Aicha DEMIDEM, *France*
- THU-456** **Polyploidy spectrum: a new marker of molecular HCC tumour classification**  
Chantal DESDOUETS, *France*
- THU-457** **DoubleCortin/Like Kinase 1 (DCLK1) expression characterized specific cancer stem cell subpopulations of human cholangiocarcinoma primary cell cultures where its inhibition exerts anti-neoplastic effects**  
YI  
Sabina DI MATTEO, *Italy*
- THU-458** **Identification of relevant oncogenes in RAS-activated primary liver cancer using a targeted screening approach**  
Ursula EHMER, *Germany*
- THU-459** **Non-parenchymal TREM2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation**  
YI  
Ibone LABIANO, *Spain*
- THU-460** **Longitudinal monitoring of cell-free DNA predicts for transarterial chemo-embolization failure in hepatocellular carcinoma**  
YI  
Joanne EVANS, *United Kingdom*

- THU-461** **A diet-induced lean nonalcoholic steatohepatitis-associated hepatocellular carcinoma mouse model**  
Paraskevi FARAZI, *United States*
- THU-462** **StARD1 is induced in human HCC and its overexpression aggravates cholesterol-mediated hepatocarcinogenesis in vivo**  
José FERNANDEZ-CHECA, *Spain*
- THU-463** **Role of natural killer cells receptors on the development and progression of hepatocellular carcinoma**  
YI  
Francesco FIGORILLI, *Italy*
- THU-464** **NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2 alpha**  
YI  
Beatrice FOGLIA, *Italy*
- THU-465** **Variation of different histone deacetylases and the functional effects of HDAC inhibitors in hepatocellular carcinoma**  
YI  
Kim FREESE, *Germany*
- THU-466** **Epigenetic regulation of gene expression in a HCC-NASH murine model**  
YI  
Antonio GIL-GOMEZ, *Spain*
- THU-467** **Comparison of the immune tumour microenvironment between primary and metastatic hepatocellular carcinoma: Implication for biomarker research of immunotherapy**  
YI  
Chiun HSU, *Taiwan*
- THU-468** **SLU7 controls genome integrity: New role of truncated SRSF3 proteins**  
YI  
Maddalen JIMENEZ, *Spain*
- THU-469** **Nanoparticulate bisphosphonate to selectively target and repolarize liver macrophages for efficient anti-tumour response**  
YI  
Leonard KAPS, *Germany*
- THU-470** **The mRNA-binding protein tristetraprolin promotes hepatocarcinogenesis but inhibits tumour progression in liver cancer**  
YI  
Sonja KESSLER, *Germany*
- THU-471** **Establishment of a short-termed orthotopic transplantation model in C57/B6 mice that recapitulates characteristic features of human intrahepatic cholangiocarcinoma**  
YI  
Theresa Hildegard WIRTZ, *Germany*

Posters

Thursday 11 April 2019

**Liver tumours: Experimental and pathophysiology (Cont.)**

- THU-472 Pharmacological inhibition of PIM1 suppresses tumor progression and enhances chemosensitivity in hepatocellular carcinoma**  
Ming Sum LEUNG, *Hong Kong*
- THU-473 Role of intracellular lysyl oxidase in progression of primary liver cancer**  
YI  
Monika LEWINSKA, *Denmark*
- THU-474 Existence of intratumoral tertiary lymphoid structures predicts better prognosis in Barcelona clinic of liver cancer stage 0-a hepatocellular carcinoma**  
YI  
Hui LI, *China*
- THU-475 CENPF translocation for autoantigen presentation and autoimmune activation in hepatocellular carcinoma**  
YI  
Xiaojin LI, *China*
- THU-476 Modeling cancer stem cell and differentiated cancer cell phenotypes in liver cancer organoids**  
YI  
Ruby LIESHOUT, *Netherlands*
- THU-477 Sumoylation/acetylation drives forward oncogenic role of LKB1 in Liver**  
Fernando LOPITZ OTSOA, *Spain*
- THU-478 CXCL5 induced by transforming growth factor-beta and Axl signalling causes neutrophil extracellular trap formation in hepatocellular carcinoma**  
Wolfgang MIKULITS, *Austria*
- THU-479 The hepatocyte specific role of the NRF2/KEAP1 axis for HCC Progression during chronic liver disease**  
YI  
Antje MOHS, *Germany*
- THU-480 Imaging mechanical stiffness and molecular landscapes of cancer stem cell niches in human hepatocellular carcinomas**  
Orlando MUSSO, *France*
- THU-481 Classification of intrahepatic cholangiocarcinoma microenvironment based on immune cell and tumor stromal features**  
YI  
Hiep NGUYEN CANH, *Japan*
- THU-482 A human anti-MICA/B antibody boost NK cell responses in hepatocellular carcinoma**  
Barbara OLIVIERO, *Italy*

- THU-483** **Blood based weighted gene co-expression network analysis identifies miRNA prognostic biomarkers for HCC**  
Devis PASCUT, *Italy*
- THU-484** **Mass spectrometric analysis of serum haptoglobin fucosylation in patients stratified according to fibrosis stages, and the presence of hepatocellular carcinoma**  
Valentina PETA, *France*
- THU-485** **Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma**  
David James PINATO, *United Kingdom*
- THU-486** **A pro-regenerative environment triggers premalignant to malignant transformation and pinpoints new therapeutic targets**  
Anna POTAPOVA, *Singapore*
- THU-487** **Circulating MIR-4492 as a biomarker to predict therapy response and disease free survival in hepatocellular carcinoma**  
Muhammad Yogi PRATAMA, *Italy*
- THU-488** **Acquisition of stem-like features in cholangiocarcinoma is associated with an oxidative metabolism**  
Chiara RAGGI, *Italy*
- THU-489** **Mixed HCC-ICC liver cancer derives from hepatic progenitor cells: A lineage tracing investigation in a mouse liver inflammation model**  
Nofar ROSENBERG, *Israel*
- THU-490** **Liver NK cells from NLG4 KO mice inhibit progressions of hepatocellular carcinoma of C57BL/6 mice model through decrease in p53 and AKT expressions**  
Ahmed SALHAB, *Israel*
- THU-491** **The role of alanine glyoxylate aminotransferase in hepatocellular carcinoma**  
Letizia SATRIANO, *Denmark*
- THU-492** **Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma**  
Ulrich SPENGLER, *Germany*
- THU-493** **Reciprocal changes in ARID1A and EZH2 are associated with cholangiocarcinoma development in a mouse model of caroli disease with high Yap expression**  
Luca FABRIS, *Italy*

Posters

Thursday 11 April 2019

**Liver tumours: Experimental and pathophysiology (Cont.)**

- THU-494** **MicroRNA-96 in non-B non-C hepatocellular carcinoma**  
Matsui TAKESHI, *Japan*
- THU-496** **Real-time, intravital imaging of diethylnitrosamine-induced hepatocellular carcinoma**  
Alexandra THOMPSON, *United Kingdom*
- THU-497** **Molecular fingerprint of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis**  
YI  
Roger ESTEBAN-FABRÓ, *Spain*
- THU-498** **Mass-spectrometric analysis of deregulated proteins in gallbladder carcinoma**  
YI  
Felicia TRUCKENMUELLER, *Germany*
- THU-499** **Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein**  
Yuki TSUJI, *Japan*
- THU-500** **EGFR is a preventative target for NASH-induced liver cancer**  
Atsushi UMEMURA, *Japan*
- THU-501** **Myeloid-specific IRE1 alpha deletion reduces tumour development in a non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model**  
YI  
Sanne VAN CAMPENHOUT, *Belgium*
- THU-502** **ZEB1 expression in myofibroblasts regulates their interaction with cholangiocarcinoma cells promoting tumour progression**  
YI  
Javier VAQUERO, *France*
- THU-503** **Macrophage migration inhibitory factor shows a pro-proliferative and anti-apoptotic effect on hepatoma cells in vitro and promotes tumour growth in vivo**  
YI  
Theresa Hildegard WIRTZ, *Germany*
- THU-504** **lncRNA HOTAIR promotes cancer stem cell properties in hepatocellular carcinoma via the STAT3/NANOG pathway**  
YI  
Jiajia ZHOU, *China*

**POSTERS**

FRIDAY 12 APRIL 2019

## Friday 12 April 2019

### Autoimmune and chronic cholestatic liver disease: Clinical aspects

- FRI-001** **The PBC-10: A validated short clinic symptom screening tool for primary biliary cholangitis**  
Laith ALRUBAIY, *United Kingdom*
- FRI-002** **Sustained remission after treatment withdrawal in autoimmune hepatitis : A multicenter retrospective study**  
Yasmina BEN MERABET, *France*
- FRI-003** **Early response to corticosteroid treatment supports differentiation of drug-induced liver injury and autoimmune hepatitis**  
Andreas BENESIC, *Germany*
- FRI-004** **Cirrhosis status at diagnosis, non-Caucasian descent, treatment response and age determine long term survival in autoimmune hepatitis**  
Maaïke BIEWENGA, *Netherlands*
- FRI-005** **Characteristics and outcome of autoimmune hepatitis-primary biliary cholangitis and autoimmune hepatitis-primary sclerosing cholangitis overlap patients compared to autoimmune hepatitis patients**  
Maaïke BIEWENGA, *Netherlands*
- FRI-006** **Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis**  
Lars BOSSEN, *Denmark*
- FRI-007** **Serum markers of macrophage activation CD163 and Mannose receptor predict transplant-free survival in primary sclerosing cholangitis**  
Lars BOSSEN, *Denmark*
- FRI-008** **Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study**  
Marco CARBONE, *Italy*
- FRI-009** **Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements**  
Christophe CORPECHOT, *France*

- FRI-010** **Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with an improvement of fibrometer and fibrometer-VCTE, two high-accuracy non-invasive fibrosis tests extensively validated in frequent chronic liver diseases**  
Christophe CORPECHOT, *France*
- FRI-011** **Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis**  
Laura CRISTOFERI, *Italy*
- FRI-012** **Analysis of clinical and histological factors to differentiate autoimmune hepatitis of drug induced liver injury**  
Lidia CUEVAS DEL CAMPO, *Spain*
- FRI-013** **A combined blood and MR imaging risk score for monitoring liver inflammation in paediatric AIH**  
Andrea DENNIS, *United Kingdom*
- FRI-014** **Diagnostic criteria for autoimmune hepatitis: what is a normal ,IgG'?**  
Jessica DYSON, *United Kingdom*
- FRI-015** **Environmental triggering in primary biliary cholangitis: Disease risk relates to coal mining activity**  
Jessica DYSON, *United Kingdom*
- FRI-016** **Validation of the PRESto machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis**  
John EATON, *United States*
- FRI-017** **High prevalence of possible PSC recurrence post transplant evaluated by protocol biopsies**  
Lise Katrine ENGESÆTER, *Norway*
- FRI-018** **High risk of no response and poor prognosis of immunosuppressive therapy in patients of pbc-aih overlap syndrome**  
Xiaoli FAN, *China*
- FRI-019** **Readmission in hospitalized patients with autoimmune hepatitis in nationwide inpatient setting**  
Xiaowen FAN, *United States*
- FRI-020** **Identification of risk factors for histological progression with sequential liver biopsies in primary cholangitis patients**  
Yukihisa FUJINAGA, *Japan*

**Autoimmune and chronic cholestatic liver disease: Clinical aspects  
(Cont.)**

- FRI-021** **Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis**  
YI  
Jorn GOET, *Netherlands*
- FRI-022** **Characteristics of autoimmune hepatitis with acute presentation**  
Ana GOMEZ, *Spain*
- FRI-023** **Inadequate response to UDCA among PBC patients under routine care in the US: Rising serum bilirubin even in the normal range is a risk factor and subsequent clinical follow-up differs based on treatment response**  
Stuart C GORDON, *United States*
- FRI-024** **Incidence and prevalence of autoimmune hepatitis in England 1997-2015. A population-based cohort study**  
YI  
Lisbet GRØNBÆK, *Denmark*
- FRI-025** **Long-term outcome in autoimmune hepatitis: The second twenty years**  
Laura HARRISON, *United Kingdom*
- FRI-026** **Long-term assessment of the effects of obeticholic acid in patients with primary biliary cholangitis on immune and inflammatory markers**  
Gideon HIRSCHFELD, *United Kingdom*
- FRI-027** **Serum bile acids significantly associate with the fibrogenesis biomarker Pro-C3: analysis of a randomized, placebo-controlled trial of NGM282 in patients with primary sclerosing cholangitis**  
Gideon HIRSCHFELD, *Canada*
- FRI-028** **Spleen stiffness and liver stiffness measurements as surrogate markers of liver fibrosis in patients with autoimmune hepatitis: prospective, single-center study**  
YI  
Maciej K. JANIK, *Poland*
- FRI-029** **Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander?**  
Zachou KALLIOPI, *Greece*
- FRI-030** **Treatment choice and long-term prognosis for elderly PBC**  
Hiroteru KAMIMURA, *Japan*
- FRI-031** **Association between serum immunoglobulin G levels and intrahepatic plasmacytic gene signature in human autoimmune hepatitis**  
Atsumasa KOMORI, *Japan*

- FRI-032** **Liver transplantation ameliorates chronic fatigue and improves quality of life in patients with primary sclerosing cholangitis**  
Marcin KRAWCZYK, *Poland*
- FRI-033** **Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis**  
Andreas E KREMER, *Germany*
- FRI-034** **Clinical phenotype of significantly elevated serum IgG4: Single center experience**  
Hadi KURIRY, *Canada*
- FRI-035** **Clinical outcomes associated with additional fibrate treatment in UDCA-refractory PBC patients: A multicenter study**  
Cheol-Hyung LEE, *Rep. of South Korea*
- FRI-036** **Perception by patients with autoimmune and chronic cholestatic disease of their own health condition: Results of a survey led by the French patient association (ALBI)**  
Sara LEMOINNE, *France*
- FRI-037** **Change in lipids: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort**  
Cynthia LEVY, *United States*
- FRI-038** **Good performance of the biochemical response criteria after three months of ursodeoxycholic acid treatment in patients with primary biliary cholangitis**  
Laura Patricia LLOVET, *Spain*
- FRI-039** **Autoimmune hepatitis-related cirrhosis: The importance of treatment response and the utility of Baveno VI criteria**  
Laura Patricia LLOVET, *Spain*
- FRI-040** **Imaging and clinical correlations of macro regenerative nodules in primary sclerosing cholangitis**  
Beatrice MADRAZO, *United States*
- FRI-041** **Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment**  
Lily MAO, *United States*
- FRI-042** **Prevalence and male/female ratio of autoimmune liver diseases are increasing over time in Japan: Hospital-based epidemiological study**  
Kosuke MATSUMOTO, *Japan*

**Autoimmune and chronic cholestatic liver disease: Clinical aspects  
(Cont.)**

- FRI-043** **Primary biliary cholangitis – Autoimmune hepatitis overlap syndrome: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort**  
Marlyn J. MAYO, *United States*
- FRI-044** **PNPLA3 polymorphism is associated with disease progression in patients with autoimmune hepatitis**  
YI  
Ingmar MEDERACKE, *Germany*
- FRI-045** **Treatment of patients with primary biliary cholangitis with seladelpar for 52 weeks improves predicted transplant-free survival**  
YI  
Carla Fiorella MURILLO PEREZ, *Canada*
- FRI-046** **Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test**  
YI  
Carla Fiorella MURILLO PEREZ, *Canada*
- FRI-047** **Metabolic syndrome delays biochemical remission in autoimmune hepatitis**  
Richard PARKER, *United Kingdom*
- FRI-048** **Faecal calprotectin in PSC-IBD is a prognostic marker of cholangitis associated complications**  
YI  
Polychronis PAVLIDIS, *United Kingdom*
- FRI-049** **Real world experience of obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis in the secondary care setting**  
Anthony PRATT, *United Kingdom*
- FRI-050** **Antibodies to human beta-tubulin isotype 5 in autoimmune liver disorders – re-evaluation of their specificity and clinical relevance**  
Beate PREUSS, *Germany*
- FRI-051** **Pregnancy outcomes in women with autoimmune hepatitis**  
YI  
Mussarat RAHIM, *United Kingdom*
- FRI-052** **Long-term bezafibrate therapy does not prevent the progression of primary biliary cholangitis in patients with advanced disease**  
YI  
Anna REIG, *Spain*
- FRI-053** **Overlap of primary biliary cholangitis and autoimmune hepatitis. Natural history and prognosis in a large cohort of patients from Spain**  
YI  
Anna REIG, *Spain*

- FRI-054** **Immune-related hepatitis as an independent entity from autoimmune hepatitis: clinical, prognostic and therapeutic differences**  
Mar RIVEIRO BARCIELA, *Spain*
- FRI-055** **Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry**  
YI  
Surain ROBERTS, *Canada*
- FRI-056** **Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of early real-world experience**  
YI  
Surain ROBERTS, *Canada*
- FRI-057** **A review of primary biliary cholangitis practice in Wales: Time for specialist care**  
YI  
Lavanya SHENBAGARAJ, *United Kingdom*
- FRI-058** **Randomized controlled trial to compare efficacy of albumin dialysis using MARS versus new adsorbent recirculation for pruritus treatment**  
Jan STANGE, *Germany*
- FRI-059** **Systematic review and meta-analysis of bezafibrate in combination with ursodeoxycholic acid in patients with treatment refractory primary biliary cirrhosis**  
YI  
Ted STOKLOSA, *Australia*
- FRI-060** **Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia: phase 2 study results**  
Ekkehard STURM, *Germany*
- FRI-061** **Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: A systematic review and meta-analysis**  
YI  
Tom THOMAS, *United Kingdom*
- FRI-062** **Identifying research priorities in primary sclerosing cholangitis: Driving clinically meaningful change from the patients' perspective**  
Palak TRIVEDI, *United Kingdom*
- FRI-063** **Low-dose prednisone increases the risk of adverse events in autoimmune hepatitis patients**  
YI  
Floris VAN DEN BRAND, *Netherlands*
- FRI-064** **Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis**  
YI  
Bart VAN HOEK, *Netherlands*

Posters

Friday 12 April 2019

**Autoimmune and chronic cholestatic liver disease: Clinical aspects  
(Cont.)**

- FRI-065** **The Amsterdam cholestatic complaints score is a valid patient reported outcome measure for cholestatic symptoms in PSC patients**  
YI  
Kim VAN MUNSTER, *Netherlands*
- FRI-066** **Rituximab therapy is effective for inducing remission in IgG4-RD hepatobiliary disease: A retrospective case series**  
Danielle T VANNAN, *Canada*
- FRI-067** **Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database**  
Umberto VESPASIANI GENTILUCCI, *Italy*
- FRI-068** **Quantitative biliary tree imaging by MRI: Evaluating new technology across patient cohorts with autoimmune liver disease**  
Gary WOODWARD, *United Kingdom*
- FRI-069** **Quantitative MRCP imaging: Preliminary observations in a cohort of paediatric patients with liver and biliary diseases**  
Gary WOODWARD, *United Kingdom*
- FRI-070** **Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country**  
Sun YOO, *Rep. of South Korea*
- FRI-071** **AMA-positives without PBC and healthy subjects have similar bile acid profiles but are different from PBC patients**  
YI  
Stephan ZANDANELL, *Austria*
- FRI-072** **Alteration of glucocorticoid metabolism in patients with cholestasis**  
Gernot ZOLLNER, *Austria*

**Acute liver failure and drug induced liver injury**

- FRI-076** **On the role of inflammation in acute paracetamol injury**  
YI Saleh ALABBAS, *Australia*
- FRI-077** **Influence of drug categorization according to labelling information in the phenotypic presentation of drug-induced liver injury (DILI): An analysis in the Spanish DILI registry**  
Raul J. ANDRADE, *Spain*
- FRI-078** **Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases**  
Fernando BESSONE, *Argentina*
- FRI-079** **HLA B\*14:01 is associated with Trimethoprim-sulfamethoxazole induced liver injury**  
Naga CHALASANI, *United States*
- FRI-080** **Herbal medicines induces severe liver injury than western medications: A nationwide multicenter retrospective research**  
Jun CHEN, *China*
- FRI-081** **Characterisation of severe liver injury induced by immune checkpoint inhibitors**  
Yana DAVIDOV, *Israel*
- FRI-082** **Super stealth immunoliposomes as a strategy to overcome liposome-induced liver toxicity**  
Sara DE MARTIN, *Italy*
- FRI-083** **Impact of acetaminophen on acute liver failure of unknown cause**  
YI Claire DECOSTER, *France*
- FRI-084** **Targeting Toll-Like Receptor 4 signalling with TAK-242: A novel therapy for acute liver failure**  
YI Cornelius ENGELMANN, *United Kingdom*
- FRI-085** **Development and validation of a novel non-invasive model to predict drug-induced liver injury recurrence**  
Chun-Yan WANG, *China*
- FRI-086** **Stem cell treatment on acute liver failure model using semipermeable Poly Lactic-co-Glycolic Acid membrane pouch**  
Bo-Kyeong KANG, *Rep. of South Korea*

Posters

Friday 12 April 2019

## Acute liver failure and drug induced liver injury (*Cont.*)

- FRI-087**    **The good use of paracetamol: prospective assessment of the knowledge of prescribers (practitioners, residents), pharmacists, care providers (nurses, others) and students in an university medical center**  
Dominique LARREY, *France*
- FRI-088**    **The good use of non steroidal anti-inflammatory drugs (nsaids): prospective assessment of the knowledge of prescribers (practitioners, residents), care providers (nurses), pharmacists and students in an university medical center**  
Dominique LARREY, *France*
- FRI-089**    **Genetic deletion of Keap in hepatocytes improves liver damage, but triggers hepatitis in an Nrf2-dependent manner, in experimental toxic liver injury**  
YI  
Laura MORAN BLANCO, *Spain*
- FRI-090**    **Enhanced ASPP2 improves liver injury by way of an inflammatory immune regulatory mechanism in acute liver failure**  
Feng REN, *China*
- FRI-091**    **HGF protector effect in intrahepatic cholestasis**  
YI  
Elsy Soraya SALAS SILVA, *Mexico*
- FRI-092**    **Metamizole as a leading cause of drug-induced liver injury**  
Marcial SEBODE, *Germany*
- FRI-093**    **Low volume plasma exchange in patients with acute liver failure: A real world study**  
YI  
Mohammed SHEIKH, *United Kingdom*
- FRI-094**    **Targeting NEDDylation protects liver from acute drug-induced damage**  
YI  
Jorge SIMÓN, *Spain*
- FRI-095**    **The overweight role in the occurrence of hepatotoxic reactions during chemotherapy of chronic lymphocytic leukaemia**  
Igor SKRYPNYK, *Ukraine*
- FRI-096**    **Technetium-99m-GSA within the first 3d after admission as an early predictor of outcome in severe acute liver injury**  
Yuji SUZUKI, *Japan*
- FRI-097**    **PBI-4050 treatment decreases sepsis-induced liver injury in mice**  
YI  
Jean-François THIBODEAU, *Canada*

- FRI-098** **Targeting cholesterol with atorvastatin protects against valproic acid-induced sensitization to acetaminophen hepatotoxicity**  
YI  
Sandra TORRES, *Spain*
- FRI-099** **PD-1+ monocytes and macrophages contribute to impaired microbial clearance following acute liver failure**  
YI  
Evangelos TRIANTAFYLLOU, *United Kingdom*
- FRI-100** **Protective effects of glutathione and lipoic acid against cadmium-induced oxidative stress in rat's liver**  
YI  
Andrej VELJKOVIC, *Serbia*
- FRI-101** **FGL2 deficiency resists viral fulminant hepatitis through abrogating inflammatory macrophage activation**  
Xiaoyang WAN, *China*
- FRI-102** **Metabolomic and inflammatory mediator based biomarkers analysis for identification of severe drug induced liver injury**  
Zhongyang XIE, *China*
- FRI-103** **A sublethal dose of acetaminophen suffices to induce the unfolded protein response in hepatocytes through an IRE1alpha-JNK1-XBP1s-dependent mechanism**  
YI  
Hui YE, *Spain*

Posters

Friday 12 April 2019

## Cirrhosis and its complications: Experimental and pathophysiology



**FRI-106**     **Combining endozepine-4 and blood ammonia: Does it improve the diagnosis of hepatic encephalopathy in patients with liver cirrhosis?**

YI

Mohamed ABAZA, *Egypt*

**FRI-107**     **Emerging role of taurine conjugated bile acids in the gut liver axis and on hepatic bile acid receptors in chronic hepatitis C**

YI

Rabab Oun Ali Anwar ALI, *United States*

**FRI-108**     **Gut-derived GABA is strongly linked with cognitive impairment in cirrhosis**

Jasmohan S BAJAJ, *United States*

**FRI-109**     **Increased plasma leukotriene B4 in decompensated cirrhosis associates with disease progression and leads to increased skin window neutrophil infiltration**

YI

Natalia BECARES, *United Kingdom*

**FRI-110**     **A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a pre-clinical model of chronic liver disease**

Zoe BOYER-DIAZ, *Spain*

**FRI-111**     **Albumin modulates endosomal TLR9 signaling in human peripheral leukocytes: A mechanism for its anti-inflammatory role in ACLF**

YI

Mireia CASULLERAS, *Spain*

**FRI-112**     **Prediction of treatment failures in a multicentre feasibility trial using human albumin solution to prevent infection in acute decompensation of liver cirrhosis**

YI

Louise China, *United Kingdom*

**FRI-113**     **Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins**

YI

Sergi GUIXÉ-MUNTET, *Switzerland*

**FRI-114**     **Progression of splenic fibrosis in cirrhotic patients with portal hypertension**

Yuji IIMURO, *Japan*

**FRI-115**     **Toll-like receptor 4: A novel therapeutic target for the treatment of hyperammonemia**

YI

Annarein KERBERT, *United Kingdom*

**FRI-116**     **Capturing the complexities of the immune system in patients with advanced cirrhosis using a whole blood culture system reveals a robust inflammatory response to endotoxin stimulation**

YI

Victoria KRONSTEN, *United Kingdom*

- FRI-117** **The gain of function mutation of SerpinB3 (SCCA-PD) is associated with the severity of portal hypertension and complications onset in patients with advanced liver disease**  
Andrea MARTINI, *Italy*
- FRI-118** **Decreased cognitive performance is associated with reduced resting state connectivity and gray matter atrophy in patients with minimal hepatic encephalopathy**  
Carmina MONTOLIU, *Spain*
- FRI-119** **Distinct salivary microbiome profile in patients with decompensated cirrhosis**  
Theodora OIKONOMOU, *Greece*
- FRI-120** **Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension**  
Nikolaj Worm ORNTOFT, *Denmark*
- FRI-121** **Portal hypertension in nodular regenerative hyperplasia is caused by vascular remodeling with extensive regression of portal vein branches**  
Christian PEREZ SHIBAYAMA, *Switzerland*
- FRI-122** **Sarcopenia improves after sustained virologic response to DAAs in chronic hepatitis C patients with cirrhosis, but not in those who develop HCC**  
Colombatto PIERO, *Italy*
- FRI-123** **Transcriptomic and functional analysis of Kupffer cells in patients with cirrhosis reveals a tumour associated macrophages profile and an impaired immune response that are associated with increased risk of infections**  
Elisa POSE, *Spain*
- FRI-124** **Increased prevalence of low-frequency and rare NOD2 variants in patients with liver cirrhosis**  
Matthias REICHERT, *Germany*
- FRI-125** **The phase angle determined by bioelectrical impedance is a predictive factor of hospitalization, falls and mortality in patients with cirrhosis**  
Eva ROMAN, *Spain*
- FRI-126** **Innovative potential biomarkers in spontaneous bacterial peritonitis from ascitic fluid**  
Sophia SCHERM, *Germany*
- FRI-127** **Measuring dynamics of portal pressure and vital parameters in conscious rats using real-time telemetry**  
Philipp SCHWABL, *Austria*

## Cirrhosis and its complications: Experimental and pathophysiology (*Cont.*)



**FRI-128** **Mesenchymal stem cells cultured in hypoxic conditions had multi-directional effects on mice with liver cirrhosis through prostaglandin E2 and miR210 production**

Atsunori TSUCHIYA, *Japan*

**FRI-129** **A defect in the Nrf2/HO-1 pathway and Nox2 activation results in regulatory T cell mitochondrial dysfunction in alcohol related cirrhosis**

Trishan VAIKUNTHANATHAN, *United Kingdom*

**FRI-130** **Changes in the extracellular matrix of the heart and the liver assessed by MRI with T1-mapping are closely linked in cirrhosis: Is inflammation the shared pathway?**

Signe WIESE, *Denmark*

Posters

Friday 12 April 2019

## Viral Hepatitis A, B, C, D, E: Immunology



- FRI-131**    **Impact of HBsAg level on cellular immune responses in HBeAg negative patients with chronic hepatitis B virus infection**  
 YI  
 Elmira ALIABADI, *Germany*
- FRI-132**    **In vitro modulation by TLR8 agonist GS-9688 of multiple regulatory cell types in patients with chronic hepatitis B**  
 YI  
 Oliver E AMIN, *United Kingdom*
- FRI-133**    **HCV neutralizing antibody responses in natural infections mapped by metric multi-dimensional scaling reveals new insights into HCV antigenicity and broadly neutralizing antibodies**  
 YI  
 Dorothea BANKWITZ, *Germany*
- FRI-134**    **Comparative analysis of intrahepatic and peripheral chemokine responses in chronic hepatitis B, C and D in vivo**  
 YI  
 Jan-Hendrik BOCKMANN, *Germany*
- FRI-135**    **Toll-like receptor signalling induces changes in the Hippo signalling pathway that counter regulates innate immune responses in hepatocytes**  
 Ruth BROERING, *Germany*
- FRI-136**    **Hepatitis B core antibody (anti-HBc) mirrors activation of hepatitis B virus-specific immune responses and exhibits direct effect on hepatitis B virus control**  
 YI  
 Chengcong CHEN, *China*
- FRI-137**    **I-carnitine impedes hepatitis B surface antigen loss through immunosuppressive effect in chronic hepatitis B virus infection**  
 YI  
 Shuqin GU, *China*
- FRI-138**    **HBVcore- versus HBVpolymerase-specific CD8+ T cells differ in chronically HBV-infected patients**  
 YI  
 Kathrin HEIM, *Germany*
- FRI-139**    **Intrahepatic transcriptional profiling of chronic hepatitis B patients during interferon-alpha treatment**  
 Ning LI, *China*
- FRI-140**    **Chemokine (C-X-C motif) ligand 13-mediated recruitment of intrahepatic chemokine (C-X-C motif) receptor 5+CD8+ T cells contribute to viral control in chronic hepatitis B patients and hepatitis B virus mouse model**  
 Yongyin LI, *China*

Posters

Friday 12 April 2019

## Viral Hepatitis A, B, C, D, E: Immunology (Cont.)



- FRI-141** **Rapid decrease in titer and breath of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved sustained virological response**  
Isidoro MARTÍNEZ, *Spain*
- FRI-142** **Interferon regulatory factor 5 and soluble fibrinogen-like protein 2 in hepatitis B virus related liver diseases**  
Xuan Hoan NGHIEM, *Germany*
- FRI-143** **Liver-resident HBV-specific CD8+ T cells are long-lived and can be replenished by allogenic responses following transplantation**  
Laura J PALLETT, *United Kingdom*
- FRI-144** **Performance study of new geenius HCV supplemental assay**  
Anthony PALVADEAU, *France*
- FRI-145** **Direct acting antiviral treatment decreases inhibitoryTIM-3 immune checkpoint receptor expression on NK cells in patients with chronic HCV**  
Gabriella PAR, *Hungary*
- FRI-146** **Long-term nucleos(t)ide-analogue treatment in chronic hepatitis B eAg(-) together with a low level of HBsAg leads to a non-exhausted HBV-specific T CD8+ response**  
Julia PEÑA ASENSIO, *Spain*
- FRI-147** **Gradual restoration of HCV-specific CD8+ T cell frequency but persistence of altered phenotype in cirrhotic HCV-infected patients after successful direct-acting antiviral therapy**  
Elena PERPIÑAN, *Spain*
- FRI-148** **Downregulation of innate and adaptive gene expression alleviated by host protein osteopontin in an immunocompetent model of hepatitis B infection**  
Sandra PHILLIPS, *United Kingdom*
- FRI-149** **Comprehensive transcriptome analysis of liver biopsies from chronically infected HBV patients**  
Ricardo RAMIREZ, *United States*
- FRI-150** **Association of the immunodominant HLA-B35:01 restricted CD8+ T cell epitope with clustered viral evolution in HBV polymerase**  
Elahe SALIMI ALIZEI, *Germany*
- FRI-151** **Characterization of regulatory T cells and the role of PD-1 and TNF-alpha in spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B**  
Wai-Kay SETO, *Hong Kong*

- FRI-152** **Immunoregulatory activity of preimplantation-factor on HCV stimulated primary human hepatocytes demonstrates preclinical activity for treating inflammatory liver diseases**  
Emmanuel THOMAS, *United States*
- FRI-153** **Potent hepatitis B core-specific B cell responses associate with clinical parameters in untreated and virally suppressed chronic HBV patients**  
Thomas VANWOLLEGHEM, *Netherlands*
- FRI-154** **Augmentation of HBV-specific CD4 T cell responses via combined OX40 stimulation and PD-L1 blockade**  
YI  
Katharina WILD, *Germany*
- FRI-155** **Characterization of a library of CD4+ T cells for T-cell therapy of HBV infection**  
Karin WISSKIRCHEN, *Germany*
- FRI-156** **Hyperactivation and proliferation of B cells in hbeag positive hepatitis B patients revealed by high throughput RNA sequencing**  
YI  
Chao WU, *China*

Posters

Friday 12 April 2019

**Viral hepatitis B/D: therapy**

- FRI-157** **Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation**  
Leda BASSIT, *United States*
- FRI-158** **Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment**  
Maria BUTI, *Spain*
- FRI-159** **Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers?**  
Ivana CAREY, *United Kingdom*
- FRI-160** **The role of soluble proapoptotic cell death protein 1 on HBV relapse after cessation of entecavir therapy in HBeAg-negative non-cirrhotic patients**  
Chien-Hung CHEN, *Taiwan*
- FRI-161** **Complication is a major risk factor for mortality of cirrhotic hepatitis B virus-related acute-on-chronic liver failure patients: A multi-national study from Asian-pacific region**  
Tao CHEN, *China*
- FRI-162** **Prime-boost vaccination strategies using chimpanzee-adenovirus and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice**  
Senthil Kumar CHINNAKANNAN, *United Kingdom*
- FRI-163** **Reduced liver-related complications after 13 years of follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B: The ELITE-B study**  
YI Hannah S.J. CHOI, *Canada*
- FRI-164** **Prognostic value of various liver scoring systems in cirrhotic chronic hepatitis B patients with and without tenofovir disoproxil fumarate treatment**  
YI Jonggi CHOI, *Rep. of South Korea*
- FRI-165** **No detectable resistance to tenofovir in patients with Adefovir- and Entecavir-resistant chronic hepatitis B after 240 weeks of treatment with tenofovir disoproxil fumarate monotherapy**  
YI Jonggi CHOI, *Rep. of South Korea*

- FRI-166** **Treatment recommendations for chronic hepatitis B and the risk of hepatocellular carcinoma**  
Moon Seok CHOI, *Rep. of South Korea*
- FRI-167** **Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice**  
Michael CURRY, *United States*
- FRI-168** **Understanding HDV and HBsAg kinetics during nucleic acid polymerase chain reaction (PCR) mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modeling**  
Harel DAHARI, *United States*
- FRI-169** **Liver transplantation for hepatitis B induced end stage liver disease: Is it possible to do away with anti virals after liver transplantation?**  
Rajesh DEY, *India*
- FRI-170** **Real-world effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients in Canada**  
Mina FARAG, *Canada*
- FRI-171** **A phase 1 single ascending dose study of the safety, tolerability and pharmacokinetics of CRV431**  
Robert FOSTER, *United States*
- FRI-172** **Outcomes of response guided therapy with pegylated interferon alpha 2a in chronic hepatitis B and D**  
George Sebastian GHERLAN, *Romania*
- FRI-173** **Modeling HBV kinetics in mice treated by a novel TLR7 agonist, alone or in combination with entecavir**  
Jeremie GUEDJ, *France*
- FRI-174** **Discovery of novel therapeutic targets for decreasing HBsAg, focusing on host proteins binding to HBV RNAs**  
Ryota HABA, *Japan*
- FRI-175** **Frequency, severity and impact of Peg-IFN $\alpha$ -associated flares in HDV infection: Results from the HIDIT-II study**  
Svenja HARDTKE, *Germany*
- FRI-176** **Orally administered TQ-A3334 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics single and multiple ascending doses in healthy Chinese subjects**  
Yue HU, *China*

**Viral hepatitis B/D: therapy (Cont.)**

- FRI-177 Association of prophylactic anti-HBV therapy with improved long-term survival in patients with hepatocellular carcinoma undergoing transarterial therapy**  
Jeong Won JANG, *Rep. of South Korea*
- FRI-178 The clinical significance and predictors for precipitous HBsAg decline in off entecavir therapy HBeAg negative patients**  
Rachel Wen-Juei JENG, *Taiwan*
- FRI-179 Antiviral therapy might not be required for chronic hepatitis B patients in the immune-tolerant phase with a significantly low incidence rate of liver-related events**  
Mi Young JEON, *Rep. of South Korea*
- FRI-180 JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers**  
Thomas KAKUDA, *United States*
- FRI-181 YI Efficacy and safety of switching therapy from tenofovir disoproxil fumarate to tenofovir alafenamide for hepatitis B virus infection**  
Shun KANEKO, *Japan*
- FRI-182 Anti-viral treatment in patients with immune tolerant-phase chronic hepatitis B may be cost-effective**  
Hye-Lin KIM, *Rep. of South Korea*
- FRI-183 A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results**  
Pietro LAMPERTICO, *Italy*
- FRI-184 Function and drug combination studies in cell culture models for AB-729, a subcutaneously administered siRNA investigational agent for chronic hepatitis B infection**  
Amy C.H. LEE, *Canada*
- FRI-185 Virological and immunological predictors of long-term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B**  
I-Cheng LEE, *Taiwan*

- FRI-186** **Entecavir plus pegylated interferon alfa-2a and sequential HBV vaccination increases the chance of HBsAg-seroclearance: Results from a randomized controlled E+VIP trial**  
Jeonghoon LEE, *Rep. of South Korea*
- FRI-187** **Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and liver-related events in patients with chronic hepatitis B: A propensity score analysis**  
Sung Won LEE, *Rep. of South Korea*
- FRI-188** **Sequence analysis of baseline and on-treatment samples from HBV-infected chronic hepatitis B patients treated for 28 days with JNJ-56136379 monotherapy**  
Oliver LENZ, *Belgium*
- FRI-189** **HBcAg decline in JNJ-56136379-treated chronic hepatitis B patients: Results of a phase 1 study**  
Oliver LENZ, *Belgium*
- FRI-190** **Incidence and predictors of flares after discontinuing nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP study**  
Seng LIEM, *Canada*
- FRI-191** **EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo**  
Kai LIN, *United States*
- FRI-192** **Tenofovir disoproxil fumarate treatment in chronic hepatitis B patients with cirrhosis reduces hepatic decompensation, hepatocellular carcinoma and death**  
Ken LIU, *Australia*
- FRI-193** **Long-term renal and bone safety of tenofovir disoproxil fumarate in chronic hepatitis B patients with cirrhosis**  
Ken LIU, *Australia*
- FRI-194** **The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid assembly inhibitor resistant HBV in vitro**  
Stephen LOCARNINI, *Australia*
- FRI-195** **Long-term effect of nucleos(t)ide analogs on hepatitis B surface antigen in chronic hepatitis B patients**  
Kenichi MORIKAWA, *Japan*

**Viral hepatitis B/D: therapy (Cont.)**

- FRI-196** **The development of HCC in chronic hepatitis B patients with nucleos(t)ide analogs: Focus on hepatitis B surface antigen and core-related antigen**  
Itaru OZEKI, *Japan*
- FRI-197** **Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients**  
George PAPTAEODORIDIS, *Greece*
- FRI-198** **A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral JNJ-64794964, a toll-like receptor-7 agonist, in healthy adults**  
Mina PASTAGIA, *United States*
- FRI-199** **First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis**  
Daniela PAULSEN, *Germany*
- FRI-200** **Spend less get more; cost effectiveness of various models of care in hepatitis C treatment**  
Jeyamani RAMACHANDRAN, *Australia*
- FRI-201** **Hepatitis B virus vaccine immunogenicity in anti-HBc+ immunocompromised patients with low anti-HBs levels: Preliminary results of the Hepbare study**  
Mar RIVEIRO BARCIELA, *Spain*
- FRI-202** **Outcomes of hepatitis B patients transplanted without hepatitis B immunoglobulin**  
Sheetal SHAH, *United Kingdom*
- FRI-203** **Inhibition of hepatitis B virus replication by FAM176A via activation of PI3K-AKT-mTOR signaling pathway**  
Zhongliang SHEN, *China*
- FRI-204** **ASPP2: A potential strategy to inhibit HBV replication through reducing hepatocytes autophagy**  
Ying SHI, *China*
- FRI-205** **Entecavir improves liver function and fibrosis in hepatitis B virus-associated cirrhosis: A 6 years-multicenter study**  
Seung Kak SHIN, *Rep. of South Korea*

- FRI-206** **Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos(t)ide analogues**  
Milan SONNEVELD, *Netherlands*
- FRI-207** **Subgroup analysis of patients undergoing switch of nucleos(t)ide regimen for HBV treatment during the prospective BONIKA trial**  
Kathrin SPRINZL, *Germany*
- FRI-208** **Predictors of treatment response during addition of pegylated Interferon alfa-2a to an ongoing nucleos(t)id treatment in chronic hepatitis B: Results from the PADD-ON trial**  
Martin SPRINZL, *Germany*
- FRI-209** **Exploring TH1/TH2 adjuvants to improve the efficacy of the therapeutic vaccination against chronic hepatitis B**  
Jinpeng SU, *Germany*
- FRI-210** **Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: Ongoing follow-up results from the REP 401 study**  
Andrew VAILLANT, *Canada*
- FRI-211** **Evaluation of the safety and tolerability of transaminase flares during antiviral therapy in patients with HBeAg negative chronic HBV infection or HBV/HDV co-infection**  
Andrew VAILLANT, *Canada*
- FRI-212** **HBV RNA can be detected more frequently than HBcrAg but decreases during long term treatment with nucleos(t)ide analogues up to 14 years in patients with HBeAg negative chronic hepatitis B**  
Florian VAN BÖMMEL, *Germany*
- FRI-213** **HBV RNA at 6 months predicts HBeAg loss in nucleos(t)ide analogue treated HBeAg positive patients: Demonstration of clinical utility?**  
Bo WANG, *United Kingdom*
- FRI-214** **Novel hepatitis B virus X gene mutants emerge during antiviral therapy to increase covalently closed circular DNA accumulation conferring pseudo-drug-resistance and increasing hepatocellular carcinoma risk**  
Chau-Ting YEH, *Taiwan*
- FRI-215** **Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: 144 weeks results of phase 3 trial**  
Hyung Joon YIM, *Rep. of South Korea*

Posters

Friday 12 April 2019

**Viral hepatitis B/D: therapy (Cont.)**

- FRI-216** **Tenofovir monotherapy versus tenofovir plus entecavir combination therapy for multi-drug resistant chronic hepatitis B: Five year follow-up data of multicenter prospective cohort study (Final results)**  
Hyung Joon YIM, *Rep. of South Korea*
- FRI-217** **Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-56136379, in Asian and non-Asian patients with chronic hepatitis B**  
Jeysen YOGARATNAM, *United States*
- FRI-218** **Dynamic changes of serum hbv pgrna levels in patients with chronic hepatitis B treated with entecavir or peg-interferon YI**  
Xiaoqi YU, *China*
- FRI-219** **R07049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients**  
Man-Fung YUEN, *Hong Kong*
- FRI-220** **Antiviral effect and predictors of hepatitis B surface antigen seroconversion in children of 1-6 years old with chronic hepatitis B**  
Min ZHANG, *China*

## Viral hepatitis C: Clinical aspects except therapy

- FRI-221** **Management of drug-drug interactions in chronic hepatitis C patients treated with second generation direct acting antivirals in Belgium**  
Stefan BOURGEOIS, *Belgium*
- FRI-222** **Redundancy of elastography in mono-infected HCV individuals less than 30 years old – Development of Dillon's Rule**  
Paul BRENNAN, *United Kingdom*
- FRI-223** **Contribution of HBV and HCV infection in mortality of B-NHL subjects**  
Myagmarjav BUDEEBAZAR, *Mongolia*
- FRI-224** **Reaching out to the undiagnosed people with hepatitis C infection in Belgium: A pilot study**  
Dana BUSSCHOTS, *Belgium*
- FRI-225** **Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection**  
Joaquin CABEZAS, *Spain*
- FRI-226** **Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients**  
Harel DAHARI, *United States*
- FRI-227** **Interleukin-6 -174G/C genotype and interleukin-10 ATA haplotype are associated with clinical comorbidities in chronic hepatitis C patients**  
Luciana DINIZ SILVA, *Brazil*
- FRI-228** **Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment And Prevention) study**  
Joseph DOYLE, *Australia*
- FRI-229** **Reflex testing in patients with chronic hepatitis C in Spain improves healthcare outcomes and is cost effective**  
Federico GARCIA GARCIA, *Spain*
- FRI-230** **Rapid starts to stop hepatitis C: Same day hepatitis C treatment starts enhancing patient engagement and follow up in a vulnerable, treatment naïve group living with hepatitis C**  
Shawn GREENAN, *Canada*
- FRI-231** **Hostel-based models can improve the engagement of homeless individuals with liver services: VALID (vulnerable adults liver disease) study**  
Ahmed HASHIM, *United Kingdom*

Posters

Friday 12 April 2019

**Viral hepatitis C: Clinical aspects except therapy (Cont.)**

- FRI-232 YI** **An outpatient endoscopy-based patient navigator model improves hepatitis C virus screening among high risk patients: A 3-year prospective observational study among a safety-net health system**  
Grishma HIRODE, *United States*
- FRI-233** **The impact of community-based rapid point-of-care testing on enhancing uptake of hepatitis C treatment for people who inject drugs in needle and syringe services**  
Jessica HOWELL, *Australia*
- FRI-234** **Viral interference between dengue virus and hepatitis C virus infections**  
Jee-Fu HUANG, *Taiwan*
- FRI-235** **Hepatitis C virus risk factors and test uptake in an English prison**  
Kathryn JACK, *United Kingdom*
- FRI-236** **Hepatitis C virus related liver fibrosis in people who inject drugs at the Stockholm Needle Exchange evaluated with liver elasticity**  
Martin KÅBERG, *Sweden*
- FRI-237** **Triple E (engagement, education and eradication) for patients chronically infected with hepatitis C: Results of a self-sustaining, comprehensive education, screening and treatment program for patients in substance abuse treatment facilities**  
Marcelo KUGELMAS, *United States*
- FRI-238 YI** **Shifty business: Task shifting is essential to sustained increases in hepatitis C care engagement**  
Danielle LEBLANC, *Canada*
- FRI-239** **SAMBA II HCV: A new point of care molecular assay for HCV diagnostics and DAA monitoring**  
Helen LEE, *United Kingdom*
- FRI-240** **Comparison of Abbott RealTime HCV genotype II, Abbott HCV genotype plus RUO with Roche Cobas HCV genotyping assays for hepatitis C virus genotyping**  
Chen-Hua LIU, *Taiwan*
- FRI-241** **Barriers to HCV elimination among drug users: HepCare-Spain**  
Juan MACIAS SANCHEZ, *Spain*

- FRI-242** **Absence of hepatitis C infection despite high-risk sexual behavior in a cohort of men who have sex with men screened in the community: preliminary results of SEXCHECK study**  
Pietro MALOSSO, *Italy*
- FRI-243** **Utility of simple serum based tests to exclude cirrhosis prior to HCV treatment in non-hospital based settings**  
Jonathan MITCHELL, *Australia*
- FRI-244** **Platelet-derived growth factor alpha might mediate hepatic fibrosis by enhancing insulin resistance in patients with hepatitis C**  
Anna MRZLJAK, *Croatia*
- FRI-245** **Improvement in cognitive impairment following 12 weeks of aerobic exercise in individuals with non-cirrhotic, chronic hepatitis C**  
Phillip O'GORMAN, *Ireland*
- FRI-246** **Elimination of HCV in a Large Urban Health System in the United States: A Big-data Approach**  
Ponni PERUMALSWAMI, *United States*
- FRI-247** **Influence of HCV coinfection and HCV treatment on risk of diabetes mellitus in HIV infected persons**  
Lars PETERS, *Denmark*
- FRI-248** **Cost-effectiveness of elbasvir/grazoprevir (EBR/GZR) for treatment-naive (TN) patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection in Russia**  
Amy PUENPATOM, *United States*
- FRI-249** **HCV in french prisoner, the study 2017: Fewer patients but more treatment than in 2015**  
André-Jean REMY, *France*
- FRI-250** **Test to cure: Increase outreach linkage to care by use of real time HCV viral load**  
André-Jean REMY, *France*
- FRI-251** **Impact of hepatitis C treatment on patterns of drug use and subsequent treatment outcomes: High SVR rates despite increasing intravenous drug use in the post treatment period**  
Trina RITCHIE, *United Kingdom*
- FRI-252** **Comparing the efficacy of hepatitis C diagnostic pathways: Standard testing vs. targeted testing**  
Emma ROBINSON, *United Kingdom*

Posters

Friday 12 April 2019

## Viral hepatitis C: Clinical aspects except therapy (Cont.)

- FRI-253** **Changing epidemiology of hepatitis C: A Hospital-level study**  
**YI** Joana ROSEIRA, *Portugal*
- FRI-254** **The impact of virally induced hepatic inflammation and low to moderate alcohol consumption on liver transient elastography (Fibroscan) in patients with chronic hepatitis C virus infection treated with direct-acting antivirals**  
**YI** Christoffer RUUS, *Sweden*
- FRI-255** **Dynamics of HCV epidemiology among HIV+ patients in Vienna**  
 Caroline SCHMIDBAUER, *Austria*
- FRI-256** **Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage**  
**YI** Giordano SIGON, *Italy*
- FRI-257** **Making OraQuick quicker: A hepatitis C point-of-care assay reduced to five minutes for viremic individuals**  
 David SMOOKLER, *Canada*
- FRI-258** **Sustained virologic response among non-cirrhotic persons who inject drugs: Results from the CanHepC retrospective hepatitis C registry**  
 Daniel SMYTH, *Canada*
- FRI-259** **Characteristics and sustained virologic response of persons reporting illicit substance use in the past 6 months: Results from the CANUHC prospective patient registry**  
 Daniel SMYTH, *Canada*
- FRI-260** **Improving hepatitis C care cascade through electronic health engagement**  
 Zohha TARIQ ALAM, *United States*
- FRI-261** **Large-scale screening is not useful to identify individuals with hepatitis B or C virus infection: Final results of a Swiss prospective study**  
**YI** Aicha TRABELSI, *Switzerland*
- FRI-262** **Genetic variants in the promotor region of the macrophage migration inhibitory factor are associated with severity of HCV-induced liver fibrosis**  
**YI** Theresa Hildegard WIRTZ, *Germany*
- FRI-263** **The VirA+EmiC project: Opt out hepatitis B and C testing of 38704 patients in an urban emergency department**  
 Terence WONG, *United Kingdom*
- FRI-264** **Silencing clusterin suppress the progression of hepatitis C virus-related HCC by regulating autophagy and attenuating HCC cell properties**  
 Xiaoxiao ZHANG, *China*

## Gut microbiota and liver disease

- FRI-265** **Twelve weeks of effective resistance training did not change the gut microbiota in patients with cirrhosis**  
Luise AAMANN, *Denmark*
- FRI-266** **Saccharomyces boulardii modulates the colonic microbiota towards a more favourable composition in patients with non-alcoholic fatty liver disease (simple steatosis)**  
Pavel SELIVERSTOV, *Russia*
- FRI-267** **Serial measurement of serum dextran absorption by novel competition ELISA demonstrates larazotide acetate significantly improves „leaky gut“ in a Western diet murine model of metabolic liver disease**  
Rebecca CAFFREY, *United States*
- FRI-268** **Microbiota signature differs significantly between NAFLD and healthy controls but not between NAFL and NASH**  
Münevver DEMIR, *Germany*
- FRI-269** **Regulation of lymphangiogenesis by Paneth cells in normal physiology and experimental portal hypertension**  
Mohsin HASSAN, *Switzerland*
- FRI-270** **Association between gut microbiota and hepatocellular carcinoma in patients with chronic liver disease**  
Takashi HONDA, *Japan*
- FRI-271** **Rifaximin alleviates endotoxemia with improved intestinal hyperpermeability with partially modified fecal microbiota in cirrhotic patients**  
Kosuke KAJI, *Japan*
- FRI-272** **Identification of novel glycans that target gut microbiota-associated ammonia production**  
Margaret KOZIEL, *United States*
- FRI-273** **Intestinal microbiota signature related to hbeag seroconversion after oral antiviral therapy**  
Jin-Shui PAN, *China*
- FRI-274** **Exercise modulates gut microbiota and intestinal barrier functionality counteracting early obesity and NAFLD in an in vivo model**  
David PORRAS, *Spain*

Posters

Friday 12 April 2019

**Gut microbiota and liver disease (Cont.)****FRI-275 Fecal microbiota profiles as a diagnosis marker in PSC and PSC-IBD patients compare to healthy controls**Michal SAFRAN, *Israel***FRI-276 Effect of korean red ginseng on non-alcoholic steatohepatitis: Randomized controlled trial**Ki Tae SUK, *Rep. of South Korea***FRI-277 Effect of probiotics in the treatment of NASH: A randomized clinical trial**Cristiane TOVO, *Brazil*

Posters

Friday 12 April 2019

## NAFLD: Experimental and pathophysiology



- FRI-278** **RIP3-dependent signalling exerts divergent effects on liver steatosis and carcinogenesis in experimental non-alcoholic fatty liver disease**  
**YI**  
 Marta B. AFONSO, *Portugal*
- FRI-279** **Stat2 is a pathogenic factor in human non-alcoholic steatohepatitis and mouse models of liver injury and mediates fatty acid-induced Inflammasome activation in hepatocytes**  
**YI**  
 William ALAZAWI, *United Kingdom*
- FRI-280** **Common dietary component, wheat amylase trypsin inhibitors, driver of chronic liver disease in pre-clinical models of NASH and liver fibrosis**  
**YI**  
 Muhammad ASHFAQ-KHAN, *Germany*
- FRI-281** **IL-4 receptor alpha knock-out mice are protected against fibrotic NASH in a representative mouse model of non-alcoholic steatohepatitis**  
**YI**  
 Muhammad ASHFAQ-KHAN, *Germany*
- FRI-282** **Effect of the farnesoid X receptor agonist, obeticholic acid, in hepatocellular carcinoma: Is it NASH-dependent or -independent?**  
 Yasmien ATTIA, *Egypt*
- FRI-283** **Impact on NAFLD of long-term weight loss after bariatric surgery**  
**YI**  
 Chiara BARBIERI, *Italy*
- FRI-284** **A combination of fenofibrate with a liver-targeted acetyl-CoA carboxylase inhibitor enhances efficacy while reversing plasma triglyceride increases in a murine model of NASH**  
 Jamie BATES, *United States*
- FRI-285** **The benchmarks obeticholic acid and elafibranor show variable effects on NASH and hepatic fibrosis in diet-induced or chemically-induced animal models**  
 Francois BRIAND, *France*
- FRI-286** **Integrated transcriptomic analysis of human NASH livers, rodent models and hepatic stellate cells reveals molecular mechanisms underlying ASK1-mediated hepatic fibrosis**  
 Grant BUDAS, *United States*
- FRI-287** **The glucocorticoid antagonist ST001 prevents development of NASH and improves aspects of the metabolic syndrome in the DIAMOND(TM) mouse model**  
 Rebecca CAFFREY, *United States*

Posters

Friday 12 April 2019

NAFLD: Experimental and pathophysiology (*Cont.*)

- FRI-288**    **Physiological levels of cardiotrophin-1 (CT-1) contribute to fasting-induced free fatty acid mobilization**  
YI  
David CARNEROS TRUJILLO, *Spain*
- FRI-289**    **Effect of MSDC-0602K treatment on the metabolome of a diet-induced murine model**  
Jerry COLCA, *United States*
- FRI-290**    **The role of bile acids profile and insulin resistance for the prediction of gallstone disease in a prospective cohort of blood donors**  
YI  
Elton DAJTI, *Italy*
- FRI-291**    **Glucokinase sensitizes hepatocarcinoma cells to the lipogenic activity of fructose and controls accumulation of lipid droplets and secretion of triglyceride-rich lipoproteins**  
Olivier DIAZ, *France*
- FRI-292**    **Liver polyploidization during NAFLD: A gatekeeper against the replication stress**  
YI  
Romain DONNE, *France*
- FRI-293**    **Recipient PNPLA3 and TM6SF2 genotypes and risk of NAFLD following liver transplantation**  
YI  
Speranta IACOB, *Romania*
- FRI-294**    **Mitochondrial GNMT-complex II is recovered by miR-873-5p targeting in NAFLD**  
David FERNÁNDEZ RAMOS, *Spain*
- FRI-295**    **Advanced glycation end products (AGEs) exacerbate NAFLD progression to liver fibrosis via receptor for AGEs (RAGE) in high fat fed mice**  
YI  
Hettya Kandage Dinali Helan FERNANDO, *Australia*
- FRI-296**    **Interaction between the soluble guanylate cyclase and the NLRP3 inflammasome in Kupffer cells: Implications for the anti-inflammatory actions of sGC stimulation in liver**  
YI  
Roger FLORES-COSTA, *Spain*
- FRI-297**    **Trans-signaling blockade induces mature-onset obesity and insulin resistance in mice via suppression of PPARalpha**  
Eithan GALUN, *Israel*

- FRI-298 Hypoxia-inducible factor 2 alpha drives lipid accumulation in human hepatocytes through the fatty acid translocase CD36**  
Carmelo GARCÍA-MONZÓN, *Spain*
- FRI-299 Transcriptomic and epigenetic characterization of a NAFLD murine model**  
**YI**  
Antonio GIL-GOMEZ, *Spain*
- FRI-300 E2F2 mediated repression of fatty acid B-oxidation is mitigated through**  
**YI**  
**CREB1 in progressive non-alcoholic fatty liver disease**  
Francisco GONZALEZ-ROMERO, *Spain*
- FRI-301 The differential expression of the CIDE family is associated with NAFLD progression from steatosis to steatohepatitis**  
Philippe GUAL, *France*
- FRI-302 Impact of exercise on advanced fibrotic stage of NASH and liver**  
**YI**  
**carcinogenesis**  
Maria GUARINO, *Italy*
- FRI-303 How to develop a differentiated FXR agonist: GS-9674 shows a reduced side effect profile in mice, monkeys and human phase I studies compared to its predecessor Px-102**  
Eva HAMBRUCH, *Germany*
- FRI-304 Elafibranor and pioglitazone reduce NASH and fibrosis in a genetically-obese dietary-induced NASH mouse model**  
Katie R. HEADLAND, *United Kingdom*
- FRI-305 Long acting GLP-1/Glucagon co-agonist ameliorates steatosis, inflammation and fibrogenesis in a rodent model of NASH**  
Dorte HOLST, *Denmark*
- FRI-306 RIP3 deficiency restores mitochondrial bioenergetics and function in**  
**YI**  
**experimental NAFLD**  
Tawhidul ISLAM, *Portugal*
- FRI-307 Metadoxine prevents diet-induced non-alcoholic steatohepatitis in mice**  
**YI**  
Du JINGHUA, *China*
- FRI-308 Inhibition of alpha 2A adrenergic receptors reduces liver inflammation in experimental NASH**  
Helen JONES, *United Kingdom*

Posters

Friday 12 April 2019

**NAFLD: Experimental and pathophysiology (Cont.)**

- FRI-309** **Hepatitis B virus B and T cell specific responses are reduced in adults with a body mass index >35 and non-alcoholic fatty liver disease and in a mice model of NAFLD compared to adults with a BMI of <35 patients and normal animals**  
Shivali JOSHI, *Canada*
- FRI-310** **Alcohol dehydrogenase activity in liver and blood is altered in non-alcoholic fatty liver disease**  
Finn JUNG, *Austria*
- FRI-311** **Gut lymphatic vascular disorder associates with severity of cirrhosis in non-alcoholic fatty liver disease**  
Savneet KAUR, *India*
- FRI-312** **Increased levels of bile acid in feces plays an important role in pathophysiology of nonalcoholic steatohepatitis**  
Takaomi KESSOKU, *Japan*
- FRI-313** **A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis**  
Kevin KLUCHER, *United States*
- FRI-314** **A novel semicarbazide-sensitive amine oxidase inhibitor, TERN-201, reduces NAS and fibrosis in rodent models of non-alcoholic steatohepatitis**  
Kevin KLUCHER, *United States*
- FRI-315** **Lipoprotein lipase deficiency in myeloid cells aggravates the progression of non-alcoholic steatohepatitis**  
Anja KOOP, *Germany*
- FRI-316** **Liver fetuin-A in activated macrophages is a key feature of non-alcoholic steatohepatitis in mice and humans**  
Nicolas LANTHIER, *Belgium*
- FRI-317** **Progression of fatty liver disease to steatohepatitis and liver fibrosis is associated with altered Oncostatin M type I and type II receptor expression**  
Philipp LEDERER, *Germany*
- FRI-318** **Effects of fatty acids and polyphenols from extra virgin olive oil in a murine animal dietary model knockout for the LDL receptor**  
Álvarez Amor LETICIA, *Spain*

- FRI-319** **HEME oxygenase-1 mediates mitochondrial dysfunction in non-alcoholic steatohepatitis**  
YI  
Dondong LI, *China*
- FRI-320** **TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion**  
YI  
Miriam LONGO, *Italy*
- FRI-321** **Hepatocyte expression of the protein kinase ERK5 regulates insulin sensitivity**  
YI  
Giulia LORI, *United States*
- FRI-322** **Metabolic inflammation: The role of chemokine C-C motif ligand 2 in the crosstalk between liver tissue and muscle**  
YI  
Fedra LUCIANO-MATEO, *Spain*
- FRI-323** **Pegbelfermin (BMS-986036) reduces serum levels of secondary bile acids in patients with non-alcoholic steatohepatitis**  
Yi LUO, *United States*
- FRI-324** **Introducing a new pre-clinical model of advanced NASH that mimics the main pathophysiologic characteristics and transcriptomic signature of the human disease**  
YI  
Raquel MAESO DÍAZ, *Spain*
- FRI-325** **rs641738 C>T variant near MBOAT7-TMC4 increases risk of fibrosis, NASH, and HCC: A meta-analysis**  
YI  
Jake MANN, *United Kingdom*
- FRI-326** **Preclinical evaluation of endothelial dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles**  
Mario MASARONE, *Italy*
- FRI-327** **Liver mitochondrial hydrogen sulfide oxidation: From nutritional physiology to non-alcoholic fatty liver pathology**  
YI  
Inès MATEUS, *France*
- FRI-329** **Comparison of seladelpar and combinations with liraglutide or selonsertib for improvement of fibrosis and NASH in a diet-induced and biopsy-confirmed mouse model of NASH**  
Charles MCWHERTER, *United States*
- FRI-330** **MBOAT7 downregulation induces hepatic lipid accumulation**  
YI  
Marica MERONI, *Italy*

Posters

Friday 12 April 2019

## NAFLD: Experimental and pathophysiology (*Cont.*)

- FRI-331**    **Do N1-methylnicotinamide and nicotinamide administration differentially alleviate hepatic steatosis?**  
Makoto NAKAMUTA, *Japan*
- FRI-332**    **Effect of combined farnesoid X receptor agonist and angiotensin 2 receptor blocker on established liver fibrosis in rats**  
Tadashi NAMISAKI, *Japan*
- FRI-333**    **ATG7 genetic variant and defective autophagy: A novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus**  
Serena PELUSI, *Italy*
- FRI-334**    **Cerium oxide nanoparticles present antilipogenic and anti-inflammatory effects in rats with diet-induced non-alcoholic fatty liver disease**  
Meritxell PERRAMON COROMINAS, *Spain*
- FRI-335**    **Lect2, a new hepatokine regulating cholesterol metabolism in liver during non-alcoholic fatty liver disease**  
Sandrine PHAM, *France*
- FRI-336**    **Lack of CCL2 limits the development of HCC in a model of obesity-associated carcinogenesis**  
Benedetta PIOMBANTI, *Italy*
- FRI-338**    **Mitochondrial uncoupler HU6 reduces hepatic oxidative stress in the DIAMOND(TM) mouse model, thus abrogating NASH development**  
Francisco PORTELL, *United States*
- FRI-339**    **Clinical translatability of a diet-induced obese mouse model of non-alcoholic steatohepatitis**  
Kristoffer RIGBOLT, *Denmark*
- FRI-340**    **In vivo effects of a novel inhibitor of apoptosis signal-regulating kinase 1 in mouse models of liver injury and metabolic disease**  
Manuel ROQUETA-RIVERA, *United States*
- FRI-341**    **Sexual aspects of liver metabolism: A computational approach**  
Damjana ROZMAN, *Slovenia*
- FRI-342**    **Combining probiotics and an angiotensin-2 type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis**  
Yasuhiko SAWADA, *Japan*

- FRI-343** **NEDDylation inhibition as a new potential therapy of non-alcoholic fatty liver disease**  
YI  
Marina SERRANO-MACIA, *Spain*
- FRI-344** **Preclinical characterization of FM101, a first-in-class A3 adenosine receptor modulator for the treatment of non-alcoholic steatohepatitis**  
YI  
Changho SHON, *Rep. of South Korea*
- FRI-345** **Whole transcriptome analysis uncovers NorUDCA as a ligand of the aryl hydrocarbon receptor**  
YI  
Daniel STEINACHER, *Austria*
- FRI-346** **The effect of exercise training and canagliflozin on hepatic lipid metabolism of nonalcoholic fatty liver disease**  
Kenichi TANAKA, *Japan*
- FRI-347** **OPN inhibits autophagy and accelerates lipid accumulation in non-alcoholic fatty liver disease**  
YI  
Min TANG, *China*
- FRI-348** **Monoacylglycerol lipase deletion protects against obesity-induced hepatic steatosis via PPAR $\gamma$  regulation in adipose tissue and fatty acid malabsorption in the intestine**  
YI  
Matteo TARDELLI, *Austria*
- FRI-349** **Development of humanized nonalcoholic steatohepatitis model using chimeric mice with highly repopulated humanized livers**  
Chise TATENO, *Japan*
- FRI-350** **Dietary cholesterol mitigates bile acid toxicity in NASH and cholestatic mouse models**  
Oren TIROSH, *Israel*
- FRI-351** **DNA methylation pattern of TM6SF2 influences NAFLD progression in genotype-dependent manner**  
Burge ULUKAN, *Turkey*
- FRI-352** **Inflammation provokes hepatic but not adipose tissue diacylglycerol acyltransferase 2 expression and concomitant triglyceride synthesis in an experimental non-alcoholic fatty liver disease**  
Balasubramaniyan VAIRAPPAN, *India*
- FRI-353** **Metabolic implications of methionine adenosyltransferase 1A depletion during fasting**  
Marta VARELA-REY, *Spain*

**NAFLD: Experimental and pathophysiology (Cont.)**

- FRI-354** **Novel Gubra Amylin NASH diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis**  
Sanne VEIDAL, *Denmark*
- FRI-355** **Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment**  
Robert WALCZAK, *France*
- FRI-356** **Single cell peripheral innate and adaptive immune signature of non-alcoholic steatohepatitis by cytometry time of flight**  
Kathryn WALLER, *United Kingdom*
- FRI-357** **Fibrinogen-like protein 2 aggravates non-alcoholic steatohepatitis by enhancing inflammatory signaling in macrophages**  
Xiaojing WANG, *China*
- FRI-358** **Differentiation of glucagon and glucagon-like peptide-1 effects on hepatocytes**  
Xiaozhen WANG, *United States*
- FRI-359** **Ductular reaction predicts the progression of non-alcoholic fatty liver disease**  
Ramy YOUNES, *Italy*
- FRI-360** **The role of Paneth cells in the pathogenesis of non-alcoholic fatty liver disease: A potential gut microbiota-associated mechanism**  
Saisai ZHANG, *Hong Kong*

Posters

Friday 12 April 2019

## Liver transplantation and hepatobiliary surgery: Clinical aspects



- FRI-361** **Impact of cardiovascular complications on patients' outcome after orthotopic liver transplantation**  
 YI  
 Niklas AEHLING, *Germany*
- FRI-362** **Exercise training for liver transplant candidates**  
 Bandar ALJUDAIBI, *United States*
- FRI-363** **Iron metabolism imbalance is associated with increased mortality following orthotopic liver transplantation**  
 Edouard BARDOU-JACQUET, *France*
- FRI-364** **Frequency and impact of discordance between pre-transplant imaging and explant histology on post liver transplant outcomes for patients with hepatocellular carcinoma**  
 YI  
 Amine BENMASSAOUD, *Canada*
- FRI-365** **Efficacy of combined partial hepatectomy and cyst fenestration on health-related quality of life in polycystic liver disease**  
 YI  
 Lucas H.P. BERNTS, *Netherlands*
- FRI-366** **Portal vein thrombosis in patients on the waiting list for liver transplantation: A single center cohort study**  
 YI  
 Josephine BERT, *Belgium*
- FRI-367** **Pre-liver transplant profile of cardiovascular risk factors and its impact on early post-transplant outcome**  
 YI  
 Claudia CHIALÀ, *Italy*
- FRI-368** **Clinical analysis of emergency liver transplantation in patients with high MELD score**  
 Ho Joong CHOI, *Rep. of South Korea*
- FRI-369** **The role of adipose tissue in metabolic and cardiovascular complication after liver transplantation**  
 YI  
 Daria D'AMBROSIO, *Italy*
- FRI-370** **Application of an extended-release tacrolimus formulation allows dose reduction and stabilizes graft function after liver transplantation**  
 YI  
 Alexandra FREY, *Germany*
- FRI-371** **Correlation between classification of circulating tumor cells in peripheral blood and early recurrence in patients with hepatocellular carcinoma after liver transplantation**  
 Binsheng FU, *China*

Posters

Friday 12 April 2019

## Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.)



**FRI-372** **Next generation sequencing outperforms standard microbiological cultivation for detection of bacteria in the biliary tract in patients with ischemic type biliary lesions and/or anastomotic stricture**

Björn GROBE, *Germany*

**FRI-373** **Mismatch in C-locus Eplets between donor and recipient as independent factor of acute T-cell mediated rejection in liver transplantation**

Sandra GUIRAL, *Spain*

**FRI-374** **Von Willebrand factor independently predicts mortality on the waitlist for liver transplantation and facilitates additional risk stratification in low MELD patients**

G GYOERI, *Austria*

**FRI-375** **Direct oral anticoagulants are safe and effective in patients after liver/kidney transplantation**

Adam HERBER, *Germany*

**FRI-376** **Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival**

Federica INVERNIZZI, *Italy*

**FRI-377** **Survival outcome after liver transplantation in US patients with hepatocellular carcinoma**

Mohamed Saleh ISMAIL, *United States*

**FRI-378** **Should we change the allocation policy for NASH patients?**

Assaf ISSACHAR, *Israel*

**FRI-379** **Renal dysfunction between tenofovir and entecavir in patients with hepatitis B virus after liver transplantation**

Jong Man KIM, *Rep. of South Korea*

**FRI-380** **Factors and models for predicting posthepatectomy liver failure in patients undergoing hepatic resection for hepatocellular carcinoma**

So-Hyun KIM, *Rep. of South Korea*

**FRI-381** **Latent trajectory analysis of serum creatinine in patients with end stage liver disease: Predictors of pre- and post-transplant outcomes**

W. Ray KIM, *United States*

**FRI-382** **Biological assessment comprising alpha-fetoprotein, albumin-bilirubin score and C-reactive protein provides better prognostic competence than tumor size criteria in liver transplant patients with HCC**

Arno KORNBERG, *Germany*

Posters

Friday 12 April 2019

- FRI-383** **Role of traditional cardiovascular risk factors in predicting long term survival after liver transplantation**  
YI  
Anoop KOSHY, *Australia*
- FRI-384** **Early cardiovascular mortality following liver transplantation: 30-year temporal trends from the Australian & New Zealand liver transplant registry**  
YI  
Anoop KOSHY, *Australia*
- FRI-385** **Use of machine learning algorithms to predict HCC recurrence after liver transplantation: A proof of concept**  
YI  
Lawrence LAU, *Canada*
- FRI-386** **Impact of acute-on-chronic liver failure on survival after liver transplantation**  
Sebastián MARCIANO, *Argentina*
- FRI-387** **Risk factors associated with early post-operative acute kidney injury requiring renal replacement therapy following liver transplantation**  
YI  
Jeremy NAYAGAM, *United Kingdom*
- FRI-388** **Hepatitis C infected liver grafts transplanted into non-infected recipients are safe in the era of highly effective direct-acting antiviral therapy**  
YI  
Heather O'DELL, *United States*
- FRI-389** **Impact of coronary artery disease on long term mortality after liver transplantation**  
Samarth PATEL, *United States*
- FRI-390** **Management of dyslipidemia after liver transplantation**  
YI  
Samarth PATEL, *United States*
- FRI-391** **Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are markers for biliary damage and predict graft survival**  
Christian RUPP, *Germany*
- FRI-392** **Sarcopenia associated with worse pre-transplant psychosocial status and predicted post-transplant diabetes**  
Rifaat SAFADI, *Israel*
- FRI-393** **Arterial stiffness in the assessment of cardiovascular risk after liver transplantation**  
YI  
Lydia SASTRE, *Spain*
- FRI-394** **Impact of early kidney dysfunction in the incidence of major cardiovascular events after liver transplantation**  
YI  
Lydia SASTRE, *Spain*

## Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.)

- FRI-395 Etiology of liver disease affects weight gain after liver transplantation**  
Mohammad Bilal SIDDIQUI, *United States*
- FRI-396 Hypoadiponectinemia as a predictor of cardiovascular events in liver transplant recipients**  
Mohammad Bilal SIDDIQUI, *United States*
- FRI-397 Sepsis is a major risk factor for delirium post liver transplantation**  
**YI**  
Oliver TAVABIE, *United Kingdom*
- FRI-398 Impact of sarcopenia and myosteatosis on post-transplant complications and survival**  
**YI**  
Daniele TAVANO, *Italy*
- FRI-399 Impact of a temporary cardiac arrest in a brain dead liver donor on liver transplantation results**  
**YI**  
Elodie TIMSIT, *France*
- FRI-400 Poor long term outcome of patients undergoing liver transplantation with preterminal renal dysfunction**  
**YI**  
Marcel TOUMA, *Germany*
- FRI-401 Direct-acting antiviral agents are not associated with an increased risk of hepatocellular carcinoma recurrence in liver transplant recipients with hepatitis C**  
**YI**  
Chung Sang TSE, *United States*
- FRI-402 Outcomes after liver transplantation for argininosuccinate lyase deficiency: A longitudinal study**  
**YI**  
Nipun VERMA, *United States*
- FRI-403 Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome**  
**YI**  
Elia VETTORE, *Italy*
- FRI-404 Multicenter experience evaluating outcomes of HCV-seropositive donors to HCV-seronegative recipients liver transplantation**  
**YI**  
Karn WIJARNPREECHA, *United States*
- FRI-405 Predictors of outcomes for patients with non-alcoholic steatohepatitis undergoing liver transplantation in the United States**  
**YI**  
Zobair YOUNOSSI, *United States*

## Nurses and AIH research in Hepatology

- FRI-407 Elevating liver disease management in Egypt: A Project ECHO® experience**  
Noha ABDELGELIL, *United States*
- FRI-408 Self-stigma among patients with hepatitis B and C and its association with delayed diagnosis and treatment**  
Shireen ABU ELHIJA, *Israel*
- FRI-409 Measuring the impact of a new liver specialist nursing service on patient care**  
Dianne BACKHOUSE, *United Kingdom*
- FRI-410 Health literacy in outpatients with liver cirrhosis**  
Palle BAGER, *Denmark*
- FRI-411 Nurse-led out-patient-clinic for patients with cirrhosis**  
Hanne BENNICK, *Denmark*
- FRI-412 A collaborative approach to increase access to hepatitis C treatment for the homeless population in Cornwall**  
Helen HAMPTON, *United Kingdom*
- FRI-413 Integrating nurses in the management and care of patients with NAFLD: Better adherence and outcomes**  
Anna Marie HEFNER, *United States*
- FRI-414 The impact of self and parental perception of body image on management in patients with NAFLD**  
Anna Marie HEFNER, *United States*
- FRI-415 People are scared: what they don't know don't hurt them. A qualitative exploration of reasons for low uptake of hepatitis C virus testing in an English prison**  
Kathryn JACK, *United Kingdom*
- FRI-416 Assessment of written patient information pertaining to cirrhosis and its complications: A pilot study**  
Lea LADEGAARD GRØNKJÆR, *Denmark*
- FRI-417 Impact of a nurse educational program and accessibility in the management of patients with hepatocellular carcinoma under systemic treatment**  
Neus LLARCH, *Spain*
- FRI-418 Evaluating patient's experience in liver transplantation: Role of the focus group technique**  
Eva LOPEZ-BENAGES, *Spain*

Posters

Friday 12 April 2019

## Nurses and AIH research in Hepatology (*Cont.*)

**FRI-419** **Is a lack of patient awareness holding back self-management of NAFLD?**

Bronwen WILLIAMS, *United Kingdom*

**FRI-420** **A nurse-led advice and lifestyle intervention shows high levels of patient-reported satisfaction and motivation in community-based management of NAFLD**

Bronwen WILLIAMS, *United Kingdom*

Posters

Friday 12 April 2019

## Rare liver diseases (including pediatric and genetic)

- FRI-422** **Genetic and pathophysiological factors leading to deficient acyl-CoA oxidase 2 (ACOX2) activity in hepatocytes, an alteration which causes oxidative and endoplasmic reticulum stress in liver cells**  
 YI  
 Marta ALONSO-PEÑA, *Spain*
- FRI-423** **Role of antithrombin deficiency in splanchnic vein thrombosis**  
 YI  
 Anna BAIGES, *Spain*
- FRI-424** **Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in pre-menopausal patients**  
 YI  
 Lucas H.P. BERNTS, *Netherlands*
- FRI-425** **Maintenance therapy for Wilson disease with zinc: A comparison between zinc acetate and alternative zinc salts**  
 YI  
 Michelle CAMARATA, *United Kingdom*
- FRI-426** **Overexpression of c-Jun N-terminal Kinase-1 coincides with the acquisition of cholangiocytic markers in experimental cholangiocarcinoma**  
 YI  
 Chaobo CHEN, *Spain*
- FRI-427** **Liver humanized mouse as models for human metabolic liver diseases**  
 Raghuraman CHITTOOR SRINIVASAN, *Sweden*
- FRI-428** **Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension**  
 YI  
 Simone DI COLA, *Italy*
- FRI-429** **Impact of allelic variants of platelet receptors and coagulation system genes in the development of clinical manifestations of Wilson's disease**  
 YI  
 Saglara FASTOVETS, *Russian Federation*
- FRI-430** **Preclinical validation of copper 64 as a translational tool for evaluating the pharmacodynamics of VTX-801 gene therapy in Wilson's disease**  
 Gloria GONZÁLEZ-ASEGUINOLAZA, *Spain*
- FRI-431** **Clinical spectrum of congenital hepatic fibrosis in children: 15 year experience from a tertiary care centre in north India**  
 YI  
 Vybhav GUMMADI, *India*
- FRI-432** **Current long-term outcome of 302 patients with noncirrhotic nontumoral extrahepatic portal vein thrombosis**  
 Guohong HAN, *China*

Posters

Friday 12 April 2019

**Rare liver diseases (including pediatric and genetic) (Cont.)**

- FRI-433** **Bevacizumab for the treatment of liver involvement in patients with hereditary hemorrhagic telangiectasia**  
Assaf ISSACHAR, *Israel*
- FRI-434** **Role of next generation sequencing in the etiological diagnosis of splanchnic venous thrombosis**  
Marta MAGAZ, *Spain*
- FRI-435** **Progression to cirrhosis is not infrequent in patients with Wilson's disease despite treatment**  
Zoe MARIÑO, *Spain*
- FRI-436** **Congenital porto-systemic shunts in children: Preliminary results from the IRCPSS**  
Valérie MCLIN, *Switzerland*
- FRI-437** **Diagnosis of sickle cell liver disease may be aided by non-invasive tests**  
**YI**  
Jibran MECCI, *United Kingdom*
- FRI-438** **Histone deacetylase 5 methylation changes in mice and patients with Wilson disease**  
Valentina MEDICI, *United States*
- FRI-439** **Factor V and VIII may predict the risk of recurrent splanchnic thrombosis in patients with non-cirrhotic chronic portal vein thrombosis of local and idiopathic etiology not receiving anticoagulation**  
Bogdan PROCOPET, *Romania*
- FRI-440** **Management of acute hepatic porphyria attacks in europe and united states: EXPLORE international, prospective, natural history study**  
Eliane SARDH, *Sweden*
- FRI-441** **A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adults**  
Benedetta TERZIROLI, *Switzerland*
- FRI-442** **Acute hepatic porphyria disease manifestations and daily life impacts in EXPLORE international, prospective, natural history study**  
Paolo VENTURA, *Italy*
- FRI-443** **Non-invasive fibrosis assessment in hyperferritinemia and hemochromatosis**  
**YI**  
André VIVEIROS, *Austria*

- FRI-444 VTX-803 AAV-mediated correction of progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model**  
Nicholas D WEBER, *Spain*
- FRI-445 Safety and efficacy of trientine treatment in Wilson disease in patients withdrawn from d-Penicillamine: Final results from a prospective study**  
Karl Heinz WEISS, *Germany*
- FRI-446 Reduction of hepatic Z-alpha1 antitrypsin by RNA interference prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model**  
Dawn CHRISTIANSON, *United States*
- FRI-447 Clinical characteristics of liver cirrhosis and hepatocellular carcinoma occurring after Fontan operation**  
YI  
Jun Sik YOON, *Rep. of South Korea*
- FRI-448 Correction of a metabolic liver disease after ex vivo gene editing of defective human primary hepatocytes**  
Mihaela ZABULICA, *Sweden*
- FRI-449 Complex ATP7B mutation patterns in Wilson disease and a evaluation of a yeast model for functional analysis of the individual variant**  
Donghu ZHOU, *China*

Posters

Friday 12 April 2019

**Liver tumours: Therapy**

- FRI-451**    **Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumour thrombus**  
YI  
Xiao XIANG, *China*
- FRI-452**    **Synergistic reduction of cancer proliferation and tumour growth in advanced murine hepatocellular carcinoma vis skewing and activation of innate and adoptive immunity**  
YI  
Muhammad ASHFAQ-KHAN, *Germany*
- FRI-453**    **Rapamycin promotes tumoricidal immunity in murine HCC by inducing M1-type macrophages and dendritic cells polarization and enhancement of cytotoxic T-cells**  
YI  
Misbah ASLAM, *Germany*
- FRI-454**    **Reappraisal of portal vein tumor thrombosis as a prognostic factor for patients with hepatocellular carcinoma**  
YI  
Young CHANG, *Rep. of South Korea*
- FRI-455**    **Effect of huaier granule on recurrence after curative resection of HCC: A multicenter, randomized clinical trial**  
YI  
Qian CHEN, *China*
- FRI-456**    **MELD score is the only predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by emergent transarterial embolization**  
YI  
Ya-Ting CHENG, *Taiwan*
- FRI-457**    **Comparative long-term outcomes of laparoscopic liver resection and radio frequency ablation for hepatocellular carcinoma: Location of tumor matters**  
YI  
Jai Young CHO, *Rep. of South Korea*
- FRI-458**    **Response evaluation using modified RECIST criteria predict outcomes better than RECIST 1.1 criteria in patients with HCC treated with Yttrium-90 radioembolization**  
YI  
Hongjun CHOI, *Rep. of South Korea*
- FRI-459**    **Prognostic performance of ten non-invasive liver function tests in patients with hepatocellular carcinoma submitted to transarterial chemoembolization**  
YI  
Pedro COSTA-MOREIRA, *Portugal*
- FRI-460**    **What are the predictive factors for long-term survivors with advanced hepatocellular carcinoma treated with sorafenib?**  
YI  
Filipe DE SOUSA DAMIÃO, *Portugal*

- FRI-461** **Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis**  
YI  
Alvaro DIAZ-GONZALEZ, *Spain*
- FRI-462** **A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis**  
YI  
Alvaro DIAZ-GONZALEZ, *Spain*
- FRI-463** **Long-term outcomes of irreversible electroporation for hepatocellular carcinoma**  
YI  
Elliot FREEMAN, *Australia*
- FRI-464** **Percutaneous microwave is better than radiofrequency ablation to obtain complete response in cirrhotic patients with very early and early hepatocellular carcinoma**  
Silvia GALA, *Italy*
- FRI-465** **The lncRNA H19 is an oncogenic driver of HCC in chronic inflammation-mediated mouse model**  
Eithan GALUN, *Israel*
- FRI-466** **A single centre experience of transarterial radioembolisation using Rhenium 188 for treatment of liver space occupying lesions**  
Jeffrey GEORGE, *India*
- FRI-467** **Optimal time-point of response assessment was associated with tumour burden in patients with unresectable hepatocellular carcinoma undergoing repeated transarterial chemoembolization**  
Guohong HAN, *China*
- FRI-468** **Identifying optimal candidates for combining transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma: A multicenter observational study**  
Guohong HAN, *China*
- FRI-469** **Vitamin K dosing could improve anti-cancer outcome of transarterial chemoembolization for patients with hepatocellular carcinoma-an open label, randomized, phase II study**  
Yoshimichi HARUNA, *Japan*
- FRI-470** **External beam radiotherapy as an effective and safe treatment in all stages of hepatocellular carcinoma with cirrhotic liver disease : A single institution experience**  
YI  
Clémence HOLLANDE, *France*

Posters

Friday 12 April 2019

**Liver tumours: Therapy (Cont.)**

- FRI-471** **Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization**  
Chiun HSU, *Taiwan*
- FRI-472** **ALBI grade determines survival of nivolumab-treated patients with advanced hepatocellular carcinoma: a real-world observational study**  
Yi-Hsiang HUANG, *Taiwan*
- FRI-473** **Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study**  
Massimo IAVARONE, *Italy*
- FRI-474** **AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma**  
Massimo IAVARONE, *Italy*
- FRI-475** **Experience impacts on reasons leading to sorafenib discontinuation and chance of long-term response**  
YI  
Luca IELASI, *Italy*
- FRI-476** **Repeated surgical resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after surgical resection : A propensity score matching analysis**  
YI  
Chang KE-BIN, *Taiwan*
- FRI-477** **Factors associated with good postprogression survival in post-sorafenib progressed advanced hepatocellular carcinoma pateitns not eligible for regorafenib**  
Chang Wook KIM, *Rep. of South Korea*
- FRI-478** **Survival outcomes of TACE in treatment-naive and recurrent HCC after curative resection: A propensity score-matched analysis**  
David KIM, *Rep. of South Korea*
- FRI-479** **Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?**  
Jihye KIM, *Rep. of South Korea*
- FRI-480** **Laparoscopic right hepatectomy is feasible and safe in solitary hepatocellular carcinoma**  
Jong Man KIM, *Rep. of South Korea*

- FRI-481** **Predicting hepatocellular carcinoma recurrence beyond Milan criteria after liver resection for solitary hepatocellular carcinoma**  
Jong Man KIM, *Rep. of South Korea*
- FRI-482** **Ideal number of lymph nodes to harvest for intrahepatic cholangiocarcinoma**  
**YI** Sung Hyun KIM, *Rep. of South Korea*
- FRI-483** **Endoscopic biliary drainage in patients with cholangiocarcinoma:**  
**YI** **Polyethylene versus self-expanding metal stents**  
Martha KIRSTEIN, *Germany*
- FRI-484** **The early clinical response at 2 weeks of lenvatinib therapy for patients with advanced HCC**  
Teiji KUZUYA, *Japan*
- FRI-485** **Laparoscopic liver resection vs. Percutaneous radiofrequency ablation for small single nodular HCC: Comparison of treatment outcome**  
Dong Ho LEE, *Rep. of South Korea*
- FRI-486** **Serum cytokines and chemokines correlated with tumor recurrence and survival after surgical resection for overt and occult HBV-related hepatocellular carcinoma**  
I-Cheng LEE, *Taiwan*
- FRI-487** **A new prognosis prediction model in patients with hepatocellular carcinoma after Yttrium-90 radioembolization**  
Jae Seung LEE, *Rep. of South Korea*
- FRI-488** **Prognostic value of tumor markers after a complete response to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma following curative resection**  
Jae Seung LEE, *Rep. of South Korea*
- FRI-489** **Downstaging by 90-yttrium radioembolization of unresectable locally advanced hepatocellular carcinoma: A single center experience**  
**YI** Carolina MARTELLETTI, *Italy*
- FRI-490** **The real world practice of systemic therapies in patients with advanced hepatocellular carcinoma in Japan: what has changed since lenvatinib approval?**  
Susumu MARUTA, *Japan*
- FRI-492** **Long-term outcome according to initial treatment modality in multiple hepatocellular carcinoma within the Milan criteria**  
**YI** Joo Hyun OH, *Rep. of South Korea*

**Liver tumours: Therapy (Cont.)**

- FRI-493**    **Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma**  
Takuya OKAMOTO, *Japan*
- FRI-494**    **Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis**  
Markus PECK-RADOSAVLJEVIC, *Austria*
- FRI-495**    **Post transarterial chemoembolization fever can predict poor survival in patients with TNM stage I hepatocellular carcinoma**  
Chien-Wei PENG, *Taiwan*
- FRI-496**    **Recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice**  
Christie PERELLÓ, *Spain*
- FRI-497**    **Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience**  
Lin PO-TING, *Taiwan*
- FRI-498**    **A current status of therapeutic choice and feasibility for hepato cellular carcinoma patients over 70 years old**  
Seoung Yoon RHO, *Rep. of South Korea*
- FRI-499**    **Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040**  
Bruno SANGRO, *Spain*
- FRI-500**    **Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: Intrinsic resistance or not?**  
Vito SANSONE, *Italy*
- FRI-501**    **Survival among patients with advanced hepatocellular carcinoma in the pre-TKI versus TKI eras**  
Miyuki SENSUI, *Japan*
- FRI-502**    **Factors impacting survival in a large cohort of patients with unresectable hepatocellular carcinoma treated with Y-90 resin microspheres at a single centre**  
Rucha SHAH, *United States*

- FRI-503 Sorafenib starting dose impacts on survival in the elderly population with hepatocellular cancer**  
Rohini SHARMA, *United Kingdom*
- FRI-504 Sorafenib use in patients with HCC on a background of non-alcoholic fatty liver disease**  
Rohini SHARMA, *United Kingdom*
- FRI-505 Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting**  
Takuya SHO, *Japan*
- FRI-506 A nationwide multicenter study in Japanese patients treated with lenvatinib in real world practice**  
Kaoru TSUCHIYA, *Japan*
- FRI-507 Hepatocyte-specific role of c-Jun N-terminal kinase 2 for disease progression and therapy in chronic liver disease**  
YI Marius WOITOK, *Germany*
- FRI-508 How reliable is initial liver resection before salvage liver transplantation and what are the predictors of dropout?**  
Sun Young YIM, *Rep. of South Korea*

Posters

Friday 12 April 2019

Project duration

6 ¼ years

Start

01 January 2019

[www.microb-predict.eu](http://www.microb-predict.eu)

Grant amount

15 million €

10 Countries

22 Partners

## MICROB-PREDICT

**will investigate** the human microbiome to identify predictors and mechanisms associated with the development of decompensation of cirrhosis and progression to **acute-on-chronic liver failure (ACLF) and death.**

- ➔ New microbiome-based tests for better stratification of cirrhosis patients
- ➔ Personalized prediction and prevention of decompensation and ACLF
- ➔ Clinical trial to predict response to treatment
- ➔ Modern, effective nanobiosensors as clinical tools with improved specificity
- ➔ More personalized treatment
- ➔ Increased survival times
- ➔ Decreased costs for the health systems



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825694.



**POSTERS**

SATURDAY 13 APRIL 2019

## Saturday 13 April 2019

### Cirrhosis and its complications: Clinical

**SAT-001** **Validity of urinary bio markers and cardiac echo in diagnosis of acute kidney injury in patients with liver cirrhosis**

YI

Amany ABBASY, *Egypt*

**SAT-002** **Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure: Pooled safety analysis from 3 studies**

Nezam AFDHAL, *United States*

**SAT-003** **Real-world data demonstrate safety and effectiveness of lusutrombopag in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures: Interim analysis**

Nezam AFDHAL, *United States*

**SAT-004** **Bacterial translocation in patients with liver cirrhosis and variceal bleeding**

YI

Christos TRIANTOS, *Greece*

**SAT-005** **Prognostic factors associated with mortality of acute variceal hemorrhage in cirrhotic patients : Multi-center results**

Kuntapon AKKARACHINORES, *Thailand*

**SAT-006** **Efficacy of oral thrombopoietin receptor agonist lusutrombopag in chronic liver disease by underlying disease aetiology**

Naim ALKHOURI, *United States*

**SAT-007** **Survival and risk factors of mortality after emergency transjugular intrahepatic portosystemic shunt for uncontrolled acute variceal bleeding caused by cirrhosis-related portal hypertension**

YI

Manon ALLLAIRE, *France*

**SAT-008** **Quality of medical care measurement in hepatic cirrhosis outpatients: Is there room for improvement?**

YI

Alberto AMADOR, *Spain*

**SAT-009** **Pharmacokinetics of ertapenem in plasma and ascitic fluid in cirrhotic patients with spontaneous bacterial peritonitis**

YI

Alberto AMADOR, *Spain*

**SAT-010** **Predictors of mortality in Child B cirrhotic patients with acute variceal bleeding**

YI

Alberto AMADOR, *Spain*

- SAT-011** **Cirrhotic patients: Is there any role to malnutrition in predicting mortality?**  
Cátia ARIEIRA, *Portugal*
- SAT-012** **Alterations in skin microbiota, serum bile acids and autotaxin modulate itching intensity in patients with cirrhosis**  
Jasmohan S BAJAJ, *United States*
- SAT-013** **Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort**  
Jasmohan S BAJAJ, *United States*
- SAT-014** **Efficacy of rifaximin soluble solid dispersion in patients with early decompensated cirrhosis and a Conn score of 0: A post hoc analysis of a randomized, double-blind, placebo-controlled trial**  
Jasmohan S BAJAJ, *United States*
- SAT-015** **Sarcopenia is associated with a worst prognosis in cirrhotic patients in the context of liver transplantation**  
Chantal BEMEUR, *Canada*
- SAT-016** **Impact of sarcopenia in patients undergoing transjugular intrahepatic portosystemic shunt insertion for refractory ascites**  
YI  
Amine BENMASSAOUD, *Canada*
- SAT-017** **Anticoagulant effect of edoxaban in patients with cirrhosis: The POET study**  
YI  
Sarah BOS, *Netherlands*
- SAT-018** **Relation of CT determined sarcopenia and anthropometry to serum C-reactive protein levels in patients with chronic liver disease**  
Sarah BROWN, *United Kingdom*
- SAT-019** **Minimal hepatic encephalopathy: Which test should we use in clinical practice?**  
Benjamin BUCHARD, *France*
- SAT-020** **Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites**  
YI  
Theresa BUCSICS, *Austria*
- SAT-021** **How to use platelets and liver stiffness to rule out esophageal varices needing treatment?**  
Paul CALES, *France*
- SAT-022** **Transjugular intrahepatic portosystemic shunts is still an effective treatment for refractory variceal haemorrhage in patients with high MELD/ Child Pugh scores**  
YI  
Rigers CAMA, *United Kingdom*

**Cirrhosis and its complications: Clinical (Cont.)**

- SAT-023** **The lack of benefit of prophylactic transfusions of patients with cirrhosis and esophageal varices undergoing endoscopic variceal ligation**  
Andres CARDENAS, *Spain*
- SAT-024** **Effect of acute kidney injury on long-term outcomes of spontaneous bacterial peritonitis in cirrhotics using ICA-AKI criteria**  
Ju-Yeon CHO, *China*
- SAT-025** **Mid-arm muscle circumference: A new cut-off to identify low muscularity in advanced liver disease**  
YI  
Dalila COSTA, *Portugal*
- SAT-026** **Mid-arm circumference and triceps skinfold thickness independently predicts mortality in hospitalized patients with decompensated cirrhosis**  
Valesca DALL'ALBA, *Brazil*
- SAT-027** **Effects of propranolol on liver- and spleen-stiffness measured by MR-Elastography in patients with cirrhosis**  
YI  
Karen Vagner DANIELSEN, *Denmark*
- SAT-028** **Diabetes is associated with TIPS failure in cirrhotic patients with refractory ascites**  
Stella DE NICOLA, *Italy*
- SAT-029** **Prediction of hepatic hydrothorax in cirrhosis patients with ascites**  
YI  
Thomas DELEURAN, *Denmark*
- SAT-030** **Annual contrast-enhanced MRI is highly effective in the surveillance of hepatocellular carcinoma in cirrhotic patients**  
YI  
Coskun Ozer DEMIRTAS, *Turkey*
- SAT-031** **Bleeding risk-scores for prediction of acute variceal bleeding outcome**  
Marwa ELFAYOUMY, *Egypt*
- SAT-032** **Spleen to liver stiffness ratio significantly differs between ALD and HCV and predicts disease specific complications**  
YI  
Omar ELSHAARAWY, *Germany*
- SAT-033** **Body fat composition determines outcomes before and after liver transplantation in cirrhosis**  
YI  
Cornelius ENGELMANN, *United Kingdom*

- SAT-034** **The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability**  
YI Chiara FORMENTIN, *Italy*
- SAT-035** **The negative impact of skeletal muscle volume loss during transarterial chemoembolization for hepatocellular carcinoma**  
Masashi FUJITA, *Japan*
- SAT-036** **Prognostic implications of encephalopathy to adequately define differentiated stages of decompensated cirrhosis**  
YI Marta GARCÍA GUIX, *Spain*
- SAT-037** **Applying the new nutritional screening and assessment algorithm to estimate malnutrition prevalence in Greek cirrhotic patients as suggested by the 2018 EASL nutritional guidelines for chronic liver disease**  
YI Maria Vasiliki PAPAGEORGIOU, *Greece*
- SAT-038** **Lusutrombopag for treatment of thrombocytopenia in patients with chronic liver disease who are undergoing planned invasive procedures: pooled safety analysis of bleeding-related adverse events**  
Edoardo Giovanni GIANNINI, *Italy*
- SAT-039** **The assessment of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis**  
YI Stefania GIOIA, *Italy*
- SAT-040** **Is spleen stiffness the new frontier for non-invasive assessment of portal hypertension?**  
YI Mauro GIUFFRÉ, *Italy*
- SAT-041** **The adjunct of sarcopenia with MHE increases the 1 year risk of developing OHE**  
YI Rohit GUPTA, *Australia*
- SAT-042** **The stroop test is better at predicting the 6-month risk of developing overt hepatic encephalopathy compared to the PHES and CFF tests**  
YI Rohit GUPTA, *Australia*
- SAT-043** **Is carvedilol better than propranolol in preventing variceal bleeding**  
Muhammad Farooq HANIF, *Pakistan*
- SAT-044** **Serum Myostatin in liver cirrhosis: A marker beyond malnutrition**  
YI Rewan HANNO, *Egypt*

## Cirrhosis and its complications: Clinical (*Cont.*)

- SAT-045** **Prevalence, type and risk factors of colonization by multidrug-resistant bacteria in a large series of patients with decompensated cirrhosis**  
**YI** Maria HERNANDEZ-TEJERO, *Spain*
- SAT-046** **Clinical impact of rectal colonization by multidrug-resistant bacteria in patients with decompensated cirrhosis**  
**YI** Maria HERNANDEZ-TEJERO, *Spain*
- SAT-047** **Easy surveillance method without need of special equipment for muscle volume loss in patients with chronic liver disease**  
 Atsushi HIRAOKA, *Japan*
- SAT-048** **Changes in the intestinal microbiome during probiotic intervention in cirrhosis**  
**YI** Angela HORVATH, *Austria*
- SAT-049** **Lactate but not hemoglobin is a predictor for mortality in patients with liver cirrhosis and upper GI bleeding**  
**YI** Thomas HORVATITS, *Germany*
- SAT-050** **Silymarins significantly improve long term survival in patients with liver cirrhosis regardless of MELD score**  
 Chien-Hao HUANG, *Taiwan*
- SAT-051** **The effects of portal vein thrombosis to patients with cirrhotic variceal bleeding underwent endoscopic treatment**  
**YI** Xiaoquan HUANG, *China*
- SAT-052** **Right psoas muscle area: Prognostic factor in patients with cirrhosis Child Pugh class C included on the waiting list for liver transplantation**  
 Speranta IACOB, *Romania*
- SAT-053** **Liver stiffness-spleen size-to-platelet ratio risk score detects esophageal varices and HCC risk in HCV- and HBV-related cirrhosis responsive to DAA**  
**YI** Barbara IMPERATRICE, *Italy*
- SAT-054** **A higher prevalence of colorectal adenomatous polyps in patients with liver cirrhosis compared with non-cirrhotics**  
 Mohamed Saleh ISMAIL, *United States*
- SAT-055** **Dobutamine counteracts the decrease in cardiac output after terlipressin in patients with cirrhosis and impaired kidney function but does not improve GFR: A randomised exploratory trial**  
**YI** Mads IsraelSEN, *Denmark*

- SAT-056** **Development of a novel prognostic model for cirrhotic patients with difficult-to-treat ascites and low MELD scores**  
Peter JEPSEN, *Denmark*
- SAT-057** **Proton pump inhibitors as a risk factor for hepatic encephalopathy and infections in cirrhotic patients: A clinical evidence**  
Mafalda JOÃO, *Portugal*
- SAT-058** **In hepatic cirrhosis, the systemic levels of short chain fatty acids inversely correlate with the level of endotoxemia, and are negatively associated with an increased inflammatory response, impaired liver function and a higher HVPG**  
YI Oriol JUANOLA, *Spain*
- SAT-059** **Prevalence and clinical characteristics of malnutrition in cirrhosis according to new EASL practice guidelines**  
Dae Won JUN, *Rep. of South Korea*
- SAT-060** **Prognostic effect of subcutaneous adipose tissue on survival outcome in patients with liver cirrhosis**  
Seong Hee KANG, *Rep. of South Korea*
- SAT-061** **Performance of Baveno criteria with shear-wave elastography in patients with compensated advanced chronic liver disease**  
Seong Hee KANG, *Rep. of South Korea*
- SAT-062** **Edema index measured by bioelectrical impedance analysis predicts ascites or acute kidney injury after liver resection for hepatocellular carcinoma**  
Soon Sun KIM, *Rep. of South Korea*
- SAT-063** **Third-generation cephalosporins are still useful as the empirical antibiotics for spontaneous bacterial peritonitis in Korea**  
YI Sun Woong KIM, *Rep. of South Korea*
- SAT-064** **The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis**  
YI Ji Jade KING, *United Kingdom*
- SAT-065** **Shear wave elastography for skeletal muscle: A novel approach to insulin resistance in cirrhosis**  
Kazufumi KOBAYASHI, *Japan*
- SAT-066** **Modified SAE technique provides a long last sustained hemodynamic response on splenic artery blood velocity in patients with cirrhosis and clinically significant portal hypertension**  
Sergii KOZLOV, *Ukraine*

**Cirrhosis and its complications: Clinical (Cont.)**

- SAT-067** **Prospective assessment of sarcopenia as a prognostic factor for survival in patients with liver cirrhosis**  
YI  
Wolfgang Maximilian KREMER, *Germany*
- SAT-068** **Presence of liver cirrhosis is the strongest negative predictor of survival for patients admitted to intensive care unit**  
Alica KUBESCH, *Germany*
- SAT-069** **Interleukin 6: A marker for hepatic encephalopathy**  
YI  
Christian LABENZ, *Germany*
- SAT-070** **A clinical pathway to manage patients with decompensated cirrhosis: Assessing the level of compliance with evidence based guidelines**  
Abdulnasser LAFTA, *Australia*
- SAT-071** **Insulin resistance in cirrhotic patients: results from a large prospective study**  
Nicolas LANTHIER, *Belgium*
- SAT-072** **Predict improvement of liver cirrhosis after antiviral treatment in patients with chronic hepatitis B**  
Hye Won LEE, *Rep. of South Korea*
- SAT-073** **Micronutrient deficiencies in patients with decompensated cirrhosis**  
YI  
Gemma LLIBRE NIETO, *Spain*
- SAT-074** **Prevalence and risk factors of colonization by multidrug resistant bacteria in cirrhotic patients admitted to the intensive care unit in a Spanish tertiary hospital**  
Sara LORENTE, *Spain*
- SAT-075** **Clinical efficacy of transjugular intrahepatic portosystemic shunt created with expanded polytetrafluoroethylene-covered stent-grafts: 8-mm versus 10-mm**  
Xuefeng LUO, *China*
- SAT-076** **Long term palliative abdominal drains versus large volume paracentesis in refractory ascites due to cirrhosis: a multi-centre feasibility randomised controlled trial (the REDUCe Study)**  
YI  
Lucia MACKEN, *United Kingdom*
- SAT-077** **Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease**  
YI  
Mattias MANDORFER, *Austria*

- SAT-078** **Characterizing compensated cirrhosis patients with potential etiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Findings from large Italian administrative databases**  
Giulio MARCHESINI REGGIANI, *Italy*
- SAT-079** **Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients**  
Javier MARTINEZ, *Spain*
- SAT-082** **Cholemic nephropathy is a cause of acute kidney injury in patients with liver disease and accompanied by loss of epithelial barrier in distal tubuli**  
Young-Seon MEDERACKE, *Germany*
- SAT-083** **Simple non-invasive surrogates of portal hypertension predict clinical decompensation in overweight/obese patients with cACLD**  
Yuly Paulin MENDOZA, *Switzerland*
- SAT-084** **Validation of hand grip strength as a nutritional assessment tool for patients with advanced liver fibrosis**  
Topan MIRABELA-MADALINA, *Romania*
- SAT-085** **Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy**  
Carmina MONTOLIU, *Spain*
- SAT-086** **Opioid use is common among non-surgical inpatients with cirrhosis and is associated with increased length of stay and persistent use post-discharge**  
Andrew MOON, *United States*
- SAT-087** **Screening endoscopy in patients with advanced chronic liver disease beyond portal hypertension: Higher prevalence of upper gastrointestinal neoplasia in comparison to a healthy screening population**  
Rui MORAIS, *Portugal*
- SAT-088** **Sarcopenia and Myosteatosis are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis**  
Silvia NARDELLI, *Italy*
- SAT-089** **Evaluating the impact of non-selective beta-blocker use in decompensated cirrhosis based on setting of patient care**  
Rooshi NATHWANI, *United Kingdom*
- SAT-090** **Location of onset of acute kidney injury in cirrhosis affects survival**  
Janardhan NAVARATNAM, *United Kingdom*

Posters

Saturday 13 April 2019

## Cirrhosis and its complications: Clinical (*Cont.*)

**SAT-091** **The collagen hormone Endotrophin, a biomarker of type VI collagen formation – is associated with severe decompensation and predicts transplant-free survival in patients with trans-jugular intrahepatic portosystemic shunt**  
 YI  
 Mette Juul NIELSEN, *Denmark*

**SAT-092** **The efficacy and safety of rifaximin-a: a 2-year observational study of overt hepatic encephalopathy**  
 YI  
 Rosalie OEY, *Netherlands*

**SAT-093** **Underutilization of hospice in inpatients with cirrhosis: The NACSELD experience**  
 Jacqueline O'LEARY, *United States*

**SAT-094** **Effects of branched-chain amino acids on the progression of advanced liver disease: A Korean nationwide, multicenter, prospective, observational, cohort study**  
 Jung Gil PARK, *Rep. of South Korea*

**SAT-096** **Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis**  
 YI  
 Michael PRAKTIKNJO, *Germany*

**SAT-097** **Non-invasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility Indices of the inferior vena cava using bedside echocardiography**  
 Madhumita PREMKUMAR, *India*

**SAT-098** **Transjugular intrahepatic portosystemic shunt with 7 mm covered stent reduces hepatic encephalopathy without losing shunt function for prevention of portal hypertensive rebleeding**  
 YI  
 Xiaolong QI, *China*

**SAT-099** **Portal pressure gradient measured immediately after transjugular intrahepatic portosystemic shunt placement: Poor in predicting rebleeding in patients with portal hypertension**  
 YI  
 Xiaolong QI, *China*

**SAT-100** **Expanding the Baveno VI criteria for the screening of varices in advanced liver disease patients**  
 Iulia RATIU, *Romania*

**SAT-101** **Detrimental effect of proton pump inhibitors in cirrhosis depends on common genetic variation**  
 YI  
 Matthias REICHERT, *Germany*

- SAT-102** **Cirrhotic patients with vitamin d deficiency fail to respond to oral replacement therapy**  
YI  
Freya RHODES, *United Kingdom*
- SAT-103** **Bone disease does not correlate with severity of liver disease in cirrhosis**  
YI  
Freya RHODES, *United Kingdom*
- SAT-104** **Factors associated with renal replacement therapy and mortality following first episode of acute kidney injury in inpatients with cirrhosis**  
YI  
Susana G. RODRIGUES, *Switzerland*
- SAT-105** **Rising economic burden following the diagnosis of compensated cirrhosis among hospitalized patients with Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in Spain**  
Manuel ROMERO GOMEZ, *Spain*
- SAT-106** **Prevalence and survival of fungal peritonitis in decompensated cirrhosis**  
YI  
Noam ROTH, *United Kingdom*
- SAT-107** **Effect of a multifactorial intervention (non-alcoholic beer, diet and exercise) on endothelial function, nutritional status and quality of life in patients with cirrhosis**  
YI  
Astrid RUIZ-MARGAIN, *Mexico*
- SAT-108** **Sarcopenia and nutritional status predict mortality in patients with cirrhosis undergoing liver transplant assessment**  
John RYAN, *United Kingdom*
- SAT-109** **Spontaneous bacterial peritonitis: Will the diagnostic follow-up paracentesis be essential in approaching these patients?**  
YI  
Ana SANTOS, *Portugal*
- SAT-110** **Impact of rifaximin monotherapy or rifamixin plus lactulose on markers of inflammation in patients with cirrhosis and a history of hepatic encephalopathy**  
Arun SANYAL, *United States*
- SAT-111** **Precalcitonin level is a prognostic marker in patients with liver cirrhosis**  
Sho SATO, *Japan*
- SAT-112** **Each additional infection significantly increases mortality in patients with decompensated liver cirrhosis**  
YI  
Marie SCHULTALBERS, *Germany*
- SAT-113** **Non-invasive assessment of HVPG with quantitative MRI measures of liver T1 and superior mesenteric artery velocity at 3T**  
YI  
Robert SCOTT, *United Kingdom*

**Cirrhosis and its complications: Clinical (Cont.)**

- SAT-114** **Impact of farnesoid X receptor polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension**  
Georg SEMMLER, *Austria*
- SAT-115** **Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients with cirrhosis**  
Marco SENZOLO, *Italy*
- SAT-116** **Development and validation of a novel model for outcome in patients with cirrhosis and acute variceal bleeding**  
Bruce BACON, *United States*
- SAT-117** **Enhanced liver fibrosis score is an accurate non-invasive predictor of clinically significant and high-risk portal hypertension**  
Benedikt SIMBRUNNER, *Austria*
- SAT-118** **Estimating proportion of cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C in clinical centres in Sofia (Bulgaria) and Lisbon (Portugal): Results from a European pilot**  
Marieta SIMONOVA, *Bulgaria*
- SAT-119** **Comparison of liver frailty index at admission and 30 days after discharge from hospital in patients with advanced chronic liver disease**  
Lubomir SKLADANY, *Slovakia*
- SAT-120** **Influence of previous acute decompensation and organ failure on the long-term prognosis in cirrhotic patients with decompensation**  
Do Seon SONG, *Rep. of South Korea*
- SAT-121** **Predicting sarcopenia in patients with cirrhosis based on clinical and laboratory parameters using machine learning**  
Guido STIRNIMANN, *Switzerland*
- SAT-122** **Cirrhotic cardiomyopathy: An observational study pre-liver transplant**  
Mohsan SUBHANI, *United Kingdom*
- SAT-123** **Serum Mac-2 binding protein glycosylation isomer and handgrip strength correlate with serum myostatin level in chronic liver disease**  
Tomoyuki SUEHIRO, *Japan*
- SAT-124** **Microbiological culture yield from ascitic fluid and changing antimicrobial sensitivities over time**  
Rachael SWANN, *United Kingdom*

- SAT-125** **Animal naming test is simple and reliable for diagnosis of minimal hepatic encephalopathy and prediction of development of overt hepatic encephalopathy in patients with cirrhosis**  
Sunil TANEJA, *India*
- SAT-126** **Minimal hepatic encephalopathy: Proper diagnosis for a better quality of life**  
YI  
Vlad TARU, *Romania*
- SAT-127** **The clinical course of recurrent versus refractory ascites in outpatients with cirrhosis**  
YI  
Marta TONON, *Italy*
- SAT-128** **The natural history of acute kidney disease in patients with cirrhosis**  
YI  
Marta TONON, *Italy*
- SAT-129** **Type 2 diabetes in patients with liver cirrhosis: prevalence, associated factors and influence on survival**  
YI  
Maria TORNER, *Spain*
- SAT-130** **Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study**  
YI  
Giulia TOSETTI, *Italy*
- SAT-131** **The impact of sustained virological response on the criteria used to rule out high risk esophageal varices in HCV-related compensated advanced chronic liver disease**  
YI  
Giulia TOSETTI, *Italy*
- SAT-132** **Incidence and prognostic factors of de novo development /worsening of esophageal varices in HCV-related compensated advanced chronic liver disease after sustained virological response achieved by direct antiviral agents**  
YI  
Giulia TOSETTI, *Italy*
- SAT-133** **2D-Shear-Wave elastography predicts survival in advanced chronic liver disease**  
YI  
Jonel TREBICKA, *Germany*
- SAT-134** **Hypercoagulopathy risk factors in liver cirrhosis due to non-alcoholic steatohepatitis and clinical manifestations of hypercoagulation during 5 years**  
YI  
Nataliya VIRSTYUK, *Ukraine*

**Cirrhosis and its complications: Clinical (Cont.)**

- SAT-135** **Splenomegaly status does not impact the efficacy of avatrombopag in increasing platelet counts and reducing platelet transfusions or rescue procedures for bleeding in chronic liver disease patients with thrombocytopenia**  
Michael VREDENBURG, *United States*
- SAT-136** **Hepatocellular carcinoma does not impact the efficacy of avatrombopag in increasing platelet counts and reducing platelet transfusions or rescue procedures for bleeding in chronic liver disease patients with thrombocytopenia**  
Michael VREDENBURG, *United States*
- SAT-137** **Adverse drug reactions in patients with cirrhosis: analysis of spontaneous reports from the Dutch Pharmacovigilance Centre Lareb**  
Rianne A. WEERSINK, *Netherlands*
- SAT-138** **Cirrhotic cardiomyopathy: A 2-year longitudinal follow-up study using advanced cardiac imaging**  
Signe WIESE, *Denmark*
- SAT-139** **Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation**  
Florence WONG, *Canada*
- SAT-140** **The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites**  
Florence WONG, *Canada*
- SAT-141** **The diagnosis of hepatorenal syndrome: How much does use of the 2015 revised consensus recommendations affect earlier treatment and serum creatinine at treatment start?**  
Florence WONG, *Canada*
- SAT-142** **Incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: A territory-wide cohort study**  
Vincent Wai-Sun WONG, *Hong Kong*
- SAT-143** **Albumin-bilirubin as a simple prognostic score for chronic hepatitis B-related liver cirrhosis**  
Chao WU, *China*

- SAT-144** **Red blood cell distribution width to albumin ratio as a novel prognostic indicator for patients with chronic hepatitis B-related liver cirrhosis**  
YI  
Chao WU, *China*
- SAT-145** **The prognostic significance of hbeag status on the long-term outcome for chronic hepatitis b-related liver cirrhosis: A propensity score matching analysis**  
YI  
Chao WU, *China*
- SAT-146** **Assessing liver function in patients who underwent balloon occluded retrograde transvenous obliteration**  
Thomas XU, *United States*
- SAT-147** **Interaction between renal and liver impairment on the risk of lactic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis**  
YI  
Terry Cf YIP, *Hong Kong*
- SAT-148** **The role of kidney biomarkers in cirrhotic patients with acute kidney injury: interim analysis of multicenter, prospective cohort study**  
Jeong-Ju YOO, *Rep. of South Korea*
- SAT-149** **Optimal selection of sedative drug during endoscopy in cirrhotic patients to avoid minimal encephalopathy**  
Jeong-Ju YOO, *Rep. of South Korea*
- SAT-150** **Validation of Korean stroop test in the screening of minimal hepatic encephalopathy**  
Eileen YOON, *Rep. of South Korea*
- SAT-151** **What are the predictors of impairment of patient-reported outcome in non-alcoholic steatohepatitis?**  
Zobair YOUNOSSI, *United States*
- SAT-152** **Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation**  
YI  
Giacomo ZACCHERINI, *Italy*
- SAT-153** **A systematic review and meta-analysis of the efficacy of magnetic resonance spectroscopy in the diagnosis of hepatic encephalopathy**  
YI  
Georgia ZENG, *Australia*
- SAT-154** **Acute hemodynamic response to I.V propranolol during hepatic hemodynamic study in 26 cirrhotic patients with portal hypertention and nonbleeding esophageal varices. Correlation with esophageal bleeding and survival**  
Eli ZUCKERMAN, *Israel*

Posters

Saturday 13 April 2019

## Viral Hepatitis A, B, C, D, E: Virology



- SAT-159** **Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma**  
YI  
Mohammad ALKHATIB, *Italy*
- SAT-160** **Timing of exposure to dimethylxalylglycine-mediated hypoxia determines opposite effects in an experimental model of hepatitis C virus infection**  
YI  
Matteo Nazzareno BARBAGLIA, *Italy*
- SAT-161** **Prevalence of HBV and syphilis co-infection in Ulaanbaatar population, Mongolia**  
YI  
Delgerbat BOLDBAATAR, *Mongolia*
- SAT-162** **Serum HBV RNA as a predictor of incomplete HBV DNA suppression following initiation of nucleoside therapy in HBV/HIV co-infected individuals**  
YI  
Ruth BYRNE, *United Kingdom*
- SAT-163** **HBeAg-negative chronic infection: more complex and conserved quasispecies in Hepatitis B X gene**  
YI  
Maria Francesca CORTESE, *Spain*
- SAT-164** **Characterization of HBV kinetics during infection and treatment in primary human hepatocytes**  
YI  
Harel DAHARI, *United States*
- SAT-165** **Identification of chromatin-accessible domains on the host genome and hepatitis B virus mini-chromosome in infected primary human hepatocytes**  
YI  
Oceane FLORIOT, *France*
- SAT-166** **Hepatitis C virus-based experimental models in the study of liver-driven altered glucose homeostasis**  
YI  
Diana GOMES, *Switzerland*
- SAT-167** **Hepatitis-E-genome sequencing via capture-probe targeting and NGS allows characterisation of viral variability**  
YI  
Swantje GUNDLACH, *Germany*
- SAT-168** **HBV splice DNA forms detected in serum in majority of patients with chronic HBV infection**  
YI  
Charlotte HEDSKOG, *United States*
- SAT-169** **Prevalence of resistance associated substitutions and phylogeographic analysis of HCV infection in Russia**  
YI  
Vasily ISAKOV, *Russian Federation*

- SAT-170** **A phenotypic resistance assay for clinical HCV isolates could help rationalise DAA therapy in individuals experiencing recurrent virologic failure**  
Christopher R. JONES, *United Kingdom*
- SAT-171** **HEV seroprevalence in blood donors in Turkey: Comparison of two commercial anti-HEV total Ab ELISA kit**  
Senem Ceren KARATAYLI, *Turkey*
- SAT-172** **Novel mathematical modeling of HBsAg kinetics during long-term antiviral treatment: A pilot study**  
Hwi Young KIM, *Rep. of South Korea*
- SAT-173** **Global patterns of HBV genotype E epidemic dispersal from Africa determined using a full-genome phylogenetic and phylogeographic approach**  
Evangelia-Georgia KOSTAKI, *Greece*
- SAT-174** **Formation of the occult chronic hepatitis B during antiviral therapy in patients with HIV+HBV+HDV+HCV infection: Clinical cases**  
Konstantin KOZLOV, *Russian Federation*
- SAT-175** **Recruitment of HBx on HBV DNA depends on FXR and is inhibited by FXR agonist**  
Benoît LACOMBE, *France*
- SAT-176** **The effect of HBV and HCV infection on pregnancy status**  
Tadeusz, Wojciech LAPINSKI, *Poland*
- SAT-177** **Loss of HBsAg by patients with high levels of HBV-DNA during treatment with nucleoside or nucleotide analogues**  
Tadeusz, Wojciech LAPINSKI, *Poland*
- SAT-178** **Identification of Hepatitis B virus events in liver and peripheral blood mononuclear cells in individuals with chronic hepatitis B infection**  
Keith LAU, *Canada*
- SAT-179** **Human liver organoids culture as a novel in vitro model of HBV infection**  
Chuan Kok LIM, *Australia*
- SAT-180** **Hepatitis delta genotype 1 and 3 do not replicate after coinfection in the same cell in vivo**  
Marc LÜTGEHETMANN, *Germany*
- SAT-181** **Efficacy and safety of glecaprevir/pibrentasvir in patients with severe renal impairment in Japan: A prospective, multicenter study (KTK 49 Liver Study Group)**  
Masanori ATSUKAWA, *Japan*

## Viral Hepatitis A, B, C, D, E: Virology (Cont.)



- SAT-182** **Full length deep sequencing of South African hepatitis B virus isolates reveals increased viral diversity and X-gene deletions in hepatocellular carcinoma patients**  
 YI  
 Anna MCNAUGHTON, *United Kingdom*
- SAT-183** **High resolution insight into hepatitis B virus infection and immunity in Africa to inform on intervention strategies**  
 YI  
 Anna MCNAUGHTON, *United Kingdom*
- SAT-184** **Approximation of the genotype distribution within global chronic hepatitis B virus infections**  
 Thomas MICHLER, *Germany*
- SAT-185** **Is the performance of ultra-sensitive HBsAg Fujirebio assay consistent across HBV genotypes (comparison between CLEIA HBsAg HQ Fujirebio and Abbott Architect assays)**  
 YI  
 Christiana MOIGBOI, *United Kingdom*
- SAT-186** **Pathophysiological impact of HCV on mitochondrial composition and functions**  
 YI  
 Léa MONNIER, *France*
- SAT-187** **characterization of hepatitis e infection in israel: identification of HEV-7 in camels and high seroprevalence in specific human populations**  
 Orna MOR, *Israel*
- SAT-188** **Expansion and genetic modification of primary hepatocytes to study long-term hepatitis B virus infection**  
 YI  
 Paul PARK, *United States*
- SAT-189** **GCAC1809-1812TTCT a novel viral quadruple mutation is strongly associated with basal core promotor double mutation and viral load in Hepatitis B e antigen negative chronic hepatitis B virus infected patients**  
 Kai-Henrik PEIFFER, *Germany*
- SAT-190** **Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection**  
 YI  
 Lorenzo PIERMATTEO, *Italy*
- SAT-191** **Host genome integration of hepatitis B is prolific and is the primary contributor to viral HBs antigen gene expression**  
 Ondrej PODLAHA, *United States*

- SAT-192** **Targeting the HBx-DDB1-Cullin complex inhibits transcription from HBV covalently closed circular DNA in susceptible hepatoma cells**  
YI  
Bingqian QU, *Germany*
- SAT-193** **Evolutionary relationship among hepatitis B virus genotype D in Latin America and Europe**  
João Renato REBELLO PINHO, *Brazil*
- SAT-194** **The utility of monomeric HBV genomes for interrogating the HBV cccDNA minichromosome, using in vitro and in vivo models of HBV replication**  
Peter REVILL, *Australia*
- SAT-195** **The novel HBx mutation F30V correlates with HCC in vivo, hampers HBV replicative efficiency and enhances anti-apoptotic activity of HBx N-terminus in vitro**  
YI  
Romina SALPINI, *Italy*
- SAT-196** **The integrated use of highly sensitive HBV markers can predict HBV reactivation in HBsAg-negative/Anti-HBc positive patients from oncohematological setting**  
YI  
Romina SALPINI, *Italy*
- SAT-197** **Quality of life measurement using wrist actigraphy in HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving ombitasvir, paritaprevir, and ritonavir tablets and dasabuvir tablets (Viekirax/Exviera; 3D regimen)**  
David SEMELA, *Switzerland*
- SAT-198** **Full-length 5'RACE analysis discriminates all major intracellular and extracellular viral RNAs during the course of infection**  
Bernd STADELMAYER, *France*
- SAT-199** **Recombinant hepatitis E viruses harbouring tags in the ORF1 protein allow visualisation of the viral replicase**  
YI  
Dagmara SZKOLNICKA, *Switzerland*
- SAT-200** **AMPK activation in response to hepatitis E virus infection inhibited viral infection by attenuating autophagy and promoting innate immunity**  
YI  
Yijin WANG, *China*
- SAT-201** **Alternation of lipid metabolism and dysfunction of mitochondria might contribute to HCC development in the absence of overt necroinflammation**  
Jaw-Ching WU, *Taiwan*
- SAT-202** **Endogenous and exogenous IFN responses suppress HDV persistence during proliferation of hepatocytes in vitro**  
Zhenfeng ZHANG, *Germany*

**Viral hepatitis A/E: Clinical aspects**

- SAT-204** **Hepatitis E virus antigen in urine as a useful diagnostic method for monitoring infection and detection of recent infection**  
Patrick BEHRENDT, *Germany*
- SAT-205** **Associated risk factors for hepatitis E seroprevalence among liver transplant recipients**  
YI  
Petra DINJAR KUJUNDŽIĆ, *Croatia*
- SAT-206** **The impact of hepatitis E virus infection on the Scottish solid organ transplant population**  
YI  
Mhairi DONNELLY, *United Kingdom*
- SAT-207** **Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland**  
Jérôme GOUTTENOIRE, *Switzerland*
- SAT-208** **Zinc/Ribavirin: A possible treatment option in chronically HEV genotype 3 infected patients without SVR under ribavirin monotherapy**  
YI  
Thomas HORVATITS, *Germany*
- SAT-209** **Role of estrogen and its receptors in HEV associated feto-maternal outcomes**  
Premashis KAR, *India*
- SAT-210** **Circulation of hepatitis a genotypes in Israel 2017-2018: Environmental surveillance supports clinical findings**  
Orna MOR, *Israel*
- SAT-211** **HEV infection in Italy: Beyond the hepatic disease**  
Giovanna PICCHI, *Italy*
- SAT-212** **Treatment with mTOR inhibitors is an independent risk factor for chronic hepatitis E in transplant patients with increased transaminases levels**  
Mar RIVEIRO BARCIELA, *Spain*
- SAT-213** **Hepatitis E virus prevalence in Flemish blood donors**  
YI  
Ann-Sofie VERCOUTER, *Belgium*
- SAT-214** **Incidence, predictors and prognosis of liver failure in patients with hepatitis E as an acute insult**  
YI  
Yijin WANG, *China*
- SAT-215** **Cryoglobulinemia in asymptomatic, symptomatic acute and chronic HEV infections**  
YI  
Dirk WESTHÖLTER, *Germany*

**Viral Hepatitis C: Post SVR and long term follow up**

- SAT-217** **Effectiveness and safety of sofosbuvir-based regimens in treatment of chronic HCV patients aged 60 years and older, egyptian single center experience**  
Shereen ABDEL ALEM, *Egypt*
- SAT-218** **Impact of sofosbuvir-based therapy on renal functions indices in chronic hepatitis c patients who achieved sustained virological response**  
Reham ABDELMONIEM, *Egypt*
- SAT-219** **Effect of treatment of hepatitis C by directly acting antivirals on chronic hepatitis C and B co-infected patients**  
Afify AHMED, *Egypt*
- SAT-220** **Higher frequency of occult HCV infection in HIV/HCV coinfectd patients with advanced liver disease: Post DAAs treatment observation**  
Sabrina BAGAGLIO, *Italy*
- SAT-221** **Autoantibodies to apolipoprotein A1 (apoA-1): A new prognostic biomarker in HCV infection**  
Margaret BASSENDINE, *United Kingdom*
- SAT-222** **Improvement in liver fibrosis among patients with hepatitis C who achieved sustained viral response after direct acting antivirals treatment, in country of Georgia**  
Maia BUTSASHVILI, *Georgia*
- SAT-223** **AA genotype of the deSNP rs6726639 of gene MERTK (MER Tyrosine Kinase) is associated with development of hepatocellular carcinoma after hepatitis C virus clearance**  
Vincenza CALVARUSO, *Italy*
- SAT-224** **Design and validation of a risk prediction model for hepatocellular carcinoma development after sustained virological response in chronic hepatitis C patients**  
Ho Soo CHUN, *Rep. of South Korea*
- SAT-225** **The risk of hepatic decompensation is reduced, but not abolished after direct-acting antivirals: The role of portal hypertension**  
Elton DAJTI, *Italy*
- SAT-226** **beneficial effects of DAAs on right cardiac function in hcv patients with low-mild liver fibrosis**  
Andrea DALBENI, *Italy*

Posters

Saturday 13 April 2019

**Viral Hepatitis C: Post SVR and long term follow up (Cont.)**

- SAT-227** **Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals: A 3-year study in 509 patients**  
YI  
Elisabetta DEGASPERI, *Italy*
- SAT-228** **Sustained virologic response induced by direct-acting antivirals suppresses skeletal muscle loss in patients with type C liver disease**  
Kei ENDO, *Japan*
- SAT-229** **Risk of hepatocellular carcinoma in patients with chronic hepatitis C and stage-3 liver fibrosis after sustained virological response with direct acting antivirals**  
YI  
Conrado FERNÁNDEZ- RODRÍGUEZ, *Spain*
- SAT-230** **HCV re-infection among HIV-infected MSM in New York City**  
Daniel FIERER, *United States*
- SAT-231** **Impact of the HCV cure with DAAs in the use of concomitant medication and the serum lipid profile: Follow-up data one year after the SVR12**  
Elena GONZÁLEZ-COLOMINAS, *Spain*
- SAT-232** **Reinfection following successful HCV DAA therapy among people with recent injecting drug use**  
Jason GREBELY, *Australia*
- SAT-233** **Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression**  
Behzad HAJARIZADEH, *Australia*
- SAT-234** **Risk of hepatocellular carcinoma and efficacy of direct-acting antivirals in patients with concurrent hepatitis C virus**  
YI  
Elizabeth HARROD, *United Kingdom*
- SAT-235** **Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia**  
YI  
Samira HOSSEINI HOOSHYAR, *Australia*
- SAT-236** **Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals**  
Chung-Feng HUANG, *Taiwan*
- SAT-237** **Histological improvement of hepatitis C virus patients after achieving sustained virological response with direct-acting antivirals**  
YI  
Rui HUANG, *China*

- SAT-238** **The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort**  
Naveed JANJUA, *Canada*
- SAT-239** **Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: A prospective analysis in the PITER cohort**  
Loreta KONDILI, *Italy*
- SAT-240** **Metabolic liver function improves 12 weeks after successful sofosbuvir-based direct-acting antiviral therapy in patients with chronic hepatitis C and advanced liver disease**  
Tea Lund LAURSEN, *Denmark*
- SAT-241** **The dynamics of two plasma markers of type III collagen formation and degradation in the course of chronic hepatitis C viral clearance with direct-acting antiviral therapy**  
Tea Lund LAURSEN, *Denmark*
- SAT-242** **Liver stiffness measurement is not a predictive factor of HCC in HCV patients with severe fibrosis who achieved SVR by DAA**  
Aline LE CLEACH, *France*
- SAT-243** **Ledipasvir/sofosbuvir is highly effective and safe in patients with chronic hepatitis B virus and hepatitis C virus coinfection: Final study results**  
Chun-Jen LIU, *Taiwan*
- SAT-244** **Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers**  
Serena LORINI, *Italy*
- SAT-245** **Prospective evaluation of the impact of hepatitis C cure on sexual dysfunction**  
Zoe MARIÑO, *Spain*
- SAT-246** **Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: Results from a multicenter study**  
Chiara MASETTI, *Italy*
- SAT-247** **The evaluation of the inhibitory effect of oral anti-hepatitis C virus agents on carcinogenesis**  
Seiichi MAWATARI, *Japan*
- SAT-248** **Patients treated for HCV and listed for LT in a French multicenter study: What happens at 3 years ?**  
Lucy MEUNIER, *France*

Posters

Saturday 13 April 2019

**Viral Hepatitis C: Post SVR and long term follow up (Cont.)**

- SAT-249** **Increased cardiovascular risk associated with chronic hepatitis C infection still remains at SVR24**  
Ann MONAGHAN, *Ireland*
- SAT-250** **Effects of sustained virological response on the endothelial dysfunction and the cardiovascular risk in hepatitis C after direct antiviral agents treatment: HEPCAR study**  
Rocio MUNOZ HERNANDEZ, *Spain*
- SAT-251** **The association of serum IFN- $\lambda$ 3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents**  
Miyako MURAKAWA, *Japan*
- SAT-252** **Long-term effect of direct-acting antivirals therapy in patients with hepatitis C-related decompensated cirrhosis: Russian single academic center experience**  
Ekaterina NABATCHIKOVA, *Russian Federation*
- SAT-253** **Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients**  
Mina NAKAGAWA, *Japan*
- SAT-254** **Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study**  
Eiichi OGAWA, *Japan*
- SAT-255** **Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in the TOPAZ-I and TOPAZ-II trials**  
Fred POORDAD, *United States*
- SAT-256** **Influence of metabolic syndrome on fibrosis regression regulated by LOXL-2 after SVR**  
Angela PUENTE, *Spain*
- SAT-257** **Incidence and predictors of liver outcomes in chronic hepatitis C patients: Comparison of an American and a Chinese cohort**  
Huiying RAO, *China*
- SAT-258** **Indocyanine green retention test predicts the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients**  
Federico RAVAIOLI, *Italy*

- SAT-259** **Achieving accelerated elimination of hepatitis C virus infection by 2025: A case study in France**  
Homie RAZAVI, *United States*
- SAT-260** **Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets**  
Homie RAZAVI, *United States*
- SAT-261** **Elevated HCV reinfection rates after cure on spontaneous clearance among HIV-infected and uninfected men who have sex with men**  
Carmine ROSSI, *Canada*
- SAT-262** **Long-term liver function outcome and related risk factors in HCV cirrhotic patients treated with direct-acting antiviral therapy: Results from the Navigatore platform in Veneto-Italy**  
Francesco Paolo RUSSO, *Italy*
- SAT-263** **Immediate versus delayed hepatitis C treatment is cost-saving in the United Kingdom: A pan-genotypic cost-effectiveness analysis**  
Yuri SANCHEZ, *United States*
- SAT-264** **Prediction of hepatocellular carcinoma development using liver stiffness after sustained virological responses by magnetic resonance elastography in patients with chronic hepatitis C**  
Nobuharu TAMAKI, *Japan*
- SAT-265** **Anti-VHC therapy does not increase the risk of developing splanchnic vein thrombosis in patients with cirrhosis**  
Fanny TURON, *Spain*
- SAT-266** **High rates of early HCV reinfections after DAA therapy in active intravenous drug users attended at mobile harm reduction units**  
Jorge VALENCIA, *Spain*
- SAT-267** **Occult hepatitis C in immunocompetent patients who have achieved sustained viral response is associated with persistent histological abnormality**  
Yijin WANG, *China*
- SAT-268** **Noninvasive prediction of gastroesophageal varices by serum wisteria floribunda agglutinin positive Mac-2 binding protein and FIB-4 index in chronic hepatitis C**  
Keiya WATAKABE, *Japan*
- SAT-269** **The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who don't achieve sustained virologic response**  
Zobair YOUNOSSI, *United States*

Posters

Saturday 13 April 2019

## NAFLD: Diagnostics and non-invasive assessment



- SAT-271** **Genetic risk factors for advanced alcoholic and non-alcoholic liver disease in the general population**  
Fredrik ÅBERG, *Sweden*
- SAT-272** **A simple algorithm based on electronic medical records to identify NAFLD with advanced fibrosis in patients with Type 2 diabetes**  
Naim ALKHOURI, *United States*
- SAT-273** **Impact of age on routinely available noninvasive tests for the discrimination of advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib**  
Naim ALKHOURI, *United States*
- SAT-274** **Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver in children**  
Velicia BACHTIAR, *United Kingdom*
- SAT-275** **Interleukin-32 as a novel NAFLD biomarker in PNPLA3 I148M variant carriers**  
**YI**  
Guido Alessandro BASELLI, *Italy*
- SAT-276** **Point shear wave elastography by ElastPQ accurately stages hepatic fibrosis in patients with NAFLD: A prospective, multicentric study**  
**YI**  
David Jm BAUER, *Austria*
- SAT-277** **Screening diabetic patients at risk for complications of non-alcoholic fatty liver disease: Prospective evaluation of national and international guideline recommendations**  
**YI**  
Valentin BLANK, *Germany*
- SAT-278** **Integrated analysis of dna methylation and mRNA expression to identify mechanisms of non-alcoholic steatohepatitis**  
**YI**  
Noemí CABRÉ, *Spain*
- SAT-279** **Comparison of different and new types of non-invasive fibrosis tests in NAFLD**  
Paul CALES, *France*
- SAT-280** **Comparison of CAP, MRI-PDFF, Steatotest, FLI and HSI performances for diagnosing NAFLD and NASH in morbidly obese patients undergoing bariatric surgery**  
Laurent CASTERA, *France*
- SAT-281** **Protease activity sensors for non-invasive monitoring of NASH**  
Sophie CAZANAVE, *United States*

- SAT-282** **Decrease in HbA1c accounts for the rapid decline in the measurement of liver stiffness by transient elastography in diabetic patients**  
YI  
Tugba CELEBI, *Turkey*
- SAT-283** **Plasma acylcarnitines are biomarkers of magnetic resonance imaging-proton density fat fraction response in NASH patients treated with the ACC inhibitor GS-0976**  
Michael CHARLTON, *United States*
- SAT-284** **Diagnostic performance of transient elastography on liver fibrosis of patients with non-alcoholic fat hepatitis**  
Chun-Yan WANG, *China*
- SAT-285** **Fibroscan-based score for detection of active nash and significant fibrosis is better than fib-4 in 361 chronic hepatitis B patients with non-alcoholic fatty liver disease**  
Xiaoling CHI, *China*
- SAT-286** **Application of guidelines for fatty liver in two prospective cohorts of human immunodeficiency virus positive patients**  
YI  
Sila COCCIOLILLO, *Canada*
- SAT-287** **A novel non-invasive index based on extracellular matrix markers can identify NAFLD patients with active disease and significant fibrosis: analysis of the CENTAUR study**  
Samuel DANIELS, *Denmark*
- SAT-288** **Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease**  
Victor DE LEDINGHEN, *France*
- SAT-289** **Follow-up of NAFLD/NASH progression using an automated histological image analysis**  
YI  
Maxime DE RUDDER, *Belgium*
- SAT-290** **Association of liver inflammation and fibrosis score with non-invasive biomarkers in non-alcoholic fatty liver disease: Preliminary results from the MAST4HEALTH study**  
George DEDOUSSIS, *Greece*
- SAT-291** **Identifying NAFLD at the source: A novel approach to capturing nonalcoholic fatty liver disease in a diabetes practice**  
Amreen DINANI, *United States*

Posters

Saturday 13 April 2019

## NAFLD: Diagnostics and non-invasive assessment (*Cont.*)



- SAT-292** **Effectively reducing screen failure rate in non-alcoholic fatty liver disease clinical trial using the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST**  
Peter EDDOWES, *United Kingdom*
- SAT-293** **Combination of FibroScan and FibroMeter (FibroMeter VCTE) improves identification of patients with advanced fibrosis in patients with NAFLD**  
Peter EDDOWES, *United Kingdom*
- SAT-294** **Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD**  
YI  
Roberta FORLANO, *United Kingdom*
- SAT-295** **Diagnostic accuracy of non-invasive methods (NFS Score and FIB-4) for detecting advanced fibrosis: A validation study of NFS score and FIB-4 in a cohort of South Indian patients with NAFLD**  
YI  
Joe FRANCIS, *India*
- SAT-296** **Oxidized LDL is a distinctive biomarker of NASH independently of liver fibrosis in patients with NAFLD**  
YI  
Rocio GALLEGO-DURÁN, *Spain*
- SAT-297** **Prediction of incident severe liver disease in the general population using non-invasive scoring systems**  
Hannes HAGSTRÖM, *Sweden*
- SAT-298** **MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study**  
Ma Ai Thanda HAN, *United States*
- SAT-299** **Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS $\geq$ 4) and significant fibrosis (F $\geq$ 2) in patients at risk of NASH**  
Remy HANF, *France*
- SAT-300** **Prospective liver biopsy-based prevalence of non-alcoholic fatty liver disease and steatohepatitis among a large middle-aged population utilizing FibroScan, LiverMultiscan and magnetic resonance elastography to guide liver biopsy**  
Stephen HARRISON, *United States*

- SAT-301** **The FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST can efficiently screen for presence of at risk fibrotic NASH: Evaluation in an American cohort of patients screened for NAFLD**  
Stephen HARRISON, *United States*
- SAT-302** **Predicting the severity of hepatic steatosis and fibrosis by transient elastography and MRI-based techniques in adults patients with suspected NAFLD**  
Stephen HARRISON, *United States*
- SAT-303** **Liver fibrosis together with PNPLA3 p.I148M variant affects quality of life in patients with non-alcoholic fatty liver disease: prospective liver stiffness-based study**  
Lena HEINTZ, *Germany*
- SAT-304** **The association between visceral fat and evolution of patients with nonalcoholic fatty liver disease**  
Marta HERNÁNDEZ CONDE, *Spain*
- SAT-305** **Alignment between physician-estimated versus objectively derived fibrosis scores in non-alcoholic steatohepatitis: Real-world evidence suggests clinicians underestimate disease severity in secondary care**  
Victoria HIGGINS, *United Kingdom*
- SAT-306** **Autotaxin is a valuable biomarker for predicting liver fibrosis in patients with non-alcoholic fatty liver disease**  
Yasushi HONDA, *Japan*
- SAT-307** **A direct comparative study among magnetic resonance elastography, vibration controlled transient elastography and shear wave elastography in patients with nonalcoholic fatty liver disease**  
Kento IMAJO, *Japan*
- SAT-308** **The optimal cut-off points of FIB-4 index for predicting the incidences of HCC and extra-hepatic malignancies in biopsy-proven Japanese NAFLD patients**  
Takanori ITO, *Japan*
- SAT-309** **Prevalence of NAFLD and metabolic syndrome in rural and regional Victoria, Australia**  
William KEMP, *Australia*
- SAT-310** **Real-world evaluation of NASH in US clinical practice: Underutilization of liver biopsy and liver imaging**  
Michelle LAI, *United States*

## NAFLD: Diagnostics and non-invasive assessment (*Cont.*)



- SAT-311** **The PDGFR-beta containing PRTA-score is a novel non-invasive diagnostic algorithm for significant liver fibrosis in patients with viral, alcoholic, and metabolic liver disease**  
 YI Joeri LAMBRECHT, *Belgium*
- SAT-312** **Serial liver stiffness and controlled attenuation parameter measurements by transient elastography in patients with type 2 diabetes: A prospective cohort study**  
 Hye Won LEE, *Rep. of South Korea*
- SAT-313** **Exosomal miRNA analysis for classifying severity of disease in biopsy-proven NAFLD patients**  
 Young-Sun LEE, *Rep. of South Korea*
- SAT-314** **Liver fibrosis by FibroScan is highly prevalent in type 2 diabetic patients with NAFLD and fairly normal liver enzymes but increased uric acid**  
 YI Rosa LOMBARDI, *Italy*
- SAT-315** **Clinical utility and application of noninvasive tests of fibrosis in the selection of patients with advanced fibrosis due to NASH in the Phase 2 ATLAS trial**  
 Rohit LOOMBA, *United States*
- SAT-316** **Non-invasive assesment of arterial stiffness and carotid intima-media thickness in children with non-alcoholic fatty liver disease**  
 YI Olha LUKIANENKO, *Ukraine*
- SAT-317** **Fibroscan as a tool to improve cardiovascular disease stratification: Truth or myth?**  
 Rui MAGALHÃES, *Portugal*
- SAT-318** **Comparative accuracy of NAFLD fibrosis score, apri score, and FIB-4 score in predicting significant fibrosis in African Americans and Caucasians with non-alcoholic fatty liver disease**  
 YI Hemnishi MARELLA, *United States*
- SAT-319** **Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients**  
 YI Michael PRAKTIKNJO, *Germany*
- SAT-320** **The use of the fatty liver index and fibroscan to determine the prevalence of non-alcoholic fatty liver disease in an Irish population**  
 Louise RABBITT, *Ireland*

- SAT-321** **Liver fibrosis scores predict mortality in the general population**  
Cristina RIPOLL, *Germany*
- SAT-322** **Comparison of point shear wave elastography (ElastPQ-pSWE) and FibroScan Transient Elastography (F-TE) for liver fibrosis staging in patients with NAFLD**  
Davide ROCCARINA, *United Kingdom*
- SAT-323** **Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease**  
**YI**  
Chiara ROSSO, *Italy*
- SAT-324** **Sonic hedgehog immunohistochemistry is a tissue biomarker of ballooned hepatocytes**  
**YI**  
Michael SCHILD, *United States*
- SAT-325** **Implementation of a primary care shear-wave elastography-based pathway to identify non-alcoholic fatty liver disease patients with advanced fibrosis in a large North American urban population**  
Abdel-Aziz SHAHEEN, *Canada*
- SAT-326** **Influence of NAFLD diagnosed by controlled attenuation parameter in patients of chronic hepatitis B with mildly elevated alt**  
**YI**  
Asim SHARIF, *Pakistan*
- SAT-327** **The change of skeletal muscle mass is associated with hepatic steatosis in non-alcoholic fatty liver disease**  
Do Seon SONG, *Rep. of South Korea*
- SAT-328** **Controlled attenuation parameter for evaluating liver steatosis in type 2 diabetes patients**  
Ioan SPOREA, *Romania*
- SAT-329** **Ethyl glucuronide in hair uncovers a high rate of harmful alcohol consumption in patients with presumed NAFLD**  
Katharina STAUFER, *Austria*
- SAT-330** **Whole metabolome profiling identifies the combination of an eicosanoid, a bile acid and an androgen as a highly accurate marker of liver fibrosis in patients with non-alcoholic fatty liver disease**  
Felix STICKEL, *Switzerland*
- SAT-331** **Use of machine learning to predict diagnosis codes for non-alcoholic steatohepatitis in administrative healthcare data**  
Laura TELEP, *United States*

**NAFLD: Diagnostics and non-invasive assessment (Cont.)****SAT-332 Association of plasmatic and hepatic miR-34a with the degree of severity of non-alcoholic fatty liver disease in a Mexican population****YI**Marion VELÁZQUEZ VILLAFANA, *Mexico***SAT-333 Non-alcoholic steatohepatitis significantly decreases microsomal liver function in the absence of fibrosis, which allows the use of the 13C-aminopyrine breath test for its non-invasive detection****SAT-333**Wim VERLINDEN, *Belgium***SAT-334 Liver steatosis in HIV-positive patients with and without HBV coinfection accessing care in a programmatic setting in Africa****YI**Giovanni VILLA, *United Kingdom***SAT-335 A simple biomarker panel predictive of advanced fibrosis in patients with non-alcoholic steatohepatitis****SAT-335**Zobair YOUNOSSI, *United States***SAT-336 Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease****SAT-336**Ming-Hua ZHENG, *China*

Posters

Saturday 13 April 2019

**NAFLD: Therapy**

- SAT-337** **Evaluation of anti-fibrotic properties of OCA and INT-767 in an in vitro system of NAFLD**  
Beatrice ANFUSO, *Italy*
- SAT-338** **Oral arginine supplementation attenuates the progression of steatosis to non-alcoholic steatohepatitis through preventing translocation of bacterial endotoxin**  
Anja BAUMANN, *Austria*
- SAT-339** **Socioeconomic deprivation is associated with non-response to lifestyle interventions in non-alcoholic fatty liver disease**  
Kris BENNETT, *United Kingdom*
- SAT-340** **Activating the hormonal effect of MIR-122 reverses NASH**  
Chofit CHAI, *Israel*
- SAT-341** **MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects**  
Hubert CHEN, *United States*
- SAT-342** **Morphometric collagen analysis discerns anti-fibrotic effects of INT-767 and OCA in NASH mouse models using second harmonic generation imaging**  
Li CHEN, *United States*
- SAT-343** **Alagebrium ameliorates NAFLD progression in mice fed a high advanced glycation end products diet via direct inhibition of Kupffer cells and indirect inhibition of hepatic stellate cell activation**  
Hettya Kandage Dinali Helan FERNANDO, *Australia*
- SAT-344** **MSDC-0602K targets the mitochondrial pyruvate carrier to treat non-alcoholic steatohepatitis**  
Brian FINCK, *United States*
- SAT-345** **Novel mitochondrial pyruvate carrier modulators to treat non-alcoholic steatohepatitis and insulin resistance**  
Brian FINCK, *United States*
- SAT-346** **Icosabutate induces a potent reduction in hepatic oxidative stress in rodent models of metabolic stress and fibrosing NASH**  
David A. FRASER, *Netherlands*

Posters

Saturday 13 April 2019

**NAFLD: Therapy (Cont.)**

- SAT-347** **MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study**  
Stephen HARRISON, *United States*
- SAT-348** **Low frequencies of lifestyle interventions and liver-specific medications in a multicentric prospective real world NAFLD cohort: The fatty liver assessment in Germany (FLAG) study**  
Wolf Peter HOFMANN, *Germany*
- SAT-349** **Improvement of hepatic inflammation and fibrosis independently of weight loss from a short, individualized, web-based exercise program in patients with NAFLD**  
Yvonne HUBER, *Germany*
- SAT-350** **YH25724, a novel long-acting GLP-1/FGF21 dual agonist, exhibits marked anti-fibrotic effects in different experimental models of liver fibrosis**  
Junhwan KIM, *Rep. of South Korea*
- SAT-351** **Biomarkers and clinical characteristics associated with nonalcoholic steatohepatitis fibrosis progression in the CENTAUR study**  
Nicolas LANTHIER, *Belgium*
- SAT-352** **A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with nonalcoholic steatohepatitis**  
Eric LAWITZ, *United States*
- SAT-353** **The effect of metformin on hepatic fatty acid partitioning; an investigation using human in vivo and in vitro models**  
Thomas MARJOT, *United Kingdom*
- SAT-354** **Aramchol, SCD1 inhibitor, improves liver glucose homeostasis in NASH**  
José M. MATO, *Spain*
- SAT-355** **Fatty liver trends in Southern Italy: Mediterranean or Americanized lifestyle habits?**  
Emilio MOLINA MOLINA, *Italy*
- SAT-356** **Anti-metabolic, anti-inflammatory and anti-fibrotic properties of ART-648, a novel phosphodiesterase 4 inhibitor as a potential clinical candidate for non-alcoholic steatohepatitis**  
Hiroshi NAGABUKURO, *Japan*

- SAT-357** **Tropifexor, a farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR**  
Arun SANYAL, *United States*
- SAT-358** **Sodium glucose cotransporter 2 inhibitor, canagliflozin ameliorate liver function in Japanese patients with type 2 diabetes mellitus: Subgroup analyses of clinical trials**  
Yuya SEKO, *Japan*
- SAT-359** **Pharmacokinetics and safety of pegbelfermin (BMS-986036) administered in the abdomen and upper arm to normal, overweight, and obese healthy participants**  
Giridhar TIRUCHERAI, *United States*
- SAT-360** **A phospholipid-based therapeutic perspective for the regression of liver fibrosis: a study on human immortalized hepatic stellate cells**  
Gina VALENTINO, *Germany*

Posters

Saturday 13 April 2019

## Immunology except viral hepatitis



- SAT-371** **Alleviation in NK cells cytotoxicity following inhibitions of Neuroligin-4 (NLG4) receptor by recombinant beta-neurexin involving IL-4 pathway**  
 YI  
 Johnny AMER, *Israel*
- SAT-372** **High prevalence of anti HLA Class II de novo donor-specific antibodies during rejection after liver transplantation**  
 Jordi COLMENERO, *Spain*
- SAT-373** **Peritoneal mucosal-associated invariant T cells functionally differ from their exhausted circulating counterparts in decompensated cirrhosis**  
 YI  
 Oluwatomi IBIDAPO-OBE, *Germany*
- SAT-374** **Interleukin 35 exerts its suppressive function in chronic liver failure through the induction of an immunosuppressive HLA-G+CD4+ regulatory T -cell population**  
 Wafa KHAMRI, *United Kingdom*
- SAT-375** **Therapeutic interleukin 4 modulates monocyte dynamics and accelerates repair and regeneration following acute liver injury**  
 YI  
 Ruairi LYNCH, *United Kingdom*
- SAT-376** **Bile acids induce STAT3 and repress FOXP3 expression in hepatic CD4 lymphocytes under cholestatic conditions**  
 Alexander MIETHKE, *United States*
- SAT-377** **Significant reductions in intrahepatic Mucosal Associated Invariant T cells with increased terminal activation marker expression amongst NAFLD patients following a 12 week aerobic exercise program: a paired liver biopsy study**  
 YI  
 Sara NAIMIMOHASSES, *Ireland*
- SAT-378** **The NIF mouse as a model for acute, late stage non-alcoholic steatohepatitis**  
 YI  
 Julia NILSSON, *Sweden*
- SAT-379** **Myeloid cells require gp130 signalling for protective anti-inflammatory functions during sepsis**  
 Tobias OTTO, *Germany*
- SAT-380** **Liver-resident memory CD8 T cells do not egress into hepatic venous blood**  
 YI  
 Sergio RODRÍGUEZ-TAJES, *Spain*
- SAT-381** **TAA-specific CD8+ T-cell responses are inefficiently induced in hepatocellular carcinoma**  
 YI  
 Catrin TAUBER, *Germany*

**SAT-382 Crosstalk between liver NKT cells and liver sinusoidal endothelial cells**

**YI** Abdallah YASSIN, *Germany*

**SAT-383 Human mesenchymal stem cells-derived exosomes attenuate liver ischemia/reperfusion injury by up regulation of notch-1-related autophagy in CD4 T cell**

**YI** Xiaomei ZHANG, *China*

Posters

Saturday 13 April 2019

**Molecular and cellular biology**

- SAT-385** **Production and characterization of human liver extracellular matrix hydrogels for in vitro culture of distinct human primary liver cell populations**  
YI  
Niki ALEVRA SARIKA, *Belgium*
- SAT-386** **Insulin resistance in NK cells of F4 fibrosis inhibit mTOR expressions and are associated with decreased F-actin and killing ability in NASH patients**  
YI  
Johnny AMER, *Israel*
- SAT-387** **Pharmacological inhibition of P2X7 receptor ameliorates liver injury in nonhuman primates by reducing liver inflammation and fibrosis**  
Bernat BAEZA-RAJA, *United States*
- SAT-388** **How to infuse heterologous human adult liver-derived progenitor cells safely?**  
YI  
Louise COPPIN, *Belgium*
- SAT-389** **Obeticholic acid reduces matrix metalloproteinases activity via iNOS modulation in hepatic ischemia/reperfusion injury**  
YI  
Laura Giuseppina DI PASQUA, *Italy*
- SAT-390** **Dengue virus protein NS3 activates hexokinase activity in hepatocytes to support virus replication**  
Olivier DIAZ, *France*
- SAT-391** **The influence of Caveolin-1 on hepatocyte metabolism**  
YI  
Mei HAN, *Germany*
- SAT-392** **Dickkopf-1 from hepatocellular carcinoma cells promotes the angiogenic potential of endothelial cells by activating the VEGFR-2 signaling pathway**  
YI  
Bora JIN, *Rep. of South Korea*
- SAT-393** **Melatonin attenuates dysregulation of the circadian clock pathway in liver fibrosis and progression to hepatocarcinoma**  
Francisco JORQUERA, *Spain*
- SAT-394** **Genetic Features Associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma**  
Koo Jeong KANG, *Rep. of South Korea*
- SAT-395** **Bone marrow-mesenchymal stem cells of cirrhosis patients show insulin resistance and bioenergetic exhaustion**  
YI  
Deepanshu MAHESHWARI, *India*

- SAT-396** **Heat activation of hepatocytes is sufficient to account for post radiofrequency ablation induced tumorigenesis**  
YI  
Aurelia MARKEZANA, *Israel*
- SAT-397** **HIC-5 and GARP expression is upregulated by hydrogen peroxide and TGF beta in primary human hepatic stellate cells cultured on decellularized human liver 3D ECM scaffolds**  
YI  
Simona ONALI, *Italy*
- SAT-398** **Pterostilbene reduces liver steatosis associated with obesity**  
María P. PORTILLO, *Spain*
- SAT-399** **The profile on intracellular gangliosides correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cells adhesion**  
Chiara RAGGI, *Italy*
- SAT-400** **IL-1 beta-mediated macrophage-hepatocyte crosstalk upregulates hepcidin under physiologic low oxygen levels**  
Ines SILVA, *Germany*
- SAT-401** **Necroptosis signaling molecules regulate hepatic stellate cell activation via MLKL oligomerization-cell death independent pathway**  
Joo Hyun SOHN, *Rep. of South Korea*
- SAT-402** **Hepamine 2.0: Visualization and data-mining resource for liver disease**  
Andreas TEUFEL, *Germany*
- SAT-403** **Polycyclic aromatic hydrocarbons can trigger a hepatocyte release of cytotoxic extracellular vesicles**  
YI  
Nettie VAN METEREN, *France*
- SAT-404** **Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients**  
YI  
Riccardo VERCESI, *Italy*
- SAT-405** **Genomic expression in circulating PBMCs of patients with hepatocellular carcinoma: Effect of ablative treatment**  
Palmieri VINCENZO, *Italy*
- SAT-406** **Elevated biliary cholesterol in spite of hepatic ABCG5/G8 deficiency: Biliary lipid secretion in conditional knock-out mice**  
YI  
Susanne N WEBER, *Germany*
- SAT-407** **The Wilson's disease mouse (*Atp7b*<sup>-/-</sup>) has profound alterations in the hepatic metabolome and improved insulin sensitivity**  
Ruth WOOTON-KEE, *United States*

## Non-invasive assesment of liver disease except NAFLD



- SAT-409** **Hepatic vein arrival time assessed by contrast-enhanced ultrasound in the non-invasive evaluation of portal hypertension**  
Irene ANDALUZ, *Spain*
- SAT-410** **Higher spleen iron content estimated by MRI T2\* signal is associated with lower insulin-resistance in patients with dysmetabolic iron overload syndrome**  
Edouard BARDOU-JACQUET, *France*
- SAT-411** **Clinical comparison and conversion of international normalized ratio and prothrombin index**  
Paul CALES, *France*
- SAT-412** **The utility of the enhanced liver fibrosis test in alcoholic liver disease**  
**YI** Declan CONNOLEY, *Australia*
- SAT-413** **Selected cytokines associated with chronic hepatitis b histological activity and fibrosis: A 78-week prospective study**  
**YI** Xiao-Qin DONG, *China*
- SAT-414** **Baveno VI principle for noninvasive assessment of high risk varices is also applicable with shear wave elastography**  
**YI** Oana FARCAU, *Romania*
- SAT-415** **High levels of basement membrane remodelling (C4M) and low activity of wound healing (FPA) reflect fibrosis in alcoholic liver disease**  
**YI** Natasja GUDMANN, *Denmark*
- SAT-416** **Transient elastography in normal pregnancies: A prospective cohort study**  
Hannes HAGSTRÖM, *Sweden*
- SAT-417** **Serum levels of keratin 19 fragments (CYFRA 21-1) are elevated in advanced liver disease and predict poor survival**  
**YI** Karim HAMESCH, *Germany*
- SAT-418** **Splenic stiffness measurement using the ultrasound-fusion method**  
Masashi HIROOKA, *Japan*
- SAT-419** **Endotrophin, a fragment of collagen type VI formation (PRO-C6) is associated with progression free survival and mortality in patients with hepatocellular carcinoma**  
**YI** Signe HOLM NIELSEN, *Denmark*

- SAT-420** **The value of liver stiffness to platelet ratio and liver stiffness to spleen diameter to platelet ratio score compared with hepatic venous pressure gradient to predict the portal hypertension in patients with alcoholic and viral cirrhosis**  
Soung Won JEONG, *Rep. of South Korea*
- SAT-421** **A novel score to select patients for treatment in chronic hepatitis B: Results from a large Ethiopian cohort**  
Asgeir JOHANNESSEN, *Norway*
- SAT-422** **Spleen stiffness by shear wave elastography for the screening of varices in patients with compensated advanced chronic liver disease**  
YI  
Krishnadas DEVADAS, *India*
- SAT-423** **Spleen extracellular volume fraction and platelet count/spleen volume ratio are accurate non-invasive markers of portal hypertension**  
YI  
Christina LEVICK, *United Kingdom*
- SAT-424** **Spleen transient elastography and suprahepatic vein dumping index can be useful to identify patients without acute and chronic response to beta-blockers**  
Elba LLOP, *Spain*
- SAT-425** **Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis**  
Rocio Ir MACIAS, *Spain*
- SAT-426** **Abnormal liver function tests: Current waiting times and comparison to iLFTs**  
YI  
Iain MACPHERSON, *United Kingdom*
- SAT-427** **The role of liver and spleen stiffness measurement in predicting hepatic decompensation after HCV eradication with direct antiviral agents therapy**  
YI  
Giovanni MARASCO, *Italy*
- SAT-428** **Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection**  
Juan MACIAS SANCHEZ, *Spain*
- SAT-429** **Von Willebrand factor a noninvasive serum biomarker of portal pressure in cirrhosis: Evidence in human and rodent**  
YI  
Xiaolong QI, *China*
- SAT-430** **Spleen stiffness measured with ElastPQ point shear wave elastography has a good performance in predicting clinically significant portal hypertension in patients with primary sclerosing cholangitis**  
Davide ROCCARINA, *United Kingdom*

**Non-invasive assesment of liver disease except NAFLD (Cont.)**

**SAT-431** **Spleen stiffness measurement with ElastPQ point shear wave elastography has an excellent performance in predicting the presence of clinically significant portal hypertension in primary biliary cholangitis**

**YI**

*Francesca SAFFIOTI, United Kingdom*

**SAT-432** **The CT1 multi-parametric MRI value is more sensitive and reliable than transient elastography for the non-invasive monitoring of intra-hepatic inflammation/fibrosis response to DAA therapy in CHC patients**

**YI**

*Antonio SALVATI, Italy*

**SAT-433** **Portal venous velocity and platelet count as a simple non invasive tool to rule out the presence of varices needing treatment in patients with compensated cirrhosis**

**YI**

*Francesco SANTOPAULO, Italy*

**SAT-434** **Liver stiffness measurement by transient elastography for the prognosis of hepatic carcinoma, decompensation, and death in patients with chronic liver diseases: A systematic review and meta analysis**

**YI**

*Yue SHEN, China*

**SAT-435** **Quantitative MRCP imaging (MRCP+): Accuracy, repeatability and reproducibility evaluation in healthy and liver disease patients**

*Gary WOODWARD, United Kingdom*

Posters

Saturday 13 April 2019

**Liver transplantation and hepatobiliary surgery: Experimental**

- SAT-436** **Inhibition of autophagy prolongs recipient survival through accelerating CD8+ T-cell apoptosis in a rat liver transplantation model**  
YI  
Xiaolong CHEN, *China*
- SAT-437** **An mTor-based immunosuppression reduces the antiviral efficacy of NS3/4A and NS5A inhibitors for HCV genotype 1b treatment in vitro**  
YI  
Alexandra FREY, *Germany*
- SAT-438** **Effect of chondroitin sulfate in the rat liver cold ischemia and warm reperfusion injury**  
YI  
Maria PIERRE, *Brazil*
- SAT-439** **Identification of new drug targets to prevent ischemia-induced bile toxicity using a human biliary organoid model**  
YI  
Floris ROOS, *Netherlands*
- SAT-440** **Molecular fingerprint of T cell-mediated and antibody-mediated rejection after human liver transplantation**  
Richard TAUBERT, *Germany*

Posters

Saturday 13 April 2019

**Liver tumours: Clinical aspects except therapy**

- SAT-451**    **Gallbladder disease in the absence of cirrhosis is a significant risk factor for hepatocellular carcinoma**  
Kenda AL-ASSI, *United States*
- SAT-452**    **Analysis of intrahepatic sarcomatoid cholangiocarcinoma compared with intrahepatic adenocarcinoma**  
Yanghyon BAEK, *Rep. of South Korea*
- SAT-453**    **Effects of sorafenib on pancreatic volume and their clinical implications in patients with hepatocellular carcinoma**  
YI  
Francesca BENEVENTO, *Italy*
- SAT-454**    **Management of hepatocellular carcinoma in a real life multinational, longitudinal, observational study (TARGET-HCC)**  
Roniel CABRERA, *United States*
- SAT-455**    **Efficacy of sorafenib and lenvatinib for hepatitis status: a network meta-analysis of phase III trial**  
YI  
Andrea CASADEI GARDINI, *Italy*
- SAT-456**    **New multi inflammation indicators in advanced hepatocellular carcinoma patients receiving sorafenib**  
YI  
Andrea CASADEI GARDINI, *Italy*
- SAT-457**    **Sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure**  
YI  
Tsung-Yi CHENG, *Taiwan*
- SAT-458**    **Subtraction arterial images of hepatocyte-specific contrast-enhanced MRI: Added value for the diagnosis of hepatocellular carcinoma in the liver imaging reporting and data system v2018**  
Sang Hyun CHOI, *Rep. of South Korea*
- SAT-459**    **NASH as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role: Case-control study**  
YI  
Stefania DE LORENZO, *Italy*
- SAT-460**    **Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis**  
YI  
Ana GOMEZ, *Spain*
- SAT-461**    **HCC recurrence after DAA treatment in HCV patients**  
YI  
Maria GUARINO, *Italy*

- SAT-462** **Current non-invasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma**  
YI  
Shu Yein HO, *Taiwan*
- SAT-463** **Albumin-bilirubin grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma**  
YI  
Shu Yein HO, *Taiwan*
- SAT-464** **Predictive value of pretreatment neutrophil-to-lymphocyte ratio in survival of patients with hepatocellular carcinoma**  
Young Mi HONG, *Rep. of South Korea*
- SAT-465** **The NIACE Score: A prognostic indicator in Hepatocellular carcinoma**  
William KEMP, *Australia*
- SAT-466** **A meta-analysis of risk factors for intrahepatic and extrahepatic cholangiocarcinoma**  
Shahid KHAN, *United Kingdom*
- SAT-467** **Pathologic identity of indeterminate hepatic nodules on dynamic computed tomography images of cirrhotic patients undergoing liver transplantation: A potential bias in evaluating suitability for transplantation**  
Ha Il KIM, *Rep. of South Korea*
- SAT-468** **Prognostic value of post-treatment liver stiffness in hepatocellular carcinoma with histologically confirmed cirrhosis**  
Jung Il LEE, *Rep. of South Korea*
- SAT-469** **Frequency of TP53, CTNNB1, and TERT promoter mutations in patients with hepatocellular carcinoma from Southern Italy**  
YI  
Daniele LOMBARDO, *Italy*
- SAT-470** **Circulating levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of cholangiocarcinoma**  
YI  
Sven LOOSEN, *Germany*
- SAT-471** **Hepatic adenomatosis increases risk of hepatic adenoma bleeding**  
Chelsea MCDERMOTT, *United States*
- SAT-472** **Massive sequencing of circulating DNA as a potential tool for diagnosis and follow-up in patients with hepatocellular carcinoma**  
Beatriz MINGUEZ, *Spain*
- SAT-473** **Transition to the era of direct-acting antiviral changes in the prognosis of patients with hepatitis C virus-related hepatocellular carcinoma**  
Yoshifumi MIURA, *Japan*

Posters

Saturday 13 April 2019

## Liver tumours: Clinical aspects except therapy (*Cont.*)

- SAT-474** **Misdiagnosis of focal liver lesions by means of CEUS**  
**YI** Tudor-Voicu MOGA, *Romania*
- SAT-475** **Clinical validation of the role of contrast-enhanced ultrasound in the EASL guidelines for the diagnosis of hepatocellular carcinoma**  
**YI** Lorenzo MULAZZANI, *Italy*
- SAT-476** **Discordance between clinical judgement and genetic differentiation of intrahepatic metastasis and multicentric occurrence in multinodular HCC**  
 Yuji IIMURO, *Japan*
- SAT-477** **Impact of skeletal muscle quality and quantity on outcomes following curative therapy of hepatocellular carcinoma**  
 Tomoaki NAKAJIMA, *Japan*
- SAT-478** **Comparison of prediction models for hepatocellular carcinoma development in treatment naive chronic hepatitis B patients with cirrhosis**  
 Hyunwoo OH, *Rep. of South Korea*
- SAT-479** **Analysis of the relationship between serum creatinine/cystatin C ratio and muscle mass in patients with hepatocellular carcinoma**  
 Hiroataka OURA, *Japan*
- SAT-480** **Long-term survivors in patients with hepatocellular carcinoma: An ITA.LI.CA report**  
**YI** Filippo PELIZZARO, *Italy*
- SAT-481** **Intratumoral mast cell infiltration and recurrence of hepatocellular carcinoma in patients undergoing orthotopic liver transplantation**  
 Nataliya ROHR-UDILOVA, *Austria*
- SAT-482** **Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program**  
**YI** Marco SANDUZZI ZAMPARELLI, *Spain*
- SAT-483** **Hepatic epithelioid hemangioendotelioma: An international multicenter study**  
**YI** Marco SANDUZZI ZAMPARELLI, *Spain*
- SAT-484** **CEUS pattern of hepatocellular carcinoma: Prognostic implication**  
**YI** Vito SANSONE, *Italy*

- SAT-485** **European cholangiocarcinoma (EU-CCA) registry: An initiative to broaden awareness on the second most common primary liver cancer**  
Alvaro SANTOS-LASO, *Spain*
- SAT-486** **Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma**  
Bernhard SCHEINER, *Austria*
- SAT-487** **Reliability of a single biopsy in evaluating immune tumor microenvironment of hepatocellular carcinoma**  
Ying-Chun SHEN, *Taiwan*
- SAT-488** **Both ALBI/delta ALBI grade are good predictive parameters for prognosis in chc/hcc patients with transarterial chemoembolization treatment**  
Wei TENG, *Taiwan*
- SAT-489** **Efficacy and safety of thermal ablation in patients with hepatocellular carcinoma and high comorbidity**  
Maria TORNER, *Spain*
- SAT-490** **No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort**  
Anais VALLET PICHARD, *France*
- SAT-491** **Assessment of liver function by 13C methacetin breath test may help to predict liver function deterioration after selective transarterial chemoembolisation of hepatocellular carcinomas**  
Florian VAN BÖMMEL, *Germany*
- SAT-492** **Associating spleen volume and liver stiffness measurements improves prediction of persistent post-hepatectomy decompensation after resection of hepatocellular carcinoma**  
Eric VIBERT, *France*
- SAT-493** **Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma**  
Luca VIGANO, *Italy*
- SAT-494** **Global hepatocellular carcinoma mortality trends: An analysis of the world health organization cancer mortality database**  
Robert WONG, *United States*
- SAT-495** **Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the US**  
Ming YANG, *China*

Posters

Saturday 13 April 2019

**Liver tumours: Clinical aspects except therapy (Cont.)**

- SAT-496** **Circulating cell-free HBV-human chimera DNA as new marker for HCC recurrence and clonality after curative resection**  
Shiou-Hwei YEH, *Taiwan*
- SAT-497** **Individual surveillance using PAGE-B score-based hepatocellular carcinoma risk in chronic hepatitis B patients under potent antiviral therapy**  
Minjong LEE, *China*

Posters

Saturday 13 April 2019

## ACKNOWLEDGEMENTS

## Abstract reviewers

**Aithal** Guru, *United Kingdom*

**Albillos** Agustín, *Spain*

**Alemann** Soo, *Sweden*

**Altamirano** Jose, *Spain*

**Ampuero** Javier, *Spain*

**Anstee** Quentin, *United Kingdom*

**Armstrong** Matthew, *United Kingdom*

**Asselah** Tarik, *France*

**Avila** Mathias, *Spain*

**Banales** Jesus, *Spain*

**Bansal** Ruchi, *Netherlands*

**Behrendt** Patrick, *Germany*

**Berasain** Carmen, *Spain*

**Bertoletti** Antonio, *Singapore*

**Björkström** Niklas, *Sweden*

**Boursier** Jerome, *France*

**Bruno** Raffaele, *Italy*

**Buggisch** Peter, *Germany*

**Bugianesi** Elisabetta, *Italy*

**Burra** Patrizia, *Italy*

**Cabezas** Joaquin, *Spain*

**Calvaruso** Vincenza, *Italy*

**Cantz** Tobias, *Germany*

**Castro** Rui, *Portugal*

**Chazouillères** Olivier, *France*

**Cheung** Michelle, *United Kingdom*

**Clayton** Michelle, *United Kingdom*

**Coco** Barbara, *Italy*

**Crespo** Javier, *Spain*

**del Pulgar** Sofia, *Spain*

**Demir** Münevver, *Germany*

**Deuffic-Burban** Sylvie, *France*

**Devisscher** Lindsey, *Belgium*

**Durand** François, *France*

**Elkrief** Laure, *Switzerland*

**Engelmann** Cornelius, *United Kingdom*

**Faivre** Sandrine, *France*

**Feray** Cyrille, *France*

**Floreani** Annarosa, *Italy*

**Forner** Alejandro, *Spain*

**França** Manuela, *Portugal*

**Francoz** Claire, *France*

**Francque** Sven, *Belgium*

**Friedman** Scott, *United States*

**Fuchs** Claudia, *Austria*

**Galle** Peter, *Germany*

**Gastaldelli** Amalia, *Italy*

**Gastaminza** Pablo, *Spain*

**Gerbes** Alexander, *Germany*

**Gissen** Paul, *United Kingdom*

**Gonzales** Emmanuel, *France*

**Goutte** Nathalie, *France*

Acknowledgements

- Gracia-Sancho** Jordi, *Spain*  
**Grebely** Jason, *Australia*  
**Gustot** Thierry, *Belgium*  
**Hatzakis** Angelos, *Greece*  
**Heinzow** Hauke, *Germany*  
**Henderson** Neil, *United Kingdom*  
**Hoener zu Siederdisen** Christoph, *Germany*  
**Housset** Chantal, *France*  
**Hov** Johannes, *Norway*  
**Jaeckel** Elmar, *Germany*  
**Jaroszewicz** Jerzy, *Poland*  
**Jepsen** Peter, *Denmark*  
**Karlas** Thomas, *Germany*  
**Kennedy** Patrick, *United Kingdom*  
**Knolle** Percy, *Germany*  
**Koek** Ger, *Netherlands*  
**Kremer** Andreas, *Germany*  
**Laleman** Wim, *Belgium*  
**Lammers** Twan, *Netherlands*  
**Larrey** Dominique, *France*  
**Lazarus** Jeffrey, *Denmark*  
**Leclercq** Isabelle, *Belgium*  
**Lens** Sabela, *Spain*  
**Lesurtel** Mickaël, *Switzerland*  
**Leth Hjort** Kristine, *Denmark*  
**Line** Paal Dag, *Norway*  
**Llarch** Neus, *Spain*  
**Longerich** Thomas, *Germany*  
**Lucena** Maria Isabel, *Spain*  
**Maasoumy** Benjamin, *Germany*  
**Maini** Mala, *United Kingdom*  
**Makara** Michael, *Hungary*  
**Mallet** Vincent, *France*  
**Mandorfer** Mattias, *Austria*  
**Martin** Natasha, *United Kingdom*  
**Mathurin** Philippe, *France*  
**Mauss** Stefan, *Germany*  
**Mazza** Giuseppe, *United Kingdom*  
**Melum** Espen, *Norway*  
**Mertens** Joachim, *Switzerland*  
**Meulemann** Philipp, *Belgium*  
**Miele** Luca, *Italy*  
**Missale** Gabriele, *Italy*  
**Moeller** Soeren, *Denmark*  
**Montagnese** Sara, *Italy*  
**Mueller** Sebastian, *Germany*  
**Mülhaupt** Beat, *Switzerland*  
**Nahon** Pierre, *France*  
**Nault** Jean-Charles, *France*  
**Neumann-Haeflin** Christoph, *Germany*

Acknowledgements

## Acknowledgements

- Parola** Maurizio, *Italy*
- Perugorria** Maria Jesus, *Spain*
- Piano** Salvatore, *Italy*
- Pietrangelo** Antonello, *Italy*
- Piscaglia** Fabio, *Italy*
- Pollicino** Teresa, *Italy*
- Rimassa** Lorenza, *Italy*
- Ripoll** Cristina, *Germany*
- Romagnoli** Renato, *Italy*
- Rombouts** Krista, *United Kingdom*
- Ronot** Maxime, *France*
- Rutter** Harry, *United Kingdom*
- Sanchez-Fueyo** Alberto, *United Kingdom*
- Schuppan** Detlef, *Germany*
- Schurich** Anna, *Germany*
- Schwabl** Philipp, *Austria*
- Seehofer** Daniel, *Germany*
- Solá** Elsa, *Spain*
- Spengler** Ulrich, *Germany*
- Sperle** Jan, *Czech Republic*
- Sposito** Carlo, *Italy*
- Stål** Per, *Sweden*
- Strassburg** Christian, *Germany*
- Strnad** Pavel, *Germany*
- Svegliati Baroni** Gianluca, *Italy*
- Testoni** Barbara, *France*
- Thiele** Maja, *Denmark*
- Thorburn** Douglas, *United Kingdom*
- Tiegs** Gisa, *Germany*
- Tomasiewicz** Krzysztof, *Poland*
- Toniutto** Pierluigi, *Italy*
- Trautwein** Christian, *Germany*
- Trivedi** Palak, *United Kingdom*
- Tsochatzis** Emmanuel, *United Kingdom*
- Urban** Stephan, *Germany*
- Van der Meer** Adriaan, *Netherlands*
- Vanwolleghem** Thomas, *Netherlands*
- Varela Calvo** Maria, *Spain*
- Vermehren** Johannes, *Germany*
- Villanueva** Augusto, *United States*
- vom Dahl** Stephan, *Germany*
- Waidman** Oliver, *Germany*
- Wedemeyer** Heiner, *Germany*
- Weiland** Ola, *Sweden*
- Weiss** Emmanuel, *France*
- Wiest** Reiner, *Switzerland*
- Wree** Alexandre, *Germany*
- Yki-Jarvinen** Hannelle, *Finland*
- Yurdaydin** Cihan, *Turkey*
- Zelber-Sagi** Shira, *Israel*
- Zoulim** Fabien, *France*

## Sponsors

### GOLD SPONSORS

abbvie



Intercept



Acknowledgements

### SILVER SPONSORS



### BRONZE SPONSORS



GRIFOLS

## CONGRESS SPONSORS




CHALLENGE ACCEPTED



Acknowledgements




A better way.





Leader in HDV




PHARMACEUTICAL COMPANY OF  
JOHNSON & JOHNSON









imagine.

## BIOTECH VILLAGE




Innovative Diagnostic Solutions






EXHIBITORS



Acknowledgements





## Acknowledgements



## National associations' village

<b>Country</b>	<b>Association</b>	<b>Abbreviation</b>
Armenia	Armenian Association for the Study of the Liver	
Austria	Austrian Society of Gastroenterology and Hepatology	OEGGH
Azerbaijan	Azerbaijan Gastroenterology and Hepatology Association	
Belgium	Belgian Association for the Study of the Liver	BASL
Bulgaria	Bulgarian Association for the Study of the Liver	BgASL
Czech Republic	Czech Society of Hepatology	CSH
Denmark	Danish Society of Gastroenterology and Hepatology	DSGH
France	French Association for the Study of Liver Diseases	AFEF
Georgia	Georgian Hepatology Association	GHA
Germany	German Association for the Study of the Liver	GASL
Greece	Hellenic Association for the Study of Liver	HASL
Israel	Israel Association for the Study of Liver Diseases	IsASL
Italy	Italian Association for the Study of the Liver	AISF
Poland	Polish Association for the Study of the Liver	PASL
Romania	Romanian Society of Gastroenterology and Hepatology	SRGH
Serbia	Hepatology Section of the Serbian Medical Association	HSSMA
Slovakia	Slovak Society of Hepatology	SHS
Spain	Spanish Association for the Study of the Liver	AEEH
Sweden	Swedish Society of Gastroenterology	
Switzerland	Swiss Association for the Study of the Liver	SASL
The Netherlands	Netherlands Association for the Study of the Liver	NASL
Turkey	Turkish Association for the Study of Liver	TASL
United Kingdom	British Association for the Study of the Liver	BASL
	Mediterranean Association for the Study of the Liver	MASL

Acknowledgements



---

**JOIN** THE **EASL**  
**COMMUNITY**

---

Reduced fees to The International  
Liver Congress™ and EASL meetings

Journal of Hepatology


LiverTree™

EASL Schools and Masterclass

EASL Fellowships and Mentorship

Funding support

Discover more benefits on:  
[www.easl.eu/join-the-community](http://www.easl.eu/join-the-community)



**INDUSTRY**

## Industry programme overview

	WEDNESDAY 10 APRIL 2019	THURSDAY 11 APRIL 2019	
07:30-08:00		<b>SYMPOSIA</b> <b>■ Strauss 1-2</b> Genfit: Towards a comprehensive management of patients with chronic non-viral liver diseases <b>■ Hall C1</b> Gilead: Together we can... Reducing risks in hepatitis B virus infection <b>■ Strauss 3</b> Grifols: Extending the treatment paradigm for cirrhosis: long-term albumin administration and beyond  <b>MINI-WORKSHOP</b> <b>■ Lehar 3</b> Cepheid: Scaling up Testing and Treatment for Hepatitis with Decentralised Molecular Testing	
08:00-08:30			
12:30-13:00			
13:00-13:30			
13:30-14:00			
18:00-18:30	<b>SYMPOSIA</b> <b>■ Hall C3</b> AbbVie: Transforming the HCV Care Cascade: Making HCV Elimination a Reality <b>■ Strauss 3</b> Norgine: Preventing a domino effect in the management of hepatic encephalopathy <b>■ Strauss 1-2</b> Novo Nordisk: Understanding NASH as a metabolic disease	<b>SYMPOSIA</b> <b>■ Hepatology Arena</b> Bristol-Myers Squibb: Navigating patients through the evolving HCC treatment landscape <b>■ Strauss 3</b> Intercept: Advances in PBC Management: Looking Beyond Biochemical Markers	<b>MINI-WORKSHOPS</b> <b>■ Lehar 3</b> Alexion: My patient care vs restricted access to medicines <b>■ Lehar 4</b> Sequana Medical: Managing Ascites, improving Quality of Life
18:30-19:00			
19:00-19:30		19:30-20:00	

FRIDAY 12 APRIL 2019	SATURDAY 13 APRIL 2019	
		07:30-08:00
		08:00-08:30



	<p><b>Hall C3</b> Gilead: Making a difference in diagnosing patients with advanced fibrosis due to NASH</p>	12:30-13:00
	<p><b>Hall C1</b> MSD: Assessing Response in Advance Liver Cancer – Does Response Matter?</p>	13:00-13:30
		13:30-14:00

			18:00-18:30
<p><b>SYMPOSIA</b></p> <p><b>Main Plenary</b> Gilead: Together we can... Achieving HCV elimination through simplification</p> <p><b>Hepatology Arena</b> Intercept: NASH: What does the evidence tell us?</p> <p><b>Strauss 3</b> Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate</p>	<p><b>MINI-WORKSHOP</b></p> <p><b>Lehar 3</b> Perspectum Diagnostics: Introducing quantitative MRCP: Improving the clinical landscape for biliary disease</p>		18:30-19:00
			19:00-19:30
			19:30-20:00

## Satellite symposia programmes

### Wednesday 10 April 2019

#### AbbVie: Transforming the HCV Care Cascade: Making HCV Elimination a Reality

Hall C3

Effective and well-tolerated pan-genotypic DAA regimens, together with emerging integrated care models mean we now have the capabilities to meet the WHO target of HCV elimination as a public health burden by 2030.

However, remaining barriers in the care cascade must be addressed to maximise the impact of available treatments.

Join our expert faculty panel for an engaging, dynamic and interactive meeting where we will explore the challenges we have overcome and those that remain in the care cascade to make HCV elimination a reality.

**Chair:**

Stefan ZEUZEM, *Germany*

18:00-18:10

**Welcome and Introduction**

Stefan ZEUZEM, *Germany*

18:10-19:10

**Simplifying the HCV Care Cascade: Interactive Panel Discussion**

Stefan ZEUZEM, *Germany*

Panelists:

Ashley BROWN, *United Kingdom*

Gregory DORE, *Australia*

19:10-19:25

**Q/A**

Stefan ZEUZEM, *Germany*

Panelists:

Ashley BROWN, *United Kingdom*

Gregory DORE, *Australia*

19:25-19:30

**Summary and Close**

Stefan ZEUZEM, *Germany*

Industry

**Norgine: Preventing a domino effect in the management of hepatic encephalopathy****Strauss 3***Chair:**Jasmohan S. BAJAJ, United States*

18:00-18:05

**Welcome and introductions***Jasmohan S. BAJAJ, United States*

18:05-18:20

**Starting off right: Understanding HE and improving diagnosis***Thomas BERG, Germany*

18:20-18:35

**Fighting back: Mechanisms of treatment***Debbie SHAWCROSS, United Kingdom*

18:35-18:50

**Impact on patient outcomes: the effect of different management strategies***Aleksander KRAG, Denmark*

18:50-19:05

**Barriers and solutions to improving management of HE***Jasmohan S. BAJAJ, United States*

19:05-19:25

**Panel discussion and Q&A***Jasmohan S. BAJAJ, United States*

Panelists:

*Thomas BERG, Germany**Aleksander KRAG, Denmark**Debbie SHAWCROSS, United Kingdom*

19:25-19:30

**Summary and Close***Jasmohan S. BAJAJ, United States*

Industry

## Novo Nordisk: Understanding NASH as a metabolic disease

Strauss 1-2

**Chair:**

Zobair YOUNOSSI, *United States*

18:00-18:10

**Welcome and introduction**

Zobair YOUNOSSI, *United States*

18:10-18:30

**Connecting NASH with its metabolic risk factors: understanding the pathophysiology**

Arun SANYAL, *United States*

18:30-18:50

**NASH in the clinic: overcoming barriers to diagnosis for patients at risk**

Rohit LOOMBA, *United States*

18:50-19:10

**Managing NASH by targeting metabolic risk: current and emerging strategies**

Stephen HARRISON, *United States*

19:10-19:25

**Panel discussion**

Zobair YOUNOSSI, *United States*

Panelists:

Stephen HARRISON, *United States*

Rohit LOOMBA, *United States*

Arun SANYAL, *United States*

19:25-19:30

**Meeting close**

Zobair YOUNOSSI, *United States*

Industry

## Thursday 11 April 2019

### Genfit: Towards a comprehensive management of patients with chronic non-viral liver diseases

Strauss 1-2

**Chair:**

Mary RINELLA, *United States*

- 07:30-07:45 **Future of NASH therapeutics: rationale for combination therapy**  
Vlad RATZIU, *France*
- 07:45-08:00 **Future of NASH diagnostics: current landscape and what to expect in 2020**  
Quentin ANSTEE, *United Kingdom*
- 08:00-08:15 **Innovation in PBC: paving the way for new therapeutic strategies**  
Jörn M. SCHATTENBERG, *Germany*
- 08:15-08:30 **Importance of physician and patient advocacy**  
Donna CRYER, *United States*

Industry

### Gilead: Together we can... Reducing risks in hepatitis B virus infection

Hall C1

**Chair:**

Markus PECK-RADOSAVLJEVIC, *Austria*

- 07:30-07:40 **Assessing the risk of CHB**  
Markus PECK-RADOSAVLJEVIC, *Austria*
- 07:40-07:55 **Reducing the risk of long-term liver disease**  
Kosh AGARWAL, *United Kingdom*
- 07:55-08:10 **Reducing the risks when treating patients with CHB**  
George PAPANATHAN, *Greece*
- 08:10-08:20 **Continuing to reduce the risks of hepatitis B virus infection: future perspectives**  
Henry CHAN, *Hong Kong*
- 08:20-08:30 **Together we can reduce risks in hepatitis B virus infection**  
Markus PECK-RADOSAVLJEVIC, *Austria*
- Panelists:  
Kosh AGARWAL, *United Kingdom*  
Henry CHAN, *Hong Kong*  
George PAPANATHAN, *Greece*

## Grifols: Extending the treatment paradigm for cirrhosis: long-term albumin administration and beyond

Strauss 3

### Chair:

Jonel TREBICKA, *Germany*

07:30-07:35

### Welcome and introduction

Jonel TREBICKA, *Germany*

07:35-07:50

### The role of albumin in liver cirrhosis: the mechanism behind the clinical evidence

Jonel TREBICKA, *Germany*

Industry

07:50-08:10

### The clinical effect of long-term albumin administration: a disease-modifying strategy in cirrhosis?

Paolo CARACENI, *Italy*

08:10-08:25

### The cost-effectiveness of albumin in decompensated cirrhosis: a worthy investment

Javier FERNÁNDEZ, *Spain*

08:25-08:29

### Q&A's / Discussion

Jonel TREBICKA, *Germany*

Panelists:

Paolo CARACENI, *Italy*

Javier FERNÁNDEZ, *Spain*

08:29-08:30

### Conclusions and end of Symposium

Jonel TREBICKA, *Germany*

## Bristol-Myers Squibb: Navigating patients through the evolving HCC treatment landscape

Hepatology Arena

Objectives:

- Understand the evolving systemic therapy landscape for advanced HCC
- Discuss treatment options for difficult-to-treat patients (eg, Child-Pugh score class B)
- Explore approaches to transitioning patients from locoregional to systemic therapy

### Chair:

Peter GALLE, *Germany*

18:30-18:35

### Welcome and Introductions

Peter GALLE, *Germany*

- 18:35-19:15 **Systemic therapy for HCC: How do we choose from an expanding list of options?**  
Peter GALLE, *Germany*
- Panelists:  
Matthias PINTER, *Austria*  
Fabio PISCAGLIA, *Italy*
- 19:15-19:55 **When is the optimal time to transition patients from locoregional to systemic therapy?**  
Peter GALLE, *Germany*
- Panelists:  
Daniel PALMER, *United Kingdom*  
Jens RICKE, *Germany*
- 19:55-20:00 **Meeting close**  
Peter GALLE, *Germany*

Industry

### Intercept: Advances in PBC Management: Looking Beyond Biochemical Markers

Strauss 3

**Chair:**Michael TRAUNER, *Austria*

- 18:30-18:40 **Chair's welcome**  
Michael TRAUNER, *Austria*
- 18:40-18:50 **Second Line therapy in PBC: How can we optimise patient care?**  
Gideon HIRSCHFIELD, *United Kingdom*
- 18:50-19:05 **Real World Experience with Obeticholic Acid therapy**  
Aliya GULAMHUSEIN, *Canada*
- 19:05-19:20 **Histological features in PBC: A pathologist's perspective**  
Luigi Maria TERRACCIANO, *Switzerland*
- 19:20-19:45 **Histological Outcomes with Long term Obeticholic Acid therapy**  
Panelists:  
Christopher BOWLUS, *United States*  
Andreas E. KREMER, *Germany*
- 19:45-19:55 **Discussion**  
Michael TRAUNER, *Austria*
- 19:55-20:00 **Conclusion**  
Michael TRAUNER, *Austria*

## Friday 12 April 2019

### Gilead: Together we can... Achieving HCV elimination through simplification

Main Plenary

#### Chairs:

Michael GSCHWANTLER, *Austria*  
Stefan ZEUZEM, *Germany*

18:30-18:31

#### Introductory video

18:31-18:33

#### Welcome

Michael GSCHWANTLER, *Austria*

18:33-18:38

#### HCV elimination through simplification

Michael GSCHWANTLER, *Austria*

Panelist:

Stefan ZEUZEM, *Germany*

18:38-18:53

#### Simplification through innovation, partnership and access

Gregg ALTON, *United States*

18:53-19:08

#### Simplification: Why?

Marc BOURLIERE, *France*

19:08-19:45

#### Simplification: How?

Stefan ZEUZEM, *Germany*

Panelists:

Marc BOURLIERE, *France*

Maria BUTI, *Spain*

Michael GSCHWANTLER, *Austria*

Alessandra MANGIA, *Italy*

Mark SULKOWSKI, *United States*

19:45-19:58

#### Achieving elimination through simplification in action

Maria BUTI, *Spain*

19:58-20:00

#### Together we can: Achieve HCV elimination through simplification

Stefan ZEUZEM, *Germany*

Industry

**Intercept: NASH: What does the evidence tell us?****Hepatology Arena****Chair:**Zobair YOUNOSSI, *United States*

18:30-18:35

**Welcome and introductions**Zobair YOUNOSSI, *United States*

18:35-18:45

**What does the epidemiology tell us? – US and Global perspective**Zobair YOUNOSSI, *United States*

18:45-18:50

**What does the epidemiology tell us? – European perspective**Jörn M. SCHATTENBERG, *Germany*

18:50-19:00

**Applying the evidence to current practice: Diagnosis case study**Jörn M. SCHATTENBERG, *Germany*

19:00-19:15

**Recognising and monitoring the NASH patient- just how difficult is it?**Quentin ANSTEE, *United Kingdom*

19:15-19:25

**Applying the evidence to current practice: Current practice and management case study**Mary RINELLA, *United States*

19:25-19:40

**The emerging treatment landscape**Vlad RATZIU, *France*

19:40-19:50

**Future challenges in achieving meaningful outcomes for patients with NASH**Arun SANYAL, *United States*

19:50-20:00

**Q&A and meeting close**Zobair YOUNOSSI, *United States*

## Panelists:

Quentin ANSTEE, *United Kingdom*Vlad RATZIU, *France*Mary RINELLA, *United States*Arun SANYAL, *United States*Jörn M. SCHATTENBERG, *Germany*

Industry

## Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate

Strauss 3

### Chairs:

Nezam AFDHAL, *United States*

Markus PECK-RADOSAVLJEVIC, *Austria*

18:30-18:40

### Welcome and introduction

Nezam AFDHAL, *United States*

18:40-19:00

### Debating the management of a CLD patient with thrombocytopenia undergoing a procedure: case 1

Edoardo Giovanni GIANNINI, *Italy*

Panelist:

Mark THURSZ, *United Kingdom*

19:00-19:20

### Debating the management of a CLD patient with thrombocytopenia undergoing a procedure: case 2

Mark THURSZ, *United Kingdom*

Panelist:

Edoardo Giovanni GIANNINI, *Italy*

19:20-19:40

### Emerging TPO-R agonists for the management of thrombocytopenia in CLD patients undergoing a procedure

Markus PECK-RADOSAVLJEVIC, *Austria*

19:40-19:55

### Panel discussion and Q&A

Nezam AFDHAL, *United States*

Panelists:

Edoardo Giovanni GIANNINI, *Italy*

Markus PECK-RADOSAVLJEVIC, *Austria*

Mark THURSZ, *United Kingdom*

19:55-20:00

### Closing remarks

Markus PECK-RADOSAVLJEVIC, *Austria*

Industry

## Saturday 13 April 2019

### Gilead: Making a difference in diagnosing patients with advanced fibrosis due to NASH

Hall C3

**Chair:**

Laurent CASTERA, *France*

12:30-12:37

**The challenges and consequences of NASH**

Laurent CASTERA, *France*

12:37-12:57

**Use of liver biopsy to diagnose advanced fibrosis due to NASH: a debate**

Laurent CASTERA, *France*

Panelists:

Elisabetta BUGIANESI, *Italy*

Rohit LOOMBA, *United States*

12:57-13:17

**Applying guideline recommendations to clinical practice**

Kenneth CUSI, *United States*

Panelist:

Michael RODEN, *Germany*

13:17-13:32

**Recent developments in noninvasive testing**

Rohit LOOMBA, *United States*

13:32-13:47

**Best practice pathways for early identification of NASH**

Emmanuel TSOCHATZIS, *United Kingdom*

13:47-13:50

**Making a difference**

Laurent CASTERA, *France*

Industry

## MSD: Assessing Response in Advance Liver Cancer – Does Response Matter?

Hall C1

Objective –Develop Understanding of Why Response is Important Through Relationship to Overall Survival

### Chair:

Arndt VOGEL, *Germany*

12:30-12:40

### Assessing Response in Advanced Liver Cancer – Does Response Matter ? What Does the Previous Data Suggest?

Arndt VOGEL, *Germany*

12:40-12:55

### How Do We Measure Response and How Does this Affect Clinical Decisions?

Riad Salem, *United States*

12:55-13:10

### What Does the Latest Data Show About How Meaningful Response Is?

Richard FINN, *United States*

13:10-13:30

### Real World Experience on Response and Safety Data and Implications

Masatoshi KUDO, *Japan*

13:30-13:45

### The Future of Response and Conclusion on the Question of Does Response Matter in Advanced Liver Cancer

Arndt VOGEL, *Germany*

13:45-14:00

### Question and Answer

Arndt VOGEL, *Germany*

#### Panelists:

Richard FINN, *United States*

Masatoshi KUDO, *Japan*

Riad Salem, *United States*

Industry

## Mini-workshops programmes

### Thursday 11 April 2019

#### Cepheid: Scaling up Testing and Treatment for Hepatitis with Decentralised Molecular Testing

Lehar 3

**Chair:**

Jeffrey LAZARUS, *Spain*

07:30-07:35

**Introduction**

Jeffrey LAZARUS, *Spain*

07:35-07:50

**POC HCV RNA testing in a harm-reduction setting as the first step to treatment decentralization**

Elisa Martró, *Spain*

07:50-08:05

**Improving access to Hepatitis B Testing and Treatment in Resource Limited Settings**

Maud LEMOINE, *United Kingdom*

08:05-08:20

**Expanding access to HCV Viral Load testing outside centralized settings in LMIC**

Chukwuemeka AGWUOCHA, *Nigeria*

08:20-08:30

**Introduction**

Jeffrey LAZARUS, *Spain*

**Panelists:**

Chukwuemeka AGWUOCHA, *Nigeria*

Maud LEMOINE, *United Kingdom*

Elisa Martró, *Spain*

Industry

**Alexion: My patient care vs restricted access to medicines****Lehar 3**

18:30-18:35

**Welcome and Introduction**Claus NIEDERAU, *Germany*

18:35-18:55

**How to translate my clinical decision in access?**Claus NIEDERAU, *Germany*

19:55-19:15

**How to translate value into access?**Andrew WALKER, *Scotland*

19:15-19:30

**Q&A**

Panelists:

Claus NIEDERAU, *Germany*Andrew WALKER, *Scotland*

Industry

**Sequana Medical: Managing Ascites, improving Quality of Life****Lehar 4****Chair:**François DURAND, *France*

18:30-18:50

**Overall experience from Bern University with the Alfapump program**Andrea DE GOTTARDI, *Switzerland*

18:50-19:10

**Patient Selection and Care Protocols**Niels Kristian AAGAARD, *Denmark*

19:10-19:30

**Procedure, complications and solutions**Jean-Marc REGIMBEAU, *France*

## Friday 12 April 2019

### Perspectum Diagnostics: Introducing quantitative MRCP: Improving the clinical landscape for biliary disease

Lehar 3

**Chair:**

Michael P. MANNS, *Germany*

18:30-18:45

**Case studies of patients with PSC analysed with quantitative imaging**

Kris V. KOWDLEY, *United States*

18:45-19:00

**Clinical data with quantitative MRCP: From diagnosis to prognosis to longitudinal change**

Gideon HIRSCHFIELD, *United Kingdom*

19:00-19:15

**Panel Discussion: What is the highest potential value of quantitative MRCP in clinical practice?**

Michael P. MANNS, *Germany*

Panelists:

Gideon HIRSCHFIELD, *United Kingdom*

Kris V. KOWDLEY, *United States*

Christoph SCHRAMM, *Germany*

Palak TRIVEDI, *United Kingdom*

Martine WALMSLEY, *United Kingdom*

19:15-19:30

**Panel Discussion: What role would quantitative MRCP play in PSC clinical development?**

Michael P. MANNS, *Germany*

Panelists:

Gideon HIRSCHFIELD, *United Kingdom*

Kris V. KOWDLEY, *United States*

Christoph SCHRAMM, *Germany*

Palak TRIVEDI, *United Kingdom*

Martine WALMSLEY, *United Kingdom*

Industry

# Exhibition

## Exhibition opening hours

Thursday 11 April 09:00-18:30

Friday 12 to Saturday 13 April 09:00-17:00

## Exhibition floor plan

Industry



LEGEND: MEETING ROOMS

102	Novo Nordisk A/S
109	Eiger BioPharmaceuticals, Inc.
110	SuperSonic Imagine
114	Endra Life Sciences
115	Philips Healthcare
130	Perspectum Diagnostics
140	AbbVie
143	Biotest AG
150	Norgine
153	WHA: World Hepatitis Alliance
155	Humedics
156	Research Diets, Inc.
160	Intercept
161	Siemens Healthcare GmbH
163	OraSure Technologies
200	Dr. Falk Pharma GmbH
210	Novartis Pharma AG
220	Alexion Pharma GmbH
230	MSD
240	Genfit
250	Allergan
251	Enanta Pharmaceuticals, Inc.
253	CymaBay Therapeutics
260	Helena Biosciences
270	Resoundant Inc.
300	Cepheid
302	Apollo Endosurgery UK Ltd
303	BioPredictive
320	Gore & Associates
330	Echosens
332	Grifols
334	VIDC: Vancouver Infectious Diseases Centre
336	Fujirebio Europe N.V.
337	The Cochrane Hepato-Biliary Group
338	Shionogi Limited
339	TASL: Taiwan Association for the Study of the Liver
340	Liverpool Drug Interactions
342	WGO: World Gastroenterology Organisation
343	INHSU: International Network on Hepatitis in Substance Users
344	Hep C Action Aotearoa
345	UEG: United European Gastroenterology
346	Alnylam Pharmaceuticals
348	Virology Education
349	EFSUMB: European Federation of Societies for Ultrasound
350	ALEH: Latin American Association for the Study of the Liver
351	ICE-HBV: International Coalition to Eliminate HBV
352	Intercept
360	Gilead Sciences Europe Ltd
370	Gilead Sciences Europe Ltd
380	Gilead Sciences Europe Ltd
400	Ipsen
401	ELPA: European Liver Patients' Association
410	ELPA: European Liver Patients' Association
420	AASLD: American Association for the Study of Liver Diseases
424	AASLD: Meeting room
430	PhoenixBio
431	Gubra ApS
432	APASL: Asian Pacific Association for the Study of the Liver
433	Genedrive Diagnostics Ltd.
434	APHC: PHC 2020
435	GMP Orphan Deutschland GmbH
440	Wisepress
442	Zero Gravity Skin
443	High Point Clinical Trials Center
450	MYR Pharma
451	ProSciento
455	FIANOSTICS GmbH
Biotech Village	Albutec GmbH
Biotech Village	Liver Systems Medicine (LiSyM) Network
Biotech Village 1	Barcelona Liver Bioservices – BLB
Biotech Village 2	Diafir
Biotech Village 3	Sanyal Biotechnology LLC
Biotech Village 4	Sequana Medical NV
Biotech Village 5	VLVbio
Biotech Village 6	Promethera Biosciences
Delegates Lounge	Bristol-Myers Squibb

Industry

## Exhibitors' list

<b>Company</b>	<b>Booth Space</b>	<b>Company</b>	<b>Booth Space</b>
AASLD: American Association for the Study of Liver Diseases	420	Echosens	330
AbbVie	140	EFSUMB: European Federation of Societies for Ultrasound	349
Albutec GmbH	Biotech Village	Eiger BioPharmaceuticals, Inc.	109
ALEH: Latin American Association for the Study of the Liver	350	ELPA: European Liver Patients' Association	401, 410
Alexion Pharma GmbH	220	Enanta Pharmaceuticals	251
Allergan	250	Endra Life Sciences	114
Alnylam Pharmaceuticals	346	FIANOSTICS GmbH	455
APASL: Asian Pacific Association for the Study of the Liver	432	Fujirebio Europe NV	336
APHC: PHC 2020	434	Genedrive Diagnostics Ltd.	433
Apollo Endosurgery UK Ltd	302	Genfit	240
Barcelona Liver Bioservices – BLB	Biotech Village 1	Gilead Sciences Europe Ltd	360, 370, 380
BioPredictive	303	GMP Orphan Deutschland GmbH	435
Biotest AG	143	Gore & Associates	320
Bristol-Myers Squibb	Delegates Lounge	Grifols	332
Cepheid	300	Gubra ApS	431
CymaBay Therapeutics	253	Helena Biosciences	260
Diafir	Biotech Village 2	Hep C Action Aotearoa	344
Dr. Falk Pharma GmbH	200	High Point Clinical Trials Center	443
		Humedics	155


Industry

<b>Company</b>	<b>Booth Space</b>	<b>Company</b>	<b>Booth Space</b>
ICE-HBV: International Coalition to Eliminate HBV	351	Sequana Medical NV	Biotech Village 4
INHSU: International Network on Hepatitis in Substance Users	343	Shionogi Limited	338
Intercept	160, 352	Siemens Healthcare GmbH	161
Ipsern	400	SuperSonic Imagine	110
Liver Systems Medicine (LiSyM) Network	Biotech Village	TASL: Taiwan Association for the Study of the Liver	339
Liverpool Drug Interactions	340	The Cochrane Hepato-Biliary Group	337
MSD	230	United European Gastroenterology (UEG)	345
MYR Pharma	450	VIDC: Vancouver Infectious Diseases Centre	334
Norgine	150	Virology Education	348
Novartis Pharma AG	210	VLVbio	Biotech Village 5
Novo Nordisk A/S	102	WGO: World Gastroenterology Organisation	342
OraSure Technologies	163	WHA: World Hepatitis Alliance	153
Perspectum Diagnostics	130	Wisepress	440
Philips Healthcare	115	Zero Gravity Skin	442
PhoenixBio	430		
Promethera Biosciences	Biotech Village 6		
ProSciento	451		
Research Diets, Inc.	156		
Resoundant Inc.	270		
Sanyal Biotechnology LLC	Biotech Village 3		


Industry

# MEETING ROOMS OVERVIEW

## 1<sup>ST</sup> FLOOR



## GROUND FLOOR



## Company profiles

### AbbVie

**Booth 140**

1 North Waukegan Road  
North Chicago, Illinois 60064  
USA

[www.abbvie.com](http://www.abbvie.com)

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at [www.abbvie.com](http://www.abbvie.com). Follow @abbvie on Twitter, Facebook or LinkedIn.

### Albutec GmbH

**Biotech Village**

Schillingallee 68  
Rostock, 18057  
Germany

[www.albutec.com](http://www.albutec.com)

Albutec is a research and development company with 6 permanent and 2 part-time employees.

The company is based in the Hanseatic city of Rostock at the Biomedical Research Center.

Albutec developed the Hepalbin®-Adsorbent, which can easily remove unwanted stabilizers from human albumin solutions in order to enhance albumin binding capacity significantly.

According to the literature this is associated with a survival benefit for liver patients.

The nano structured Hepalbin®-Adsorbent can be used for a bed-side removal of contaminations or to prepare large albumin pools for albumin dialysis, e.g. MARS® or OPAL®

The new CE certified infusion device bears the world wide first technology for applying human albumin solutions without caprylate and acetyltryptophanate, which is most important for patients with liver failure.

Albutec is DIN EN ISO 13485 certified. It has authorisation for wholesale trade in medicinal products in accordance with § 52 AMG (German Medicines Act).

Industry

**Alexion Pharma GmbH****Booth 220**

Giesshübelstrasse 30  
Zürich 8045  
Switzerland

[www.alexion.com](http://www.alexion.com)

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies – Kanuma™ (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D), and Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP). Alexion also developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas.

**Allergan****Booth 250**

5 Giralda Farms  
Madison, NJ 07940  
USA

[www.allergan.com](http://www.allergan.com)

Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the industry.

For more information, visit Allergan's website at [www.Allergan.com](http://www.Allergan.com).

**Alnylam Pharmaceuticals****Booth 346**

Grafenauweg 4  
Zug 6300  
Switzerland

[www.alnylam.com](http://www.alnylam.com)

Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a clinically validated approach for the treatment of diseases with high unmet need. Alnylam's first U.S. FDA-approved RNAi therapeutic

is ONPATTRO™ (patisiran) available in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Additionally, Alnylam has three investigational medicines in late-stage development. For more information visit [www.alnylam.com](http://www.alnylam.com).

### **Apollo Endosurgery UK Ltd**

**Booth 302**

Unit 10, Grimbald Crag Court  
Knaresborough HG5 8QB  
United Kingdom

[www.apolloendo.com](http://www.apolloendo.com)

Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal conditions. Apollo's device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the ORBERA365™ IntraGastric Balloon, and the LAP-BAND® Adjustable Gastric Banding System.

Industry

### **Barcelona Liver Bioservices – BLB**

**Biotech Village (BV 1)**

Diagonal 682, 3<sup>rd</sup> floor  
Barcelona 08036  
Spain

[www.liver.barcelona](http://www.liver.barcelona)

BLB is a contract research organization that aims to contribute with pharmaceutical partners to ultimately accelerate the development of new treatments for patients with liver disease.

BLB provides superior quality research services and consulting in the fields of Hepatology and Toxicology. We combine exclusive cutting-edge technology with reliable traditional models that altogether permits high-value characterization of new chemical entities.

In BLB we truly believe that refinement of pre-clinical research, by using smarter experimental models that closer reflect patients pathophysiology, is the only way to shorten the bridge between bench work and clinical practice.

### **Bayer**

100 Bayer Boulevard, P.O.Box 915  
Whippany, NJ 07981  
USA

[www.bayer.com](http://www.bayer.com)

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. In just over a decade, the advancing oncology portfolio at Bayer has expanded significantly and includes four marketed products, as well as several investigational compounds in clinical development. We are driven every day by what matters most to the cancer community and work hard to transform the lives of people impacted by cancer, fueled by science and innovation.

**BioPredictive****Booth 303**

218 Boulevard Saint Germain  
Paris 75007  
France

[www.biopredictive.com](http://www.biopredictive.com)

BioPredictive offers diagnostic and prognostic blood tests for liver diseases. BioPredictive is dedicated to improve the management of liver diseases. Over 2 million tests performed worldwide. BioPredictive's diagnosis and prognosis patented tests (FibroTest-ActiTest, SteatoTest, and just released NASH-Fibro Test) are available on line via a secured and anonymous Internet connection [www.biopredictive.com](http://www.biopredictive.com)

Industry

FibroTest App (free) including ElastoFibroTest and DAAFibroTest is also available on iPhone and Android.

We invite you to take a look at our online scientific library: <http://library.biopredictive.com/>

**Biotest AG****Booth 143**

Landsteinerstr. 5  
Dreieich 63303  
Germany

[www.biotest.com](http://www.biotest.com)

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematoses, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide.

**Boehringer Ingelheim Pharma GmbH & Co.KG**

Binger Str. 173  
Ingelheim am Rhein 55216  
Germany

[www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

**Bristol-Myers Squibb**

3401 Princeton Pike  
Lawrenceville 08648  
USA

[www.bms.com](http://www.bms.com)

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through the Bristol-Myers Squibb Foundation, we promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world's most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.

**Booth BMS Delegate Lounge****Cepheid**

Vira Solelh  
81470 Maurens Scopont  
France

[www.cepheidinternational.com](http://www.cepheidinternational.com)

Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases, virology and cancer.

**Booth 300****Cook Medical**

Limerick  
Ireland

[www.cookmedical.eu](http://www.cookmedical.eu)

Cook Medical, one of the first companies to help popularise interventional medicine, has pioneered many of the devices now commonly used to perform minimally invasive medical procedures. The company integrates device design, biopharma, gene & cell therapy & biotech to enhance patient safety & improve clinical outcomes in the fields of aortic intervention; interventional cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access & oncology; surgery & soft tissue repair; urology; assisted reproductive technology, gynaecology & high-risk obstetrics. Visit [www.cookmedical.eu](http://www.cookmedical.eu)

Industry

**CymaBay Therapeutics****Booth 253**

7575 Gateway Boulevard Suite 110  
Newark, California 94560  
USA

[www.cymbay.com](http://www.cymbay.com)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.

**Diafir****Biotech Village (BV 2)**

Industry

Parc Lorans 26J Avenue Chardonnet  
Rennes 35000  
France

[www.diafir.com](http://www.diafir.com)

DIAFIR develops, manufactures and markets diagnostic tests through its proprietary mid-infrared (MIR) metabolic signature technology. The MIR technology, combined with proprietary algorithm, enables to deliver a score within 15 minutes from a simple drop of blood serum. The current development is focused on the non-invasive diagnosis of NASH and its complications. The aim is to propose a simple test permitting fast and accurate NASH patient screening and monitoring.

**Dr. Falk Pharma GmbH****Booth 200**

Leinenweberstrasse 5  
Freiburg 79108  
Germany

[www.drpharmade.de](http://www.drpharmade.de)

Dr. Falk Pharma GmbH is a family-owned enterprise based in Freiburg/Germany with affiliates in UK and Ireland, the BeNeLux countries, Spain, Portugal, Russia and Austria. Dr. Falk Pharma and its over 200 employees are specialised in the development and distribution of pharmaceuticals for hepatological and gastroenterological diseases. These, mainly prescription drugs, are marketed in Germany and more than 60 countries worldwide.

The Falk Foundation e.V. is a medical education organisation associated with Dr. Falk Pharma, offering a wide variety of congresses and media to support product independent postgraduate education for doctors on a national and international level.

## Echosens

**Booth 330**

30, place d'Italie  
Paris 75013  
France

[www.echosens.com](http://www.echosens.com)

In 2003, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the unique device using patented and validated VCTE™ technology for liver stiffness assessment, and CAP™ technology for steatosis quantification.

FibroScan® device is recognized worldwide as the reference for non invasive liver diagnosis with more than 2,000 medical publications and 40 guidelines recommendations.

We are working hand in hand with physicians, medical academic research, pharmaceutical companies for patient identification and monitoring in NAFLD/NASH.

As patient education is a major issue, we have created the «myliverexam» website that provides information about the role of the liver and why it is vital to the global health.

Industry

## Eiger BioPharmaceuticals, Inc.

**Booth 109**

2155 Park Boulevard  
Palo Alto 94306  
USA

[www.eigerbio.com](http://www.eigerbio.com)

Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted therapies for rare and ultra-rare diseases. The company's lead program is in Phase 3, developing lonafarnib, a first-in-class, oral prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also preparing an NDA with plans to file in 2019 for lonafarnib in the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. For additional information about Eiger, please visit [www.eigerbio.com](http://www.eigerbio.com).

## Eisai

### About Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hnc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hnc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology.

### About Eisai EMEA in Oncology

Eisai is committed to the development and delivery of highly beneficial new treatments for people with cancer. The development of therapeutic options in oncology is a major strategic area for Eisai in Europe, the Middle East, Africa, Russia and Oceania (EMEA).

For more information about Eisai Co., Ltd., please visit [www.eisai.com](http://www.eisai.com)

**Enanta Pharmaceuticals****Booth 251**

500 Arsenal Street  
Watertown, MA 02472  
USA

[www.enanta.com](http://www.enanta.com)

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).

Industry

**Endra Life Sciences****Booth 114**

3600 Green Court, Suite 350  
Ann Arbor 48105-1570  
USA

[www.endrainc.com](http://www.endrainc.com)

ENDRA Life Sciences (NASDAQ: NDRA) is a development stage company with a breakthrough Thermo-Acoustic Enhanced UltraSound (TAEUS) enabling clinicians to visualize human tissue composition, function and temperature. Initial application is quantification of fat in the liver, for early detection and monitoring of NAFLD, which affects over 1 billion people globally.

KEYWORDS: NAFLD, Fatty liver disease, Therm-Acoustic Enhanced Ultrasound

**Fianostics GmbH****Booth 455**

Viktor Kaplan Strasse 2  
Wiener Neustadt 2700  
Austria

FIANOSTICS develops, manufactures and sells highly sensitive direct fluorescence immunoassays for based on a recently in cooperation with STRATEC Consumables GmbH developed metal enhanced fluorescence assay platform. We use this "FluoBolt™" -Technology to make Biomarkers accessible, which circulate in very low amounts in human serum and plasma.. FluoBolt™ – immunoassay offer the following advantages:

- High Sensitivity
- Single Step Assay
- No Enzyme Substrates required

We offer assays for PERIOSTIN, ASPORIN and NOGGIN which are interesting biomarkers for research in the field of liver diseases.

For more information about our technology and its application please visit [www.fianostics.at](http://www.fianostics.at).

**Fujirebio Europe NV****Booth 336**

Technologiepark 6  
Zwijnaarde 9052  
Belgium

[www.fujirebio-europe.com](http://www.fujirebio-europe.com)

Fujirebio is a global leader within high quality IVD testing. The company counts more than 50 years' experience, is a world-wide reference in oncology for routine and novel markers, has solid experience with immunoassay testing solutions and has, under the name Innogenetics (now Fujirebio Europe), been pioneering the field of molecular diagnostics and multiparameter testing.

Fujirebio's infectious diseases products are focused on chronic liver disease, providing molecular monitoring tools for HBV (genotyping, drug resistance mutations, basal core/precure mutations). The LUMIPULSE® G1200 and G600II offer fully automated screening solutions for specialty infectious diseases (HBcAg, HBsAg Quant) and markers for HCC (AFP/PIVKA-II).

**Genedrive Diagnostics Ltd.****Booth 433**

48 Grafton Street  
Manchester M13 9XX  
United Kingdom

[www.genedrive.com](http://www.genedrive.com)

Genedrive Diagnostics Limited is a molecular diagnostics company based in Manchester, UK.

We have developed a revolutionary nucleic acid based point of need system that provides near patient results for use in decentralised settings. Genedrive® is rapid, simple to use and low cost molecular diagnostics platform for the identification and treatment selection of infectious diseases, human genotyping, animal health, pathogen identification, and other applications. It is rapidly reconfigurable for specific assays, works on different sample types (including sputum, plasma, buccal swabs) and is suitable for use outside a traditional hospital setting.

**Genfit****Booth 240**

885 Avenue Eugène Avinée  
Loos 59000  
France

[www.genfit.com](http://www.genfit.com)

GENFIT is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions targeting metabolic and liver-related diseases where there is considerable unmet medical need. Its most advanced drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial as a potential treatment for nonalcoholic steatohepatitis, or NASH, and recently obtained positive results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC. GENFIT is also developing a non-invasive, blood-based in vitro diagnostic test to identify patients with NASH who may be appropriate candidates for drug therapy.

Industry

**Gilead Sciences Europe Ltd****Booths 360, 370 & 380**

2 Roundwood Avenue, Stockley Park  
Uxbridge UB11 1AF  
United Kingdom

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead is committed to patients with liver disease. Together we have helped change the face of hepatitis C and support efforts towards HCV elimination worldwide. We are working on optimizing treatment for HBV, with the ultimate aim of finding a cure, and on innovations in liver fibrosis.

Industry

**GMP ORPHAN****Booth 435**

27-29 rue du Faubourg Saint Jacques  
Paris, 75014  
France

[www.gmp-o.com](http://www.gmp-o.com)

gmp-orphan was founded in 2011 to identify, develop and provide access to innovative treatments to patients with rare diseases. The company's first commercialized product is Cuprior for the treatment of Wilson Disease.

**Gore & Associates****Booth 320**

Werher-von-Braun Str 18, Werk 1 / Financial Services  
Putzbrunn D – 85639  
Germany

[www.goremedical.com/eu](http://www.goremedical.com/eu)

Gore Medical Products Division engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives.

[www.goremedical.com/eu](http://www.goremedical.com/eu)

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives.

**Grifols****Booth 332**

Avda. Generalitat 152-158  
Sant Cugat del Valles 08174  
Spain

<https://www.grifols.com/en/home>

For more than 75 years, Grifols has worked to improve the health and well-being of people around the world. We are a global healthcare company that produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to deliver expert medical care.

Our three main divisions – Bioscience, Diagnostic and Hospital – develop, manufacture and market innovative products and services available in more than 100 countries. Headquartered in Barcelona, Spain, Grifols has nearly 18,500 employees in 30 countries.

With the world's largest network of plasma donation centers, Grifols, through its Bioscience Division, is a leading producer of plasma-derived medicines for the treatment of rare, chronic, and sometimes life-threatening conditions.

For more information, visit [grifols.com](http://grifols.com).

**Gubra ApS****Booth 431**

Hørsholm Kongevej 11B  
Hørsholm 2970  
Denmark

[www.gubra.dk](http://www.gubra.dk)

Gubra provides state of the art pre-clinical NASH models. We have a very high availability of animals constantly being diet-induced, which enables us to start a study with short notice. Our pre-/post liver biopsies have proven especially valuable to our customers.

Gubra is a Danish biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (obesity, diabetes, NASH and diabetic complications), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, imaging, stereology, NGS, bioinformatics and ex vivo assays.

**Helena Biosciences****Booth 260**

Queensway South  
Gateshead NE11 0SD  
United Kingdom

[www.glyco-liver-profile.co.uk](http://www.glyco-liver-profile.co.uk)

In 2019 Helena Biosciences launch our Glyco Liver Profile, a revolutionary new test which uses a single serum sample to provide a comprehensive picture of liver health via four indices: inflammation including NASH, fibrosis, cirrhosis and a prognostic risk index for 7-year HCC development.

Industry

Running on Helena's fully automated V8 NEXUS clinical capillary electrophoresis platform, this unique product enables hepatologists to diagnose, prioritise and monitor patients across any period of time. Our intuitive Platinum Touch software provides a clear, detailed result together with powerful data management and reporting capabilities.

Please visit our team at Stand 260 to learn more.

### **High Point Clinical Trials Center**

**Booth 443**

4160 Mendenhall Oaks Pkwy Suite 105  
High Point 27265  
USA

[www.highpointctc.com](http://www.highpointctc.com)

High Point Clinical Trials Center has provided comprehensive (Phase I-III) clinical site services since 2008. Our 42,000 ft<sup>2</sup> facility consists of three units for the execution of outpatient and inpatient studies. In addition to Healthy Normal, HPCTC focuses on specialty populations such as Healthy Normal, Metabolic Diseases, NASH, Respiratory, Nicotine.

### **Humedics GmbH**

**Booth 155**

Marie-Elisabeth-Lüders Str. 1  
Berlin 10625  
Germany

[www.humedics.de](http://www.humedics.de)

Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAX, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with valid information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes.

LiMAX has already been used on thousands of patients and the company is currently expanding its operation.

Humedics aims to improve the overall outcomes for patients with liver disease by enabling physicians' clinical decision making through fast and accurate information about real-time liver function capacity.

### **Intercept**

**Booth 160 (Intercept)  
Booth 352 (Intercept Medical Affairs)**

Two Pancras Square  
London N1C 4AG  
United Kingdom

[www.interceptpharma.com](http://www.interceptpharma.com)

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

**Ipsen****Booth 400**

65 Quai George Gorse  
92100 Boulogne-Billancourt  
France

[www.ipsen.com](http://www.ipsen.com)

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases.

For more information on Ipsen, visit [www.ipsen.com](http://www.ipsen.com)

**Janssen Pharmaceutical Companies of Johnson & Johnson**

<https://www.janssen.com/infectious-diseases-and-vaccines>

At Janssen, we have an ambitious goal. We strive to bring forth transformational medical innovations that improve the lives of people affected by hepatitis B and ensure future generations can live without fear of the disease.

With a goal like this, there's no time to waste. That is why we partner with organizations around the world, connecting our own expertise with that of others.

Only together we can achieve a world with #NoHep

**MSD****Booth 230**

200 Galloping Hill Road  
Kenilworth 07033  
USA

[www.msd.com](http://www.msd.com)

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit [www.msd.com](http://www.msd.com) and connect with us on Twitter, LinkedIn and YouTube.

**MYR Pharma****Booth 450**

Hessenring 89  
Bad Homburg 61348  
Germany

<http://www.myr-pharma.com/>

MYR Pharma is focused on the development of Bulevirtide, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. MYR Pharma started its operations in 2011.

Industry

Its technology was originally developed at the University of Heidelberg (Germany) and INSERM (France) and represents one of the most clinically advanced novel approaches for treatment of hepatitis B and D.

## **Norgine**

**Booth 150**

Norgine House, Moorhall Road  
Harefield UB9 6NS  
United Kingdom

[www.norgine.com](http://www.norgine.com)

Norgine is a European specialist pharmaceutical company that has been established for over 110 years. Norgine provides expertise and 'know how' in Europe to develop, manufacture and market products that offer value to healthcare professionals, payers and patients.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands.

Join us for our symposium on Wednesday 10<sup>th</sup> April at 6:00pm, Title – Preventing a Domino Effect in the Management of Hepatic Encephalopathy

For more information, please visit [www.norgine.com](http://www.norgine.com)

## **Novartis Pharma AG**

**Booth 210**

Asklepios 8  
Basel 4002  
Switzerland

[www.novartis.com](http://www.novartis.com)

### **About Novartis**

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world. Find out more at [www.novartis.com](http://www.novartis.com).

## **Novo Nordisk A/S**

**Booth 102**

Vandtaarnsvej 114  
Soeborg DK-2860  
Denmark

[www.novonordisk.com](http://www.novonordisk.com)

At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also

enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders, obesity, chronic kidney disease, cardiovascular disease and NASH .

Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries.

## **OraSure Technologies**

**Booth 163**

220 East 1<sup>st</sup> Street  
Bethlehem, PA 18015  
USA

[www.orasure.com](http://www.orasure.com)

OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.

Industry

## **Perspectum Diagnostics**

**Booth 130**

23-38 Hythe Bridge Street  
Oxford OX1 2ET  
United Kingdom

[www.perspectum-diagnostics.com](http://www.perspectum-diagnostics.com)

Perspectum Diagnostics provides digital health solutions for liver and metabolic disease. LiverMultiScan, uses multiparametric MRI to provide quantitative analysis of liver tissue, measuring fat and correlates of iron and fibroinflammatory disease. There is a burgeoning interest in using LiverMultiScan in clinical practice to improve the patient pathway and experience, as research has shown that LiverMultiScan correlates with biopsy and clinical outcomes. Perspectum will be showcasing MRCP+, which allows 3D visualisation and quantitative mapping of the pancreatobiliary system by enhancing conventional MRCP images. Perspectum are pleased to announce they will also be hosting a workshop on MRCP+ at the conference.

## **Pfizer Inc.**

235 East 42<sup>nd</sup> Street  
New York 10017  
USA

[www.pfizer.com](http://www.pfizer.com)

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines and many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time.

**Philips Healthcare****Booth 115**

Boschdijk 525, Building VB-10-360, P.O. Box 90050  
Eindhoven 5621 JG  
The Netherlands

[www.philips.com.tr/healthcare/solutions/ultrasound/ultrasound-hepatology](http://www.philips.com.tr/healthcare/solutions/ultrasound/ultrasound-hepatology)

Creating a healthier future, together.

At Philips, we look beyond technology to the experiences of patients, providers and caregivers across the health continuum from healthy living to prevention, diagnosis, treatment, recovery and home care. We unlock insights leading to meaningful innovations from hospital to home. Our solutions combine clinical breadth and depth of expertise, technology and services, actionable data, consultative new business models and partnerships. Together, with our customers, we take risks and share responsibility – so that we can transform how care is delivered and experienced. It's a unique perspective empowering us all to create a healthier future.

Industry

**PhoenixBio****Booth 430**

65 Broadway Suite 605  
New York, NY 10006  
USA

[www.phoenixbio.co.jp/en/](http://www.phoenixbio.co.jp/en/)

PhoenixBio — supplier of the PXB-Mouse® and PXB-cells®, provides comprehensive drug development study services tailored for therapeutics targeting the human liver, including HBV/HDV/HCV, DMPK/Toxicology, Oligonucleotide, and Gene Therapy studies.

The PXB-Mouse®, the world's most widely used humanized liver mouse model for pharmaceutical discovery and development, features up to 95% human hepatocyte engraftment, ensuring accurate and predictable translatability in pre-clinical development studies resulting in accelerated discovery pipelines.

PXB-cells®, hepatocytes freshly isolated from the PXB-Mouse®, are also available for in vitro study services or direct shipment. Long-term stability, high enzyme activity, and study-to-study consistency make PXB-cells® superior to cryopreserved cells.

**Promethera Biosciences****Biotech Village (BV 6)**

Watson & Crick Hill | Rue Granbonpré 11  
Mont-Saint-Guibert 1435  
Belgium

[www.promethera.com](http://www.promethera.com)

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our

therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera®, HepaStem®, H2stem®, Cytonet®, Heparesc® are all registered trademarks of the PROMETHERA group.

## **ProSciento**

**Booth 451**

855 3<sup>rd</sup> Avenue, Suite 3340  
Chula Vista 91911  
USA

[www.prosciento.com](http://www.prosciento.com)

ProSciento is a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and contributed to the development of more than 15 approved metabolic drugs and devices. For more information, please visit [www.prosciento.com](http://www.prosciento.com).

## **Research Diets, Inc.**

**Booth 156**

20 Jules Lane  
New Brunswick, New Jersey 08901  
USA

[www.researchdiets.com](http://www.researchdiets.com)

Research Diets, Inc. formulates and produces purified OpenSource Diets® for laboratory animals. Our Resource Center is staffed with scientists who consult with our customers around the world on diet formulations. We have formulated over 20,000 original diets and regularly incorporate compounds. Custom diets shipped in 5-7 days. BioDAQ® Food and Liquid Intake Monitor for mice and rats controls spillage and reduces interaction between scientists and animals while recording the moment-to-moment, bout-by-bout intake. Automated gate is programmable by time or amount consumed. Data is interpreted using powerful analysis software. BioDAQ NHP monitors food intake of socially housed NHPs.

## **Resoundant Inc.**

**Booth 270**

421 1<sup>st</sup> Ave SW suit 204W  
Rochester 55902  
USA

[www.Resoundant.com](http://www.Resoundant.com)

Resoundant Inc. is the developer of Magnetic Resonance Elastography (MRE), an advanced imaging technique for measuring tissue stiffness and aiding the diagnosis and staging of liver fibrosis. Through strategic partnerships with GE, Philips, and Siemens, MRE is available at over 1000 leading imaging centers and hospitals throughout the world. MRE provides physicians with the most comprehensive and accurate picture of liver health available, and is recognized

Industry

by numerous professional societies as a standard of care for the clinical management of liver disease. MRE has also become a widely required Biomarker for many drug trial protocols.

Follow us @Resoundant or visit us at Booth #270 to learn more MRE.

## **Sanyal Biotechnology LLC**

## **Biotech Village (BV 3)**

700 West Olney Rd  
Norfolk 23507  
USA

[www.sanyalbio.com](http://www.sanyalbio.com)

Sanyal Biotechnology is a contract research organization specializing in pre-clinical small animal models screening of drugs. We are a full service CRO with the ability to run basic toxicology, proof of concept, and efficacy studies on small rodent models. Our flagship model, the DIAMONDTM mouse, that develops full metabolic syndrome solely as a result of Western Diet exactly parallels development of human liver disease due to metabolic syndrome. The DIAMONDTM mice develop symptoms of metabolic syndrome including obesity, dyslipidemia, and insulin resistance; additionally, their liver pathology also progresses to cirrhosis and HCC. Our CRO services are performed in an AAALAC-accredited environment.

## **Sequana Medical NV**

## **Biotech Village (BV 4)**

Technologiepark 122  
Zwijnaarde 9052  
Belgium

[www.sequanamedical.com](http://www.sequanamedical.com); [alfapump.com](http://alfapump.com)

Sequana Medical is a commercial stage medical device company and an innovator in the management of liver disease.

The alfapump® is a fully implantable, programmable, transcutaneously-charged, battery-powered pump for the management of RA due to liver cirrhosis or malignant ascites with a life expectancy of 6 months or less. It is one of the first real alternatives to LVP for drainage of excess fluid. By moving ascites to the bladder, the alfapump® prevents fluid build-up and its possible complications, improving patient quality of life and nutrition, and potentially reducing hospital visits and healthcare costs.

The alfapump® DirectLink Technology allows clinicians to receive pump performance information and more effectively manage patients treated by the alfapump®. The product is CE Marked. The alfapump® is currently under evaluation in the US under an IDE study.

**Shionogi Limited****Booth 338**

33 Kingsway  
London WC2B 6UF  
United Kingdom

[www.shionogi.eu](http://www.shionogi.eu)

From our beginnings over 140 years ago in Osaka, Japan, Shionogi & Co. Ltd. has built a strong heritage in research-based medicine, matched by world-class market access and patient insight capabilities. Shionogi Europe was launched in 2012 and is committed to applying our patient-first approach in everything we do across the region.

Our research-led organisation is defined by a distinct openness and close partnership approach to discovering and developing medicines addressing unmet medical needs. Our development approach goes hand in hand with the collaborative drug discovery process that lies at the heart of Shionogi and our people.

**Siemens Healthcare GmbH****Booth 161**

Karlheinz Kaske Strasse 2  
Erlangen DE-91052  
Germany

[www.healthcare.siemens.com](http://www.healthcare.siemens.com)

**Siemens Healthineers**

Making healthcare providers successful by offering solutions that improve outcomes and reduce costs Siemens Healthineers Ultrasound Imaging Systems enhance your diagnosis with improved imaging performance and adaptive technologies. Our portfolio of ultrasound machines and sonography equipment meet your clinical needs with the versatility and functionality you need for patient diagnosis.

With unmatched image quality and cutting-edge versatility for the full range of clinical applications, Siemens ultrasound imaging systems enhance confidence in your diagnoses for improved patient outcomes.

Partner with us to expand your clinical capabilities and improve care by personalizing the way you care for your patients.

**SuperSonic Imagine****Booth 110**

510 rue René Descartes – Les Jardins de la Duranne  
Aix en Provence 13852  
France

[www.supersonicimagine.com](http://www.supersonicimagine.com)

SuperSonic Imagine introduces this year its new ultrasound system, Aixplorer MACH 30 that combines a sleek design, intuitive user experience and enhance performance. Aixplorer MACH 30 provides non-invasive diagnostic tools for the assessment of liver fibrosis and steatosis. It is the only imaging ultrasound system that is cleared by the FDA as an aid to clinical management with liver disease.

Industry

The new generation of real-time ShearWave Elastography, ShearWave™ PLUS, enables non-invasive liver stiffness measurements under ultrasound-image guidance and delivers a live color-coded map of liver stiffness. Over 150 publications demonstrate the reliability and effectiveness of ShearWave Elastography for chronic hepatopathies.

## **Virology Education**

**Booth 348**

Biltstraat 106  
Utrecht 3572BJ  
The Netherlands

[www.virology-education.com](http://www.virology-education.com)

Virology Education is the leading provider of top quality educational and scientific programs for healthcare professionals involved in HIV, hepatitis, tuberculosis, emerging viruses, NASH, Liver disease, Pharmacology, and oncology. With over two decades of experience, an expert in-house team and over 30,000 opt-in subscribers, Virology Education is committed to delivering highly acclaimed and accredited programs that reach healthcare professionals worldwide.

The company takes on the role of identifying needs, driving new initiatives, designing tailored programs, developing educational and scientific content, and handling the face-to-face logistical management of programs.

## **VLVbio**

**Biotech Village (BV 5)**

Hästholsvägen 32  
Nacka 13130  
Sweden

[www.vlvbio.com](http://www.vlvbio.com)

At VLVbio, we offer unique assays for accurate and non-invasive detection of liver damage and disease.

Our biomarker assays, M30® and M65®, measure apoptosis and total cell death respectively, and are used globally within academia, industry and healthcare sectors.

Measuring apoptosis and levels of total cell death is of interest in the diagnosis and treatment follow-up of patients suffering from liver diseases such as NASH and ASH, in the development of new drugs, and when assessing toxicological effects of pharmaceuticals and other substances.

Join us at our booth and let us discuss more about our biomarker assays!

**Wisepress Ltd****Booth 440**

15 Lyon Road, Merton  
London Sw19 2RL  
United Kingdom

[www.wisepress.com](http://www.wisepress.com)

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

Industry 

## Association profiles

### **AASLD: American Association for the Study of Liver Diseases**

**Booth 420**

1001 N Fairfax St., 4<sup>th</sup> Floor  
Alexandria VA 22314  
USA

[www.aasld.org](http://www.aasld.org)

AASLD is the professional home of more than 6,000 scientists, researchers, educators and health care professionals dedicated to the study and cure of liver diseases. We are a growing global community on a mission to advance and disseminate the science and practice of hepatology and improve outcomes for patients. Learn more and become a member at stand 420

Industry

### **ALEH: Latin American Association for the Study of the Liver**

**Booth 350**

Estoril 50, office 1005  
Santiago 7591047  
Chile

[www.Alehatam.org](http://www.Alehatam.org)

ALEH is a non-profit scientific association founded in 1968, whose main objective is to promote and disseminate the study of Hepatology in Latin America, through training and the exchange of scientific knowledge and experiences, to reduce current gaps in the world. Through academic activities, ALEH seeks to establish a solid leadership within the field at an international and Latin America level. ALEH is also a member of GLOBAL LIVER SUMMIT. Member countries are: Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Cuba, Ecuador, Guatemala, Mexico, Paraguay, Panama, Peru, Puerto Rico Dominican Republic, Uruguay and Venezuela.

### **APASL: Asian Pacific Association for the Study of the Liver**

**Booth 432**

1-24-7-920 Shinjuku, Shinjuku-ku  
Tokyo 160-0022  
Japan

[www.apasl.info](http://www.apasl.info)

APASL is the leading associations based on investigation and treatment of liver diseases in the world and the largest scientific body that upholds the standards and profession, research and create improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region. APASL's main objectives are to promote the latest scientific advancement and education of hepatology science, exchange of information and the development of consensus, encourage the practice of medicine in liver diseases and also coordinate scientific studies between various scientists and clinicians throughout the region.

**APHC: PHC 2020****Booth 434**

176 Rue Legendre  
Paris 75017  
France

[www.aphc.info](http://www.aphc.info)

The APHC (Association for the Promotion of Hepatologic Care) is a not-for-profit association, created by Professor Patrick Marcellin.

The main objectives of APHC are the promotion of education, research, awareness and healthcare in liver diseases.

Educational activities include annual meetings organized by Pr Patrick Marcellin: the Paris Hepatology Conference (PHC), the Young European Hepatologists Course (YEHC), the Jeunes Hépatologues Conference (JHC).

The PHC created in 2004 is a well recognized annual "Rendez-vous" of worldwide specialists and scientists interested in the field of Hepatology. This meeting provides the state of the art for the optimal management of patients with liver disease.

**EFSUMB: European Federation of Societies for Ultrasound****Booth 349**

PO Box 72718  
London SW19 9HD  
United Kingdom

[www.efsumb.org](http://www.efsumb.org)

EFSUMB promotes communication and understanding in the field of ultrasound ; our objectives are to promote the science, the research and development of ultrasound in Medicine and Biology and to publish the results of research; to propose standards and to give advice concerning criteria for optimum equipment and techniques and clinical applications; to arrange congresses and study and development meetings on an international level both in and outside Europe by the member organisations, including organising, in co-operation with a local committee, a European or World Congress for ultrasound in Medicine and Biology (WFUMB) at least once every four years; to represent the interests of its membership in WFUMB and in any other international organisation such as EASL whose purposes are consistent with those of EFSUMB.

**ELPA: European Liver Patients' Association****Booths 401, 410**

Rue de la Loi 235  
Brussels 1040  
Belgium

[www.elpa.eu](http://www.elpa.eu)

ELPA emerged from a desire amongst European liver patient groups to share their experiences on very different healthcare approaches which often vary from country to country. ELPA was formally launched in Paris on April 14<sup>th</sup> 2005 and now has 25 association members from 22 countries.

Industry

ELPA's vision is that all liver patients are diagnosed on time, are treated with respect, and have equal access to the best standard of medical care – regardless of origin, lifestyle and type of liver disease. Our ultimate goal is a world without liver disease.

### **Hep C Action Aotearoa**

**Booth 344**

PO Box 12-180  
Christchurch 8081  
New Zealand

[www.hepc-action.nz](http://www.hepc-action.nz)

Hep C Action Aotearoa is the patient voice of the hep C elimination campaign in Aotearoa, New Zealand. We are working to eliminate the virus by 2025 – 5 years ahead of the WHO target.

A key part of our work is to combat stigma around the virus through the promotion of the butterfly symbol, nationally and globally. This positive symbol represents treatment, cure, new beginnings and optimism. The butterfly is a significant conversation starter for everyone who wears it. We are enabling people to get tested, get treated and get cured.

Industry

### **ICE-HBV: International Coalition to Eliminate HBV**

**Booth 351**

University of Melbourne  
Melbourne 3000  
Australia

[www.ice-hbv.org](http://www.ice-hbv.org)

ICE-HBV is an international research-driven forum, which is coordinating, promoting and fostering collaborative partnerships to fast-track the discovery of a safe, effective, affordable and scalable cure to benefit all people living with CHB, including children and people living with HCV, HDV and HIV co-infection.

Created in 2016, ICE-HBV is composed of more than 100 leaders in HBV virology, immunology, technologies, clinical research and key HBV research stakeholders from five continents, including regional and international organizations.

To get involved, contact [info@ice-hbv.org](mailto:info@ice-hbv.org).

### **International Network on Hepatitis in Substance Users (INHSU)**

**Booth 343**

Level 7, 46-56 Kippax Street  
Surry Hills 2010  
Australia

[www.inhsu.org](http://www.inhsu.org)

The International Network on Hepatitis in Substance Users (INHSU) is an international organisation dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care for people who use drugs. We do this through the following objectives: 1) Support and facilitate scientific exchange and dissemination of knowledge; 2)

Educate health care workers, policy makers, researchers, and people who use drugs on hepatitis C prevention, screening, linkage to care, and treatment; 3) Collaborate with other societies, government organisations, professional associations, community members, and individuals to advocate for hepatitis C prevention and care among people who use drugs.

## **Liverpool Drug Interactions**

**Booth 340**

70 Pembroke Place  
Liverpool L69 3GF  
United Kingdom

[www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Based at the University of Liverpool, UK, the Liverpool Drug Interactions team is a world-leading provider of clinically useful, reliable, comprehensive, up-to-date, evidence-based drug-drug interaction (DDI) resources for Hepatology and HIV.

Our websites [www.hep-druginteractions.org](http://www.hep-druginteractions.org) and [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org) and companion apps enable rapid screening for DDIs and are freely available to healthcare workers, patients and researchers. Our mission is to support DDI education and promote safer prescribing, thereby improving quality of care and patient outcomes. Our websites receive almost 50,000 unique visitors and respond to over 500,000 DDI queries each month.

## **Liver Systems Medicine (LiSyM) Network**

**Biotech Village**

Hermann-Herder-Straße 3  
Freiburg 79104  
Germany

[www.lisym.org](http://www.lisym.org)

LiSyM (Liver Systems Medicine) is a non-commercial, multidisciplinary research network funded by the German Federal Government. Adopting a systems medicine approach, the network aims to identify key mechanisms in the progression of non-alcoholic liver disease from early metabolic injury through fibrosis to cirrhosis and alterations causing organ failure, and to apply multi-scale modeling and simulation technologies to represent liver (dys)function. Research is directed towards identifying realistic, personalized clinical interventions for diagnosis, treatment and organ repair.

The Network involves collaboration among 37 research groups of experimentalists, computer modelers and clinical researchers in 23 research centers, institutions and hospitals around Germany

## **TASL: Taiwan Association for the Study of the Liver**

**Booth 339**

15F.-37, No.50, Sec. 1, Zhongxiao W. Rd., Zhongzheng Dist.  
Taipei 100  
Taiwan

[www.ghs2020taipei.com](http://www.ghs2020taipei.com)

Industry

Taiwan Association for the Study of the Liver (TASL) was founded in January 1990, by the same founder of The Gastroenterological Society of Taiwan (GEST), Professor Juei-Low Sung, named "the father of Taiwan's liver research".

The tenets of TASL are to enhance the medical education and academic intercommunication for hepatology, to elevate the standard of hepatology, to facilitate the basic and clinical research for hepatology, to exchange research insights, and to reinforce the interconnection with other international hepatology groups.

TASL is also the organizer of ISVHLD GHS 2020 and the event will take place on June 18-21, 2020 in Taipei.

## **The Cochrane Hepato-Biliary Group**

**Booth 337**

Tagensvej 22, Dept. 7812  
Copenhagen 2200  
Denmark

[www.hbg.cochrane.org](http://www.hbg.cochrane.org)

### **The Cochrane Hepato-Biliary Group (The CHBG)**

The CHBG, part of The Cochrane Collaboration, is a non-profit, international clinical research group with more than 2000 members. Cochrane systematic reviews of interventions for hepatic and biliary diseases are our main product. In issue 12, 2018 of The Cochrane Library, we published 366 peer-reviewed protocols for systematic reviews and 216 systematic reviews. A CHBG Register with about 17000 references on randomised or controlled clinical trials is maintained in the CENTRAL database in The Cochrane Library. Cochrane reviews are not industry funded.

## **UEG: United European Gastroenterology**

**Booth 345**

Wickenburggasse 1  
Vienna  
1080  
Austria

[www.ueg.eu](http://www.ueg.eu)

UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive health.

Together, our member societies represent over 30,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.

Our mission is continually to advance gastroenterology care, to improve the prevention and care of digestive diseases in Europe through providing education, supporting research and improving clinical standards.

Together, we are advancing gastroenterological care.

Visit [www.ueg.eu](http://www.ueg.eu)

Industry

**VIDC: Vancouver Infectious Diseases Centre****Booth 334**

201-1200 Burrard Street  
Vancouver V6Z 2C7  
Canada

[www.vidc.ca](http://www.vidc.ca)

The Vancouver Infectious Diseases Centre (VIDC) is a non-profit society dedicated to innovative care and research in the field of infectious diseases, with emphasis on HIV and HCV infections. Led by Dr. Brian Conway, VIDC delivers specialty healthcare and state-of-the-art diagnosis and treatment of chronic infectious diseases through a multidisciplinary model, available in both English and French. We utilize the “Four-Legged Chair” model, which support the medical, social, psychological, and addictions-related needs of our patients. Our Community Pop-up Clinics (CPCs) offer point-of-care HIV and HCV testing in inner city Vancouver, and have proven to be a successful form of engagement.

**WHA: World Hepatitis Alliance****Booth 153**

86bis, route de Frontenex, 1211 Genève 6  
Geneva  
Case Postale 6364  
Switzerland

[www.worldhepatitisalliance.org](http://www.worldhepatitisalliance.org)

The World Hepatitis Alliance is an ambitious patient-led and patient-driven not-for-profit organisation who works with governments, national members and other key partners to raise awareness of viral hepatitis and influence global change – harnessing the power of the people living with viral hepatitis to achieve its elimination.

With 260+ member patient groups from over 89 countries, WHA provides global leadership in awareness-raising, advocacy and in the fight to end social injustice to help achieve a world free from viral hepatitis.


**WGO: World Gastroenterology Organisation****Booth 342**

E. Wells St., Suite 1100  
Milwaukee, WI 53202  
USA

[www.worldgastroenterology.org](http://www.worldgastroenterology.org)

The World Gastroenterology Organisation (WGO) is a federation comprised of over 100 member societies representing more than 50,000 individuals worldwide. WGO focuses on the improvement of standards in gastroenterology training and education globally. The WGO Foundation is the philanthropic resource for the WGO mission.

Industry



## Introducing Quantitative MRCP

Improving the clinical landscape for biliary disease

---

**18:30 – 18:45**

**Case studies of patients with PSC analysed with quantitative imaging**

*Dr. Kris Kowdley, United States*

**18:45 – 19:00**

**Clinical data with quantitative MRCP: From diagnosis to prognosis to longitudinal change**

*Dr. Gideon Hirschfield, Canada*

**19:00 – 19:15**

**Panel Discussion: What is the highest potential value of quantitative MRCP in clinical practice?**

*All panel members*

**19:15 – 19:30**

**Panel Discussion: What role would quantitative MRCP play in PSC clinical development?**

*All panel members*

---

**Panel chair:**

Prof. Michael Manns, Germany

**Panel members:**

Dr. Kris Kowdley, United States; Dr. Gideon Hirschfield, Canada; Dr. Palak Trivedi, United Kingdom; Prof. Christoph Schramm, Germany; Martine Walmsley, United Kingdom

# When you see the symptoms but no clear diagnosis Test for Acute Hepatic Porphyria (AHP)



**AHP is a family of rare genetic diseases that is often confused with other conditions.** It most often manifests in women of childbearing age, who may go an average of 15 years before receiving a correct diagnosis.<sup>1-4</sup>

Acute exacerbations often require hospitalisation and are potentially life-threatening. Many patients also report chronic debilitation.<sup>1-3</sup> In a large natural history study of patients with recurrent attacks, 65% reported chronic symptoms and 46% had daily symptoms.<sup>5</sup>

**Severe, diffuse abdominal pain** occurs in up to 92% of patients. Additional symptoms may include nausea and vomiting, dark or reddish urine, confusion and anxiety, tachycardia and hyponatraemia, and limb pain or weakness. The presentation is highly variable.<sup>1-5</sup>

**Confirm suspicion of AHP by running simple spot urine tests of PBG, ALA, and porphyrins.**

Due to enzyme defects in the liver, patients develop neurotoxic accumulations of ALA and PBG. These neurotoxic intermediates occur naturally in the haem biosynthesis pathway in the liver, but abnormally high accumulations can produce serious neurovisceral symptoms—and a path to a firm diagnosis.<sup>1-3</sup>

**Help guide them to a correct diagnosis.**

Consider early testing for elevated urine PBG, ALA, and porphyrins.

Porphyrins is a nonspecific test and should not be used alone to diagnose AHP.<sup>4</sup>

**FOR MORE INFORMATION, PLEASE VISIT ALNYLAM AT BOOTH 346.**

ALA=delta-aminolaevulinic acid; PBG=porphobilinogen.

**References:** 1. Bissell DM, Anderson KE, Bonkovsky HL. *N Engl J Med.* 2017;377(9):862-872. 2. Bonkovsky HL, Maddukuri VC, Yazici C, et al. *Am J Med.* 2014;127(12):1233-1241. 3. Simon A, Pompilus F, Querbes W, et al. *Patient.* 2018;11(5):527-537. 4. Anderson KE, Bloomer JR, Bonkovsky HL, et al. *Ann Intern Med.* 2005;142(6):439-450. 5. Gouya L, Bloomer JR, Balwani M, et al. Presented at: European Association for the Study of the Liver International Liver Congress; April 14, 2018; Paris, France.

© 2019 Alnylam Pharmaceuticals, Inc. All rights reserved.  
01.2019 AS1-AUT-00001-012019

 **Alnylam**<sup>®</sup>  
PHARMACEUTICALS



**Shionogi sponsored  
integrated symposium:**

Procedural risk of  
bleeding – does the  
management of TCP in  
CLD patients make a  
difference? A debate.

**Date:** 12 April 2019

**Time:** 18:30 - 20:00

**Location:** Strauss 3

**Shionogi  
Europe works to  
meet the needs of patients  
and the community around them.**

From our beginnings over 140  
years ago in Osaka, Japan, Shionogi  
& Co. Ltd. has built a strong  
heritage in research-based medicine.  
Shionogi Europe was launched  
in 2012 and is committed  
to applying our patient-first  
approach in everything  
we do.

To discover more,  
visit us at booth  
**#338** or come to  
the symposium



# Understanding NASH as a metabolic disease

Chaired by  
Dr. Zobair Younossi

**Wednesday, 10 April,  
18.00–19.30  
Strauss 1-2, Messe Wien**

**Topics include:**

- Pathophysiology in the context of metabolic risk factors (Dr. Arun Sanyal)
- Non-invasive diagnostic techniques (Dr. Rohit Loomba)
- Emerging treatment strategies (Dr. Stephen Harrison)

Novo Nordisk is a global health-care company headquartered in Denmark. Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.



Nadia Sadi,  
Denmark  
Nadia has NASH

**NEW**

**FibroScan®**  
**expert** 630

**BRING LIVER  
DISEASE  
MANAGEMENT  
TO A NEXT  
LEVEL**

**#ILC 2019**  
Join us on  
booth 330  
for a live demo

- ◎ **New spleen stiffness measurement and embedded ultrasound guidance system for risk stratification of patients with advanced chronic liver disease.**
- ◎ **Enhanced ergonomics and advanced features for optimized exam efficiency.**




**echosens™**

FibroScan® is a class IIa medical device according to Directive EEC/93/42 and is manufactured by Echosens™ (FibroScan® 630 Expert: CE mark in progress). This device is designed to be used in a physician's office to measure the stiffness and ultrasonic attenuation of the liver in patients with liver disease. It is expressly recommended to carefully read the guidance and instruction of the users' guide and labeling of the device. Results obtained must be interpreted by a physician experienced in dealing with liver disease, taking into account the complete medical record of the patients. This marketing material is not intended for French and US audience. ISO 13485 - Echosens™, FibroScan®, are trademarks of Echosens™ Company. © Copyright Echosens™ all rights reserved - 02/2019

# D-LIVR

## First-Ever Phase 3 Study in Hepatitis Delta Virus (HDV) Infection



**WORKING TO CHANGE  
THE FACE OF HDV**

[www.clinicaltrials.gov: NCT03719313](http://www.clinicaltrials.gov: NCT03719313)

[www.eigerbio.com](http://www.eigerbio.com)  
[DLIVR@eigerbio.com](mailto:DLIVR@eigerbio.com)



Liver



Liver **history**  
Liver **future**  
Liver **cancer**  
Liver **disease**  
Liver **function**  
Liver **discussion**  
Liver **leaders**  
Liver **care**

**Stop searching.  
Learn more at booth 230.**

**Learn more about MSD's commitment to advancing liver health.**

Join Arndt Vogel, MD, Riad Salem, MD; Masatoshi Kudo, MD, PhD;  
and Richard Finn, MD for their presentation,

**“Assessing Response in Advanced Liver Cancer -  
Does Response Matter?”** as they discuss the question and  
relevance of response in advanced HCC.

**April 13, 12:30-14:00, room C-1**

**Visit us at booth 230 and join the conversation.  
MSD. Leadership in liver disease.**



# BOLD FOR LIFE

Allergan is a bold, global pharmaceutical company with a purpose. We are focused on developing, manufacturing and commercializing products for eye care, medical aesthetics & dermatology, women's health, the central nervous system, urology, gastroenterology and anti-infective therapeutic categories.

We are committed to working with healthcare providers for patients—to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives. We are Bold for Life.

[www.Allergan.com](http://www.Allergan.com)

*Wil G.  
Global Medical Affairs  
Irvine, CA*

 **Allergan**

# ADVANCES IN PBC MANAGEMENT: LOOKING BEYOND BIOCHEMICAL MARKERS

An Intercept-sponsored integrated symposium at the International Liver Congress™ 2019, 54<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver

**THURSDAY 11<sup>th</sup>**  
**APRIL 2019, 18.30-20.00**

**STRAUSS 3**

REED MESSE, WIEN EXHIBITION & CONGRESS CENTER

## Advances in PBC Management: Looking Beyond Biochemical Markers

18:30-18:35	Chair's welcome	Professor M Trauner
18:35-18:50	Second line therapy in PBC: how can we optimise care?	Professor G Hirschfield
18:50-19:05	Real world experience with obeticholic acid therapy	Professor A Gulamhusein
19:05-19:20	Histological features of PBC: a pathologist's perspective	Professor L Terracciano
19:20-19:40	Histological outcomes with long term obeticholic acid therapy	Professor C Bowlus Professor A Kremer
19:40-19:55	Discussion	All speakers
19:55-20:00	Conclusion	Professor M Trauner

### Abbreviated Prescribing Information

#### OCALIVA<sup>▼</sup> (obeticholic acid)

(Please refer to the Full Summary of Product Characteristics (SmPC) before prescribing)

**Presentation:** OCALIVA supplied as film-coated tablets containing 5 mg and 10 mg obeticholic acid. **Indication:** For the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. **Dosage and administration:** Oral administration. Hepatic status must be known before initiating treatment. In patients with normal or mildly impaired (Child Pugh Class A) hepatic function, the starting dose is 5 mg once daily. Based on an assessment of tolerability after 6 months, the dose should be increased to 10 mg once daily if adequate reduction of alkaline phosphatase (ALP) and/or total bilirubin have not been achieved. No dose adjustment of concomitant UDCA is required in patients receiving obeticholic acid. For cases of severe pruritus, dose management includes reduction, temporal interruption or discontinuation for persistent intolerable pruritus; use of bile acid binding agents or antihistamines (see SmPC). **Moderate to Severe Hepatic Impairment:** In patients with Child-Pugh B or C hepatic impairment, a reduced starting dose of 5mg once weekly is required. After 3 months, depending on response and tolerability, the starting dose may be titrated to 5 mg twice weekly and subsequently to 10 mg twice weekly (at least 3 days between doses) if adequate reductions in ALP and/or total bilirubin have not been achieved. No dose adjustment required in Child Pugh Class A function. **Mild or moderate renal impairment:** No dose adjustments are required. **Paediatric population:** No data. **Elderly:** No dose adjustment required; limited data exists. **Contraindications:** Hypersensitivity to the active substance or any excipients. Complete biliary obstruction. **Special warnings and precautions for use:** After initiation, patients should be monitored for progression of PBC with frequent clinical and laboratory assessment of those at increased risk of hepatic decompensation. Dose frequency should be reduced in patients who progress from Child Pugh A to Child Pugh B or C Class disease. Serious liver injury and death have been reported in patients with moderate/severe impairment who did not receive appropriate dose reduction. Liver-related adverse events have been observed within the first month of treatment and have included elevations in alanine amino transferase (ALT), aspartate aminotransferase (AST) and hepatic decompensation. **Interactions:** Following co-

administration of warfarin and obeticholic acid, International Normalised Ratio (INR) should be monitored and the dose of warfarin adjusted, if needed, to maintain the target INR range. Therapeutic monitoring of OATP1A2 substrates with narrow therapeutic index (e.g. theophylline and lizanidine) is recommended. Obeticholic acid should be taken at least 4-6 hours before or after taking a bile acid binding resin, or at as great an interval as possible. **Fertility, pregnancy and lactation:** Avoid use in pregnancy. Either discontinue breast-feeding or discontinue/abstain from obeticholic acid therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No clinical data on fertility effects. **Undesirable effects:** Very common (≥1/10) adverse reactions were pruritus, fatigue, and abdominal pain and discomfort. The most common adverse reaction leading to discontinuation was pruritus. The majority of pruritus occurred within the first month of treatment and tended to resolve over time with continued dosing. Other commonly (≥ 1/100 to < 1/10) reported adverse reactions are, thyroid function abnormally, dizziness, palpitations, oropharyngeal pain, constipation, eczema, rash, arthralgia, peripheral oedema, and pyrexia. Please refer to the SmPC for a full list of undesirable effects. **Overdose:** Liver-related adverse reactions were reported with higher than recommended doses of obeticholic acid. Patients should be carefully observed, and supportive care administered, as appropriate. **Legal category:** POM **Marketing authorisation numbers:** EU/1/16/1193/001 & 002 **Marketing authorisation holder:** Intercept Pharma Ltd, 2 Pancras Square, London, N1C 4AG, United Kingdom **Package Quantities and Basic NHS costs:** OCALIVA 5 mg and 10 mg £2,384.04 per bottle of 30 tablets. **Date of revision:** 11th April 2018.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).

Adverse events should also be reported to Intercept Pharma Ltd on +44 (0)330 100 3694 or email: [drugsafety@interceptpharma.com](mailto:drugsafety@interceptpharma.com)

INTEGRATED SYMPOSIUM OF THE INTERNATIONAL LIVER CONGRESS™ 2019, 54TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

## Navigating Patients Through the Evolving HCC Treatment Landscape

GET  
INTERACTIVE!



Download the app

Thursday, 11 April 2019 | 18:30–20:00  
Reed Messe Wien Exhibition & Congress Center  
Hepatology Arena  
Vienna, Austria

Join us for live clinical debates on the treatment of HCC!

### Welcome and introductions



**Peter Galle, MD, PhD**  
*Universitätsmedizin Mainz*  
*Germany*

Meeting Chair

### Systemic Therapy for HCC: How Do We Choose From an Expanding List of Options?



**Fabio Piscaglia, MD, PhD**  
*University of Bologna*  
*Italy*



**Matthias Pinter, MD, PhD**  
*Medical University of Vienna*  
*Austria*

### When Is the Optimal Time to Transition Patients From Locoregional to Systemic Therapy?



**Daniel Palmer, MD, PhD**  
*University of Liverpool*  
*England*



**Jens Ricke, MD, PhD**  
*Ludwig Maximilian University*  
*of Munich*  
*Germany*

HCC=hepatocellular carcinoma.



**Bristol-Myers Squibb**

**PREVENTING A**

# domino effect

**IN THE MANAGEMENT OF  
HEPATIC ENCEPHALOPATHY (HE)**

---

**WELCOME AND INTRODUCTIONS:  
WHAT IS THE DOMINO EFFECT?**

**Dr Jasmohan Bajaj**  
Virginia Commonwealth  
University, USA

---

**STARTING OFF RIGHT:  
UNDERSTANDING HE AND  
IMPROVING DIAGNOSIS**

**Prof Thomas Berg**  
University of Leipzig, Germany

---

**FIGHTING BACK:  
MECHANISMS OF TREATMENT**

**Dr Debbie Shawcross**  
Institute of Liver Studies,  
King's College London, UK

---

**IMPACT ON PATIENT OUTCOMES:  
THE EFFECT OF DIFFERENT  
MANAGEMENT STRATEGIES**

**Prof Aleksander Krag**  
Odense University Hospital,  
Denmark

---

**BARRIERS AND SOLUTIONS TO  
IMPROVING MANAGEMENT OF HE**

**Dr Jasmohan Bajaj**  
Virginia Commonwealth  
University, USA

---

**PANEL DISCUSSION AND Q&A**

**ALL**

---

INTEGRATED SATELLITE SYMPOSIUM OF THE INTERNATIONAL LIVER CONGRESS™ 2019

**WEDNESDAY 10 APRIL | 18.00–19.30**

STRAUSS 3, REED MESSE WIEN CONGRESS CENTER, VIENNA, AUSTRIA

This symposium is organised and fully funded by Norgine.

Presentations have been developed by the faculty and represent the views of the speakers.

NORGINE and the sail logo are registered trademarks of the Norgine group of companies.

GL/XIF/0219/0202j Date of preparation: February 2019



Please  
visit us  
on stand  
No. 150

Just because they're home,  
doesn't mean they're out of danger



For the reduction in  
recurrence of overt hepatic  
encephalopathy (OHE)

Information about this product, including adverse reactions, precautions, contra-indications and method of use can be found at [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc). Please consult the Summary of Product Characteristics (SmPC) before prescribing, particularly in relation to side-effects, precautions and contra-indications. Further information is available on request from the marketing authorisation holder: Norgine Pharmaceuticals Ltd, Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex UB9 6NS, UK. Legal category: POM. Product licence number: PL20011/0020. ATC code: A07AA11. Company reference: GL/XIF/1214/0080(3). Product under licence from Alfasigma

**Adverse events should be reported to your regulatory agency. Adverse events should also be reported to your local distributor or Norgine Limited, Norgine House, Moorhall Road, Harefield, Uxbridge, Middlesex UB9 6NS, United Kingdom. Email: [globalmedinfo@norgine.com](mailto:globalmedinfo@norgine.com)**



**Xifaxan<sup>®</sup> 550**  
**Targaxan<sup>®</sup> 550**  
**Rifaximin- $\alpha$**

Long-term secondary prophylaxis in OHE

S.p.A. XIFAXAN and TARGAXAN are registered trademarks of the Alfasigma group of companies, licensed to the Norgine group of companies. NORGINE and the sail logo are registered trademarks of the Norgine group of companies.

GL/XIF/0219/0205. Date of preparation: February 2019.

XIFAXAN<sup>®</sup> 550/TARGAXAN<sup>®</sup> 550 is not available in Austria.

XIFAXAN<sup>®</sup>/TARGAXAN<sup>®</sup> has varying availability and licensing internationally. Before prescribing, consult your country approved prescribing information, available from your local distributor or Norgine Ltd.



**NORGINE**

Partner for a healthy life

You are Invited: AbbVie-Sponsored Symposium

# Transforming the HCV Care Cascade: Making HCV Elimination a Reality

**Wednesday 10 April 2019,  
18:00 – 19:30**

Professor Stefan Zeuzem (Chair)  
Professor Ashley Brown  
Professor Greg Dore

Effective and well-tolerated DAA regimens together with emerging integrated care models mean we now have the capabilities to meet the WHO target of HCV elimination as a public health burden by 2030.

However, remaining barriers in the care cascade must be addressed. **Join our expert faculty panel for an engaging, dynamic and interactive meeting where we will explore the challenges we have overcome and those that remain in the care cascade to make HCV elimination a reality.**



# TOGETHER, **ELIMINATION** IS HAPPENING HERE.

Gilead is proud to support elimination efforts in marginalised populations. We're working with HCPs to prevent hepatitis C among people who inject drugs and those in prisons through screening support and universal access to DAAs.

Together, we're supporting elimination in Australia to help make hepatitis C history.



SEE YOU AT  
**ILC 2020**  
LONDON

[www.easl.eu](http://www.easl.eu)